Advances in Clinical Chemistry, Volume 54

ADVANCES IN CLINICAL CHEMISTRY VOLUME 54 This page intentionally left blank Advances in CLINICAL CHEMISTRY Edited b...

Author: Gregory Makowski

25 downloads 844 Views 1MB Size Report

This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!

Report copyright / DMCA form

DOWNLOAD PDF

ADVANCES IN CLINICAL CHEMISTRY VOLUME 54

This page intentionally left blank

Advances in CLINICAL CHEMISTRY Edited by GREGORY S. MAKOWSKI Clinical Laboratory Partners Newington, CT Hartford Hospital Hartford, CT

VOLUME 54

AMSTERDAM • BOSTON • HEIDELBERG • LONDON NEW YORK • OXFORD • PARIS • SAN DIEGO SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO Academic Press is an imprint of Elsevier

Academic Press is an imprint of Elsevier 32 Jamestown Road, London NW1 7BY, UK 225 Wyman Street, Waltham, MA 02451, USA 525 B Street, Suite 1900, San Diego, CA 92101-4495, USA Radarweg 29, PO Box 211, 1000 AE Amsterdam, The Netherlands This book is printed on acid-free paper. ⬁ Copyright ß 2011, Elsevier Inc. All rights reserved No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher Permissions may be sought directly from Elsevier’s Science & Technology Rights Department in Oxford, UK: phone (+44) (0) 1865 843830; fax (+44) (0) 1865 853333; email: [email protected]. Alternatively you can submit your request online by visiting the Elsevier web site at http://www.elsevier.com/locate/permissions, and selecting Obtaining permission to use Elsevier material Notice No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made Library of Congress Cataloging-in-Publication Data A catalog record for this book is available from the Library of Congress British Library Cataloguing in Publication Data A catalogue record for this book is available from the British Library ISBN: 978-0-12-387025-4 ISSN: 0065-2423 For information on all Academic Press publications visit our website at www.elsevierdirect.com Printed and bound in USA 11 12 13 14 10 9 8 7 6

5 4 3 2

1

CONTENTS CONTRIBUTORS

................................................................................

ix

PREFACE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

xi

Heat-shock Proteins in Cardiovascular Disease JULIO MADRIGAL-MATUTE, JOSE LUIS MARTIN-VENTURA, LUIS MIGUEL BLANCO-COLIO, JESUS EGIDO, JEAN-BAPTISTE MICHEL, AND OLIVIER MEILHAC 1. 2. 3. 4. 5. 6. 7.

Abstract ... ................................................................................... Introduction ................................................................................. Atherogenesis and Possible Stimuli of Inducible HSPs ................................. HSPs/Anti-HSPs as Biomarkers of Atherothrombosis ................................. Molecular Mechanisms: Bystanders or Actors? . ........................................ HSP as Therapeutic Targets in CVD/Atherothrombosis ............................... Conclusions .................................................................................. Acknowledgments........................................................................... References. ...................................................................................

3 3 4 8 15 25 28 28 29

Polyamines in Cancer EDWIN A. PAZ, JENARO GARCIA-HUIDOBRO, AND NATALIA A. IGNATENKO 1. 2. 3. 4. 5. 6. 7.

Abstract ... ................................................................................... Introduction ................................................................................. Overview of Polyamine Regulation ....................................................... Deregulation of Polyamines in Cancer ................................................... Genetic Variability in ODC Affecting Carcinogenesis.................................. EIF5A and Cancer.......................................................................... Chemoprevention Strategies Within Polyamine Pathway .............................. Acknowledgments........................................................................... References. ...................................................................................

v

46 46 47 50 54 56 60 63 63

vi

CONTENTS

Acquired Hemophilia A MASSIMO FRANCHINI, AND GIUSEPPE LIPPI 1. 2. 3. 4. 5.

Abstract....................................................................................... Introduction.................................................................................. Pathogenesis.................................................................................. Laboratory Diagnosis....................................................................... Conclusions .................................................................................. Acknowledgments ........................................................................... References ....................................................................................

71 72 72 73 78 79 79

Hypobetalipoproteinemia: Genetics, Biochemistry, and Clinical Spectrum PATRIZIA TARUGI, AND MAURIZIO AVERNA 1. 2. 3. 4. 5. 6. 7. 8. 9. 10.

Abstract....................................................................................... Introduction.................................................................................. Pathways of apoB-Containing Lipoproteins Production . .............................. Dominant Forms of Primary HBL ........................................................ Recessive Forms of Primary HBL ......................................................... Primary Orphan FHBL..................................................................... Spectrum of Clinical Manifestations in Primary HBL .................................. Main Clinical Issues of FHBL ............................................................. Secondary Hypobetalipoproteinemias .................................................... Conclusions .................................................................................. Addendum.................................................................................... Acknowledgment ............................................................................ References ....................................................................................

82 83 83 87 91 92 92 94 96 97 99 101 101

Sm Peptides in Differentiation of Autoimmune Diseases MICHAEL MAHLER 1. 2. 3. 4. 5. 6. 7. 8.

Abstract....................................................................................... Introduction.................................................................................. Systemic Lupus Erythematosus ............................................................ Mixed Connective Tissue Disease ......................................................... Biochemical Aspects of the Sm Antigen .................................................. Characteristics of Anti-Sm Antibodies.................................................... Detection of Anti-Sm Antibodies.......................................................... Clinical Association of Anti-Sm Antibodies.. ............................................

109 110 110 112 112 113 114 118

CONTENTS 9. 10. 11. 12. 13.

Meta-Analysis of Anti-Sm Antibodies.................................................... Genesis of Anti-Sm Antibodies............................................................ (Sm) Peptides as Antigens.................................................................. Summary and Conclusion.................................................................. Take Home Messages ...................................................................... References. ...................................................................................

vii 118 119 119 122 122 122

Aromatase Activity and Bone Loss LUIGI GENNARI, DANIELA MERLOTTI, AND RANUCCIO NUTI 1. 2. 3. 4. 5. 6. 7. 8. 9.

Abstract ... ................................................................................... Introduction ................................................................................. Aromatase and Sources of Estrogen Production ........................................ The Aromatase Gene and Its Tissue-Specific Regulation .............................. Aromatase Deficiency and the Bone ...................................................... Skeletal Consequences of Aromatase Excess ............................................ Threshold Estradiol Hypothesis for Skeletal Sufficiency ............................... Variability in the Level of Aromatase Activity: Effects on Bone Metabolism ....... Summary and Conclusions................................................................. References. ...................................................................................

129 130 131 133 134 145 146 148 153 154

Biochemistry of Adolescent Idiopathic Scoliosis GIOVANNI LOMBARDI, MARIE-YVONNE AKOUME, ALESSANDRA COLOMBINI, ALAIN MOREAU, AND GIUSEPPE BANFI 1. 2. 3. 4. 5. 6. 7. 8.

Abstract ... ................................................................................... Introduction ................................................................................. Bone Biochemical Parameters ............................................................. Hormones . ................................................................................... Trace Elements .............................................................................. Hematological Parameters—Platelets..................................................... Melatonin . ................................................................................... Conclusions .................................................................................. References. ...................................................................................

166 166 168 168 171 171 172 178 179

INDEX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

183

This page intentionally left blank

CONTRIBUTORS Numbers in parentheses indicate the pages on which the authors’ contributions begin.

MARIE-YVONNE AKOUME (165), Viscogliosi Laboratory in Molecular Genetics of Musculoskeletal Diseases, Sainte-Justine University Hospital Research Center; and Department of Biochemistry, Faculty of Medicine, Universite´ de Montre´al, Montre´al, Quebec, Canada MAURIZIO AVERNA (81), Department of Clinical Medicine and Emerging Diseases, University of Palermo, Palermo, Italy GIUSEPPE BANFI (165), IRCCS Istituto Ortopedico Galeazzi, Milano, Italy LUIS MIGUEL BLANCO-COLIO (1), Vascular Research Lab, IIS, Fundacio´n Jime´nez Dı´az, Auto´noma University, Av. Reyes Cato´licos 2, Madrid, Spain ALESSANDRA COLOMBINI (165), IRCCS Istituto Ortopedico Galeazzi, Milano, Italy JESUS EGIDO (1), Vascular Research Lab, IIS, Fundacio´n Jime´nez Dı´az, Auto´noma University, Av. Reyes Cato´licos 2, Madrid, Spain MASSIMO FRANCHINI (71), Department of Pathology and Laboratory Medicine, Immunohematology and Transfusion Center, University Hospital of Parma, Parma, Italy JENARO GARCIA-HUIDOBRO (45), Biochemistry and Molecular and Cellular Biology Graduate Program, University of Arizona, Tucson, Arizona, USA LUIGI GENNARI (129), Department of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, University of Siena, Siena, Italy NATALIA A. IGNATENKO (45), Department of Cell Biology and Anatomy, Arizona Cancer Center, Tucson, Arizona, USA

ix

x

CONTRIBUTORS

GIUSEPPE LIPPI (71), Clinical Chemistry Laboratory, Department of Pathology and Laboratory Medicine, University Hospital of Parma, Parma, Italy GIOVANNI LOMBARDI (165), IRCCS Istituto Ortopedico Galeazzi, Milano, Italy JULIO MADRIGAL-MATUTE (1), Vascular Research Lab, IIS, Fundacio´n Jime´nez Dı´az, Auto´noma University, Av. Reyes Cato´licos 2, Madrid, Spain MICHAEL MAHLER (109), INOVA Diagnostics Inc., San Diego, California, USA JOSE LUIS MARTIN-VENTURA (1), Vascular Research Lab, IIS, Fundacio´n Jime´nez Dı´az, Auto´noma University, Av. Reyes Cato´licos 2, Madrid, Spain OLIVIER MEILHAC (1), Inserm U698, Hemostasis, Bio-engineering and Cardiovascular Remodeling, Hospital Bichat, Paris, France DANIELA MERLOTTI (129), Department of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, University of Siena, Siena, Italy JEAN-BAPTISTE MICHEL (1), Inserm U698, Hemostasis, Bio-engineering and Cardiovascular Remodeling, Hospital Bichat, Paris, France ALAIN MOREAU (165), Viscogliosi Laboratory in Molecular Genetics of Musculoskeletal Diseases, Sainte-Justine University Hospital Research Center; Department of Biochemistry, Faculty of Medicine; and Department of Stomatology, Faculty of Dentistry, Universite´ de Montre´al, Montre´al, Quebec, Canada RANUCCIO NUTI (129), Department of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, University of Siena, Siena, Italy EDWIN A. PAZ (45), Cancer Biology Interdisciplinary Graduate Program, Arizona Cancer Center, University of Arizona, Tucson, Arizona, USA PATRIZIA TARUGI (81), Department of Biomedical Sciences, University of Modena and Reggio Emilia, Modena, Italy

PREFACE I am pleased to present Volume 54 of Advances in Clinical Chemistry series for 2011. In the second volume for this year, a number of topics for clinical laboratories are reviewed. The first review explores the potential role of heat shock proteins in cardiovascular disease including atherogenesis and atherothrombotic complications. Their role as biomarkers, mediators, and therapeutic agents is discussed. The second chapter summarizes the biochemical mechanisms of polyamine regulation by tumor suppressor genes and oncogenes during tumorigenesis. The role of autoantibodies in acquired hemophilia A is discussed in the third chapter with a focus on pathogenesis, diagnosis, and epidemiology. The fourth chapter investigates hypobetalipoproteinemias as a heterogenous group of disorders. The biochemistry, genetics, and clinical spectrum of this disease are discussed. The fifth chapter explores autoimmune disease associated with the generation of antibodies to small nuclear ribonucleoproteins in systemic lupus erythematosus. The role of aromatase in sex steroid hormone generation and their importance in acquisition and maintenance of bone mass in both males and females are elucidated in the sixth chapter. The volume concludes with the seventh chapter, which discusses the biochemical, hormonal, and hematologic factors associated with development of adolescent idiopathic scoliosis. The potential role of melatonin signaling dysfunction is explored as a pathologic mechanism in disease onset and progression. I thank each contributor of Volume 54 and those colleagues who contributed to the peer-review process. I extend my appreciation to my Elsevier liaison, Gayathri Venkatasamy, for continued editorial support. I hope the second volume for 2011 will be enjoyed and used. As always, your comments and suggestions for clinical laboratory topics of interest for the Advances in Clinical Chemistry series are always appreciated. In keeping with the tradition of the series, I would like to dedicate Volume 54 to Uncle Rich. GREGORY S. MAKOWSKI

xi

This page intentionally left blank

ADVANCES IN CLINICAL CHEMISTRY, VOL. 54

HEAT-SHOCK PROTEINS IN CARDIOVASCULAR DISEASE Julio Madrigal-Matute,* Jose Luis Martin-Ventura,* Luis Miguel Blanco-Colio,* Jesus Egido,* Jean-Baptiste Michel,† and Olivier Meilhac†,1 ´ n Jime ´ nez Dı´az, *Vascular Research Lab, IIS, Fundacio ´ noma University, Av. Reyes Cato ´ licos 2, Madrid, Spain Auto † Inserm U698, Hemostasis, Bio-engineering and Cardiovascular Remodeling, Hospital Bichat, Paris, France

1. 2. 3. 4.

Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Atherogenesis and Possible Stimuli of Inducible HSPs . . . . . . . . . . . . . . . . . . . . . . . . . . . HSPs/Anti-HSPs as Biomarkers of Atherothrombosis . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.1. Antigenic Detection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.2. Indirect Detection via Anti-HSP Antibodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5. Molecular Mechanisms: Bystanders or Actors? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5.1. Intracellular Effects. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5.2. Extracellular Effects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6. HSP as Therapeutic Targets in CVD/Atherothrombosis . . . . . . . . . . . . . . . . . . . . . . . . . 6.1. HSP Induction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6.2. Immune Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

3 3 4 8 9 12 15 15 21 25 25 27 28 29

Abbreviations 17-AAG 17-DMAG acLDL ACS AIF 1

17-allylamino-17-demethoxygeldanamycin 17-desmethoxy-17-N, N-dimethylaminoethylaminogeldanamycin acetylated LDL acute coronary syndrome apoptosis inducing factor

Corresponding author: Olivier Meilhac, e-mail: [email protected] 1

0065-2423/11 $35.00 DOI: 10.1016/B978-0-12-387025-4.00001-7

Copyright 2011, Elsevier Inc. All rights reserved.

2 AMI Ang-II APAF1 ApoE/ BAECs BMP CAD CD CHD CRP CVD eEF2 kinase eNOS ERK Foxp3 GSH HDF Hip HIV HO-1 Hop HOPE study HSE HSF HSP HSR HUVECs Ig IL kDA LDL-R/ LDLs LPS MAPK MCP1 MGP MI Mn-SOD NF-B NO NOS

MADRIGAL-MATUTE ET AL.

acute myocardial infarction angiotensin-II apoptosis protease activating factor 1 apolipoprotein E knock out bovine aortic endothelial cells bone morphogenetic protein coronary artery disease cluster of differentiation coronary heart disease C-reactive protein cardiovascular disease eukaryotic elongation factor-2 kinase endothelial NOS extracellular signal-regulated kinase forkhead box P3 glutathione human diploid fibroblasts HSP70-interacting protein human immunodeficiency virus heme oxygenase-1 HSP70–HSP90 organizing protein the heart outcomes prevention evaluation study heat-shock element heat-shock factor heat-shock protein heat-shock response human umbilical vein endothelial cells immunoglobulin interleukin kilodalton LDL receptor knock out low-density lipoproteins lipopolysaccharide mitogen-activated protein kinases monocyte chemoattractant protein 1 matrix Gla protein myocardial infarction manganese superoxide dismutase nuclear factor kappa B nitric oxide NO synthases

HEAT-SHOCK PROTEINS IN CARDIOVASCULAR DISEASE

oxLDL PAMPs ROS SA SAPK/JNK siRNA SMCs SR TGF-b Th2 cytokine TLR TNF-a Tregs VEGF VSMCs YC1

3

oxidized LDL pathogen-associated molecular patterns reactive oxygen species stable angina stress-activated protein kinase/c-Jun N-terminal kinase small interference RNA smooth muscle cells scavenger receptor transfoming growth factor beta T-helper type 2 cytokine toll-like receptor tumor necrosis factor alpha T regulatory cells vascular endothelial growth factor vascular SMCs 3-(50 -hydroxymethyl-20 -furyl)-1-benzyl-indazol

1. Abstract Heat-shock proteins (HSPs) belong to a group of highly conserved families of proteins expressed by all cells and organisms and their expression may be constitutive or inducible. They are generally considered as protective molecules against different types of stress and have numerous intracellular functions. Secretion or release of HSPs has also been described, and potential roles for extracellular HSPs reported. HSP expression is modulated by different stimuli involved in all steps of atherogenesis including oxidative stress, proteolytic aggression, or inflammation. Also, antibodies to HSPs may be used to monitor the response to different types of stress able to induce changes in HSP levels. In the present review, we will focus on the potential implication of HSPs in atherogenesis and discuss the limitations to the use of HSPs and anti-HSPs as biomarkers of atherothrombosis. HSPs could also be considered as potential therapeutic targets to reinforce vascular defenses and delay or avoid clinical complications associated with atherothrombosis.

2. Introduction Heat-shock proteins (HSPs) belong to a group of highly conserved families of proteins expressed by all cells and organisms from bacteria to humans in response to a variety of different stress stimuli, including heavy metals, inflammatory cytokines, amino acid analogues, oxidative stress, or ischemia [1].

4

MADRIGAL-MATUTE ET AL.

The name of ‘‘stress proteins’’ would be more appropriate than ‘‘HSPs’’ but for historical reasons, due to the discovery of genes of the HSP family in salivary gland cells of Drosophila subsequent to heat shock [2,3], this name is still in use today. HSP expression may be constitutive or inducible. HSPs are generally considered as protective molecules against different types of stress. They have numerous intracellular functions including roles as molecular chaperones, promoting correct protein folding of newly synthesized or denatured proteins [4], inhibitors of apoptosis [5], or maintainers of cellular integrity by stabilization of the cytoskeleton [6]. Secretion or release of HSPs has also been described, and potential roles for extracellular HSPs reported. The compartmentalization of HSPs and their role as markers or actors in atherosclerosis will be discussed in this chapter. Several other reviews deal with HSPs and cardiovascular disease [7] including cardiac protection [8] or neuroprotection [9]. In the present review, we will focus on the potential implication of HSPs in atherogenesis and atherothrombotic complications; we will discuss whether they may be considered as biomarkers, whether they participate in the etiology of vascular complications, as well as their potential use as therapeutic agents. HSPs are classified according to their molecular weight, ranging from 10 to 110 kDa. However, a new nomenclature has been recently proposed [10]. The correspondences of the principal HSPs that we will discuss here are presented in Table 1, but the old nomenclature will be used throughout this review. Table 1 also summarizes the cardiovascular origin of the different HSPs, their potential inducers, their reported functions, and whether their circulating levels (both antigens and antibodies directed against HSPs) are associated with cardiovascular disease.

3. Atherogenesis and Possible Stimuli of Inducible HSPs Several elements participating in atherogenesis have a strong impact on HSP expression and their posttranslational modifications, such as phosphorylation. We will summarize the different steps of atherogenesis leading to atherothrombotic complications and clinical manifestations with a particular emphasis on molecular events reported to induce HSP expression (Fig. 1). The formation of atheroma starts during childhood by the accumulation of phagocytic cells in the intimal layer of the arterial wall. The intima is constituted by the endothelial layer and subjacent extracellular matrix, separated by the internal elastic lamina from the tunica media, principally composed of smooth muscle cells (SMCs), elastic, and collagen fibers in association with glycoproteins and proteoglycans. The intima represents a very limited space in healthy arteries where accumulation of phagocytic cells,

TABLE 1 HSPS: NEW NOMENCLATURE, CELL EXPRESSION, INDUCING FACTORS, INTRA/EXTRACELLULAR FUNCTIONS AND USE OF HSPS AS CIRCULATING BIOMARKERS Circulating biomarker New nomenclature

Cardiovascular expression

Induced by

Intracellular function

Extracellular function

Antigen

Antibody – " carotid atherosclerosis [30] – Associated with severity of CAD [25,31] – # MI compared to CHD [32] – Predicitive of 5-year mortality in carotid atherosclerosis [30] – " higher risk of new CV event [33] – Predicted coronary risk [34] – Associated with infection [35] and CVD [36–40] – # CAD [56] – not related with prevalence of CAD [53] and high risk of ACS [30]

HSP60

HSPD [11]

– Ubiquitously expressed [11]

– Heat shock [12] – miR-1/miR-206 [13] – proinflammatory cytokines [12] – Hemodynamic factors [14]

– Cell survival [15] – Apoptosis [16] – Protein trafficking [17,18] – Peptide hormone signaling [19] – Proliferation [20]

– Proinflammatory [21] – Immunogen [22] – Proapoptotic [16]

– " in carotid atherosclerosis [23] – Associated with IMT in borderline hypertension [24] – Associated with severity of CAD [25,26] – " infection, stress, myocardial necrosis [27–29]

HSP70

HSPA [11]

– Smooth muscle cells [41] – Cardiac myocytes [42] – Monocytes/ Macrophages [41]

– – – – – –

– – – –

– Proinflammatory [49] – Proliferation and calcification [50] – Immunogen [51]

– " levels associated with decreased IMT in hypertensive patients [52] – " levels associated with low CAD risk [53] – # carotid atherosclerosis [54] – Inversely correlated with neutrophil activation [54] – " ACS [55]

Heat shock [12] Mechanical stress [43] Hyperlipidemia [44] oxLDL [45] HSP90 inhibitors [41] Other pharmacological compounds [46]

Antiinflammatory [41] Antiapoptotic [47] Antioxidant [48] Antiproliferative[46]

(continues)

TABLE 1 (Continued) Circulating biomarker New nomenclature HSP27

HSPB1 [11]

HSP90

HSPC [11]

" #

Increased Decreased

Cardiovascular expression – Smooth muscle cells [57] – Endothelial cells [58] – Cardiac myocytes [59,60] – Monocytes/ Macrophages [61] – Neutrophils [62] – Monocytes/ macrophages [41] – Smooth muscle cells [41] – Endothelial cells [72]

Induced by

Intracellular function

Extracellular function

– Chemical stressors [58] – Heat shock [63] – Hyperlipidemia [44]

– – – – – –

Actin stabilization [64] Muscle contraction [64] Cell migration [64] Cell survival [64] Antioxidant [65] Antiinflammatory [66]

– – – –

Anti-inflammatory [61] Antiapoptotic [67] Antioxidant [62] Proapoptotic [62]

– Heat shock [73] – Hyperlipidemia [44]

– – – –

Antioxidant [74] Antiapoptotic [75] Pro-angiogenic [76] Proinflammatory [77]

– Prooxidant [78] – Proinflammatory [79]

Antigen

Antibody

– # atherosclerosis [68] – " ACS [69]

– " MI in patients with ACS relative to unstable angina [70] – " acute chest pain [71]

– " atherosclerosis [80]

– " atherosclerosis [81]

HEAT-SHOCK PROTEINS IN CARDIOVASCULAR DISEASE

7

Blood-derived cells Platelets Monocyte Cytokines

HSP expression

Lymphocyte Macrophage

Proteases

Neutrophil

Inflammatory, proteolytic, and oxidative stress

ROS, MPO

Erythrocyte

Hemoglobin, iron

Hb

oxLDL

LDL,

Complement fibrinolytic system

Plasma components FIG. 1. HSP expression may be modulated by different types of stresses linked to atherogenesis [82] such as proteolytic aggression (e.g., HSP27 expression is increased in response to plasmin in human vascular smooth muscle cells, [57]), stimulation by cytokines [83], or oxidative stress. In particular, oxidized LDLs are reported to induce HSP expression [84]. Also, erythrophagocytosis was shown to induce the synthesis of different HSPs in human monocytes/macrophages [85]. Injection of lysed blood was reported to induce HSP70 expression in the brain [86], suggesting that free hemoglobin is able to trigger HSP expression. In response, HSPs may protect vascular cells against different types of aggression within the atherothrombotic plaque.

named foam cells due to their vacuolated aspect, has been detected in human fetal arteries, in particular in cases of maternal hypercholesterolemia [87]. Hypercholesterolemia is the major risk factor for the development of atheromatous disease. In particular, high circulating levels of low-density lipoproteins (LDLs) lead to their intimal deposition and the subsequent formation of foam cells due to nonregulated uptake of modified LDLs. The accumulation of foam cells produces fatty streaks observable in ‘‘en face’’ preparations of arterial samples. In humans, mutations of the LDL receptor (familial hypercholesterolemia) lead to a strong increase in plasma LDL concentration, thus favoring the development of atheromatous plaques and associated complications around the 3rd decade of life (myocardial infarction, stroke, etc.). Animal models deficient or mutated for the LDL receptor are commonly used as models of atherosclerosis (LDL-R knock-out mice, Watanabe heritable hyperlipidemic rabbits). LDLs, and in particular modified LDLs, have been reported to participate in all steps of atherogenesis. The major

8

MADRIGAL-MATUTE ET AL.

modification of LDL shown to display atherogenic effects is their oxidation. LDLs and oxidized LDLs, as well as oxidative stress in general, are known to induce HSP expression in different cell types present in the pathological arterial wall (Fig. 1), which may constitute a response to injury. Evolution of the fatty streaks toward fibroatheroma involves proliferation of SMCs within the intima that form the fibrous cap surrounding the foam cells and accumulated extracellular lipids (lipid core), characterized by a switch of the SMCs from a contractile to a secretory phenotype. HSPs could play a role in this step by interacting with the cytoskeletal proteins, such as actin, and thereby modifying SMC migration/proliferation [88]. Fibroatheromatous plaques evolve toward more complicated lesions that are very heterogeneous but often characterized by the presence of sclerotic material (calcifications) and the formation of a necrotic, lipidic, and hemocruoric core composed of cell debris, inflammatory, and blood cells (leukocytes, platelets, and red blood cells). HSPs may participate in processes associated with the evolution toward complicated plaques, such as calcification [50,89]. The presence of blood within the plaque was recently reported to be the major determinant of the clinical outcome in patients with carotid artery disease [90]. It reflects local plaque hemorrhage and is associated with increased intraplaque neovessels. Blood brings into the plaque both oxidative and proteolytic activities, which are the main driving forces of plaque vulnerability toward rupture, via fragilization of the fibrous cap and by inducing apoptosis of different vascular cells including SMCs. Many HSPs are induced in response to oxidative stress and proteolytic injury (Fig. 1); they may therefore constitute sensitive markers of these processes but also a response for restraining noxious insults potentially favoring plaque rupture and leading to clinical complications. These points will be discussed in detail in the present review.

4. HSPs/Anti-HSPs as Biomarkers of Atherothrombosis Our definition of a biomarker is a marker reflecting or integrating one or several biological activities. Such markers may be any detectable and quantifiable molecules including proteins, peptides, lipids, nucleic acids, etc. This notion is of major importance when considering HSPs as potential biomarkers of cardiovascular disease. Biomarkers are not specific of a disease but rather reflect a biological activity associated with this pathology, at one time point. We will discuss the studies reporting differences in HSP expression in patients with atherosclerosis versus healthy subjects, directly by antigenic methods such as ELISA or Western blots in plasma or tissues, or indirectly by assessment of circulating antibodies raised against HSPs.

HEAT-SHOCK PROTEINS IN CARDIOVASCULAR DISEASE

9

4.1. ANTIGENIC DETECTION 4.1.1. HSP60 Different studies have analyzed the levels of circulating HSPs. Among them, levels of HSP60 are increased in patients with carotid atherosclerosis, suggesting its potential role as a diagnostic biomarker [23]. In patients with borderline hypertension, serum HSP60 levels were associated with intima– media thickness, a surrogate marker of atherosclerosis [24]. In addition, prospective data have confirmed an association between high levels of sHSP60 and early carotid atherosclerosis [91]. Similarly, another study has undertaken a prospective analysis of the association of HSP60 with the severity of CAD, reporting that HSP60 levels were significantly correlated with both the extent index and stenoses [25]. These data have been recently confirmed in a large case–control study, suggesting that the combination of HSP60 and anti-HSP60 antibody levels may predict this risk [26]. Potential explanations for the high HSP60 levels observed in atherosclerotic patients may be responses to infection, stress, or myocardial necrosis [27–29]. In complement to the clinical observation of increased HSP antigens in patients with atherothrombosis, different authors have analyzed the presence of HSPs in atherosclerotic plaques. In initial studies, increased HSP65 expression and the presence of HSP65-specific T-cells both in experimental and human atherosclerotic lesions were reported [14,92,93]. In subsequent studies, chlamydial HSP60 was colocalized with human HSP60 in plaque macrophages in human atherosclerotic lesions [94]. 4.1.2. HSP70 An inverse relation between HSP70 and atherosclerosis has been reported by several groups. Whereas HSP70 is detectable in serum of nondiseased individuals [95], low serum HSP70 levels have been suggested to predict the development of atherosclerosis [52–54]. In hypertensive patients, increased concentrations of circulating HSP70 correlated with decreased intima/media thickness [52]. In another study by Zhu et al., high serum levels of HSP70 were found to be associated with a low risk of coronary artery disease [53]. We have reported that plasma HSP70 concentrations were decreased in patients with carotid atherosclerosis relative to control healthy subjects [54]. Interestingly, circulating levels of neutrophil activation markers (myeloperoxidase, matrix metalloprotease 9/lipocalin complexes, and elastase) were inversely correlated with those of HSP70, suggesting the proteolytic degradation of this HSP under atherothrombotic conditions. Under acute conditions, Zhang et al. recently reported that HSP70 was increased in patients with acute coronary syndrome (ACS) relative to ageand sex-matched healthy controls [55]. HSP70 levels were associated with

10

MADRIGAL-MATUTE ET AL.

increased risk and severity of ACS. Interestingly, these authors monitored HSP70 levels at the time of admission, 2, 3, and 7 days after acute myocardial infarction (AMI). They report that HSP70 plasma concentration decreased rapidly after the onset of AMI. It is likely that following ischemia, the myocardial necrotic area releases large amounts of HSP70, as described in response to heat shock where HSP70 was abundant in small blood vessels found between the ventricular cardiomyocytes [96]. Berberian et al. first reported HSP70 expression in normal human aortas and carotid atherosclerotic plaques [97]. In atherosclerotic tissue, the necrotic core and its underlying media contained significantly more HSP70 staining than did fibrotic areas [47]. Accumulation of HSP70 in VSMCs adjacent to the necrotic core was suggested to be insufficient to protect them against the noxious stimuli of the plaque. We have recently quantified HSP70 immunostaining in 60 human atherosclerotic plaques and showed an increased expression of HSP70 in the shoulder region of the plaque compared to the fibrous area, probably reflecting increased stress of this vulnerable region due to blood flow. Interestingly, when atherosclerotic plaques were classified according to the cap thickness, we observed that HSP70 expression is lower in plaques with thin caps (< 165 m), suggesting that HSP70 plays an important role in the stability of advanced human atherosclerotic plaques [41]. 4.1.3. HSP27 Plasma levels of HSP27 were shown to be decreased in atherosclerosis following a proteomic comparison between conditioned medium obtained from human carotid samples and healthy mammary endarteries [68]. At this time, HSP27 was described as an intracellular protein ubiquitously expressed by many cell types, including vascular cells. A noncandidate proteomicbased approach allowed us to discover HSP27 as a potential marker of nondiseased vascular wall. The decreased solubilization of HSP27 under atherothrombotic conditions was attributed, at least in part, to proteolytic activities such as that of plasmin present in culprit plaques and able to digest the soluble HSP27, potentially reducing its circulating levels [57]. In a prospective study including 255 female health care professionals devoid of cardiovascular disease at the time of plasma sampling, we were unable to show any association between baseline HSP27 plasma level and incidence of cardiovascular events (myocardial infarction, ischemic stroke, or cardiovascular death) during a follow-up period of up to 5.9 years [98]. These results may be explained by the apparently healthy state of the subjects at study initiation. Therefore, the results may not be applicable to other populations, such as those with advanced atherosclerosis or ACS.

HEAT-SHOCK PROTEINS IN CARDIOVASCULAR DISEASE

11

Following a global proteomic approach on homogenized carotid samples, Park et al. [99] have also identified HSP27 as a protein which is overexpressed in the nearby normal-appearing area compared with the plaque core area. These authors showed that HSP27 plasma levels were increased in 27 patients with ACS relative to patients with stable angina (SA), patients with coronary risk factors, or healthy subjects. They concluded that increased HSP27 plasma levels may reflect the presence of vulnerable plaques. However, since blood was sampled within 24 h of the onset of ACS, it cannot be ruled out that the increase in HSP27 levels is secondary to myocardial ischemia or necrosis, as previously suggested for HSP70 [69]. By immunohistochemistry, we found that both human atherosclerotic plaques and mammary arteries expressed HSP27 protein [68]. Interestingly, HSP27 expression, which was mainly present in the cap and media colocalizing with alpha-actin-positive VSMCs, was inversely correlated with markers of apoptosis [57].

4.1.4. HSP90 In a recent paper, Businaro et al. have shown increased HSP90 serum levels in patients with atherosclerosis. HSP90 was overexpressed in plaques from patients with atherosclerosis, potentially contributing to plaque instability by inducing an immune response [81]. In agreement, we have shown an increased expression of HSP90 in the vulnerable region of human atherosclerotic plaques. Moreover, atherosclerotic plaques with thin caps (< 165 m) displayed higher total HSP90 levels, suggesting that HSP90 correlates with events leading to the instability of advanced human atherosclerotic plaques [41]. As mentioned above, extensive research has been undertaken on circulating HSPs, reported to be either positively (HSP60) or negatively (HSP70) correlated with the presence and progression of atherosclerosis. HSP27 has been known for a long time for its antiapoptotic, antioxidant and thus antiatherogenic functions at a cellular level (discussed in more detail in the Section 4). However, further studies are needed to clarify the potential role of circulating HSP27 as a cardiovascular biomarker. More recently, HSP90 has also been associated with increased atherosclerosis. Only a few studies have addressed the predictive value of circulating HSPs in large patient cohorts. There is thus a need for such studies in the future. In relation to HSP expression in atherosclerotic plaques, it seems that whereas HSP70 and HSP27 are associated with features of plaque stability, HSP60 and HSP90 display the opposite pattern.

12

MADRIGAL-MATUTE ET AL.

4.2. INDIRECT DETECTION VIA ANTI-HSP ANTIBODIES Whereas HSP levels in plasma or serum may reflect transient variations in their secretion or release, detection of antibodies directed against HSPs could represent a more stable marker of a pathological state. Since HSPs are basically intracellular proteins, their presence in the extracellular compartment may trigger an immune response and lead to the production of anti-HSP antibodies. HSPs are highly conserved proteins that are also good immunogens.

4.2.1. Anti-HSP60/65 Antibodies HSP65 is one of the most highly conserved proteins: 97% homology among prokaryotes and more than 70% homology between prokaryotic and human HSP65 [100]. Heat-shock proteins can promote, as well as regulate, autoimmunity. Therefore, antimicrobial HSP65 antibodies may cross-react with self-HSP65 [101]. It is thus difficult to clearly establish which antigen was originally responsible for the production of anti-HSP60/ 65 antibodies (microbial or self-source). Several studies have suggested an association between antibodies directed against HSP60/65 (anti-HSP60/65) and atherothrombosis. In their earliest study, Xu et al. reported increased levels of serum antibodies against HSP65 in patients with carotid atherosclerosis [30]. In a subsequent study from the same group, HSP65 antibody titres were also increased in plasma of CAD patients whereas no correlation to established cardiovascular risk factors was observed. In contrast, HSP65 antibody levels were found to be significantly lower in AMI, compared to coronary heart disease (CHD) [32]. Following this study, Zhu et al. observed that anti-human HSP60 was also associated with the presence and severity of CAD [31]. In a recent study, anti-HSP60 was independently associated with CAD risk, and a combination of high anti-HSP60, hypertension, and diabetes was shown to be particularly detrimental for CAD risk [102]. The first study testing the potential prognostic value of HSP antibody levels showed that HSP65 antibody levels were predictive of 5-year mortality in patients with carotid atherosclerosis [30]. This initial observation was later confirmed in the HOPE study. Among patients with previous CV events or at high risk of such events, high serum concentration of antibodies to HSP65 was linked to a higher risk of developing new CV events during a mean follow-up of 4.5 years. This risk was even higher when combined with high levels of fibrinogen [33]. In another study, the authors observed that high IgA-class anti-HSP60 antibody levels predicted coronary risk, although the effect was modest without simultaneous occurrence of other classical risk factors [34].

HEAT-SHOCK PROTEINS IN CARDIOVASCULAR DISEASE

13

Among potential explanations for the increased levels of antibodies to HSPs observed in plasma, infections might play an important role. Mayr et al. observed that anti-HSP65 antibody titres correlated with human IgA to Chlamydia pneumoniae and with IgG to Helicobacter Pylori [35]. In subsequent studies, high levels of antibodies to human HSP60 and C. pneumoniae were observed in coronary atherosclerosis, showing that their simultaneous presence substantially increased the risk for disease development [36]. Further, Heltai et al. demonstrated associations of high levels of antihHSP60 and anti-C. pneumoniae antibodies with AMI and of the level of anti-HSP65 antibodies with SA [37]. In addition, serum levels of anti-human HSP60 IgG antibody and anti-chlamydial IgM antibody, but not IgG or IgA, were significantly higher in ACS patients than in stable ischemic heart disease patients or controls [38]. Finally, antibodies to mycobacterial HSP65 are associated with elevated levels of coronary calcification and also correlated with H. pylori infection [39]. In relation to the potential prognostic value of HSP60 antibodies commented above, it was observed that a high level of HSP60 IgA could be considered as a risk factor for coronary events, especially when it was present together with C. pneumoniae infection and inflammation [40]. 4.2.2. Anti-HSP70 Antibodies In accordance with studies suggesting that increased levels of circulating HSP70 are correlated with a low risk of coronary artery disease, a publication by Hertz et al. reports that levels of antibodies directed against HSP70 are decreased in patients with CAD (SA and unstable angina) versus control subjects [56]. In contrast, a previous study by Zhu et al. did not find any association between anti-HSP70 IgG seropositivity and the prevalence of CAD despite decreased serum HSP70 levels in these patients [53]. More recently, Zhang et al. [30] reported that lower anti-HSP70 antibody levels are independently associated with a higher risk of ACS. To date, the association between anti-HSP70 levels and coronary artery disease is still unsettled and deserves further investigation. 4.2.3. Anti-HSP27 Antibodies Antibody titres to HSP27 were reported to be elevated during the first 12 h following myocardial infarction in patients with ACS relative to patients with unstable angina [70]. These authors observed that anti-HSP27 antibody concentrations rapidly decrease during the 12–24 h period following MI. Shams et al. also reported increased anti-HSP27 titers in acute conditions, when patients where admitted to hospital with acute chest pain, as compared to patients without any history of CVD [71].

14

MADRIGAL-MATUTE ET AL.

4.2.4. Anti-HSP90 Antibodies Businaro et al. have recently shown increased HSP90 antibodies in serum from patients with atherosclerosis, implicating HSP90 as a possible autoantigen in the pathogenesis of carotid atherosclerosis [81]. 4.2.5. Limitations to the Use of HSPs and Anti-HSPs as Biomarkers of Atherothrombosis Since expression of inducible HSPs is dependent on a variety of stimuli, their levels may be modulated in different pathological states and even in physiological circumstances such as physical exercise [103,104]. For example, anti-HSP70 antibodies are increased in asthma [105], during HIV infection [106] or in patients with type II diabetes [107]. Also, increased titers of antiHSP27 antibodies have been reported in women with ovarian cancer [108]. Detection of antibodies to bacterial HSPs, such as mHSP65, is not specific of an atherothrombotic state but rather reflects the presence of bacteria that may be independent of CVD. Although the implication of bacteria in atherogenesis has been suggested, further studies are needed to establish a causal link between infection and atherosclerosis [109]. Similarly, circulating HSPs may reflect a secretion by virtually all cell types. In spite of the direct access of arterial wall cells to the blood compartment, the release (or lack of release) of HSPs from focal atherothrombotic lesions may not have sufficient impact on their plasma concentrations to explain the differences observed between patients and subjects free of CVD. Therefore, plasma concentrations of HSPs may, as is the case for C-reactive protein (CRP), reflect a general state of stress or inflammation, not directly linked to atherothrombotic plaque evolution or vulnerability. For example, the source of circulating HSP27 is still under debate since some authors could not detect it in cultured VSMCs whereas it is expressed by the medial layer in human artery samples [110]. However, incubation of human arteries devoid of atherosclerosis leads to a release of HSP27 in the conditioned medium, without trace of necrosis [68]. Macrophages can also be a source of HSP27; in vitro, human macrophages stimulated by estrogen secreted HSP27 via the exosomal pathway [111]. Since most HSPs are inducible, their expression and secretion may be rapidly modulated by an acute event. The above-mentioned work of Zhang et al. is a good example of the transient expression of HSPs [55]. These authors reported that plasma levels of HSP70 may predict risk of ACS which appears contradictory with all studies showing an inverse relation between high circulating levels of HSP70 and increased risk of atherothrombosis. Interpretation of the results should therefore take into account the time of blood sampling. It is likely that the expression of most HSPs,

HEAT-SHOCK PROTEINS IN CARDIOVASCULAR DISEASE

15

including HSP70 and HSP27, is stimulated under acute conditions such as myocardial infarction. HSP27 is a protein particularly easily detectable and identifiable by proteomic approaches. This protein is reported to be differentially expressed in many pathological situations. In fact, differential proteomics allowed identification of HSP27 as a potential marker of neuroblastoma [112], lymph node metastasis [113], chemotherapy response in patients with esophageal adenocarcinoma [114]. More than 120 publications are retrieved by a PubMed search when proteomics is combined with HSP27. Many pathological situations may module HSP expression and secretion. Caution must therefore be exercised before using HSPs as diagnostic or prognostic markers of any given disease.

5. Molecular Mechanisms: Bystanders or Actors? In addition to their well-described chaperoning and antiapoptotic functions, HSPs play different roles depending upon their cellular location. The hypothesis of the Heat-Shock Paradox [1] is based on the idea that extracellular and intracellular HSPs exert different functions. While intracellular HSPs have been reported to downregulate inflammation [115–119], extracellular HSPs have been suggested, for the most part, to be proinflammatory by triggering an immune response [120,121]. This hypothesis may not apply to all HSPs as in the case of HSP27; its atheroprotective role has been shown in both intracellular and extracellular compartments [111]. In physiological conditions, HSPs play their main role of molecular chaperones promoting the correct folding of proteins. In pathological conditions, increased HSP levels may represent a response to modulate inflammation. 5.1. INTRACELLULAR EFFECTS Heat-shock response (HSR) is triggered by a variety of stress conditions that interfere with correct protein folding, leading to accumulation of misfolded or aggregated proteins. HSR is mediated by HSF1, a transcription factor which binds to heat-shock elements (HSE), present in the promoter region of a wide range of target genes, including HSPs [122]. Under normal conditions, HSP70 [80] and HSP90 [123] remain bound to monomeric HSF1 and some other cochaperones (i.e., HSP70–HSP90 Organizing Protein, Hop [124]; HSP70-Interacting Protein, Hip [125]; members of the HSP40/DnaJ HSPs family [126] or p23 [127]) in the cytoplasmic compartment. Under stress conditions, HSF1 is released, translocates to the nucleus, trimerizes and activates the synthesis of HSPs [128–130]. In fact, a negative feedback

16

MADRIGAL-MATUTE ET AL.

mechanism modulates the stress response, since augmented levels of HSPs are able to sequester the free cytosolic HSF1 and therefore impede its translocation to the nucleus and the subsequent HSP synthesis. The complex interactions between the chaperones, cochaperones, and their client proteins decide the fate of a misfolded protein: either a new folding attempt or ubiquitination and subsequent degradation toward the proteasome pathway. However, in extreme oxidative conditions, ubiquitination can be bypassed [131]. Oxidative stress, inflammation, and apoptosis, among other processes, are involved in the initiation, development, and rupture of atherosclerotic plaques. Implication of HSPs in such events is gaining attention, and a number of studies are coming to light. 5.1.1. HSP60 Contradictory findings about the relationship of HSP60 with oxidative stress have been reported, although papers on this subject are scarce. Lee et al. raised this issue using normal human diploid fibroblasts (HDF) and found that sensitiveness to oxidative stress observed in young HDF cells was dependent upon HSP60 translocation from the mitochondria to the cytosol and subsequent massive activation of stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) occurred [132]. In contrast, the use of a specific siRNA for HSP60 augmented resistance to oxidative stress [133]. As endothelial cells are the primary barrier in atherogenesis, HSP60 levels in endothelial cells were analyzed under stress conditions. HSP60 was expressed in the cytoplasm and on the surface of endothelial cells stressed by high temperature or TNF-a, and these cells were susceptible to complement-dependent lysis by HSP60-specific antibody [134]. Due to its association with infection, several studies analyzed the potential contribution of HSP60 in relation to bacteria/viruses in atherogenesis. Among them, C. pneumoniae was able to induce VSMC proliferation via HSP60 [20]. Also, during cytomegalovirus infection, antibodies against the virus can be generated, potentially cross-reacting with human HSP60 and leading to apoptosis of nonstressed endothelial cells [135]. Taking all these data into account, although the exact intracellular function of HSP60 is not clear, it may be considered as a potential mediator of oxidative stress and inflammation. 5.1.2. HSP70 5.1.2.1. In vitro. HSP70 has been suggested to exert antioxidative effects in cells exposed to H2O2 at the mitochondrial level [136], protecting cells by preserving levels of glutathione (GSH) [137]. Since endothelial damage after exposure to oxygen free radicals is considered to be important in the first steps of atherogenesis, HSP70 upregulation could be protective in these early stages of atherosclerosis. H2O2-induced oxidative stress in HUVECs was

HEAT-SHOCK PROTEINS IN CARDIOVASCULAR DISEASE

17

significantly decreased after mild heat shock, which increased HSP70 mRNA and protein levels, providing delayed protection (up to 20 h) after preconditioning [48]. The protective role of HSP70 against inflammation has been previously reviewed [138]. Indeed, HSP70 involvement in the protection against inflammation in endothelial cells has been suggested [139], and we recently showed that HSP70 upregulation decreased inflammatory markers in macrophages and in VSMCs [41]. In addition, it was shown that an inducer of HSP70 (YC1: 3-(50 -hydroxymethyl-20 -furyl)-1-benzyl-indazol) could effectively prevent VSMC proliferation induced by oxLDL [46]. The relation between HSP70 and apoptosis has been described in detail. APAF1 (apoptosis protease activating factor 1) binds to HSP70 and HSP90, thereby inhibiting the apoptotic signaling pathway [140–143]. HSP70 also inhibits AIF (apoptosis inducing factor) release from mitochondria [144,145]. In relation with CVD, inhibition of HSP70 expression has been shown to stimulate apoptosis and intimal hyperplasia in vein segments ex vivo by upregulating manganese superoxide dismutase (Mn-SOD) activity, an enzyme that protects mitochondria from injury in myocardial ischemia–reperfusion [146]. In vitro experiments performed by Wang et al. demonstrated that increased levels of HSP72, induced either by heat shock or by a nonheat-shock pretreatment, protected human endothelial cells against neutrophil-induced necrosis [147]. A similar study was undertaken in primary cultures of porcine endothelial cells, showing that protection against lipopolysaccharide arsenite-induced apoptosis was not only due to HSP70 upregulation but also to augmented levels of the inhibitor B alpha and decreased NF-B binding activity [148]. Experiments performed in cultured endothelial cells with transient overexpression of HSP70 suggested that HSP70 could be the main factor responsible for the HSR-mediated protection against LPS-induced apoptosis [149]. Similarly, Bernardini et al. showed that the synergistic action of HSP70, HSP32, and VEGF mediated protection against LPS-induced apoptosis in aortic endothelial cells [150]. In conclusion, in vitro studies highlight antioxidant, anti-inflammatory, and antiapoptotic properties of intracellular HSP70. 5.1.2.2. In vivo. HSP70 has been already shown to exert anti-inflammatory functions [151], by inhibiting leukocyte adhesion and recruitment [152] or by decreasing NF-B activation and the number of activated macrophages in a model of brain inflammation of mice overexpressing HSP70 [119]. Other approaches, such as the induction of HSPs by low dose alcohol consumption, have been proposed. The authors suggested that the cardioprotective effect showed in rats was mediated by increased HSP levels, namely HSP70 and HSP32 [153]. We have shown that treatment of ApoE/ mice with 17-AAG/17-DMAG upregulated HSP70 expression in the aortic arch, which was associated with

18

MADRIGAL-MATUTE ET AL.

attenuated inflammation and a significant reduction in plaque size and lipid content [41]. Recently, in a mouse model of ischemia and oxidative aggression induced by severe heat stress (42 C) for 1 h, HSP72-overexpressing mice displayed higher levels of antioxidant enzymes (glutathione peroxidase and glutathione reductase) [154]. A similar approach was used in a rat model of heat-stroke circulatory shock, in which rats were heat-shocked for 1 h at 43 C. HSP72 expression was assessed 16 and 96 h following this 1 hour preconditioning and showed that HSP72 expression in the striatum peaked at 16 h, paralleled by reduced oxidative stress markers, whereas at 96 h, HSP72 expression was similar to that of basal levels [155]. In vitro and in vivo studies in the field of CVD confirm the well-described cytoprotective role of intracellular HSP70. In atherothrombosis, HSP70 could act as an intracellular shield in various cells, inhibiting different processes involved in the formation, development, and rupture of the atheromatous plaque. 5.1.3. HSP27 5.1.3.1. In vitro. Reactive Oxygen Species (ROS) represent the main trigger of protein misfolding, causing an increase in HSP expression and other protective responses (i.e., antioxidant response) [65]. Perturbations in cytoskeletal structure are one of the major consequences of extensive oxidative stress [156]. Small HSPs (i.e., HSP27) as well as other HSPs, such as HSP90 or the HSP70 families, protect intermediate filaments and microfilaments, thus preventing damage of the centrosome [6,157]. Aggregated and native LDL are both able to induce HSP27 dephosphorylation, leading to its subcellular reorganization to the tip of actin stress fibers and focal adhesion structures [110]. HSP27 was shown long ago to be involved in F-actin assembly [158] and expressed by normal medial SMCs [159]. A possible role of HSP27 in the protection against chronic inflammatory response has been suggested, due to the decreased levels of HSP27 in complicated atherosclerotic plaques [68] or unstable plaques [160]. Using two different VSMC lines, Chen et al. found that HSF-1 silencing by small interfering RNA (siRNA) decreased HSP27 levels. Moreover, the inflammatory response to angiotensin-II (Ang-II) was exacerbated in HSF-1 siRNAtransfected cells, suggesting a role for HSF-1 and HSP27 in the modulation of the inflammatory response [161]. Accordingly, Voegeli et al. later showed in VSMCs that siRNA-targeting HSP27 increased the phosphorylation of the p65 subunit of NF-B induced by Ang-II [66]. In endothelial cells, inhibition of HSP27 phosphorylation via interference with VEGF-induced p38-MAPK signaling led to decreased actin polymerization and cell migration, indicating a potential role of HSP27 and its phosphorylation state in angiogenesis or neovascularization [162]. Recently, contrasting with this

HEAT-SHOCK PROTEINS IN CARDIOVASCULAR DISEASE

19

anti-inflammatory role, it has been reported that HSP27 may participate in switching transient high activation of NF-B into a chronic sustained activation in endothelial cells [163]. Augmented levels of HSP27 are also associated with higher levels of glutathione, which protect the cell against oxidative stress [65]. The wellknown cardioprotective effect of resveratrol (an antioxidant molecule) was further studied by Wang et al. who found that inhibition of human aortic SMC proliferation by resveratrol was accompanied by a significant increase in HSP27 levels [164]. Another widely investigated intracellular effect of HSP27 is its antiapoptotic properties. HSP27 has been shown to inhibit the release of mitochondrial cytochrome c [165,166] and to inactivate cytochrome c by direct binding [167,168]. HSP27 has also been shown to enhance resistance to apoptosis in many other tissues [169–171]. VSMC disappearance is involved in the weakening of the fibrous cap [172], and this loss may come from disruption of extracellular survival signals by proteases, which degrade extracellular matrix components [173,174]. Anoikis, an apoptotic process subsequent to detachment, may contribute to plaque instability in atherosclerosis originating from the loss of extracellular matrix [174]. We showed that siRNA-mediated silencing of HSP27 in VSMCs treated with plasmin led to cell detachment accompanied by apoptotic features [57]. By modulating VSMC apoptosis, HSP27 could favor plaque stability. 5.1.3.2. In vivo. In vivo studies in a model of vascular remodeling induced by surgical injury to the rat carotid artery showed that when carotid levels of HSP27 peaked at 14 days, activation of NF-B started to decrease, suggesting a possible role of HSP27 in modulating inflammation [175]. Using a mouse model overexpressing HSP27 cross-bred with ApoE/ mice fed with a high fat diet, Rayner et al. [111] have reported a reduced progression of atheromatous lesions associated with increased HSP27 in serum, particularly in female mice. These authors attribute this atheroprotective effect to a possible competition of HSP27 for the uptake of atherogenic lipids (i.e., modified LDL) via the Scavenger Receptor A, demonstrated in vitro in macrophages. In addition, they reported that macrophages overexpressing HSP27 displayed reduced cell adhesion and migration, properties that may participate in their atheroprotective role. Recently, the same group showed that extracellular release of HSP27 involved exosomes and confirmed that atheroprotection provided by HSP27 was estrogen-dependent [176]. Thus, the intracellular effects of HSP27 have been extensively studied and include cytoskeletal stablization and protection against oxidative stress, inflammation and apoptosis, supporting its beneficial role in atherosclerosis and CV-related diseases.

20

MADRIGAL-MATUTE ET AL.

5.1.4. HSP90 5.1.4.1. In vitro. Two main functions of HSP90 are related to oxidative stress; its association with nitric oxide synthases (NOS) [177] and its protection of proteasomes from oxidative insults [178]. NOS synthesize nitric oxide, which has been shown to play a protective role against oxidative stress. In macrophages and VSMCs [179–181], NO inhibits LDL oxidation, a welldescribed proatherogenic factor involved in endothelial dysfunction and foam cell formation [182]. HSP90 enhances eNOS activity [177] and upregulates NO synthesis, thereby inhibiting oxidation of LDL. Further, stimulation of bovine aortic endothelial cells (BAECs) with native and minimally oxidized LDL impaired the calcium-dependent association HSP90/eNOS [74]. This vascular protective feature has been extensively described in vitro, such as, for example, in porcine coronary artery endothelial cells [183]. In BAECs, stimulation with vascular endothelial growth factor (VEGF) promoted the association of Akt and eNOS with HSP90 which represents a scaffold favoring eNOS phosphorylation and subsequent activation by Akt [184]. HSP90 inhibitors (herbamycin or geldanamycin) were also shown to decrease estradiol-dependent eNOS activation in HUVECs [185]. In addition, inhibition of HSP90 with 17-AAG was associated with decreased endothelial migration and angiogenesis. The role of HSP90 in angiogenesis was suggested to be due to its interaction with Akt and eNOS [76]. In addition, HSP90 has been shown to protect the cells against oxidation. Aging and oxidative stress increase the levels of oxidized proteins inside the cells; the proteasome is then in charge of the clearance of damaged proteins that cannot be refolded. HSP90 may act as a shield for the 20S proteasome or multicatalytic proteinase [178,186,187], but to our knowledge there is no published data related to HSP90 and the proteasome in the field of vascular research. However, HSP90 was shown to mediate the phosphorylation of ERK1/2, promoting its nuclear translocation, and thus increasing rat VSMC proliferation in response to oxidative stress [188]. Whether VSMC proliferation is good or bad in atherogenesis is still a matter of debate: whereas it can be considered as a healing process in response to various noxious stimuli favoring plaque stability, it can also participate in arterial wall thickening and stenosis. HSP90 could also modulate monocyte proinflammatory response. It has been recently reported that mactinin, an inducer of monocyte maturation and present in vivo at sites of monocytic activation, associates with HSP90. Mactinin was found to promote production of a number of proinflammatory and chemotactic cytokines for monocytes via the inhibition of HSP90 activity [77]. In contrast, HSP90 has been shown to activate the formation of

HEAT-SHOCK PROTEINS IN CARDIOVASCULAR DISEASE

21

bradykinin on endothelial cells [72] via activation of the prekallikrein– kininogen complex [189]. Bradykinin is a member of the kinin family which is a family of proinflammatory peptides involved in CVD such as atherosclerosis [190]. HSP90 may promote macrophage survival upon stimulation with oxLDL by binding to eukaryotic elongation factor-2 kinase (eEF2 kinase). Indeed, dissociation of this complex by the HSP90 inhibitor, geldanamycin, decreased the viability of macrophages [191]. Antiapoptotic effects of HSP90 were also reported by Lin et al. who observed that increased formation of HSP90/eNOS complexes by adiponectin protected HUVECs from Ang-IIinduced apoptosis [75]. The same group found that apoptosis of HUVECs induced by high glucose, a feature of type II diabetes which is associated with a poor cardiovascular outcome, could be prevented by increased HSP90/ NOS complex formation and recruitment of activated Akt [192]. Similar data regarding the antiapoptotic effects of HSP90 in association with Akt/eNOS and other client proteins in endothelial cells [193–196] and in other cell types involved in the atherosclerotic lesion have been described [197]. 5.1.4.2. In vivo. Confirmation in vivo that HSP90 is a modulator of eNOS activity was shown in a model of newborn piglet pulmonary circulation [198] and in rats subjected to exercise. In the physically trained group, eNOS activity was significantly higher, as was the eNOS/HSP90 association, which could explain in part the dynamic changes in redox status following chronic exercise [199]. The largest amount of literature related to HSP90 and inflammation in CVD has arisen from the use of HSP90 inhibitors because, as mentioned before, using the HSP90 inhibitors derived from geldanamycin led to the upregulation of HSP70 whose anti-inflammatory functions have been widely demonstrated. Bucci et al. described a not very well-documented role of NO in acute inflammation. In a model of inflammatory response to carrageenan in eNOS-deficient mice, the authors suggested that eNOS and its interaction with HSP90 are key factors in the modulation of the vascular inflammatory response [200]. In conclusion, HSP90 is a novel player in atherosclerosis, displaying antiapoptotic functions and a potential protective role against oxidative stress via the stimulation of eNOS activity. Its role in promoting inflammation needs to be clarified. 5.2. EXTRACELLULAR EFFECTS Based on the idea of the heat-shock paradox [1], extracellular HSPs are viewed as a trigger for the immune response due to their potent immunogenic role and their potential function as intercellular signals. Extracellular HSPs

22

MADRIGAL-MATUTE ET AL.

and their involvement in vascular diseases are gaining attention due to their importance in processes, such as inflammation, related to chronic autoimmune disease. HSPs exit the cells to the extracellular milieu by two different mechanisms; a passive release, which usually follows prior cell damage, and active release, which involves exosomes [176,201,202] or lysosomes-like vesicles [111]. In addition, infections may represent a nonendogenous source of HSPs in the extracellular compartment as mentioned above [35–37,39,40]. 5.2.1. HSP60 5.2.1.1. In vitro. To delineate the potential mechanisms whereby HSP60 is involved in atherogenesis, in vitro experiments were performed. Human serum anti-HSP65 antibodies act as autoantibodies reacting with HSP60 on stressed endothelial cells and are able to mediate endothelial cytotoxicity [203]. In addition to endothelial cells, macrophages expressing HSP60 can be lysed by autoantibodies against HSP65/60. Since macrophage death contributes to enlargement of the necrotic core, this effect can contribute to atherosclerotic plaque instability [204]. Further studies analyzed the potential effect of HSP60 on the mechanisms associated with atherothrombosis. Chlamydial HSP60 induced expression in vascular cells of matrix metalloproteases [205], key proteases promoting plaque rupture. In agreement, HSP60 was able to induce proinflammatory cytokines [21], possibly via the CD14 receptor [206], although it could be dependent on the cell type since in adult rat cardiomyocytes, extracellular HSP60 enhanced apoptosis via TLR-4 and completely independently of TLR-2 and CD14 [16]. 5.2.1.2. In vivo. To address the role of HSP60/HSP65 in atherosclerosis, in vivo studies were performed. In the earliest study, normocholesterolemic rabbits were immunized with different antigens with/without adjuvant. Atherosclerotic lesions in the intima of the aortic arch were found to have developed only in those animals immunized with antigenic preparations containing HSP65, either as part of the whole mycobacteria or purified recombinant HSP65, in spite of their normal serum cholesterol levels. Further, combined immunization with HSP65-containing material and a cholesterol-rich diet promoted the development of significantly more severe atherosclerosis [207]. C. pneumoniae infection combined with a cholesterol-rich diet induced the development of autoantibodies against mHSP60 and this was associated with the enhanced development of lipid lesions [22]. In agreement, anti-HSP60 autoantibodies isolated from blood of patients with CHD and injected into the tail vein of apolipoprotein E-deficient mice induced the formation of atherosclerotic lesions. Further, administration of a specific mouse

HEAT-SHOCK PROTEINS IN CARDIOVASCULAR DISEASE

23

monoclonal antibody to HSP60 effectively induced atherogenesis in apolipoprotein E-deficient mice [208]. Interestingly, high levels of HSP60 autoantibodies are considered to be an important prothrombotic factor that may impact cardiovascular disease [209]. Overall, extracellular HSP60 has been shown to exert a clear proatherogenic function. It has a close relationship with infection, probably due to the high homology between human and microbial HSP60/65, triggering the immune response and thus favoring a chronic state of inflammation. 5.2.2. HSP70 5.2.2.1. In vitro. Several studies have shown that HSPs, including HSP70 [210], are present in the extracellular milieu and that HSP70 can be exchanged between cells [211]. Johnson et al. reported that exogenous HSP70 was not internalized but remained associated with the cell surface of serumdeprived arterial SMCs, protecting the cells against noxious stimuli [212]. Also, HSP70 supplementation was shown to limit cytotoxic effects induced by serum starvation in aortic SMCs [47]. Oxidized LDLs were shown to induce HSP70 secretion by macrophages, which in turn stimulated IL-1 beta and IL-12 expression by naı¨ve macrophages. HSP70 could therefore have a paracrine effect. OxLDL also stimulated HSP70 production by SMCs and nonconfluent proliferating endothelial cells [45,213]. In human monocytes, the dual character of HSP70 was shown to be due to its extracellular proinflammatory function via activation of NF-B signaling and inducing proinflammatory cytokines TNF-a, IL-1b, and IL-6 [49]. Extracellular HSP70 was shown to induce proliferation of endothelial cells and tube formation in vitro and also promoted calcification of VSMCs. HSP70 may bind and activate Matrix Gla Protein (MGP), an inhibitor of Bone Morphogenetic Protein-4 (BMP-4). The authors hypothesized that HSP70 could be a key factor in unbalancing the positive feedback between BMP inhibitors and BMP signaling [50]. 5.2.2.2. In vivo. In a rat model of balloon-injury, immunization with HSP70 accelerated the intimal thickening. Increased release of HSP70 within the damaged artery may produce an anti-HSP70 response and contribute to a proinflammatory state, thus suggesting that HSP70 may be a potent immunogen and explaining the accelerated neointimal formation. Also, T-cells could migrate to HSP70-rich areas and promote SMC migration and leukocyte chemoattraction via cytokine production [51]. HSP70 release into the extracellular millieu results from various stress conditions. Extracellular HSP70 seems to trigger an immune response leading to increased levels of inflammation, proliferation, and calcification. However, some studies have provided information about the antiapoptotic

24

MADRIGAL-MATUTE ET AL.

role of HSP70. Therefore, further studies addressing the extracellular roles of HSP70 are neccesary to better understand its participation in atherothrombotic processes.

5.2.3. HSP27 Extracellular HSP27 has been suggested to play an anti-inflammatory role in atherosclerosis [111]. For example, HSP27 has been shown to induce IL-10 production by human monocytes and is thus proposed to represent an antiinflammatory stimulus [61]. Exogenous addition of recombinant HSP27 was able to reduce spontaneous apoptosis of human neutrophils isolated from peripheral blood, without any modification of cytokine secretion (TNF-a, IL-10, IL-12) by these cells [67]. In contrast, HSP70 was reported to accelerate neutrophil apoptosis, but also reduced oxidative stress and stimulated anti-inflammatory cytokine production [62]. Rayner et al. suggested the development of therapies based on supplementation by exogenous HSP27 which could interact with SR-A, leading to reduced cholesterol uptake into the vessel. They conclude suggesting that ‘‘Studies testing these innovative formulations of recombinant HSP27 are underway both pre- and postinduction of atherosclerosis.’’ [111].

5.2.4. HSP90 A possible role for HSP90 in modulating the extracellular activation of ERK1/2 in response to oxidative stress was proposed by Liao et al. in rat VSMCs [78]. Extracellular HSP90 has been recently implicated in the induction of the proatherogenic cytokine IL-8 via TLR-4 in human aortic SMCs, in addition to upregulation of IL-6, activation of ERK and p38 MAPK [79]. Also, the proinflammatory activation of the kinin-forming cascade by HSP90 in HUVECs may be extracellular in pathologic circumstances in which HSP90 is highly expressed or secreted [72]. Hence, extracellular HSP90, whose role in CVD has not been fully described, appears to be proatherogenic. It is important to note that an intense debate exists concerning whether experimental conditions have been carefully followed using recombinant HSPs as an in vitro model for extracellular HSPs [214]. LPS contamination, other PAMPs (Pathogen-associated molecular patterns) or molecules bound to and/or chaperoned by HSPs might be responsible for some of their immunogenic responses. Thus, caution should be exercised when analyzing data coming from the use of recombinant HSPs.

HEAT-SHOCK PROTEINS IN CARDIOVASCULAR DISEASE

25

6. HSP as Therapeutic Targets in CVD/Atherothrombosis Since several HSPs are considered to be protective in various stress conditions, modulation of their expression has been considered as a potential therapeutic strategy in cardiovascular disease. Other potentially deleterious HSPs have been the target of immunization. It was not until the late 1980s that HSPs were examined as potential restorative molecules in cardiovascular diseases [215–217]. 6.1. HSP INDUCTION 6.1.1. Thermal Preconditioning Thermal preconditioning was used in a rat model of atherosclerosis in which induction of HSPs (including HSP72 in the media) reduced not only the neointimal thickening but also the inflammatory infiltration (MCP1) and oxidative stress (p22-phox) [218]. Moreover, it has been found that moderate heating inhibited in-stent restenosis and neointimal hyperplasia in an atherosclerotic model in rabbits, and this beneficial effect has been associated with HSP70 overexpression [219]. These studies showed the importance of global HSP upregulation as a potential therapeutic strategy in CVD. Indeed, thermal therapy has been shown to improve vascular endothelial function in CVD patients [220,221]. This approach has the advantages of simplicity and feasibility. However, this strategy could potentially enhance both pro- and antiatherosclerogenic HSPs, as well as other beneficial or harmful mechanisms, which should be evaluated in detail. In any case, thermal therapy may only produce acute overexpression of certain HSPs, and its impact on a chronic disease such as atherosclerosis may thus be rather limited. 6.1.2. Gene Therapy/Recombinant Proteins New approaches to overexpress HSPs such as gene therapy were carried out in mice by Rayner et al. [111]. Interestingly, mice overexpressing HSP27 (ApoE/ HSP27o/e) showed significantly decreased lesion size relative to ApoE/ mice with normal levels of HSP27. It should be noted that female littermates displayed smaller atherosclerotic lesions than males, accompanied with a 10-fold higher HSP27 concentration in serum. The release of HSP27 was suggested to be mediated by acetylated LDL (acLDL) and estrogens, which could explain the differences found between female and male littermates. This was accompanied by a marked reduction in the secretion of the proinflammatory cytokine IL-1b and an increase in the extracellular levels of the anti-inflammatory cytokine IL-10. Moreover, HSP27 acts competitively by binding to scavenger receptor A, inhibiting thereby the

26

MADRIGAL-MATUTE ET AL.

engulfment of acLDL by macrophages, a step required to acquire the foam cell phenotype. In a model of rat heart transplantation, HSP70 gene overexpression caused an improvement in ventricular and endothelial function [222] and in cardioprotection against ischemia–reperfusion injury [223]. Recombinant HSPs have also been used as therapeutic compounds in a model of mice exposed to cigarette smoke [224]. Matsumoto et al. injected HSP70 intravenously into mice previously exposed to cigarette smoke, known to induce intimal thickening after arterial wall damage [225,226]. HSP70-injected mice showed a decreased intimal thickening compared to controls (saline-injected mice); the authors hypothesized that prevention of intimal thickening could be mediated by the inhibition of ERK activation. Overall, these data highlight the beneficial effects of specific upregulation of atheroprotective HSPs limiting atherosclerotic lesion development and intimal thickening associated with endothelial protection. However, suppression of proatherogenic HSP by other approaches, such as siRNAs, could also be used. In any case, to translate this approach into a clinical scenario, several parameters should be evaluated such as the safety of gene therapy, and the bio-distribution and stability of recombinant proteins or siRNAs. 6.1.3. Pharmacological Compounds These promising results obtained by thermal preconditioning and gene therapy have led to the development of pharmacological compounds affecting HSP expression for treatment of different diseases, among them atherothrombosis, because of the hazards of submitting patients to a heat shock and the difficulties of using approaches such as gene therapy in humans. In 2003, Connolly et al. found that stimulation by Herbamycin A resulting in the production of HSP27, but not of HSP70, was responsible for decreasing intimal hyperplasia in a rat carotid ballon injury model [227]. Another pharmacological compound called YC-1, an inducer of HSP70 [46], inhibited neointima formation in a model of balloon-injured rat carotid artery [228], thus suggesting a possible therapeutic use in treatment of vascular diseases. In an ApoE/ mouse model fed a high cholesterol diet, HSP70 upregulation by using low doses of HSP90 inhibitors (17-AAG/17-DMAG) decreased inflammatory markers and also reduced aortic atherosclerotic plaque size as well as its lipid content [41]. This approach using HSP90 inhibitors has been largely used in other fields such as cancer, where it is now entering clinical trials [229–233]. Finally, statins, the most widely administered pharmacological compounds used in the treatment of CVD around the world, have shown among their numerous pleiotropic effects, the ability to increase the expression of HSPs, such as HSP90, HSP70, HSP32 (HO-1), and to activate the HSP70 promoter via the HSE, thus activating heat-shock gene transcription [234].

HEAT-SHOCK PROTEINS IN CARDIOVASCULAR DISEASE

27

These latest positive data for the treatment of atherosclerosis in animal models raise the question of their use in the treatment of other CVD [235]. Thus, specific upregulation of atheroprotective HSP by pharmacological compounds could be a promising approach for the treatment of atherothrombosis. However, one important issue that should be considered is the dosage used since some of these compounds have proapoptotic actions that could have deleterious effects in terms of plaque stability. Data emanating from clinical trials using these pharmacological compounds should be examined in detail to highlight the pros and cons of their use in humans. For example, the dosage and toxicity of 17-AAG gained from phase I clinical trials in cancer patients should facilitate the evaluation of HSP90 inhibitors in non-neoplasic disorders, such as cardiovascular diseases.

6.2. IMMUNE THERAPY As stated earlier in this review, extracellular HSPs are likely to influence atherosclerosis by triggering an immune response associated with a proinflammatory state. HSP60, due to its homology with bacterial HSP65, has given rise to a number of studies in which the immune response initiated by HSP60/ HSP65 was investigated. HSP60 is now considered to be a major autoantigen in atherosclerosis [236,237]. Several approaches based on HSP60/65 immunization have been attempted in experimental models of atherosclerosis. In 2002, Harats et al. [238] tested the effect of inducing mucosal tolerance to HSP60 in an atherosclerosis model accelerated by Mycobacterium tuberculosis. LDL receptor-deficient mice (LDL-R/) were given HSP65 orally, and two different models of accelerated atherosclerosis were tested, i.e. a high fat diet or immunization with heat killed M. tuberculosis. In both proatherosclerotic scenarios, oral administration of HSP65 limited plaque formation. A possible explanation could be a cellular response to HSP65 leading to increased Th2 cytokine IL-4 in HSP65 immunized mice, which was previously described to possess a protective role in atherosclerosis [239]. A very similar paper by Maron et al. reported a decrease in atherosclerotic plaque formation in the aortic arch of LDL-R/ mice having a received nasal mucosal administration of HSP65. They hypothesized that this could be related to higher levels of IL-10 and to a greater Th2 type humoral (IgG1) response in animals which received nasal administration [240]. A third study along the same line showed that oral tolerance to a small immunogenic peptide of HSP60 or to that of full-length HSP60 both reduced the plaque size by 80%. They proposed that an increase in the number of CD4þ CD25þ Foxp3þ Tregs cells could participate in the augmented production of TGF-b and IL-10 and finally contribute to decrease inflammation in the atherosclerotic area [241]. The specificity of this response is

28

MADRIGAL-MATUTE ET AL.

shown by the fact that oral administration of a highly conserved sequence of HSP70 could not reduce atherosclerosis. In 2009 Xiong et al. showed, in wild-type rabbits fed with a high cholesterol diet, that nasal immunization with HSP65 could attenuate atherosclerosis and reduce lipid levels [242]. Similar attempts have been made in the field of other chronic inflammatory diseases such as rheumatoid arthritis [243]. Immunization against proatherogenic HSPs could open new therapeutic avenues in cardiovascular disease although similar concerns to those commented above for gene therapy should be taken into account. The extracellular roles of the different HSPs should be further studied in order to conceive new strategies aiming at modulating HSP circulating levels (supplementation or increased clearance depending on their beneficial or deleterious role in atherogenesis). 7. Conclusions HSP expression is modulated by different stimuli involved in all steps of atherogenesis including oxidative stress, apoptosis, proteolytic aggression, or inflammation. This could be reflected by changes in HSP protein levels in the extracellular compartment, potentially impacting their plasma levels. Also, antibodies to HSPs may be used to monitor the response to different types of stress able to induce changes in HSP levels. In the field of cardiovascular disease, although several HSPs have been suggested to be markers of the pathology, caution must be exercised since their expression may be transient, in response to an acute event, such as myocardial infarction for example, or reflecting a chronic state of inflammation or oxidative stress rather than a specific risk of future cardiovascular event. The biological roles of intracellular HSPs in atherogenesis are potentially very important since most of them protect the cells of the vasculature against various noxious stimuli. The emerging role of extracellular HSPs appears to be linked to CVD. As a consequence, therapeutic efforts for treating CVD such as atherosclerosis should take into account modulations in the recognition, binding, and internalization of HSPs. HSPs could then be considered as potential therapeutic targets to reinforce vascular defenses and delay or avoid clinical complications associated with atherothrombosis. ACKNOWLEDGMENTS The authors’ work have been supported by the Leducq Foundation, the Spanish Ministerio de Ciencia y Tecnologı´a (SAF 2010-21852), CAM (S2006/GEN-0247), Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III, Redes RECAVA (RD06/0014/0035; RD06/0014/0008), and European Network (HEALTH F2-2008-200647) and EUS2008-03565. The authors would like to thank Dr. Mary Osborne-Pellegrin for editing this chapter.

HEAT-SHOCK PROTEINS IN CARDIOVASCULAR DISEASE

29

REFERENCES [1] Y. Chen, T.S. Voegeli, P.P. Liu, E.G. Noble, R.W. Currie, Heat shock paradox and a new role of heat shock proteins and their receptors as anti-inflammation targets, Inflamm. Allergy Drug Targets 6 (2007) 91–100. [2] F. Ritossa, Discovery of the heat shock response, Cell Stress Chaperones 1 (1996) 97–98. [3] A. Tissieres, H.K. Mitchell, U.M. Tracy, Protein synthesis in salivary glands of Drosophila melanogaster: relation to chromosome puffs, J. Mol. Biol. 84 (1974) 389–398. [4] J.C. Ranford, B. Henderson, Chaperonins in disease: mechanisms, models, and treatments, Mol. Pathol. 55 (2002) 209–213. [5] A. Parcellier, S. Gurbuxani, E. Schmitt, E. Solary, C. Garrido, Heat shock proteins, cellular chaperones that modulate mitochondrial cell death pathways, Biochem. Biophys. Res. Commun. 304 (2003) 505–512. [6] N. Mounier, A.P. Arrigo, Actin cytoskeleton and small heat shock proteins: how do they interact? Cell Stress Chaperones 7 (2002) 167–176. [7] M. Ghayour-Mobarhan, A.A. Rahsepar, S. Tavallaie, S. Rahsepar, G.A. Ferns, The potential role of heat shock proteins in cardiovascular disease: evidence from in vitro and in vivo studies, Adv. Clin. Chem. 48 (2009) 27–72. [8] D.S. Latchman, Heat shock proteins and cardiac protection, Cardiovasc. Res. 51 (2001) 637–646. [9] D.B. DeFranco, L. Ho, E. Falke, C.W. Callaway, Small molecule activators of the heat shock response and neuroprotection from stroke, Curr. Atheroscler. Rep. 6 (2004) 295–300. [10] H.H. Kampinga, J. Hageman, M.J. Vos, H. Kubota, R.M. Tanguay, E.A. Bruford, et al., Guidelines for the nomenclature of the human heat shock proteins, Cell Stress Chaperones 14 (2009) 105–111. [11] X. Lu, V. Kakkar, The role of heat shock protein (HSP) in atherosclerosis: pathophysiology and clinical opportunities, Curr. Med. Chem. 17 (2010) 957–973. [12] A. Amberger, C. Maczek, G. Jurgens, D. Michaelis, G. Schett, K. Trieb, et al., Co-expression of ICAM-1, VCAM-1, ELAM-1 and Hsp60 in human arterial and venous endothelial cells in response to cytokines and oxidized low-density lipoproteins, Cell Stress Chaperones 2 (1997) 94–103. [13] Z.X. Shan, Q.X. Lin, C.Y. Deng, J.N. Zhu, L.P. Mai, J.L. Liu, et al., miR-1/miR-206 regulate Hsp60 expression contributing to glucose-mediated apoptosis in cardiomyocytes, FEBS Lett. 584 (2010) 3592–3600. [14] R. Kleindienst, Q. Xu, J. Willeit, F.R. Waldenberger, S. Weimann, G. Wick, Immunology of atherosclerosis. Demonstration of heat shock protein 60 expression and T lymphocytes bearing alpha/beta or gamma/delta receptor in human atherosclerotic lesions, Am. J. Pathol. 142 (1993) 1927–1937. [15] D. Chandra, G. Choy, D.G. Tang, Cytosolic accumulation of HSP60 during apoptosis with or without apparent mitochondrial release: evidence that its pro-apoptotic or pro-survival functions involve differential interactions with caspase-3, J. Biol. Chem. 282 (2007) 31289–31301. [16] S.C. Kim, J.P. Stice, L. Chen, J.S. Jung, S. Gupta, Y. Wang, et al., Extracellular heat shock protein 60, cardiac myocytes, and apoptosis, Circ. Res. 105 (2009) 1186–1195. [17] C.C. Deocaris, S.C. Kaul, R. Wadhwa, On the brotherhood of the mitochondrial chaperones mortalin and heat shock protein 60, Cell Stress Chaperones 11 (2006) 116–128. [18] A.M. Czarnecka, C. Campanella, G. Zummo, F. Cappello, Heat shock protein 10 and signal transduction: a ‘‘capsula eburnea’’ of carcinogenesis? Cell Stress Chaperones 11 (2006) 287–294.

30

MADRIGAL-MATUTE ET AL.

[19] L.H. Sigal, S. Williams, B. Soltys, R. Gupta, H9724, a monoclonal antibody to Borrelia burgdorferi’s flagellin, binds to heat shock protein 60 (HSP60) within live neuroblastoma cells: a potential role for HSP60 in peptide hormone signaling and in an autoimmune pathogenesis of the neuropathy of Lyme disease, Cell. Mol. Neurobiol. 21 (2001) 477–495. [20] S. Hirono, E. Dibrov, C. Hurtado, A. Kostenuk, R. Ducas, G.N. Pierce, Chlamydia pneumoniae stimulates proliferation of vascular smooth muscle cells through induction of endogenous heat shock protein 60, Circ. Res. 93 (2003) 710–716. [21] W. Chen, U. Syldath, K. Bellmann, V. Burkart, H. Kolb, Human 60-kDa heat-shock protein: a danger signal to the innate immune system, J. Immunol. 162 (1999) 3212–3219. [22] L. Erkkila, K. Laitinen, K. Haasio, T. Tiirola, M. Jauhiainen, H.A. Lehr, et al., Heat shock protein 60 autoimmunity and early lipid lesions in cholesterol-fed C57BL/6JBom mice during Chlamydia pneumoniae infection, Atherosclerosis 177 (2004) 321–328. [23] Q. Xu, G. Schett, H. Perschinka, M. Mayr, G. Egger, F. Oberhollenzer, et al., Serum soluble heat shock protein 60 is elevated in subjects with atherosclerosis in a general population, Circulation 102 (2000) 14–20. [24] A.G. Pockley, R. Wu, C. Lemne, R. Kiessling, F.U. de, J. Frostegard, Circulating heat shock protein 60 is associated with early cardiovascular disease, Hypertension 36 (2000) 303–307. [25] K. Mandal, A.R. Afzal, S.J. Brecker, J. Poloniecki, Q. Xu, M. Jahangiri, Association of serum soluble heat shock protein 60 with toll-like receptor 4 polymorphism and severity of coronary artery disease, Heart 92 (2006) 683–685. [26] X. Zhang, M. He, L. Cheng, Y. Chen, L. Zhou, H. Zeng, et al., Elevated heat shock protein 60 levels are associated with higher risk of coronary heart disease in Chinese, Circulation 118 (2008) 2687–2693. [27] D. Rothenbacher, A. Hoffmeister, G. Bode, M. Miller, W. Koenig, H. Brenner, Helicobacter pylori heat shock protein 60 and risk of coronary heart disease: a case control study with focus on markers of systemic inflammation and lipids, Atherosclerosis 156 (2001) 193–199. [28] J. Lewthwaite, N. Owen, A. Coates, B. Henderson, A. Steptoe, Circulating human heat shock protein 60 in the plasma of British civil servants: relationship to physiological and psychosocial stress, Circulation 106 (2002) 196–201. [29] G. Schett, B. Metzler, R. Kleindienst, A. Amberger, H. Recheis, Q. Xu, et al., Myocardial injury leads to a release of heat shock protein (hsp) 60 and a suppression of the anti-hsp65 immune response, Cardiovasc. Res. 42 (1999) 685–695. [30] Q. Xu, S. Kiechl, M. Mayr, B. Metzler, G. Egger, F. Oberhollenzer, et al., Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis: clinical significance determined in a follow-up study, Circulation 100 (1999) 1169–1174. [31] J. Zhu, A.A. Quyyumi, D. Rott, G. Csako, H. Wu, J. Halcox, et al., Antibodies to human heat-shock protein 60 are associated with the presence and severity of coronary artery disease: evidence for an autoimmune component of atherogenesis, Circulation 103 (2001) 1071–1075. [32] F. Hoppichler, M. Lechleitner, C. Traweger, G. Schett, A. Dzien, W. Sturm, et al., Changes of serum antibodies to heat-shock protein 65 in coronary heart disease and acute myocardial infarction, Atherosclerosis 126 (1996) 333–338. [33] A. Veres, G. Fust, M. Smieja, M. McQueen, A. Horvath, Q. Yi, et al., Relationship of anti-60 kDa heat shock protein and anti-cholesterol antibodies to cardiovascular events, Circulation 106 (2002) 2775–2780. [34] H. Kervinen, T. Huittinen, O. Vaarala, M. Leinonen, P. Saikku, V. Manninen, et al., Antibodies to human heat shock protein 60, hypertension and dyslipidemia. A study of joint effects on coronary risk, Atherosclerosis 169 (2003) 339–344.

HEAT-SHOCK PROTEINS IN CARDIOVASCULAR DISEASE

31

[35] M. Mayr, B. Metzler, S. Kiechl, J. Willeit, G. Schett, Q. Xu, et al., Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae: immune reactions to heat shock proteins as a possible link between infection and atherosclerosis, Circulation 99 (1999) 1560–1566. [36] K. Burian, Z. Kis, D. Virok, V. Endresz, Z. Prohaszka, J. Duba, et al., Independent and joint effects of antibodies to human heat-shock protein 60 and Chlamydia pneumoniae infection in the development of coronary atherosclerosis, Circulation 103 (2001) 1503–1508. [37] K. Heltai, Z. Kis, K. Burian, V. Endresz, A. Veres, E. Ludwig, et al., Elevated antibody levels against Chlamydia pneumoniae, human HSP60 and mycobacterial HSP65 are independent risk factors in myocardial infarction and ischaemic heart disease, Atherosclerosis 173 (2004) 339–346. [38] S. Hoshida, M. Nishino, J. Tanouchi, T. Kishimoto, Y. Yamada, Acute Chlamydia pneumoniae infection with heat-shock-protein-60-related response in patients with acute coronary syndrome, Atherosclerosis 183 (2005) 109–112. [39] J. Zhu, R.J. Katz, A.A. Quyyumi, D.A. Canos, D. Rott, G. Csako, et al., Association of serum antibodies to heat-shock protein 65 with coronary calcification levels: suggestion of pathogen-triggered autoimmunity in early atherosclerosis, Circulation 109 (2004) 36–41. [40] T. Huittinen, M. Leinonen, L. Tenkanen, M. Manttari, H. Virkkunen, T. Pitkanen, et al., Autoimmunity to human heat shock protein 60, Chlamydia pneumoniae infection, and inflammation in predicting coronary risk, Arterioscler. Thromb. Vasc. Biol. 22 (2002) 431–437. [41] J. Madrigal-Matute, O. Lopez-Franco, L.M. Blanco-Colio, B. Munoz-Garcia, P. RamosMozo, L. Ortega, et al., Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis, Cardiovasc. Res. 86 (2010) 330–337. [42] S.D. Morris, D.V. Cumming, D.S. Latchman, D.M. Yellon, Specific induction of the 70kD heat stress proteins by the tyrosine kinase inhibitor herbimycin-A protects rat neonatal cardiomyocytes. A new pharmacological route to stress protein expression? J. Clin. Invest. 97 (1996) 706–712. [43] Q. Xu, G. Schett, C. Li, Y. Hu, G. Wick, Mechanical stress-induced heat shock protein 70 expression in vascular smooth muscle cells is regulated by Rac and Ras small G proteins but not mitogen-activated protein kinases, Circ. Res. 86 (2000) 1122–1128. [44] L. Ivan, F. Antohe, Hyperlipidemia induces endothelial-derived foam cells in culture, J. Recept. Signal Transduct. Res. 30 (2010) 106–114. [45] W.M. Zhu, P. Roma, A. Pirillo, F. Pellegatta, A.L. Catapano, Oxidized LDL induce hsp70 expression in human smooth muscle cells, FEBS Lett. 372 (1995) 1–5. [46] Y.N. Liu, S.L. Pan, C.Y. Peng, D.Y. Huang, J.H. Guh, S.C. Kuo, et al., YC-1 induces heat shock protein 70 expression and prevents oxidized LDL-mediated apoptosis in vascular smooth muscle cells, Shock 30 (2008) 274–279. [47] A.D. Johnson, P.A. Berberian, M. Tytell, M.G. Bond, Differential distribution of 70-kD heat shock protein in atherosclerosis. Its potential role in arterial SMC survival, Arterioscler. Thromb. Vasc. Biol. 15 (1995) 27–36. [48] R.R. Gill, C.J. Gbur Jr., B.J. Fisher, M.L. Hess, A.A. Fowler III, R.C. Kukreja, et al., Heat shock provides delayed protection against oxidative injury in cultured human umbilical vein endothelial cells, J. Mol. Cell. Cardiol. 30 (1998) 2739–2749. [49] A. Asea, S.K. Kraeft, E.A. Kurt-Jones, M.A. Stevenson, L.B. Chen, R.W. Finberg, et al., HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine, Nat. Med. 6 (2000) 435–442. [50] Y. Yao, A.D. Watson, S. Ji, K.I. Bostrom, Heat shock protein 70 enhances vascular bone morphogenetic protein-4 signaling by binding matrix Gla protein, Circ. Res. 105 (2009) 575–584.

32

MADRIGAL-MATUTE ET AL.

[51] J. George, S. Greenberg, I. Barshack, M. Singh, S. Pri-Chen, S. Laniado, et al., Accelerated intimal thickening in carotid arteries of balloon-injured rats after immunization against heat shock protein 70, J. Am. Coll. Cardiol. 38 (2001) 1564–1569. [52] A.G. Pockley, A. Georgiades, T. Thulin, F.U. de, J. Frostegard, Serum heat shock protein 70 levels predict the development of atherosclerosis in subjects with established hypertension, Hypertension 42 (2003) 235–238. [53] J. Zhu, A.A. Quyyumi, H. Wu, G. Csako, D. Rott, A. Zalles-Ganley, et al., Increased serum levels of heat shock protein 70 are associated with low risk of coronary artery disease, Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1055–1059. [54] J.L. Martin-Ventura, A. Leclercq, L.M. Blanco-Colio, J. Egido, P. Rossignol, O. Meilhac, et al., Low plasma levels of HSP70 in patients with carotid atherosclerosis are associated with increased levels of proteolytic markers of neutrophil activation, Atherosclerosis 194 (2007) 334–341. [55] X. Zhang, Z. Xu, L. Zhou, Y. Chen, M. He, L. Cheng, et al., Plasma levels of Hsp70 and anti-Hsp70 antibody predict risk of acute coronary syndrome, Cell Stress Chaperones 15 (2010) 675–686. [56] I. Herz, R. Rosso, A. Roth, G. Keren, J. George, Serum levels of anti heat shock protein 70 antibodies in patients with stable and unstable angina pectoris, Acute Card. Care 8 (2006) 46–50. [57] J.L. Martin-Ventura, V. Nicolas, X. Houard, L.M. Blanco-Colio, A. Leclercq, J. Egido, et al., Biological significance of decreased HSP27 in human atherosclerosis, Arterioscler. Thromb. Vasc. Biol. 26 (2006) 1337–1343. [58] L. Santell, N.S. Bartfeld, E.G. Levin, Identification of a protein transiently phosphorylated by activators of endothelial cell function as the heat-shock protein HSP27. A possible role for protein kinase C, Biochem. J. 284 (Pt 3) (1992) 705–710. [59] J.L. Martin, E. Hickey, L.A. Weber, W.H. Dillmann, R. Mestril, Influence of phosphorylation and oligomerization on the protective role of the small heat shock protein 27 in rat adult cardiomyocytes, Gene Expr. 7 (1999) 349–355. [60] J.L. Martin, R. Mestril, R. Hilal-Dandan, L.L. Brunton, W.H. Dillmann, Small heat shock proteins and protection against ischemic injury in cardiac myocytes, Circulation 96 (1997) 4343–4348. [61] A.K. De, K.M. Kodys, B.S. Yeh, C. Miller-Graziano, Exaggerated human monocyte IL-10 concomitant to minimal TNF-alpha induction by heat-shock protein 27 (Hsp27) suggests Hsp27 is primarily an antiinflammatory stimulus, J. Immunol. 165 (2000) 3951–3958. [62] T.E. Callahan, J. Marins, W.J. Welch, J.K. Horn, Heat shock attenuates oxidation and accelerates apoptosis in human neutrophils, J. Surg. Res. 85 (1999) 317–322. [63] M. Zhou, H. Lambert, J. Landry, Transient activation of a distinct serine protein kinase is responsible for 27-kDa heat shock protein phosphorylation in mitogen-stimulated and heat-shocked cells, J. Biol. Chem. 268 (1993) 35–43. [64] S. Salinthone, M. Tyagi, W.T. Gerthoffer, Small heat shock proteins in smooth muscle, Pharmacol. Ther. 119 (2008) 44–54. [65] X. Preville, F. Salvemini, S. Giraud, S. Chaufour, C. Paul, G. Stepien, et al., Mammalian small stress proteins protect against oxidative stress through their ability to increase glucose-6-phosphate dehydrogenase activity and by maintaining optimal cellular detoxifying machinery, Exp. Cell Res. 247 (1999) 61–78. [66] T.S. Voegeli, R.W. Currie, siRNA knocks down Hsp27 and increases angiotensin II-induced phosphorylated NF-kappaB p65 levels in aortic smooth muscle cells, Inflamm. Res. 58 (2009) 336–343. [67] K. Sheth, A. De, B. Nolan, J. Friel, A. Duffy, R. Ricciardi, et al., Heat shock protein 27 inhibits apoptosis in human neutrophils, J. Surg. Res. 99 (2001) 129–133.

HEAT-SHOCK PROTEINS IN CARDIOVASCULAR DISEASE

33

[68] J.L. Martin-Ventura, M.C. Duran, L.M. Blanco-Colio, O. Meilhac, A. Leclercq, J.B. Michel, et al., Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis, Circulation 110 (2004) 2216–2219. [69] B. Dybdahl, S.A. Slordahl, A. Waage, P. Kierulf, T. Espevik, A. Sundan, Myocardial ischaemia and the inflammatory response: release of heat shock protein 70 after myocardial infarction, Heart 91 (2005) 299–304. [70] M. Ghayour-Mobarhan, A. Sahebkar, S.M. Parizadeh, M. Moohebati, S. Tavallaie, S.M. Rezakazemi-Bajestani, et al., Antibody titres to heat shock protein 27 are elevated in patients with acute coronary syndrome, Int. J. Exp. Pathol. 89 (2008) 209–215. [71] S. Shams, S. Shafi, K. Bodman-Smith, P. Williams, S. Mehta, G.A. Ferns, Anti-heat shock protein-27 (Hsp-27) antibody levels in patients with chest pain: association with established cardiovascular risk factors, Clin. Chim. Acta 395 (2008) 42–46. [72] K. Joseph, B.G. Tholanikunnel, A.P. Kaplan, Activation of the bradykinin-forming cascade on endothelial cells: a role for heat shock protein 90, Int. Immunopharmacol. 2 (2002) 1851–1859. [73] H. Huang, W.C. Lee, J.H. Lin, S.C. Jian, S.J. Mao, P.C. Yang, et al., Molecular cloning and characterization of porcine cDNA encoding a 90-kDa heat shock protein and its expression following hyperthermia, Gene 226 (1999) 307–315. [74] D.W. Stepp, J. Ou, A.W. Ackerman, S. Welak, D. Klick, K.A. Pritchard Jr., Native LDL and minimally oxidized LDL differentially regulate superoxide anion in vascular endothelium in situ, Am. J. Physiol. Heart Circ. Physiol. 283 (2002) H750–H759. [75] L.Y. Lin, C.Y. Lin, T.C. Su, C.S. Liau, Angiotensin II-induced apoptosis in human endothelial cells is inhibited by adiponectin through restoration of the association between endothelial nitric oxide synthase and heat shock protein 90, FEBS Lett. 574 (2004) 106–110. [76] J. Sun, J.K. Liao, Induction of angiogenesis by heat shock protein 90 mediated by protein kinase Akt and endothelial nitric oxide synthase, Arterioscler. Thromb. Vasc. Biol. 24 (2004) 2238–2244. [77] S.D. Luikart, A. Panoskaltsis-Mortari, T. Hinkel, R.T. Perri, K. Gupta, T.R. Oegema, et al., Mactinin, a fragment of cytoskeletal alpha-actinin, is a novel inducer of heat shock protein (Hsp)-90 mediated monocyte activation, BMC Cell Biol. 10 (2009) 60. [78] D.F. Liao, Z.G. Jin, A.S. Baas, G. Daum, S.P. Gygi, R. Aebersold, et al., Purification and identification of secreted oxidative stress-induced factors from vascular smooth muscle cells, J. Biol. Chem. 275 (2000) 189–196. [79] S.W. Chung, J.H. Lee, K.H. Choi, Y.C. Park, S.K. Eo, B.Y. Rhim, et al., Extracellular heat shock protein 90 induces interleukin-8 in vascular smooth muscle cells, Biochem. Biophys. Res. Commun. 378 (2009) 444–449. [80] Y. Shi, D.D. Mosser, R.I. Morimoto, Molecular chaperones as HSF1-specific transcriptional repressors, Genes Dev. 12 (1998) 654–666. [81] R. Businaro, E. Profumo, A. Tagliani, B. Buttari, S. Leone, G. D’Amati, et al., Heat-shock protein 90: a novel autoantigen in human carotid atherosclerosis, Atherosclerosis 207 (2009) 74–83. [82] I.J. Benjamin, D.R. McMillan, Stress (heat shock) proteins: molecular chaperones in cardiovascular biology and disease, Circ. Res. 83 (1998) 117–132. [83] J. Galea-Lauri, A.J. Richardson, D.S. Latchman, D.R. Katz, Increased heat shock protein 90 (hsp90) expression leads to increased apoptosis in the monoblastoid cell line U937 following induction with TNF-alpha and cycloheximide: a possible role in immunopathology, J. Immunol. 157 (1996) 4109–4118.

34

MADRIGAL-MATUTE ET AL.

[84] A. Dupont, M. Chwastyniak, O. Beseme, A.L. Guihot, H. Drobecq, P. Amouyel, et al., Application of saturation dye 2D-DIGE proteomics to characterize proteins modulated by oxidized low density lipoprotein treatment of human macrophages, J. Proteome Res. 7 (2008) 3572–3582. [85] M. Clerget, B.S. Polla, Erythrophagocytosis induces heat shock protein synthesis by human monocytes-macrophages, Proc. Natl. Acad. Sci. USA 87 (1990) 1081–1085. [86] P. Matz, P. Weinstein, B. States, J. Honkaniemi, F.R. Sharp, Subarachnoid injections of lysed blood induce the hsp70 stress gene and produce DNA fragmentation in focal areas of the rat brain, Stroke 27 (1996) 504–512. [87] W. Palinski, C. Napoli, The fetal origins of atherosclerosis: maternal hypercholesterolemia, and cholesterol-lowering or antioxidant treatment during pregnancy influence in utero programming and postnatal susceptibility to atherogenesis, FASEB J. 16 (2002) 1348–1360. [88] H.F. Chen, L.D. Xie, C.S. Xu, Role of heat shock protein 27 phosphorylation in migration of vascular smooth muscle cells, Mol. Cell. Biochem. 327 (2009) 1–6. [89] N. Vanmuylder, L. Evrard, N. Dourov, Strong expression of heat shock proteins in growth plate cartilage, an immunohistochemical study of HSP28, HSP70 and HSP110, Anat. Embryol. (Berl) 195 (1997) 359–362. [90] W.E. Hellings, W. Peeters, F.L. Moll, S.R. Piers, S.J. van, P.J. Van der Spek, et al., Composition of carotid atherosclerotic plaque is associated with cardiovascular outcome: a prognostic study, Circulation 121 (2010) 1941–1950. [91] Q. Xiao, K. Mandal, G. Schett, M. Mayr, G. Wick, F. Oberhollenzer, et al., Association of serum-soluble heat shock protein 60 with carotid atherosclerosis: clinical significance determined in a follow-up study, Stroke 36 (2005) 2571–2576. [92] Q. Xu, R. Kleindienst, W. Waitz, H. Dietrich, G. Wick, Increased expression of heat shock protein 65 coincides with a population of infiltrating T lymphocytes in atherosclerotic lesions of rabbits specifically responding to heat shock protein 65, J. Clin. Invest. 91 (1993) 2693–2702. [93] Q. Xu, G. Luef, S. Weimann, R.S. Gupta, H. Wolf, G. Wick, Staining of endothelial cells and macrophages in atherosclerotic lesions with human heat-shock protein-reactive antisera, Arterioscler. Thromb. 13 (1993) 1763–1769. [94] A. Kol, T. Bourcier, A.H. Lichtman, P. Libby, Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages, J. Clin. Invest. 103 (1999) 571–577. [95] A.G. Pockley, J. Shepherd, J.M. Corton, Detection of heat shock protein 70 (Hsp70) and anti-Hsp70 antibodies in the serum of normal individuals, Immunol. Invest. 27 (1998) 367–377. [96] J.P. Leger, F.M. Smith, R.W. Currie, Confocal microscopic localization of constitutive and heat shock-induced proteins HSP70 and HSP27 in the rat heart, Circulation 102 (2000) 1703–1709. [97] P.A. Berberian, W. Myers, M. Tytell, V. Challa, M.G. Bond, Immunohistochemical localization of heat shock protein-70 in normal-appearing and atherosclerotic specimens of human arteries, Am. J. Pathol. 136 (1990) 71–80. [98] I. Kardys, N. Rifai, O. Meilhac, J.B. Michel, J.L. Martin-Ventura, J.E. Buring, et al., Plasma concentration of heat shock protein 27 and risk of cardiovascular disease: a prospective, nested case-control study, Clin. Chem. 54 (2008) 139–146. [99] H.K. Park, E.C. Park, S.W. Bae, M.Y. Park, S.W. Kim, H.S. Yoo, et al., Expression of heat shock protein 27 in human atherosclerotic plaques and increased plasma level of heat shock protein 27 in patients with acute coronary syndrome, Circulation 114 (2006) 886–893.

HEAT-SHOCK PROTEINS IN CARDIOVASCULAR DISEASE

35

[100] R. Rajaiah, K.D. Moudgil, Heat-shock proteins can promote as well as regulate autoimmunity, Autoimmun. Rev. 8 (2009) 388–393. [101] H. Perschinka, M. Mayr, G. Millonig, C. Mayerl, R. van der Zee, S.G. Morrison, et al., Cross-reactive B-cell epitopes of microbial and human heat shock protein 60/65 in atherosclerosis, Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1060–1065. [102] X. Zhang, M.A. He, L. Cheng, L. Zhou, H. Zeng, J. Wang, et al., Joint effects of antibody to heat shock protein 60, hypertension, and diabetes on risk of coronary heart disease in Chinese, Clin. Chem. 54 (2008) 1046–1052. [103] E. Fehrenbach, H. Northoff, Free radicals, exercise, apoptosis, and heat shock proteins, Exerc. Immunol. Rev. 7 (2001) 66–89. [104] E.G. Noble, K.J. Milne, C.W. Melling, Heat shock proteins and exercise: a primer, Appl. Physiol. Nutr. Metab. 33 (2008) 1050–1065. [105] M. Yang, T. Wu, L. Cheng, F. Wang, Q. Wei, R.M. Tanguay, Plasma antibodies against heat shock protein 70 correlate with the incidence and severity of asthma in a Chinese population, Respir. Res. 6 (2005) 18. [106] G. Fust, Z. Beck, D. Banhegyi, J. Kocsis, A. Biro, Z. Prohaszka, Antibodies against heat shock proteins and cholesterol in HIV infection, Mol. Immunol. 42 (2005) 79–85. [107] A. Figueredo, J.L. Ibarra, A. Rodriguez, A.M. Molino, Gomez-de la Concha E, Fernandez-Cruz A, et al. Increased serum levels of IgA antibodies to hsp70 protein in patients with diabetes mellitus: their relationship with vascular complications, Clin. Immunol. Immunopathol. 79 (1996) 252–255. [108] A. Olejek, A. Damasiewicz-Bodzek, P. Bodzek, T. Wielkoszynski, J. Zamlynski, P. Stoltny, et al., Concentrations of antibodies against heat shock protein 27 in the sera of women with ovarian carcinoma, Int. J. Gynecol. Cancer 19 (2009) 1516–1520. [109] R.T. Demmer, M. Desvarieux, Periodontal infections and cardiovascular disease: the heart of the matter, J. Am. Dent. Assoc. 137 (Suppl.) (2006) 14S–20S. [110] M. Garcia-Arguinzonis, T. Padro, R. Lugano, V. Llorente-Cortes, L. Badimon, Lowdensity lipoproteins induce heat shock protein 27 dephosphorylation, oligomerization, and subcellular relocalization in human vascular smooth muscle cells, Arterioscler. Thromb. Vasc. Biol. 30 (2010) 1212–1219. [111] K. Rayner, Y.X. Chen, M. McNulty, T. Simard, X. Zhao, D.J. Wells, et al., Extracellular release of the atheroprotective heat shock protein 27 is mediated by estrogen and competitively inhibits acLDL binding to scavenger receptor-A, Circ. Res. 103 (2008) 133–141. [112] C. Zanini, F. Pulera, F. Carta, G. Giribaldi, G. Mandili, M.M. Maule, et al., Proteomic identification of heat shock protein 27 as a differentiation and prognostic marker in neuroblastoma but not in Ewing’s sarcoma, Virchows Arch. 452 (2008) 157–167. [113] H. Pei, H. Zhu, S. Zeng, Y. Li, H. Yang, L. Shen, et al., Proteome analysis and tissue microarray for profiling protein markers associated with lymph node metastasis in colorectal cancer, J. Proteome Res. 6 (2007) 2495–2501. [114] R. Langer, K. Ott, K. Specht, K. Becker, F. Lordick, M. Burian, et al., Protein expression profiling in esophageal adenocarcinoma patients indicates association of heat-shock protein 27 expression and chemotherapy response, Clin. Cancer Res. 14 (2008) 8279–8287. [115] D.L. Feinstein, E. Galea, D.A. Aquino, G.C. Li, H. Xu, D.J. Reis, Heat shock protein 70 suppresses astroglial-inducible nitric-oxide synthase expression by decreasing NFkappaB activation, J. Biol. Chem. 271 (1996) 17724–17732. [116] M.W. Van, B. Wielockx, T. Mahieu, M. Takada, T. Taniguchi, K. Sekikawa, et al., HSP70 protects against TNF-induced lethal inflammatory shock, Immunity 16 (2002) 685–695. [117] A. Ialenti, M.P. Di, F. D’Acquisto, B. Pisano, P. Maffia, G. Grassia, et al., Inhibition of cyclooxygenase-2 gene expression by the heat shock response in J774 murine macrophages, Eur. J. Pharmacol. 509 (2005) 89–96.

36

MADRIGAL-MATUTE ET AL.

[118] S.K. Jo, G.J. Ko, C.S. Boo, W.Y. Cho, H.K. Kim, Heat preconditioning attenuates renal injury in ischemic ARF in rats: role of heat-shock protein 70 on NF-kappaB-mediated inflammation and on tubular cell injury, J. Am. Soc. Nephrol. 17 (2006) 3082–3092. [119] Z. Zheng, J.Y. Kim, H. Ma, J.E. Lee, M.A. Yenari, Anti-inflammatory effects of the 70 kDa heat shock protein in experimental stroke, J. Cereb. Blood Flow Metab. 28 (2008) 53–63. [120] U. Zugel, S.H. Kaufmann, Immune response against heat shock proteins in infectious diseases, Immunobiology 201 (1999) 22–35. [121] E.W. van, R. van der Zee, B. Prakken, Heat-shock proteins induce T-cell regulation of chronic inflammation, Nat. Rev. Immunol. 5 (2005) 318–330. [122] J. Ananthan, A.L. Goldberg, R. Voellmy, Abnormal proteins serve as eukaryotic stress signals and trigger the activation of heat shock genes, Science 232 (1986) 522–524. [123] A. Ali, S. Bharadwaj, R. O’Carroll, N. Ovsenek, HSP90 interacts with and regulates the activity of heat shock factor 1 in Xenopus oocytes, Mol. Cell. Biol. 18 (1998) 4949–4960. [124] D.F. Smith, W.P. Sullivan, T.N. Marion, K. Zaitsu, B. Madden, D.J. McCormick, et al., Identification of a 60-kilodalton stress-related protein, p60, which interacts with hsp90 and hsp70, Mol. Cell. Biol. 13 (1993) 869–876. [125] J. Hohfeld, Y. Minami, F.U. Hartl, Hip, a novel cochaperone involved in the eukaryotic Hsc70/Hsp40 reaction cycle, Cell 83 (1995) 589–598. [126] Y. Minami, J. Hohfeld, K. Ohtsuka, F.U. Hartl, Regulation of the heat-shock protein 70 reaction cycle by the mammalian DnaJ homolog, Hsp40, J. Biol. Chem. 271 (1996) 19617–19624. [127] K.A. Hutchison, L.F. Stancato, J.K. Owens-Grillo, J.L. Johnson, P. Krishna, D.O. Toft, et al., The 23-kDa acidic protein in reticulocyte lysate is the weakly bound component of the hsp foldosome that is required for assembly of the glucocorticoid receptor into a functional heterocomplex with hsp90, J. Biol. Chem. 270 (1995) 18841–18847. [128] R. Baler, G. Dahl, R. Voellmy, Activation of human heat shock genes is accompanied by oligomerization, modification, and rapid translocation of heat shock transcription factor HSF1, Mol. Cell. Biol. 13 (1993) 2486–2496. [129] K.D. Sarge, S.P. Murphy, R.I. Morimoto, Activation of heat shock gene transcription by heat shock factor 1 involves oligomerization, acquisition of DNA-binding activity, and nuclear localization and can occur in the absence of stress, Mol. Cell. Biol. 13 (1993) 1392–1407. [130] J.T. Westwood, C. Wu, Activation of Drosophila heat shock factor: conformational change associated with a monomer-to-trimer transition, Mol. Cell. Biol. 13 (1993) 3481–3486. [131] R. Shringarpure, T. Grune, J. Mehlhase, K.J. Davies, Ubiquitin conjugation is not required for the degradation of oxidized proteins by proteasome, J. Biol. Chem. 278 (2003) 311–318. [132] Y.H. Lee, B. Govinda, J.C. Kim, T.I. Kim, N.H. Lee, J.C. Lee, et al., Oxidative stress resistance through blocking Hsp60 translocation followed by SAPK/JNK inhibition in aged human diploid fibroblasts, Cell Biochem. Funct. 27 (2009) 35–39. [133] Y.H. Lee, J.C. Lee, H.J. Moon, J.E. Jung, M. Sharma, B.H. Park, et al., Differential effect of oxidative stress on the apoptosis of early and late passage human diploid fibroblasts: implication of heat shock protein 60, Cell Biochem. Funct. 26 (2008) 502–508. [134] Q. Xu, G. Schett, C.S. Seitz, Y. Hu, R.S. Gupta, G. Wick, Surface staining and cytotoxic activity of heat-shock protein 60 antibody in stressed aortic endothelial cells, Circ. Res. 75 (1994) 1078–1085.

HEAT-SHOCK PROTEINS IN CARDIOVASCULAR DISEASE

37

[135] C. Bason, R. Corrocher, C. Lunardi, P. Puccetti, O. Olivieri, D. Girelli, et al., Interaction of antibodies against cytomegalovirus with heat-shock protein 60 in pathogenesis of atherosclerosis, Lancet 362 (2003) 1971–1977. [136] B.S. Polla, S. Kantengwa, D. Francois, S. Salvioli, C. Franceschi, C. Marsac, et al., Mitochondria are selective targets for the protective effects of heat shock against oxidative injury, Proc. Natl. Acad. Sci. USA 93 (1996) 6458–6463. [137] L. Xu, R.G. Giffard, HSP70 protects murine astrocytes from glucose deprivation injury, Neurosci. Lett. 224 (1997) 9–12. [138] M.R. Jacquier-Sarlin, K. Fuller, A.T. Dinh-Xuan, M.J. Richard, B.S. Polla, Protective effects of hsp70 in inflammation, Experientia 50 (1994) 1031–1038. [139] K.M. Stuhlmeier, Activation and regulation of Hsp32 and Hsp70, Eur. J. Biochem. 267 (2000) 1161–1167. [140] P. Pandey, A. Saleh, A. Nakazawa, S. Kumar, S.M. Srinivasula, V. Kumar, et al., Negative regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90, EMBO J. 19 (2000) 4310–4322. [141] H.M. Beere, B.B. Wolf, K. Cain, D.D. Mosser, A. Mahboubi, T. Kuwana, et al., Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome, Nat. Cell Biol. 2 (2000) 469–475. [142] A. Saleh, S.M. Srinivasula, L. Balkir, P.D. Robbins, E.S. Alnemri, Negative regulation of the Apaf-1 apoptosome by Hsp70, Nat. Cell Biol. 2 (2000) 476–483. [143] C.Y. Li, J.S. Lee, Y.G. Ko, J.I. Kim, J.S. Seo, Heat shock protein 70 inhibits apoptosis downstream of cytochrome c release and upstream of caspase-3 activation, J. Biol. Chem. 275 (2000) 25665–25671. [144] Y. Matsumori, F.J. Northington, S.M. Hong, T. Kayama, R.A. Sheldon, Z.S. Vexler, et al., Reduction of caspase-8 and-9 cleavage is associated with increased c-FLIP and increased binding of Apaf-1 and Hsp70 after neonatal hypoxic/ischemic injury in mice overexpressing Hsp70, Stroke 37 (2006) 507–512. [145] L. Ravagnan, S. Gurbuxani, S.A. Susin, C. Maisse, E. Daugas, N. Zamzami, et al., Heatshock protein 70 antagonizes apoptosis-inducing factor, Nat. Cell Biol. 3 (2001) 839–843. [146] F. Alcocer, D. Whitley, J. Salazar, W. Jordan, K.I. Bland, Mutual exclusion of apoptosis and hsp70 in human vein intimal hyperplasia in vitro, J. Surg. Res. 96 (2001) 75–80. [147] J.H. Wang, H.P. Redmond, R.W. Watson, C. Condron, D. Bouchier-Hayes, Induction of heat shock protein 72 prevents neutrophil-mediated human endothelial cell necrosis, Arch. Surg. 130 (1995) 1260–1265. [148] S.L. DeMeester, T.G. Buchman, Y. Qiu, A.K. Jacob, K. Dunnigan, R.S. Hotchkiss, et al., Heat shock induces IkappaB-alpha and prevents stress-induced endothelial cell apoptosis, Arch. Surg. 132 (1997) 1283–1287. [149] H.R. Wong, R.J. Mannix, J.M. Rusnak, A. Boota, H. Zar, S.C. Watkins, et al., The heatshock response attenuates lipopolysaccharide-mediated apoptosis in cultured sheep pulmonary artery endothelial cells, Am. J. Respir. Cell Mol. Biol. 15 (1996) 745–751. [150] C. Bernardini, A. Zannoni, M.E. Turba, P. Fantinati, C. Tamanini, M.L. Bacci, et al., Heat shock protein 70, heat shock protein 32, and vascular endothelial growth factor production and their effects on lipopolysaccharide-induced apoptosis in porcine aortic endothelial cells, Cell Stress Chaperones 10 (2005) 340–348. [151] M.A. Yenari, J. Liu, Z. Zheng, Z.S. Vexler, J.E. Lee, R.G. Giffard, Antiapoptotic and anti-inflammatory mechanisms of heat-shock protein protection, Ann. NY Acad. Sci. 1053 (2005) 74–83. [152] S.D. House, P.T. Guidon Jr., G.A. Perdrizet, M. Rewinski, R. Kyriakos, R.S. Bockman, et al., Effects of heat shock, stannous chloride, and gallium nitrate on the rat inflammatory response, Cell Stress Chaperones 6 (2001) 164–171.

38

MADRIGAL-MATUTE ET AL.

[153] M. Sato, C. Fraga, D.K. Das, Induction of the expression of cardioprotective proteins after mild-to-moderate consumption of alcohol, Pathophysiology 10 (2004) 139–145. [154] Z.C. Chen, W.S. Wu, M.T. Lin, C.C. Hsu, Protective effect of transgenic expression of porcine heat shock protein 70 on hypothalamic ischemic and oxidative damage in a mouse model of heatstroke, BMC Neurosci. 10 (2009) 111. [155] J.L. Wang, D.S. Ke, M.T. Lin, Heat shock pretreatment may protect against heatstrokeinduced circulatory shock and cerebral ischemia by reducing oxidative stress and energy depletion, Shock 23 (2005) 161–167. [156] F. Mirabelli, A. Salis, M. Perotti, F. Taddei, G. Bellomo, S. Orrenius, Alterations of surface morphology caused by the metabolism of menadione in mammalian cells are associated with the oxidation of critical sulfhydryl groups in cytoskeletal proteins, Biochem. Pharmacol. 37 (1988) 3423–3427. [157] P. Liang, T.H. MacRae, Molecular chaperones and the cytoskeleton, J. Cell Sci. 110 (Pt 13) (1997) 1431–1440. [158] T. Miron, K. Vancompernolle, J. Vandekerckhove, M. Wilchek, B. Geiger, A 25-kD inhibitor of actin polymerization is a low molecular mass heat shock protein, J. Cell Biol. 114 (1991) 255–261. [159] D. Campisi, M. Cutolo, G. Carruba, C.M. Lo, L. Comito, O.M. Granata, et al., Evidence for soluble and nuclear site I binding of estrogens in human aorta, Atherosclerosis 103 (1993) 267–277. [160] A.J. Lepedda, A. Cigliano, G.M. Cherchi, R. Spirito, M. Maggioni, F. Carta, et al., A proteomic approach to differentiate histologically classified stable and unstable plaques from human carotid arteries, Atherosclerosis 203 (2009) 112–118. [161] Y. Chen, R.W. Currie, Small interfering RNA knocks down heat shock factor-1 (HSF-1) and exacerbates pro-inflammatory activation of NF-kappaB and AP-1 in vascular smooth muscle cells, Cardiovasc. Res. 69 (2006) 66–75. [162] S. Rousseau, F. Houle, J. Landry, J. Huot, p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells, Oncogene 15 (1997) 2169–2177. [163] M.M. Gorska, Q. Liang, S.J. Stafford, N. Goplen, N. Dharajiya, L. Guo, et al., MK2 controls the level of negative feedback in the NF-kappaB pathway and is essential for vascular permeability and airway inflammation, J. Exp. Med. 204 (2007) 1637–1652. [164] Z. Wang, Y. Chen, N. Labinskyy, T.C. Hsieh, Z. Ungvari, J.M. Wu, Regulation of proliferation and gene expression in cultured human aortic smooth muscle cells by resveratrol and standardized grape extracts, Biochem. Biophys. Res. Commun. 346 (2006) 367–376. [165] A.M. Gorman, E. Szegezdi, D.J. Quigney, A. Samali, Hsp27 inhibits 6-hydroxydopamineinduced cytochrome c release and apoptosis in PC12 cells, Biochem. Biophys. Res. Commun. 327 (2005) 801–810. [166] H. Schepers, M. Geugien, M. van der Toorn, A.L. Bryantsev, H.H. Kampinga, B.J. Eggen, et al., HSP27 protects AML cells against VP-16-induced apoptosis through modulation of p38 and c-Jun, Exp. Hematol. 33 (2005) 660–670. [167] C. Garrido, J.M. Bruey, A. Fromentin, A. Hammann, A.P. Arrigo, E. Solary, HSP27 inhibits cytochrome c-dependent activation of procaspase-9, FASEB J. 13 (1999) 2061–2070. [168] J.M. Bruey, C. Ducasse, P. Bonniaud, L. Ravagnan, S.A. Susin, C. Diaz-Latoud, et al., Hsp27 negatively regulates cell death by interacting with cytochrome c, Nat. Cell Biol. 2 (2000) 645–652. [169] J.E. O’Brien Jr., M.L. Ormont, Y. Shi, D. Wang, A. Zalewski, J.D. Mannion, Early injury to the media after saphenous vein grafting, Ann. Thorac. Surg. 65 (1998) 1273–1278.

HEAT-SHOCK PROTEINS IN CARDIOVASCULAR DISEASE

39

[170] M. Vayssier, B.S. Polla, Heat shock proteins chaperoning life and death, Cell Stress Chaperones 3 (1998) 221–227. [171] A. Samali, S. Orrenius, Heat shock proteins: regulators of stress response and apoptosis, Cell Stress Chaperones 3 (1998) 228–236. [172] K. Walsh, R.C. Smith, H.S. Kim, Vascular cell apoptosis in remodeling, restenosis, and plaque rupture, Circ. Res. 87 (2000) 184–188. [173] D.E. Ingber, Tensegrity II. How structural networks influence cellular information processing networks, J. Cell. Sci. 116 (2003) 1397–1408. [174] J.B. Michel, Anoikis in the cardiovascular system: known and unknown extracellular mediators, Arterioscler. Thromb. Vasc. Biol. 23 (2003) 2146–2154. [175] B. Rinaldi, P. Romagnoli, S. Bacci, R. Carnuccio, M.C. Maiuri, M. Donniacuo, et al., Inflammatory events in a vascular remodeling model induced by surgical injury to the rat carotid artery, Br. J. Pharmacol. 147 (2006) 175–182. [176] K. Rayner, J. Sun, Y.X. Chen, M. McNulty, T. Simard, X. Zhao, et al., Heat shock protein 27 protects against atherogenesis via an estrogen-dependent mechanism: role of selective estrogen receptor beta modulation, Arterioscler. Thromb. Vasc. Biol. 29 (2009) 1751–1756. [177] G. Garcia-Cardena, R. Fan, V. Shah, R. Sorrentino, G. Cirino, A. Papapetropoulos, et al., Dynamic activation of endothelial nitric oxide synthase by Hsp90, Nature 392 (1998) 821–824. [178] M. Conconi, I. Petropoulos, I. Emod, E. Turlin, F. Biville, B. Friguet, Protection from oxidative inactivation of the 20S proteasome by heat-shock protein 90, Biochem. J. 333 (Pt 2) (1998) 407–415. [179] N. Hogg, B. Kalyanaraman, J. Joseph, A. Struck, S. Parthasarathy, Inhibition of low-density lipoprotein oxidation by nitric oxide. Potential role in atherogenesis, FEBS Lett. 334 (1993) 170–174. [180] N. Hogg, A. Struck, S.P. Goss, N. Santanam, J. Joseph, S. Parthasarathy, et al., Inhibition of macrophage-dependent low density lipoprotein oxidation by nitric-oxide donors, J. Lipid Res. 36 (1995) 1756–1762. [181] Y. Rikitake, K. Hirata, S. Kawashima, H. Akita, M. Yokoyama, Inhibitory effect of inducible type nitric oxide synthase on oxidative modification of low density lipoprotein by vascular smooth muscle cells, Atherosclerosis 136 (1998) 51–57. [182] E.M. Morrel, J.A. Holland, K.A. Pritchard, C.K. Colton, M.B. Stemerman, Endothelial cell perturbation and low-density lipoprotein. Quantitative autoradiography, Ann. NY Acad. Sci. 516 (1987) 412–417. [183] J.X. Chen, B. Meyrick, Hypoxia increases Hsp90 binding to eNOS via PI3K-Akt in porcine coronary artery endothelium, Lab. Invest. 84 (2004) 182–190. [184] J. Fontana, D. Fulton, Y. Chen, T.A. Fairchild, T.J. McCabe, N. Fujita, et al., Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase and NO release, Circ. Res. 90 (2002) 866–873. [185] K.S. Russell, M.P. Haynes, T. Caulin-Glaser, J. Rosneck, W.C. Sessa, J.R. Bender, Estrogen stimulates heat shock protein 90 binding to endothelial nitric oxide synthase in human vascular endothelial cells. Effects on calcium sensitivity and NO release, J. Biol. Chem. 275 (2000) 5026–5030. [186] M. Conconi, B. Friguet, Proteasome inactivation upon aging and on oxidation-effect of HSP 90, Mol. Biol. Rep. 24 (1997) 45–50. [187] M. Conconi, L.I. Szweda, R.L. Levine, E.R. Stadtman, B. Friguet, Age-related decline of rat liver multicatalytic proteinase activity and protection from oxidative inactivation by heat-shock protein 90, Arch. Biochem. Biophys. 331 (1996) 232–240.

40

MADRIGAL-MATUTE ET AL.

[188] D.H. Liu, H.Y. Yuan, C.Y. Cao, Z.P. Gao, B.Y. Zhu, H.L. Huang, et al., Heat shock protein 90 acts as a molecular chaperone in late-phase activation of extracellular signalregulated kinase 1/2 stimulated by oxidative stress in vascular smooth muscle cells, Acta Pharmacol. Sin. 28 (2007) 1907–1913. [189] K. Joseph, B.G. Tholanikunnel, A.P. Kaplan, Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII, Proc. Natl. Acad. Sci. USA 99 (2002) 896–900. [190] J. Duchene, A. Ahluwalia, The kinin B(1) receptor and inflammation: new therapeutic target for cardiovascular disease, Curr. Opin. Pharmacol. 9 (2009) 125–131. [191] J.H. Chen, M. Riazy, E.M. Smith, C.G. Proud, U.P. Steinbrecher, V. Duronio, Oxidized LDL-mediated macrophage survival involves elongation factor-2 kinase, Arterioscler. Thromb. Vasc. Biol. 29 (2009) 92–98. [192] L.Y. Lin, C.Y. Lin, F.M. Ho, C.S. Liau, Up-regulation of the association between heat shock protein 90 and endothelial nitric oxide synthase prevents high glucose-induced apoptosis in human endothelial cells, J. Cell. Biochem. 94 (2005) 194–201. [193] G.N. Antonova, C.M. Snead, A.S. Antonov, C. Dimitropoulou, R.C. Venema, J.D. Catravas, Nitric oxide preconditioning regulates endothelial monolayer integrity via the heat shock protein 90-soluble guanylate cyclase pathway, Am. J. Physiol. Heart Circ. Physiol. 292 (2007) H893–H903. [194] J. Haendeler, J. Hoffmann, S. Rahman, A.M. Zeiher, S. Dimmeler, Regulation of telomerase activity and anti-apoptotic function by protein-protein interaction and phosphorylation, FEBS Lett. 536 (2003) 180–186. [195] R. Zhang, D. Luo, R. Miao, L. Bai, Q. Ge, W.C. Sessa, et al., Hsp90-Akt phosphorylates ASK1 and inhibits ASK1-mediated apoptosis, Oncogene 24 (2005) 3954–3963. [196] B.J. Davis, Z. Xie, B. Viollet, M.H. Zou, Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase, Diabetes 55 (2006) 496–505. [197] R. Rezzani, L. Rodella, C. Dessy, G. Daneau, R. Bianchi, O. Feron, Changes in Hsp90 expression determine the effects of cyclosporine A on the NO pathway in rat myocardium, FEBS Lett. 552 (2003) 125–129. [198] J.L. Aschner, H. Zeng, M.R. Kaplowitz, Y. Zhang, J.C. Slaughter, C.D. Fike, Heat shock protein 90-eNOS interactions mature with postnatal age in the pulmonary circulation of the piglet, Am. J. Physiol. Lung Cell. Mol. Physiol. 296 (2009) L555–L564. [199] M.B. Harris, B.M. Mitchell, S.G. Sood, R.C. Webb, R.C. Venema, Increased nitric oxide synthase activity and Hsp90 association in skeletal muscle following chronic exercise, Eur. J. Appl. Physiol. 104 (2008) 795–802. [200] M. Bucci, F. Roviezzo, I. Posadas, J. Yu, L. Parente, W.C. Sessa, et al., Endothelial nitric oxide synthase activation is critical for vascular leakage during acute inflammation in vivo, Proc. Natl. Acad. Sci. USA 102 (2005) 904–908. [201] G.I. Lancaster, M.A. Febbraio, Exosome-dependent trafficking of HSP70: a novel secretory pathway for cellular stress proteins, J. Biol. Chem. 280 (2005) 23349–23355. [202] S. Gupta, A.A. Knowlton, HSP60 trafficking in adult cardiac myocytes: role of the exosomal pathway, Am. J. Physiol. Heart Circ. Physiol. 292 (2007) H3052–H3056. [203] G. Schett, Q. Xu, A. Amberger, R. van der Zee, H. Recheis, J. Willeit, et al., Autoantibodies against heat shock protein 60 mediate endothelial cytotoxicity, J. Clin. Invest. 96 (1995) 2569–2577. [204] G. Schett, B. Metzler, M. Mayr, A. Amberger, D. Niederwieser, R.S. Gupta, et al., Macrophage-lysis mediated by autoantibodies to heat shock protein 65/60, Atherosclerosis 128 (1997) 27–38.

HEAT-SHOCK PROTEINS IN CARDIOVASCULAR DISEASE

41

[205] A. Kol, G.K. Sukhova, A.H. Lichtman, P. Libby, Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression, Circulation 98 (1998) 300–307. [206] A. Kol, A.H. Lichtman, R.W. Finberg, P. Libby, E.A. Kurt-Jones, Cutting edge: heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells, J. Immunol. 164 (2000) 13–17. [207] Q. Xu, H. Dietrich, H.J. Steiner, A.M. Gown, B. Schoel, G. Mikuz, et al., Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65, Arterioscler. Thromb. 12 (1992) 789–799. [208] G. Foteinos, A.R. Afzal, K. Mandal, M. Jahangiri, Q. Xu, Anti-heat shock protein 60 autoantibodies induce atherosclerosis in apolipoprotein E-deficient mice via endothelial damage, Circulation 112 (2005) 1206–1213. [209] M. Dieude, M.A. Gillis, J.F. Theoret, E. Thorin, G. Lajoie, J.S. Levine, et al., Autoantibodies to heat shock protein 60 promote thrombus formation in a murine model of arterial thrombosis, J. Thromb. Haemost. 7 (2009) 710–719. [210] A.D. Johnson, P.A. Berberian, M. Tytell, M.G. Bond, Atherosclerosis alters the localization of HSP70 in human and macaque aortas, Exp. Mol. Pathol. 58 (1993) 155–168. [211] M. Tytell, S.G. Greenberg, R.J. Lasek, Heat shock-like protein is transferred from glia to axon, Brain Res. 363 (1986) 161–164. [212] A.D. Johnson, M. Tytell, Exogenous HSP70 becomes cell associated, but not internalized, by stressed arterial smooth muscle cells, In Vitro Cell. Dev. Biol. Anim. 29A (1993) 807–812. [213] W. Zhu, P. Roma, A. Pirillo, F. Pellegatta, A.L. Catapano, Human endothelial cells exposed to oxidized LDL express hsp70 only when proliferating, Arterioscler. Thromb. Vasc. Biol. 16 (1996) 1104–1111. [214] W.F. van, B. Prakken, Heat shock proteins: Darwinistic immune modulation on dangerous grounds, J. Leukoc. Biol. 88 (2010) 431–434. [215] R.W. Currie, M. Karmazyn, M. Kloc, K. Mailer, Heat-shock response is associated with enhanced postischemic ventricular recovery, Circ. Res. 63 (1988) 543–549. [216] R.W. Currie, M. Karmazyn, Improved post-ischemic ventricular recovery in the absence of changes in energy metabolism in working rat hearts following heat-shock, J. Mol. Cell. Cardiol. 22 (1990) 631–636. [217] M. Karmazyn, K. Mailer, R.W. Currie, Acquisition and decay of heat-shock-enhanced postischemic ventricular recovery, Am. J. Physiol. 259 (1990) H424–H431. [218] M. Okada, N. Hasebe, Y. Aizawa, K. Izawa, J. Kawabe, K. Kikuchi, Thermal treatment attenuates neointimal thickening with enhanced expression of heat-shock protein 72 and suppression of oxidative stress, Circulation 109 (2004) 1763–1768. [219] C. Brasselet, E. Durand, F. Addad, F. Vitry, G. Chatellier, C. Demerens, et al., Effect of local heating on restenosis and in-stent neointimal hyperplasia in the atherosclerotic rabbit model: a dose-ranging study, Eur. Heart J. 29 (2008) 402–412. [220] T. Kihara, S. Biro, M. Imamura, S. Yoshifuku, K. Takasaki, Y. Ikeda, et al., Repeated sauna treatment improves vascular endothelial and cardiac function in patients with chronic heart failure, J. Am. Coll. Cardiol. 39 (2002) 754–759. [221] M. Imamura, S. Biro, T. Kihara, S. Yoshifuku, K. Takasaki, Y. Otsuji, et al., Repeated thermal therapy improves impaired vascular endothelial function in patients with coronary risk factors, J. Am. Coll. Cardiol. 38 (2001) 1083–1088. [222] J. Jayakumar, K. Suzuki, M. Khan, R.T. Smolenski, A. Farrell, N. Latif, et al., Gene therapy for myocardial protection: transfection of donor hearts with heat shock protein 70 gene protects cardiac function against ischemia-reperfusion injury, Circulation 102 (2000) III302–III306.

42

MADRIGAL-MATUTE ET AL.

[223] J. Jayakumar, K. Suzuki, I.A. Sammut, R.T. Smolenski, M. Khan, N. Latif, et al., Heat shock protein 70 gene transfection protects mitochondrial and ventricular function against ischemia-reperfusion injury, Circulation 104 (2001) I303–I307. [224] M. Matsumoto, P.C. Dimayuga, C. Wang, J. Kirzner, M. Cercek, J. Yano, et al., Exogenous heat shock protein-70 inhibits cigarette smoke-induced intimal thickening, Am. J. Physiol. Regul. Integr. Comp. Physiol. 295 (2008) R1320–R1327. [225] T. Anazawa, P.C. Dimayuga, H. Li, S. Tani, J. Bradfield, K.Y. Chyu, et al., Effect of exposure to cigarette smoke on carotid artery intimal thickening: the role of inducible NO synthase, Arterioscler. Thromb. Vasc. Biol. 24 (2004) 1652–1658. [226] S. Tani, P.C. Dimayuga, T. Anazawa, K.Y. Chyu, H. Li, P.K. Shah, et al., Aberrant antibody responses to oxidized LDL and increased intimal thickening in apoE/ mice exposed to cigarette smoke, Atherosclerosis 175 (2004) 7–14. [227] E.M. Connolly, C.J. Kelly, G. Chen, T. O’grady, E. Kay, A. Leahy, et al., Pharmacological induction of HSP27 attenuates intimal hyperplasia in vivo, Eur. J. Vasc. Endovasc. Surg. 25 (2003) 40–47. [228] Y.N. Liu, S.L. Pan, C.Y. Peng, J.H. Guh, D.M. Huang, Y.L. Chang, et al., YC-1 [3-(5’hydroxymethyl-2’-furyl)-1-benzyl indazole] inhibits neointima formation in balloon-injured rat carotid through suppression of expressions and activities of matrix metalloproteinases 2 and 9, J. Pharmacol. Exp. Ther. 316 (2006) 35–41. [229] S. Kummar, M.E. Gutierrez, E.R. Gardner, X. Chen, W.D. Figg, M. Zajac-Kaye, et al., Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies, Eur. J. Cancer 46 (2010) 340–347. [230] R.K. Ramanathan, M.J. Egorin, C. Erlichman, S.C. Remick, S.S. Ramalingam, C. Naret, et al., Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors, J. Clin. Oncol. 28 (2010) 1520–1526. [231] J.E. Lancet, I. Gojo, M. Burton, M. Quinn, S.M. Tighe, K. Kersey, et al., Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia, Leukemia 24 (2010) 699–705. [232] S. Pacey, M. Gore, D. Chao, U. Banerji, J. Larkin, S. Sarker, et al., A Phase II trial of 17allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma, Invest. New Drugs (2010). [233] M.A. Biamonte, R. Van de Water, J.W. Arndt, R.H. Scannevin, D. Perret, W.C. Lee, Heat shock protein 90: inhibitors in clinical trials, J. Med. Chem. 53 (2010) 3–17. [234] T. Uchiyama, H. Atsuta, T. Utsugi, Y. Ohyama, T. Nakamura, A. Nakai, et al., Simvastatin induces heat shock factor 1 in vascular endothelial cells, Atherosclerosis 188 (2006) 265–273. [235] G. Niu, X. Chen, From protein-protein interaction to therapy response: molecular imaging of heat shock proteins, Eur. J. Radiol. 70 (2009) 294–304. [236] M. Benagiano, M.M. D’Elios, A. Amedei, A. Azzurri, R. van der Zee, A. Ciervo, et al., Human 60-kDa heat shock protein is a target autoantigen of T cells derived from atherosclerotic plaques, J. Immunol. 174 (2005) 6509–6517. [237] Q. Xu, Role of heat shock proteins in atherosclerosis, Arterioscler. Thromb. Vasc. Biol. 22 (2002) 1547–1559. [238] D. Harats, N. Yacov, B. Gilburd, Y. Shoenfeld, J. George, Oral tolerance with heat shock protein 65 attenuates Mycobacterium tuberculosis-induced and high-fat-diet-driven atherosclerotic lesions, J. Am. Coll. Cardiol. 40 (2002) 1333–1338.

HEAT-SHOCK PROTEINS IN CARDIOVASCULAR DISEASE

43

[239] S.A. Huber, P. Sakkinen, C. David, M.K. Newell, R.P. Tracy, T helper-cell phenotype regulates atherosclerosis in mice under conditions of mild hypercholesterolemia, Circulation 103 (2001) 2610–2616. [240] R. Maron, G. Sukhova, A.M. Faria, E. Hoffmann, F. Mach, P. Libby, et al., Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice, Circulation 106 (2002) 1708–1715. [241] G.H. van Puijvelde, E.T. van, E.J. van Wanrooij, K.L. Habets, V.P. de, R. van der Zee, Induction of oral tolerance to HSP60 or an HSP60-peptide activates T cell regulation and reduces atherosclerosis, Arterioscler. Thromb. Vasc. Biol. 27 (2007) 2677–2683. [242] Q. Xiong, J. Li, L. Jin, J. Liu, T. Li, Nasal immunization with heat shock protein 65 attenuates atherosclerosis and reduces serum lipids in cholesterol-fed wild-type rabbits probably through different mechanisms, Immunol. Lett. 125 (2009) 40–45. [243] E.W. Van, G. Wick, S. Albani, I. Cohen, Stress, heat shock proteins, and autoimmunity: how immune responses to heat shock proteins are to be used for the control of chronic inflammatory diseases, Ann. NY Acad. Sci. 1113 (2007) 217–237.

This page intentionally left blank

ADVANCES IN CLINICAL CHEMISTRY, VOL. 54

POLYAMINES IN CANCER Edwin A. Paz,* Jenaro Garcia-Huidobro,† and Natalia A. Ignatenko‡,1 *Cancer Biology Interdisciplinary Graduate Program, Arizona Cancer Center, University of Arizona, Tucson, Arizona, USA † Biochemistry and Molecular and Cellular Biology Graduate Program, University of Arizona, Tucson, Arizona, USA ‡ Department of Cell Biology and Anatomy, Arizona Cancer Center, Tucson, Arizona, USA

1. 2. 3. 4.

Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Overview of Polyamine Regulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Deregulation of Polyamines in Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.1. Deregulation of ODC. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.2. Deregulation of Other Polyamine Metabolic Genes . . . . . . . . . . . . . . . . . . . . . . . . 5. Genetic Variability in ODC Affecting Carcinogenesis. . . . . . . . . . . . . . . . . . . . . . . . . . . . 6. EIF5A and Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7. Chemoprevention Strategies Within Polyamine Pathway. . . . . . . . . . . . . . . . . . . . . . . . . 7.1. Suppression of ODC. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7.2. Induction of SAT1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7.3. Evaluation of Antitumorigenic Properties of DFMO and NSAIDS in Animal Models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7.4. Combination Chemoprevention Strategies in Humans. . . . . . . . . . . . . . . . . . . . . . References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

46 46 47 50 50 53 54 56 60 60 60 62 62 63

Abbreviations COX DAX DFMO FAP 1

cyclooxygenase diamine exporter a-difluoromethylornithine familial adenomatous polyposis

Corresponding author: Natalia A. Ignatenko, e-mail: [email protected] 45

0065-2423/11 $35.00 DOI: 10.1016/B978-0-12-387025-4.00002-9

Copyright 2011, Elsevier Inc. All rights reserved.

46 NSAID ODC SAT1

PAZ ET AL.

nonsteroidal anti-inflammatory drug ornithine decarboxylase spermidine/spermine N1-acetyltransferase

1. Abstract Polyamines are organic cations shown to control gene expression at the transcriptional, posttranscriptional, and translational levels. Multiple cellular oncogenic pathways are involved in regulation of transcription and translation of polyamine-metabolizing enzymes. As a consequence of genetic alterations, expression levels and activities of polyamine-metabolizing enzymes change rapidly during tumorigenesis resulting in high levels of polyamines in many human epithelial tumors. This review summarizes the mechanisms of polyamine regulation by canonical tumor suppressor genes and oncogenes, as well as the role of eukaryotic initiation factor 5A (EIF5A) in cancer. The importance of research utilizing pharmaceutical inhibitors and cancer chemopreventive strategies targeting the polyamine pathway is also discussed.

2. Introduction The natural polyamines (putrescine, spermidine, and spermine) are ubiquitous low molecular weight aliphatic amines that play multifunctional roles in cell growth, differentiation, and survival. Polyamines are unique because of their flexible polycationic nature that allows them to bind electrostatically to negatively charged macromolecules including nucleic acids, acidic proteins, and membranes [1]. Polyamines regulate important cellular processes, including cell proliferation and viability. Genetic evidence indicates that polyamines are required for optimal growth of bacteria [2] and are essential for aerobic growth in yeast [3]. The cellular functions of polyamines also include intestinal mucosal maturation and cell migration [4,5]. Polyamines have been shown to influence transcription, RNA stabilization, and translational frameshifting [6,7]. Complex regulation controls intracellular polyamine pool sizes through combined actions of de novo synthesis, retroconversion, degradation, efflux, and uptake of polyamines. A significant number of reviews have summarized the functions and regulation of polyamines and their potential role in cancer disease [8–14]. The present review is focused on the regulation of polyaminemetabolizing enzymes during neoplastic transformation, evaluation of agents targeting the polyamine pathway to prevent or reverse neoplastic growth, and polyamine-mediated functions of the EIF5A in cells.

POLYAMINES IN CANCER

47

3. Overview of Polyamine Regulation Polyamines are synthesized through the action of the enzyme ornithine decarboxylase (ODC). ODC is the first enzyme in polyamine biosynthesis which catalyzes the formation of putrescine from ornithine. Putrescine is subsequently converted into spermidine through the actions of S-adenosylmethionine decarboxylase 1 (AMD1) and spermidine synthase. Spermidine is then converted into spermine by AMD1 and spermine synthase. Important catabolic effectors maintain polyamine homeostasis as well. Spermidine/ spermine N1-acetyltransferase (SAT1) adds terminal acetyl groups to spermidine and spermine that subsequently promotes the export of acetylated polyamines. Spermine oxidase (SMO) converts spermine to spermidine. Acetylpolyamine oxidase (PAOX) also aids in polyamine homeostasis by converting acetylated spermidine and spermine back to putrescine and spermidine, respectively (Fig. 1). Multiple studies demonstrated that ODC is essential metabolic effector required for normal development in mammals. ODC gene knockout is lethal in murine embryos 3.5 days after fertilization [15]. ODC protein levels in cells are regulated by an ODC inhibitory protein called ornithine decarboxylase antizyme (OAZ) [16,17]. The regulation by antizyme involves the þ 1 frameshift of the translating ribosomes on the antizyme mRNA upon accumulation of polyamines, resulting in increased translation of the antizyme protein [7,16]. Full-length functional antizyme acts as a noncompetitive inhibitor of ODC and enhances ubiquitin-independent ODC degradation by the 26S proteasome [16]. In addition, antizyme increases polyamine efflux and suppresses polyamine uptake, thus decreasing the intracellular polyamine pool [18,19]. Antizyme is regulated by the antizyme inhibitor (AZIN1) which is a homolog of ODC but lacks the decarboxylation activity [20]. AZIN1 sequesters the intracellular pool of antizyme which causes an increase in levels of ODC protein, ODC activity, and polyamine levels. ODC is also regulated through transcriptional activation in response to hormones, growth factors, and tumor promoters via the response elements in the ODC gene promoter. Response elements in the ODC gene include cAMP response element, CAAT, and LSF sequences, activator proteins 1 and 2 (AP1 and AP2) sites, specificity protein (SP1) binding sites, and a TATA box (reviewed in Ref. [21]). Of special interest, the ODC gene promoter contains three Enhancer (E)-boxes (CACGTG) that are binding sites for the MYC, MAX, MAD, and MNT transcription factors [22]. AMD1 converts putrescine into the higher polyamines by producing the aminopropyl donor decarboxylated S-adenozylmethionine (dcSAM). The activity of AMD1 is highly regulated at the level of transcription, translation, and protein turnover [23]. The AMD1 gene contains a number

PAZ ET AL.

48

Ornithine Antizyme DFMO

Degradation

ODC

Putrescine AMD1, spermidine synthase

NH3+

SAT1, PAOX

NH3+

Spermidine +

AMD1, spermine synthase

NH2+

H3N

NH3+

SAT1, PAOX, SMO

Spermine +

H 3N

NH2+ NH2+

NH3+

FIG. 1. Polyamine structure and metabolism. Enzymes are shown in purple squares, except for ODC shown in blue oval (ODC, ornithine decarboxylase; AMD1, S-adenosylmethionine decarboxylase 1; SAT1, spermidine/spermine N1-acetyltransferase; SMO, spermine oxidase; PAOX, acetylpolyamine oxidase). DFMO, a-difluoromethylornithine, an irreversible inhibitor of ODC.

of binding sites for different transcription factors including a spermidine response element. Putrescine can activate mammalian AMD1 by enhancing the production of the processed form of the enzyme and improving its catalytic activity [23]. Protein ubiquitination has also been shown to regulate AMD1 turnover [24,25]. Mammalian spermidine and spermine synthase are regulated by the availability of putrescine or spermidine and dcSAM. The recent studies by Forshell et al. [26] described the induction of the spermidine synthase gene transcription by the c-MYC oncogene in a murine model of B-cell lymphoma. The putative c-MYC binding site is associated with canonic E-boxes located upstream and downstream of exon 1 in the spermidine synthase gene. A key polyamine catabolic enzyme SAT1 is highly inducible in response to a variety of stimuli including elevated polyamine levels, synthetic

POLYAMINES IN CANCER

49

polyamine analogs, toxins, hormones, cytokines, heat-shock, ischemia– reperfusion injuries, and other stresses (reviewed in Ref. [27]). The regulation of SAT1 occurs via an activation of transcription, mRNA processing, mRNA translation, and protein turnover [27–30]. The SAT1 gene contains the binding sites for common regulators of gene expression such as SP1 and AP1, CCAAT/enhancer-binding protein b (C/EBPb), cAMPresponse-element-binding protein (CREB), nuclear factor kB (NF-kB), and peroxisome proliferator-activated receptors (PPARs) transcription factors. SAT1 also contains a polyamine-response element (PRE) which binds polyamines and polyamine-responsive transcription factors [31]. The posttranscriptional regulation of SAT1 involves regulation of mRNA stability, alternative splicing of SAT1 mRNA, translational regulation of SAT1 synthesis, and stabilization of SAT1 protein, which are reviewed elsewhere [32]. Translational regulation through upstream open reading frames (uORFs) plays a significant role in polyamine metabolism. The uORFs precede main coding sequences in mRNA structures of the polyamine metabolic genes ODC, OAZ, AZIN1, AMD1, spermine synthase, and SAT1, and influence the efficiency of polyamine-responsive regulation of their translation [33]. Polyamine transport mechanisms mediate intracellular polyamine homeostasis. Polyamines are imported into the cells from extracellular sources such as luminal bacteria and diet [34]. Belting et al. [35] have shown that the polyamine transport system involves endocytic pathways with cell surface heparin sulfate proteoglycans as a possible vehicle for polyamine uptake. The more recent study by Roy et al. [36] indicates that polyamine uptake occurs via a dynamin-dependent and a clathrinindependent endocytic uptake, and that a plasma membrane lipid raft protein caveolin-1 is a potential regulator of the polyamine pathway. The significance of caveolae-dependent endocytosis in polyamine uptake has also been studied in vivo using genetically engineered mice [37]. This study has shown that putrescine uptake in the intestinal tissue is regulated by a nitric oxide (NOS2)-dependent mechanism; when the intracellular polyamine content is low, uptake is regulated by a glycosylated heavy chain of the cationic amino acid transporter SLC3A2. Polyamines are exported out of mammalian cells in the acetylated form by a diamine exporter (DAX) [38]. Recently, Uemura et al. [39] described the molecular mechanism of polyamine export as a polyamine/arginine exchange reaction which involves the amino acid transporter SLC3A2. In this study, the polyamine catabolic enzyme SAT1 was found to be colocalized with SLC3A2, indicating that this efflux system facilitates excretion of acetylated polyamines. The tight regulation imposed on intracellular polyamine levels underscores the importance of these molecules for optimal cellular growth.

50

PAZ ET AL.

4. Deregulation of Polyamines in Cancer Cancer is a major human health problem worldwide and is the second leading cause of death in the United States [40]. Over the past 40 years, significant progress has been made in understanding the molecular basis of cancer. It has been established that cancer is a neoplastic condition resulting from genetic changes that control the proliferation, maturation, metastatic behavior, and senescence of cells. These genetic changes are diverse in nature and can involve loss or gain of gene function. Tumorigenesis is a multistep process involving the acquisition of chromosomal abnormalities and development of mutations in different genes, which provide cancer cells selective growth advantages and cooperativity that leads to dysregulation of cell growth at multiple levels [41]. During tumorigenesis, cancers evolve mechanisms to deregulate polyamine metabolism. Canonical oncogenes and tumor suppressors have been shown to affect polyamine metabolism in transformed cells. Therefore, it is not surprising that deregulation of polyamine levels appear to play an essential role during tumorigenesis. The pleiotropic effects observed by alterations of the polyamines might be explained by their ability to regulate specific aspects of gene expression and protein translation.

4.1. DEREGULATION OF ODC 4.1.1. Role of ODC in Neoplastic Transformation ODC, a key polyamine biosynthesis enzyme, plays a major role in the process of carcinogenesis. An association between high levels of polyamines and cancer was first reported in the late 1960s by Russell and Snyder [42], who measured high levels of ODC activity in regenerated rat liver and in several human cancers. ODC deregulation occurs in response to a variety of oncogenic stimuli, including cancer promoters 12-O-tetradecanoylphorbol13-acetate and asbestos [43,44]. ODC is also regulated by androgens and ODC gene overexpression has been observed in human prostate cancer [45]. Numerous studies have documented changes in ODC regulation during carcinogenesis at the level of transcription, translation, and protein degradation (reviewed in Refs. [14,46]). The causative role of ODC in carcinogenesis has been observed upon overexpression of ODC by transfection in vitro and in vivo in transgenic mice (reviewed in Refs. [47,48]). Overexpression of the intracellular noncompetitive ODC inhibitor antizyme in transgenic mice has been shown to reduce carcinogenesis [49–51]. These genetic studies corroborate epidemiological studies that have documented elevated ODC expression and activity during colon tumorigenesis [52,53].

POLYAMINES IN CANCER

51

4.1.2. Role of APC and c-MYC in ODC Induction Major oncogenic pathways are involved in regulation of ODC transcription and translation. We, and others, have shown that the ODC gene is regulated by the WNT signaling pathway, one of the major cascade governing epithelial development [54,55]. The adenomatous polyposis coli (APC) tumor suppression gene is a component of the WNT cascade, and is mutated or lost in the germ line of individuals with familial adenomatous polyposis (FAP), a heritable form of colon cancer [56,57]. The APC gene is also mutated in almost 90% of human colon cancers and 30% of melanoma skin cancers. We have shown that ODC gene expression and polyamine contents are elevated in the intestinal tissue, and a specific inhibitor of ODC suppresses intestinal carcinogenesis in the ApcMin/þ mouse, an animal model for FAP [58]. In this model, mutated APC led to a decrease in antizyme and SAT1 expression, indicating that APC controls the polyamine metabolic pathway in the colon. APC mutation is an early event in colon carcinogenesis, and is, therefore, considered to be an initiating event. In carcinogenic tissue, loss of APC and dysregulation of the WNT pathway leads to increased expression of the c-MYC oncogene. APC mutation prevents GSK-3b phosphorylation of b-catenin which would normally lead to its proteosomal degradation. Mutated APC leads to stabilization and accumulation of b-catenin in the nucleus where it forms a complex with TCF/LEF (T-cell factor/lymphoidenhancing factor) transcription factor [59,60]. The heterodimer complex binds to the specific regions in the promoter of c-MYC and other growthrelated genes and alters gene expression profiles [54,59]. c-MYC is a transcription factor that is required for the proliferation of normal cells, and its over expression can lead to uncontrolled growth and cancer [61]. During APC-dependent carcinogenesis, c-MYC activation affects transcription of ODC by binding to E-boxes or MYC-binding regions in the promoter region of the gene. In vivo studies using mouse model with a conditional deletion of c-MYC in the intestinal and colonic mucosa have shown that c-MYC plays an important role in the development of intestinal tumors with activating mutations in the APC gene via increased proliferation and suppressed apoptosis (Fig. 2) [62]. Both c-MYC and ODC present an attractive target for pharmacological inhibition. Transient c-MYC inactivation can be an effective therapy for certain cancers as demonstrated in the transgenic mouse model of osteogenic sarcoma [63]. Selective transcriptional silencing of the c-MYC promoter has been achieved using a porphyrin analog that binds to the G-quadruplex DNA structure within the c-MYC promoter [64,65].

PAZ ET AL.

52 APCmut

c-MYC β-Catenin TCF ODC

DFMO

Polyamines

Proliferation

Apoptosis

Neoplasia

FIG. 2. APC-mediated effects on polyamine biosynthesis and tumorigenesis. APC mutation (APCmut) leads to proliferation and inhibition of apoptosis via upregulation of ornithine decarboxylase (ODC) activity. An irreversible inhibitor of ODC a-difluoromethylornithine (DFMO) is shown in red.

4.1.3. Role of Mutant K-RAS in ODC Induction Activating mutations of K-RAS oncogene have been observed in approximately 30% of human colon tumors [66]. Constitutive RAS activation by the substitution of amino acid residues at various positions is frequently found in human invasive cancers [66]. Oncogenic RAS influences different cellular processes via signaling pathways involving the Akt proto-oncogene, the serine/threonine protein kinase Raf-1, and the Rho small GTPase family [67]. The RAS gene family, consisting of H-RAS, K-RAS, and N-RAS genes, can also increase reactive oxygen species (ROS) levels via the RAS-mitogenactivated protein kinase kinase (MAPKK) and mitogen-activated protein kinase (MAPK) pathways [68]. Transformation of NIH 3T3 cells with the human H-RAS oncogene causes significant increase in ODC expression and polyamine contents [69]. Mutant K-RAS oncogene also increases cellular polyamine levels by increasing ODC enzyme activity [70]. Detailed analysis

POLYAMINES IN CANCER

53

of the RAS pathway using RAS partial-loss-of-function mutants and inhibitors showed that the regulation of ODC transcription occurs via Raf/Mek/ Erk pathway, while the PI3-kinase pathway mediates ODC translation [71]. 4.2. DEREGULATION OF OTHER POLYAMINE METABOLIC GENES 4.2.1. Deregulation of SAT1 During Tumorigenesis SAT1 is a key polyamine catabolic enzyme and an important regulatory step in maintaining polyamine content. In vitro experiments and genetic manipulations with SAT1 expression in experimental animal models confirmed SAT1 functions to facilitate polyamine efflux from cells [72,73]. Because tumorigenesis is associated with increased polyamine biosynthesis and polyamine levels, SAT1 expression and enzyme activity are regulated in response to these alterations via an increase in transcription, translation, and suppression of protein turnover (reviewed in Ref. [32]). Elevated SAT1 enzyme activity results in a sustained increase in acetylated polyamine levels that facilitates their excretion and degradation via the SAT1/PAOX pathway. Cancer can develop mechanisms to prevent the induction of SAT1 in order to maintain high polyamine levels. Particularly, it has been shown that the RAS pathway is implicated in SAT1 regulation via decreased expression of PPARg, a member of the nuclear hormone receptor family and an important regulator of cell proliferation and differentiation [74]. Specifically, an activated K-RAS suppressed SAT1 expression by a mechanism involving the PPARg response element 2 (PPRE-2) located at þ48 bp relative to the transcription start site of the SAT1 gene. SAT1 expression can be restored by transient expression of the PPARg protein, by treatment with the PPARg ligand ciglitazone or with the MEK1/2 inhibitor PD98059, suggesting that MAPKs are involved in the regulation of SAT1 expression by PPARg [75]. RAS is therefore a negative regulator of SAT1 that results in high polyamine levels. SAT1 expression can also influence tumorigenesis. Studies performed using genetically engineered mouse models showed that overexpression of the mouse Sat1 gene is associated with increased intestinal tumorigenesis and the knockout of Sat1 reversed this progression [76]. 4.2.2. Tumorigenesis and Polyamine Transport Experimental and clinical studies provide evidence that the polyamine transport system is hampered during neoplastic transformation. The study by Nilsson et al. [77] shows that polyamine uptake plays a significant role in the progression to lymphomagenesis. In the intestinal tract, it has been shown that

54

PAZ ET AL.

depletion of exogenous polyamines which are normally obtained from either microbial flora activity or food, using antibiotics or polyamine-deficient diet, resulted in a compensatory increase in polyamine uptake [78,79]. Bachrach and Seiler have shown that various oncogenes can increase polyamine uptake as well [80]. The upregulation of polyamine uptake in cells expressing an activated K-RAS occurs via SRC-dependent caveolin-1 phosphorylation at tyrosine residue 14 and modulation of the urokinase plasminogen activated receptor [36,81]. Mutant K-RAS oncogene also acts to suppress the polyamine export system via negative regulation of SLC3A2 protein [39]. Roy et al. [36] provided evidence for the negative regulation of polyamine uptake by caveolin-1, which can function as a tumor suppressor [82].

5. Genetic Variability in ODC Affecting Carcinogenesis The ODC gene has three E-boxes in the region from 400 to þ 400 bp relative to the start of transcription. The heterodimer transcriptional activator c-MYC/MAX or transcriptional repressor MAD1/MAX binds to these E-box elements to regulate the transcription level of ODC gene in proliferative cells [21,22]. ODC promoter activity is influenced by cooperative interactions involving these neighboring E-boxes. A single nucleotide polymorphism (SNP) exists in intron 1 of the human ODC gene between two E-boxes with a G/A variation located 316 nucleotides downstream of the transcriptional start site [83,84]. Since ODC expression has been linked to cancer development, individuals with specific sets of SNPs may exhibit an increased predisposition for colon polyp development. According to the model of colon tumorigenesis proposed by Fearon and Vogelstein in 1990, colorectal cancer develops as a multistep process that involves the progression from normal mucosa to small and large adenomas leading to invasive cancer and metastasis [41,85,86]. Removal of adenomas is associated with a lower risk of colorectal cancer; however, recurrence is common [87,88]. It is also recognized that not all colon polyps will progress to invasive cancer [89,90]. The relationship between the ODC polymorphism and the risk of adenoma recurrence has been assessed in participants of a large randomized, double-blind wheat bran fiber colon cancer; prevention trial at the Arizona Cancer Center in Tucson, Arizona [90,91]. A substantial and statistically significant effect of the ODC polymorphism on risk of adenoma recurrence has been found on this trial in aspirin users with a strong correlation between recurrent polyp size and risk of colon cancer. This suggests a modification to the accepted model of the step-wide molecular process involved in the original polyp-carcinoma sequence. The actual model proposed by Martinez et al. [90,91] predicts that carcinogenesis

55

POLYAMINES IN CANCER

resulting from certain initiating events (e.g., chemical carcinogens and genetic rick factor), and the responses to chemoprevention strategies are influenced by genetic variability among individuals (Fig. 3). Specifically, the þ 316 nucleotides SNP in the ODC promoter displayed functional consequences for E-box activation (e.g., c-MYC) and repression (e.g., MAD1), and association with recurrence of colon polyps. This association, between the genetic variability affecting ODC expression and the risk of colorectal adenoma recurrence, has since been confirmed in a number of studies, particularly for aspirin users [92–94]. A positive [95] and negative [96] association has been shown between sporadic colorectal cancer and genetic variability in ODC gene. The risk of adenoma recurrence was found lower in AA homozygous individuals who reported taking aspirin [91]. Barry et al. [93] in the Aspirin/ Folate Polyp Prevention Study found no association between ODC genotype and colorectal cancer recurrence in individuals randomly assigned to placebo

Epithelium Genetic and epigenetic changes (APC loss or mutate)

Genetic variability (SNP)

Small adenomas

Large adenomas

ODC 316 SNP A-allele

G-allele

Recurrence (cancer risk stratification)

No recurrence

Small adenomas

Large adenomas

Cancer

FIG. 3. Association between genetic variability and G316A ODC SNP. Genetic and epigenetic changes are associated with cancer progression where the final outcome is influenced by the original polyp sizes and genetic variability of G316A ODC SNP.

56

PAZ ET AL.

or aspirin treatment (81 or 325 mg daily). This study also found that ODC genotype modified the effect of aspirin on adenoma risk. Although aspirin treatment had no protective effect among subjects with a GG genotype, it was associated with statistically significant reduced risks of any adenoma among subjects with at least one A allele. Hubner et al. [94] in a United Kingdom Colorectal Adenoma Prevention trial reported that the rare 316AA homozygotes had reduced colorectal adenoma recurrence risk, with an additional lower recurrence risk if aspirin was administered. At the same time, a recent study from Hughes et al. reported no correlation between ODC 316 SNP with colorectal adenomas in the Czech Republic case control series with no data on aspirin [96]. A population-based study of 400 of stages I–III colorectal cancer cases from the California Irvine Gene-Environment Study of Familial Colorectal Cancer reported that the specific outcome of colorectal cancer patients is dependent on the ODC 316 SNP genotype with the higher colorectal cancer-specific risk of death for individuals with ODC GA/ AA genotypes [95]. In summary, the ODC A-allele may be protective for colon adenoma recurrence and detrimental for survival after colon cancer diagnosis. However, it is unlikely to play a major role in susceptibility to colorectal cancer development.

6. EIF5A and Cancer Polyamine metabolism has been linked to protein synthesis through the unique posttranslational modification of the universal translation factor EIF5A. EIF5A is an essential gene that encodes a protein that is approximately 17 kDa in size and is conserved among eukaryotes and archaebacteria [97]. EIF5A is the only known protein that is modified at a specific lysine residue to yield hypusine. Although EIF5A has been extensively studied, its biological role has not been fully elucidated. Early studies using a methionylpuromycin assay suggested a translation initiation role for EIF5A, as it promoted first peptide formation [98]. However, subsequent reports have argued against a general translation initiation role due to the finding demonstrating the depletion of EIF5A in yeast only causing a minor decrease in protein synthesis [99]. Although EIF5A is still under intense investigation, its growth altering potential has provided yet another link between polyamines, eukaryotic translation, and cancer. Hypusination of EIF5A requires the polyamine biosynthetic pathway. It is mediated by two enzymes: deoxyhypusine synthase (DHS) and deoxyhypusine hydroxylase (DOHH). EIF5A hypusination is initiated by DHS transferring an aminobutyl moiety from the polyamine spermidine onto a specific EIF5A

POLYAMINES IN CANCER

57

lysine residue. Deoxyhypusine is then hydroxylated by DOHH to yield hypusine. The importance of EIF5A hypusination is reflected through findings showing that mutating the lysine residue required for the posttranslational modification leads to growth defects in Saccharomyces cerevisae [100]. The importance of spermidine levels for EIF5A modification has also been highlighted through a study of yeast polyamine auxotrophs that were grown in low levels of spermidine. It was shown that yeast polyamine auxotrophs use a large proportion of the limited supply of spermidine for hypusination, emphasizing its importance for supporting growth [101]. Studies have also shown the vital importance of both DHS and DOHH for cell proliferation and are reviewed elsewhere [102]. The essential nature of hypusination in EIF5A reflects its importance for normal cell growth and in order to fully understand its effects, the identification of more functional binding partners may increase our understanding of its function during tumorigenesis. A recent study conducted by Lebska et al. demonstrated that maize EIF5A (ZmEIF5A) is phosphorylated at Serine 2 (Ser2) by casein kinase 2 (CK2) resulting in nuclear shuttling [103]. A proteomic approach in which CK2 binding partners were identified through mass spectrometry resulted in identification of ZmEIF5A as a novel potential substrate. Through an elegant approach, a thrombin cleavage assay was used to confirm that Ser2 of maize EIF5A is indeed phosphorylated. Phosphorylation of ZmEIF5A ultimately resulted in nuclear translocation. Confocal microscopy confirmed that replacing Ser2 with aspartic acid increased the ratio of nuclear ZmEIF5A. Although mammalian cells may not possess the Ser2 phosphorylation site, the possibility that the temporal–spatial control of EIF5A during growth is regulated by posttranslational modifications may provide insight about its biological role. One such report suggested that hypusinated EIF5A localizes mainly in the cytoplasm [104]. Although EIF5A’s role during translation has been established, further studies focusing on the nuclear presence of EIF5A could provide novel information regarding its oncogenic potential. EIF5A is also a translation factor that shares structural homology to elongation factor P (EF-P) of eubacteria. It has been suggested that EIF5A stabilizes tRNAi Met for peptidyl transferase center (PTC) positioning in the ribosome [105]. A recent report by Lee et al. [106] demonstrated a crystal structure of Thermus thermophilus EF-P bound to the 70S ribosome which promoted the alignment of charged initiator tRNA to the P site of the ribosome. EF-P was shown to bind between the P site and the E site, and appears to encourage conformational changes of a mature ribosome. The specific location of EF-P is thought to promote first peptide bond formation by properly positioning the tRNA molecule in the P site through noncovalent interactions to the tRNA backbone. Interestingly, a hypusine homology model was rendered that demonstrated the potential of a hypothetical

58

PAZ ET AL.

hypusinated EF-P extending the hypusine chain near the PTC where the catalytic mechanism for peptide bond formation resides. This model suggests that hypusination might facilitate first peptide bond formation by promoting a thermodynamically favorable microenvironment in the PTC for protein synthesis. A biochemical model where hypusination is demonstrated to affect the activation entropy for peptide bond formation in an 80S PTC would strengthen the T. thermophilus hypusine homology model hypothesis. The findings that EIF5A is structurally similar to EF-P provide evidence for a direct role of EIF5A in elongation. GST pulldown assays have previously demonstrated that GST-EIF5A copurifies with eEF2, the 60S ribosomal protein P0, and a small ribosomal protein S5 [107], and demonstrated that EIF5A associates mostly with translationally active ribosomes. A recent paper published by Saini et al. [108] provided further evidence that EIF5A is a universally conserved elongation factor. An EIF5A degron mutant (tif51a-td) was constructed and grown in both permissive and nonpermissive temperatures to determine the effects of this translation factor on growth, protein production, and polysome profiles. Growth of the degron mutant at the nonpermissive temperature reduced the growth rate of the tif51a-td yeast strain, highlighting the essential requirement of EIF5A. Depletion of EIF5A also resulted in diminished levels of [35S]methionine protein incorporation. Sucrose gradient analysis further showed that the tif51a-td strain did not appear to have translation initiation defects, but that the retention of polysomes and slower ribosomal run-off suggested EIF5A plays a role during the elongation step of translation [108]. This finding was further corroborated by a report that mammalian EIF5A promotes translation elongation and stress granule formation [109]. In humans, there are two isoforms of EIF5A that share considerable sequence homology of approximately 84% at the amino acid level. Although the EIF5A1 isoform is constitutively expressed, EIF5A2 appears to be restricted to specific tissues. Using a human multiple-tissue expression array, it was demonstrated that EIF5A2 is expressed most highly in testis, adult neuronal tissues, and the colon adenocarcinoma cell line SW480 [110]. Consistent with this finding, other cancer cell lines, including ovarian cell line UACC-1598, displayed higher levels of EIF5A2 expression [111]. Multiple studies have now shown that EIF5A2 and polyamine-metabolizing enzymes are overexpressed in many human cancer cell models (Fig. 4). EIF5A2 is located near chromosome 3q26, which is a site of multiple amplification events in many solid tumors. Overexpressed EIF5A2 in NIH3T3 cells has been shown to increase colony formation in soft agar, while hydroxyurea treatment of the ovarian cell line UACC 1598 resulted in reduction of both EIF5A2 copy number and cell growth rate [112]. In an in vivo RNAi screen to identify tumor suppressors in hepatocellular

59

POLYAMINES IN CANCER

Arginine

Ornithine

APCmut ODC

ODC RNA

ODC Putrescine

MYC

SAM

EIF5A2

dcSAM

EIF5A2 RNA

EIF5A2 (lysine 50)

AMD1

AMD1 RNA

AMD1

SRM

SRM RNA

SRM Spermidine

EIF5A2 (hypusine 50)

Oncogenic potential

FIG. 4. Role of eukaryotic translation initiation factor 5A2 (EIF5A2) in tumorigenesis and its relationship to polyamine biochemical pathway. APC and c-MYC target genes in the polyamine pathway to increase the intracellular polyamine levels. Spermidine, which is the substrate to the posttranslational modification of EIF5A2, converts a lysine residue to the novel amino acid hypusine in the EIF5A protein. Two unique chromosomal loci encode EIF5A1 and EIF5A2 isoforms.

carcinomas, exportin 4 (XPO4) was shown to genetically interact with EIF5A2 [113]. By utilizing a subcutaneous tumor growth assay, it was shown that EIF5A2 expression resulted in tumor formation of p53/;Myc liver progenitor cells. An MTT assay further demonstrated that knockdown of EIF5A2 led to decreased growth of a human hepatoma cell line with an XPO4 deletion (SK-Hep1). Furthermore, a colony formation assay of SKHep1 cells verified that EIF5A2 knockdown resulted in inhibition of proliferation. Previous reports indicated that XPO4 mediates export of EIF5A1 and Smad3 from the nucleus [113–115]. In fact, Zender et al. also demonstrated that XPO4 deletion resulted in EIF5A1 and EIF5A2 nuclear accumulation. Interestingly, EIF5A1 expression did not appear to induce higher subcutaneous tumor growth in mice. Although both translation factors appear to share large sequence homology, there is a biologically significant amount of difference leading to contrasting phenotypes. Future studies

60

PAZ ET AL.

characterizing the role of EIF5A during cancer progression could provide novel information that could be exploited for novel drugs targeting EIF5A.

7. Chemoprevention Strategies Within Polyamine Pathway 7.1. SUPPRESSION OF ODC a-Difluoromethylornithine (DFMO) is the most widely used inhibitor of polyamine metabolism. DFMO was developed over three decades ago and is now used in both experimental studies [11] and clinical applications, including cancer prevention [116] and hair removal [117]. Racemic DFMO was shown to be an enzyme-activated, irreversible inhibitor of ODC [118]. Biochemical mechanisms for inactivation of ODC by DFMO have been proposed [119] and genetic studies have corroborated features of this model [120]. Upon treatment with DFMO, there are significant cytostatic effects on eukaryotic cells. The ability of DFMO-treated cells to regain proliferation upon addition of exogenous putrescine suggests a clear functional role of polyamines during cellular growth and proliferation. In vivo, DFMO treatment inhibited dietary arginine-induced colon carcinogenesis and reduced adenoma dysplasia grade in ApcMin/þ mice [121]. DFMO has been evaluated as a cancer therapeutic agent, but the results were generally not encouraging [122]. More recent experimental studies suggest that the failure of DFMO as a single agent, in either the cancer prevention or treatment setting, is due to compensatory mechanisms affecting polyamine transport and catabolism [8]. The experimental evidence suggests that DFMO can selectively reduce viability of colon cancer cells expressing mutant K-RAS oncogene [123]. This finding was corroborated by Lan et al. [124], who reported reduction of the growth of chemically induced skin tumors in mice by DFMO. DFMO also caused regression of existing spontaneous tumors in transgenic mice over expressing both ODC and mutant H-RAS in keratinocytes. DFMO was also found to be effective in suppressing the mutant K-RAS-mediated colon tumorigenesis in vivo since it reversed the changes in experimental cell migration and cell–cell communication genes [70]. 7.2. INDUCTION OF SAT1 Several structurally diverse nonsteroidal anti-inflammatory drugs (NSAIDs) act to promote transcription of the SAT1 by both COX-dependent and COX-independent mechanisms. Laboratory work demonstrated that sulindac sulfone [125] and aspirin [126] induce SAT1 transcription. The sulfone derivative of sulindac, which recognizes a unique DNA sequence

61

POLYAMINES IN CANCER

in the SAT1 promoter, activates SAT1 gene to induce its transcription. The mechanism of activation involves the induction of PPARg protein and its binding to one of the peroxisome proliferators-activated receptors response elements (PPREs) in the SAT1 gene, namely PPRE-2. PPRE-2 is located þ 48 bp relative to the transcription start site; PPRE-1, which is located 323 bp relative to the start site, is not required for the induction of SAT1. Aspirin, which is structurally unrelated to sulindac, induces SAT1 transcription via a distinct mechanism involving NF-kΒ sites in the SAT1 promoter [126]. Studies in animal models confirm the in vitro findings and indicate that sulindac can suppress ODC enzyme activity in addition to activating SAT1 gene expression [127]. Effects on polyamine metabolism are a component of the COX-independent mechanisms by which some NSAIDS inhibit colon carcinogenesis, as depicted in Fig. 5. SAT1 expression is also induced by some synthetic polyamine analogs. Polyamine analogs are compounds that can interfere with polyamine functions in cells causing inhibition of tumor growth (for review, see [9]). Three classes of synthetic polyamine analogs have been developed: symmetrically substituted, asymmetrically substituted, and conformationally restricted analogs. These classes demonstrate multiple biological activities and improved targeting

APCmut K-RASmut

DFMO

ODC

Polyamines

Invasion

SAT1

Sulindac

Proliferation

Neoplasia

FIG. 5. Combination chemoprevention strategies targeting polyamine metabolism in cancer. Mutant APC (APCmut) and activated K-RAS (K-RAS mut) lead to upregulation of ODC and suppression of SAT1, respectively, which increases the polyamine concentration. Combined action of an irreversible ODC inhibitor DFMO and nonsteroidal anti-inflammatory drug sulindac will prevent polyamine-dependent cell proliferation and invasion and suppress neoplasia.

62

PAZ ET AL.

abilities with small changes in molecular structure [9]. Mechanisms by which polyamine analogs exert their intracellular effects include the induction of catabolism and the displacement of natural polyamines from functional sites related to the transcriptional regulation of genes [128]. Polyamine analogs with the N-terminal alkyl group, such as symmetrically substituted analog BENSpm, cause significant and prolong activation of SAT1 enzyme activity by binding to the active site of the SAT1 protein at the polyamine-binding region causing its accumulation [29]. Other analogs, such as PG-11047, which belong to a class of conformationally restricted compounds, increase the SAT1 transcript level and deplete cellular spermidine leading to total polyamine depletion in colon cancer cells [129]. Since the synthetic polyamine analogs have antitumor activity, they are currently under clinical evaluation, alone and in combination with established drugs, such as DFMO, for the targeted depletion of polyamine levels and suppression of tumor growth. 7.3. EVALUATION OF ANTITUMORIGENIC PROPERTIES OF DFMO AND NSAIDS IN ANIMAL MODELS The molecular targets for antitumor activity of NSAIDs sulindac and celecoxib within the polyamine pathway have been evaluated using the experimental animal models including ApcMin/þ mice. Specifically, sulindac increased steady state RNA levels and enzymatic activity of the polyamine catabolic enzyme SAT1 [127]. Sulindac also decreased the activity of the biosynthetic enzyme ODC, but not AMD1. The effectiveness of sulindac to suppress intestinal carcinogenesis was partially abrogated by dietary putrescine [127]. Since high concentrations of putrescine can be found in certain dietary components, it may be advantageous to restrict dietary putrescine consumption in patients undergoing treatment with sulindac. The combination of DFMO with sulindac, a nonselective inhibitor of both COX-1 and COX-2, or celecoxib, a selective COX-2 inhibitor, was additive in suppressing tumorigenesis in ApcMin/þ mice [130]. At the same time, the combination of DFMO with sulindac was more effective in reducing the intestinal polyamine contents and incidence of high-grade intestinal adenomas than combination of DFMO with celecoxib [130]. 7.4. COMBINATION CHEMOPREVENTION STRATEGIES IN HUMANS The described experimental studies set a stage for the clinical trials of DFMO and sulindac. In 2000, the University of California-Irvine and the University of Arizona started a collaboration to conduct a prospective, randomized clinical trial of 150 mg sulindac, combined with 500 mg DFMO, daily for 3 years versus placebo [11,131]. The phase III clinical

POLYAMINES IN CANCER

63

trial assessed the toxicity of this combination. The low nontoxic dose of DFMO used in this study was sufficient to suppress ODC in human rectal mucosa [122,132]. The major endpoint of the trial was colon polyp recurrence. This randomized trial showed markedly reduced recurrence of all adenomas (70% decrease), advanced adenomas (92% decrease), and recurrence of more than one adenoma (95% decrease) [116]. Putrescine and spermidine levels of rectal mucosal biopsies were also markedly reduced in the active intervention arm after both 12 and 36 months of treatment; PGE2 levels were unaffected. All toxicities, including clinical, audiologic, and cardiovascular affects, were not significantly different between the treatment and placebo groups. Larger and longer term studies will evaluate the absolute risk of this treatment [133]. The polyamine transport system presents another chemoprevention target for lowering the polyamine contents in cancer cells. A group of lipophilic polyamine analogs has been recently developed that inhibit the cellular polyamine uptake system and significantly increase the effectiveness of polyamine depletion when combined with DFMO [134]. Overall, polyamine metabolism offers an attractive direction for future advances in treatment of cancer risk factors. ACKNOWLEDGMENTS Authors would like to express their gratitude to Dr. Eugene W. Gerner, Department of Cell Biology and Anatomy, Arizona Cancer Center, for providing the helpful comments to this chapter and Rhiannon McGuire, MBA, Arizona Cancer Center, for her assistance in editing this chapter. Authors apologize to the contributors to this field, whose work is not cited due to space constraints.

REFERENCES [1] T. Thomas, T.J. Thomas, Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications, Cell. Mol. Life Sci. 5 (2001) 244–258. [2] H. Tabor, E.W. Hafner, C.W. Tabor, Construction of an Escherichia coli strain unable to synthesize putrescine, spermidine, or cadaverine: characterization of two genes controlling lysine decarboxylase, J. Bacteriol. 144 (1980) 952–956. [3] D. Balasundaram, C.W. Tabor, H. Tabor, Spermidine or spermine is essential for the aerobic growth of Saccharomyces cerevisiae, Proc. Natl. Acad. Sci. USA 88 (1991) 5872–5876. [4] G.D. Lux, L.J. Marton, S.B. Baylin, Ornithine decarboxylase is important in intestinal mucosal maturation and recovery from injury in rats, Science 210 (1980) 195–198. [5] S.A. McCormack, L.R. Johnson, Polyamines and cell migration, J. Physiol. Pharmacol. 52 (2001) 327–349. [6] K. Igarashi, K. Kashiwagi, Polyamines: mysterious modulators of cellular functions, Biochem. Biophys. Res. Commun. 271 (2000) 559–564. [7] S. Matsufuji, T. Matsufuji, Y. Miyazaki, Y. Murakami, J.F. Atkins, R.F. Gesteland, et al., Autoregulatory frameshifting in decoding mammalian ornithine decarboxylase antizyme, Cell 80 (1995) 51–60.

64

PAZ ET AL.

[8] U.K. Basuroy, E.W. Gerner, Emerging concepts in targeting the polyamine metabolic pathway in epithelial cancer chemoprevention and chemotherapy, J. Biochem. 139 (2006) 27–33. [9] R.A. Casero Jr., L.J. Marton, Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases, Nat. Rev. Drug Discov. 6 (2007) 373–390. [10] A.C. Childs, D.J. Mehta, E.W. Gerner, Polyamine-dependent gene expression, Cell. Mol. Life Sci. 60 (2003) 1394–1406. [11] E.W. Gerner, F.L. Meyskens Jr., Polyamines and cancer: old molecules, new understanding, Nat. Rev. Cancer 4 (2004) 781–792. [12] J. Janne, L. Alhonen, M. Pietila, T.A. Keinanen, Genetic approaches to the cellular functions of polyamines in mammals, Eur. J. Biochem. 271 (2004) 77–894. [13] A.E. Pegg, Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy, Cancer Res. 48 (1988) 759–774. [14] A.E. Pegg, Mammalian polyamine metabolism and function, IUBMB Life 61 (2009) 880–894. [15] H. Pendeville, N. Carpino, J.C. Marine, Y. Takahashi, M. Muller, J.A. Martial, et al., The ornithine decarboxylase gene is essential for cell survival during early murine development, Mol. Cell. Biol. 21 (2001) 6549–6558. [16] P. Coffino, Regulation of cellular polyamines by antizyme, Nat. Rev. Mol. Cell Biol. 2 (2001) 188–194. [17] C. Kahana, Regulation of cellular polyamine levels and cellular proliferation by antizyme and antizyme inhibitor, Essays Biochem. 46 (2009) 47–61. [18] K. Hoshino, E. Momiyama, K. Yoshida, K. Nishimura, S. Sakai, T. Toida, et al., Polyamine transport by mammalian cells and mitochondria: role of antizyme and glycosaminoglycans, J. Biol. Chem. 280 (2005) 42801–42808. [19] J.L. Mitchell, G.G. Judd, A. Bareyal-Leyser, S.Y. Ling, Feedback repression of polyamine transport is mediated by antizyme in mammalian tissue-culture cells, Biochem. J. 299 (Pt 1) (1994) 19–22. [20] S. Hayashi, Y. Murakami, S. Matsufuji, Ornithine decarboxylase antizyme: a novel type of regulatory protein, Trends Biochem. Sci. 21 (1996) 27–30. [21] A.E. Pegg, Regulation of ornithine decarboxylase, J. Biol. Chem. 281 (2006) 14529–14532. [22] J.A. Nilsson, K.H. Maclean, U.B. Keller, H. Pendeville, T.A. Baudino, J.L. Cleveland, Mnt loss triggers Myc transcription targets, proliferation, apoptosis, and transformation, Mol. Cell. Biol. 24 (2004) 1560–1569. [23] A.E. Pegg, H. Xiong, D.J. Feith, L.M. Shantz, S-adenosylmethionine decarboxylase: structure, function and regulation by polyamines, Biochem. Soc. Trans. 26 (1998) 580–586. [24] C. Kahana, Ubiquitin dependent and independent protein degradation in the regulation of cellular polyamines, Amino Acids 33 (2007) 225–230. [25] A. Yerlikaya, B.A. Stanley, S-adenosylmethionine decarboxylase degradation by the 26 S proteasome is accelerated by substrate-mediated transamination, J. Biol. Chem. 279 (2004) 12469–12478. [26] T.P. Forshell, S. Rimpi, J.A. Nilsson, Chemoprevention of B-cell lymphomas by inhibition of the Myc target spermidine synthase, Cancer Prev. Res. (Phila.) 3 (2010) 140–147. [27] A.E. Pegg, Spermidine/spermine-N(1)-acetyltransferase: a key metabolic regulator, Am. J. Physiol. Endocrinol. Metab. 294 (2008) E995–1010. [28] F. Golab, M. Kadkhodaee, M. Zahmatkesh, M. Hedayati, H. Arab, R. Schuster, et al., Ischemic and non-ischemic acute kidney injury cause hepatic damage, Kidney Int. 75 (2009) 783–792. [29] Y. Wang, R.A. Casero Jr., Mammalian polyamine catabolism: a therapeutic target, a pathological problem, or both? J. Biochem. 139 (2006) 17–25.

POLYAMINES IN CANCER

65

[30] K. Zahedi, A.B. Lentsch, T. Okaya, S. Barone, N. Sakai, D.P. Witte, et al., Spermidine/ spermine-N1-acetyltransferase ablation protects against liver and kidney ischemiareperfusion injury in mice, Am. J. Physiol. 296 (2009) G899–G909. [31] Y. Wang, W. Devereux, T.M. Stewart, R.A. Casero Jr., Cloning and characterization of human polyamine-modulated factor-1, a transcriptional cofactor that regulates the transcription of the spermidine/spermine N(1)-acetyltransferase gene, J. Biol. Chem. 274 (1999) 22095–22101. [32] R.A. Casero, A.E. Pegg, Polyamine catabolism and disease, Biochem. J. 421 (2009) 323–338. [33] I.P. Ivanov, J.F. Atkins, A.J. Michael, A profusion of upstream open reading frame mechanisms in polyamine-responsive translational regulation, Nucleic Acids Res. 38 (2010) 353–359. [34] E. Larque, M. Sabater-Molina, S. Zamora, Biological significance of dietary polyamines, Nutrition 23 (2007) 87–95. [35] M. Belting, K. Mani, M. Jonsson, F. Cheng, S. Sandgren, S. Jonsson, et al., Glypican-1 is a vehicle for polyamine uptake in mammalian cells: a pivotal role for nitrosothiol-derived nitric oxide, J. Biol. Chem. 278 (2003) 47181–47189. [36] U.K. Roy, N.S. Rial, K.L. Kachel, E.W. Gerner, Activated K-RAS increases polyamine uptake in human colon cancer cells through modulation of caveolar endocytosis, Mol. Carcinog. 47 (2008) 538–553. [37] T. Uemura, D.E. Stringer, K.A. Blohm-Mangone, E.W. Gerner, Polyamine transport is mediated by both endocytic and solute carrier transport mechanisms in the gastrointestinal tract, Am. J. Physiol. 299 (2010) G517–G522. [38] X. Xie, R.J. Gillies, E.W. Gerner, Characterization of a diamine exporter in Chinese hamster ovary cells and identification of specific polyamine substrates, J. Biol. Chem. 272 (1997) 20484–20489. [39] T. Uemura, H.F. Yerushalmi, G. Tsaprailis, D.E. Stringer, K.E. Pastorian, L. Hawel, Identification and characterization of a diamine exporter in colon epithelial cells, J. Biol. Chem. 283 (2008) 26428–26435. [40] A. Jemal, R. Siegel, J. Xu, E. Ward, Cancer statistics, CA Cancer J. Clin. 60 (2010) 277–300. [41] E.R. Fearon, B. Vogelstein, A genetic model for colorectal tumorigenesis, Cell 61 (1990) 759–767. [42] D. Russell, S.H. Snyder, Amine synthesis in rapidly growing tissues: ornithine decarboxylase activity in regenerating rat liver, chick embryo, and various tumors, Proc. Natl. Acad. Sci. USA 60 (1968) 1420–1427. [43] N. Ahmad, A.C. Gilliam, S.K. Katiyar, T.G. O’Brien, H. Mukhtar, A definitive role of ornithine decarboxylase in photocarcinogenesis, Am. J. Pathol. 159 (2001) 885–892. [44] J.P. Marsh, B.T. Mossman, Role of asbestos and active oxygen species in activation and expression of ornithine decarboxylase in hamster tracheal epithelial cells, Cancer Res. 51 (1991) 167–173. [45] R.R. Mohan, A. Challa, S. Gupta, D.G. Bostwick, N. Ahmad, R. Agarwal, et al., Overexpression of ornithine decarboxylase in prostate cancer and prostatic fluid in humans, Clin. Cancer Res. 5 (1999) 143–147. [46] L.M. Shantz, V.A. Levin, Regulation of ornithine decarboxylase during oncogenic transformation: mechanisms and therapeutic potential, Amino Acids 33 (2007) 213–223. [47] K. George, A. Iacobucci, J. Uitto, T.G. O’Brien, Identification of an X-linked locus modifying mouse skin tumor susceptibility, Mol. Carcinog. 44 (2005) 212–218. [48] C.S. Hayes, K. DeFeo, L. Lan, B. Paul, C. Sell, S.K. Gilmour, Elevated levels of ornithine decarboxylase cooperate with Raf/ERK activation to convert normal keratinocytes into invasive malignant cells, Oncogene 25 (2006) 1543–1553.

66

PAZ ET AL.

[49] D.J. Feith, S. Origanti, P.L. Shoop, S. Sass-Kuhn, L.M. Shantz, Tumor suppressor activity of ODC antizyme in MEK-driven skin tumorigenesis, Carcinogenesis 27 (2006) 1090–1098. [50] D.J. Feith, L.M. Shantz, A.E. Pegg, Targeted antizyme expression in the skin of transgenic mice reduces tumor promoter induction of ornithine decarboxylase and decreases sensitivity to chemical carcinogenesis, Cancer Res. 61 (2001) 6073–6081. [51] X. Tang, A.L. Kim, D.J. Feith, A.E. Pegg, J. Russo, H. Zhang, et al., Ornithine decarboxylase is a target for chemoprevention of basal and squamous cell carcinomas in Ptch1+/ mice, J. Clin. Invest. 113 (2004) 867–875. [52] F.M. Giardiello, S.R. Hamilton, L.M. Hylind, V.W. Yang, P. Tamez, R.A. Casero Jr., Ornithine decarboxylase and polyamines in familial adenomatous polyposis, Cancer Res. 57 (1997) 199–201. [53] G.D. Luk, S.B. Baylin, Ornithine decarboxylase as a biologic marker in familial colonic polyposis, N. Engl. J. Med. 311 (1984) 80–83. [54] K.E. Fultz, E.W. Gerner, APC-dependent regulation of ornithine decarboxylase in human colon tumor cells, Mol. Carcinog. 34 (2002) 10–18. [55] L. Mishra, K. Shetty, Y. Tang, A. Stuart, S.W. Byers, The role of TGF- and Wnt signaling in gastrointestinal stem cells and cancer, Oncogene 24 (2005) 5775–5789. [56] J. Groden, A. Thliveris, W. Samowitz, M. Carlson, L. Gelbert, H. Albertson, et al., Identification and characterization of the familial adenomatous polyposis coli gene, Cell 66 (1991) 589–600. [57] K.W. Kinzler, M.C. Nilbert, L.K. Su, B. Vogelstein, T.M. Bryan, D.B. Levy, et al., Identification of FAP locus genes from chromosome 5q21, Science 253 (1991) 661. [58] S.H. Erdman, N.A. Ignatenko, M.B. Powell, K.A. Blohm-Mangone, H. Holubec, J.M. Guillen-Rodrigez, et al., APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse, Carcinogenesis 20 (1999) 1709–1713. [59] T.C. He, A.B. Sparks, C. Rago, H. Hermeking, L. Zawel, L.T. da Costa, et al., Identification of c-MYC as a target of the APC pathway, Science 281 (1998) 1509–1512. [60] T. Reya, H. Clevers, Wnt signalling in stem cells and cancer, Nature 434 (2005) 843–850. [61] H. Hermeking, The MYC oncogene as a cancer drug target, Curr. Cancer Drug Targets 3 (2003) 163–175. [62] N.A. Ignatenko, H. Holubec, D.G. Besselsen, K.A. Blohm-Mangone, J.L. Padilla-Torres, R.B. Nagle, et al., Role of c-Myc in intestinal tumorigenesis of the ApcMin/+ mouse, Cancer Biol. Ther. 5 (2006) 1658–1664. [63] M. Jain, C. Arvanitis, K. Chu, W. Dewey, E. Leonhardi, M. Trinh, et al., Sustained loss of a neoplastic phenotype by brief inactivation of MYC, Science 297 (2002) 102–104. [64] J. Seenisamy, S. Bashyam, V. Gokhale, H. Vankayalapati, D. Sun, A. Siddiquui-Jain, et al., Design and synthesis of an expanded porphyrin that has selectivity for the c-MYC G-quadruplex structure, J. Am. Chem. Soc. 127 (2005) 2944–2959. [65] J. Seenisamy, E.M. Rezler, T.J. Powell, D. Tye, V. Gokhale, C.S. Joshi, et al., The dynamic character of the G-quadruplex element in the c-MYC promoter and modification by TMPyP4, J. Am. Chem. Soc. 126 (2004) 8702–8709. [66] J.L. Bos, ras oncogenes in human cancer: a review, Cancer Res. 49 (1989) 4682–4689. [67] K. Pruitt, C.J. Der, Ras and Rho regulation of the cell cycle and oncogenesis, Cancer Lett. 171 (2001) 1–10. [68] J. Mitsushita, J.D. Lambeth, T. Kamata, The superoxide-generating oxidase Nox1 is functionally required for Ras oncogene transformation, Cancer Res. 64 (2004) 3580–3585. [69] E. Holtta, L. Sistonen, K. Alitalo, The mechanisms of ornithine decarboxylase deregulation in c-Ha-ras oncogene-transformed NIH 3T3 cells, J. Biol. Chem. 263 (1988) 4500–4507.

POLYAMINES IN CANCER

67

[70] N.A. Ignatenko, H. Zhang, G.S. Watts, B.A. Skovan, D.E. Stringer, E.W. Gerner, The chemopreventive agent alpha-difluoromethylornithine blocks Ki-ras-dependent tumor formation and specific gene expression in Caco-2 cells, Mol. Carcinog. 39 (2004) 221–233. [71] L.M. Shantz, Transcriptional and translational control of ornithine decarboxylase during Ras transformation, Biochem. J. 377 (2004) 257–264. [72] J. Janne, L. Alhonen, M. Pietila, T.A. Keinanen, A. Uimari, M.T. Hyvonen, et al., Genetic manipulation of polyamine catabolism in rodents, J. Biochem. 139 (2006) 155–160. [73] E. Pirinen, T. Kuulasmaa, M. Pietila, S. Heikkinen, M. Tusa, P. Itkonen, et al., Enhanced polyamine catabolism alters homeostatic control of white adipose tissue mass, energy expenditure, and glucose metabolism, Mol. Cell. Biol. 27 (2007) 4953–4967. [74] M.T. Taylor, K.R. Lawson, N.A. Ignatenko, S.E. Marek, D.E. Stringer, B.A. Skovan, et al., Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells, Cancer Res. 60 (2000) 6607–6610. [75] N.A. Ignatenko, N. Babbar, D. Mehta, R.A. Casero Jr., E.W. Gerner, Suppression of polyamine catabolism by activated Ki-ras in human colon cancer cells, Mol. Carcinog. 39 (2004) 91–102. [76] J.M. Tucker, J.T. Murphy, N. Kisiel, P. Diegelman, K.W. Barbour, C. Davis, et al., Potent modulation of intestinal tumorigenesis in Apcmin/+ mice by the polyamine catabolic enzyme spermidine/spermine N1-acetyltransferase, Cancer Res. 65 (2005) 5390–5398. [77] J.A. Nilsson, U.B. Keller, T.A. Baudino, C. Yang, S. Norton, J.A. Old, et al., Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation, Cancer Cell 7 (2005) 433–444. [78] J. Hessels, A.W. Kingma, H. Ferwerda, J. Keij, G.A. van den Berg, F.A. Muskiet, Microbial flora in the gastrointestinal tract abolishes cytostatic effects of alpha-difluoromethylornithine in vivo, Int. J. Cancer 43 (1989) 1155–1164. [79] V. Quemener, J.P. Moulinoux, R. Havouis, N. Seiler, Polyamine deprivation enhances antitumoral efficacy of chemotherapy, Anticancer Res. 12 (1992) 1447–1453. [80] U. Bachrach, N. Seiler, Formation of acetylpolyamines and putrescine from spermidine by normal and transformed chick embryo fibroblasts, Cancer Res. 41 (1981) 1205–1208. [81] D.A. Brown, E. London, Functions of lipid rafts in biological membranes, Annu. Rev. Cell Dev. Biol. 14 (1998) 111–136. [82] J.G. Goetz, P. Lajoie, S.M. Wiseman, I.R. Nabi, Caveolin-1 in tumor progression: the good, the bad and the ugly, Cancer Metastasis Rev. 27 (2008) 715–735. [83] Y. Guo, R.B. Harris, D. Rosson, D. Boorman, T.G. O’Brien, Functional analysis of human ornithine decarboxylase alleles, Cancer Res. 60 (2000) 6314–6317. [84] A.J. Walhout, P.C. van der Vliet, H.T. Timmers, Sequences flanking the E-box contribute to cooperative binding by c-Myc/Max heterodimers to adjacent binding sites, Biochim. Biophys. Acta 1397 (1998) 189–201. [85] C.M. Fenoglio, N. Lane, The anatomical precursor of colorectal carcinoma, Cancer 34 (1974) 819–823. [86] B.C. Morson, Evolution of cancer of the colon and rectum, Cancer 34 (1974) 845–849. [87] J.A. Baron, M. Beach, J.S. Mandel, R.U. Van Stolk, R.W. Haile, R.S. Sandler, et al., Calcium supplements for the prevention of colorectal adenomas, N. Engl. J. Med. 340 (1999) 101. [88] S.J. Winawer, A.G. Zauber, M.N. Ho, M.J. O’Brien, L.S. Gottlieb, S.S. Sternberg, et al., Prevention of colorectal cancer by colonoscopic polypectomy, N. Engl. J. Med. 32 (1993) 1977–1981. [89] O. Kronborg, C. Fenger, Clinical evidence for the adenoma-carcinoma sequence, Eur. J. Cancer Prev. 8 (1999) S73–S86.

68

PAZ ET AL.

[90] M.E. Martı´nez, R. Sampliner, J.R. Marshall, A.K. Bhattacharyya, M.E. Reid, D. S. Alberts, Adenoma characteristics as risk factors for recurrence of advanced adenomas, Gastroenterology 120 (2001) 1077–1083. [91] M.E. Martinez, T.G. O’Brien, K.E. Fultz, N. Babbar, H. Yerushalmi, N. Qu, et al., Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene, Proc. Natl. Acad. Sci. USA 100 (2003) 7859–7864. [92] J.A. Baron, Epidemiology of non-steroidal anti-inflammatory drugs and cancer, Prog. Exp. Tumor Res. 37 (2003) 1–24. [93] E.L. Barry, J.A. Baron, S. Bhat, M.V. Grau, C.A. Burke, R.S. Sandler, et al., Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention, J. Natl. Cancer Inst. 98 (2006) 1494–1500. [94] R.A. Hubner, K.R. Muir, J.F. Liu, R.F.A. Logan, M.J. Grainge, R.S. Houlston, Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention, Clin. Cancer Res. 14 (2008) 2303–2309. [95] J.A. Zell, D. Pelot, W.P. Chen, C.E. McLaren, E.W. Gerner, F.L. Meyskens, Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas, Cancer Prev. Res. (Phila.) 2 (2009) 209–212. [96] D.J. Hughes, I. Hlavata´, P. Soucek, B. Pardini, A. Naccarati, L. Vodickova, et al., Ornithine decarboxylase G316A genotype and colorectal cancer risk, Colorectal Dis. (2010) accession number 20456464. [97] C.F. Zanelli, S.R. Valentini, Is there a role for eIF5A in translation? Amino Acids 33 (2007) 351–358. [98] R. Benne, M.L. Brown-Luedi, J.W. Hershey, Purification and characterization of protein synthesis initiation factors eIF-1, eIF-4C, eIF-4D, and eIF-5 from rabbit reticulocytes, J. Biol. Chem. 253 (1978) 3070–3077. [99] H.A. Kang, J.W. Hershey, Effect of initiation factor eIF-5A depletion on protein synthesis and proliferation of Saccharomyces cerevisiae, J. Biol. Chem. 269 (1994) 3934–3940. [100] J. Schnier, H.G. Schwelberger, Z. Smit-McBride, H.A. Kang, J.W. Hershey, Translation initiation factor 5A and its hypusine modification are essential for cell viability in the yeast Saccharomyces cerevisiae, Mol. Cell. Biol. 11 (1991) 3105–3114. [101] M.K. Chattopadhyay, M.H. Park, H. Tabor, Hypusine modification for growth is the major function of spermidine in Saccharomyces cerevisiae polyamine auxotrophs grown in limiting spermidine, Proc. Natl. Acad. Sci. USA 105 (2008) 6554–6559. [102] M.H. Park, The post-translational synthesis of a polyamine-derived amino acid, hypusine, in the eukaryotic translation initiation factor 5A (eIF5A), J. Biochem. 139 (2006) 161–169. [103] M. Lebska, A. Ciesielski, L. Szymona, L. Godecka, E. Lewandowska-Gnatowska, J. Szczegielniak, et al., Phosphorylation of maize eukaryotic translation initiation factor 5A (eIF5A) by casein kinase 2: identification of phosphorylated residue and influence on intracellular localization of eIF5A, J. Biol. Chem. 285 (2006) 6217–6226. [104] S.B. Lee, J.H. Park, J. Kaevel, M. Sramkova, R. Weigert, M.H. Park, The effect of hypusine modification on the intracellular localization of eIF5A, Biochem. Biophys. Res. Commun. 383 (2009) 497–502. [105] N.C. Kyrpides, C.R. Woese, Universally conserved translation initiation factors, Proc. Natl. Acad. Sci. USA 95 (1998) 224–228. [106] G. Blaha, R.E. Stanley, T.A. Steitz, Formation of the first peptide bond: the structure of EF-P bound to the 70S ribosome, Science 325 (2009) 966–970. [107] C.F. Zanelli, A.L. Maragno, A.P. Gregio, S. Kornili, J.P. Pandolfi, C.A. Mestriner, et al., eIF5A binds to translational machinery components and affects translation in yeast, Biochem. Biophys. Res. Commun. 348 (2006) 1358–1366.

POLYAMINES IN CANCER

69

[108] P. Saini, D.E. Eyler, R. Green, T.E. Dever, Hypusine-containing protein eIF5A promotes translation elongation, Nature 459 (2009) 118–121. [109] C.H. Li, T. Ohn, P. Ivanov, S. Tisdale, P. Anderson, eIF5A promotes translation elongation, polysome disassembly and stress granule assembly, PLoS One 5 (2010) e9942. [110] Z.A. Jenkins, P.G. Haag, H.E. Johansson, Human eIF5A2 on chromosome 3q25-q27 is a phylogenetically conserved vertebrate variant of eukaryotic translation initiation factor 5A with tissue-specific expression, Genomics 71 (2001) 101–109. [111] P.M. Clement, C.A. Henderson, Z.A. Jenkins, Z. Smit-McBride, E.C. Wolff, J.W. Hershey, et al., Identification and characterization of eukaryotic initiation factor 5A-2, Eur. J. Biochem. 270 (2003) 4254–4263. [112] X.Y. Guan, J.M. Fung, N.F. Ma, S.H. Lau, L.S. Tai, D. Xie, et al., Oncogenic role of eIF5A2 in the development of ovarian cancer, Cancer Res. 64 (2004) 4197–4200. [113] L. Zender, W. Xue, J. Zuber, C.P. Seminghini, A. Krasnitz, B. Ma, et al., An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer, Cell 135 (2008) 852–864. [114] G. Lipowsky, F.R. Bischoff, P. Schwarzmaier, R. Kraft, S. Kostka, E. Hartmann, et al., Exportin 4: a mediator of a novel nuclear export pathway in higher eukaryotes, EMBO J. 19 (2000) 4362–4371. [115] A. Kurisaki, K. Kurisaki, M. Kowanetz, H. Sugino, Y. Yoneda, C.H. Heldin, et al., The mechanism of nuclear export of Smad3 involves exportin 4 and Ran, Mol. Cell. Biol. 26 (2006) 1318–1332. [116] F.L. Meyskens, C.E. McLaren, D. Pelot, S. Fujikawa-Brooks, P.M. Carpenter, E. Hawk, et al., Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial, Cancer Prev. Res. 1 (2008) 32–38. [117] J. Shapiro, H. Lui, Vaniqa—eflornithine 13.9% cream, Skin Ther. Lett. 6 (2001) 1–3. [118] B.W. Metcalf, P. Bey, C. Danzin, M.J. Jung, P. Cagara, J.P. Ververt, Catalytic irreversible inhibition of mammalian ornithine decarboxylase (E.C. 4.1.1.17) by substrate and product analogues, J. Am. Chem. Soc. 100 (1978) 2551–2553. [119] R. Poulin, L. Lu, B. Ackermann, P. Bey, A.E. Pegg, Mechanism of the irreversible inactivation of mouse ornithine decarboxylase by alpha-difluoromethylornithine. Characterization of sequences at the inhibitor and coenzyme binding sites, J. Biol. Chem. 267 (1992) 150–158. [120] C.S. Coleman, B.A. Stanley, A.E. Pegg, Effect of mutations at active site residues on the activity of ornithine decarboxylase and its inhibition by active site-directed irreversible inhibitors, J. Biol. Chem. 268 (1993) 24572–24579. [121] H.F. Yerushalmi, D.G. Besselsen, N.A. Ignatenko, K.A. Blohm-Mangone, J.L. PadillaTorres, D.E. Stringer, et al., Role of polyamines in arginine-dependent colon carcinogenesis in Apc(Min) (/+) mice, Mol. Carcinog. 45 (2006) 764–773. [122] F.L. Meyskens Jr., Development of difluoromethyl-ornithine and Bowman-Birk inhibitor as chemopreventive agents by assessment of relevant biomarker modulation: some lessons learned, IARC Sci. Publ. 154 (2001) 49–55. [123] K.R. Lawson, N.A. Ignatenko, G.A. Piazza, H. Cui, E.W. Gerner, Influence of K-ras activation on the survival responses of Caco-2 cells to the chemopreventive agents sulindac and difluoromethylornithine, Cancer Epidemiol. Biomark. Prev. 9 (2000) 1155–1162. [124] L. Lan, C. Trempus, S.K. Gilmour, Inhibition of ornithine decarboxylase (ODC) decreases tumor vascularization and reverses spontaneous tumors in ODC/Ras transgenic mice, Cancer Res. 60 (2000) 5696–5703. [125] N. Babbar, N.A. Ignatenko, R.A. Casero Jr., E.W. Gerner, Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer, J. Biol. Chem. 278 (2003) 47762–47775.

70

PAZ ET AL.

[126] N. Babbar, E.W. Gerner, R.A. Casero Jr., Induction of spermidine/spermine N1-acetyltransferase (SSAT) by aspirin in Caco-2 colon cancer cells, Biochem. J. 394 (2006) 317–324. [127] N.A. Ignatenko, D.G. Besselsen, U.K. Roy, D.E. Stringer, K.A. Blohm-Mangone, J. L. Padilla-Torres, et al., Dietary putrescine reduces the intestinal anticarcinogenic activity of sulindac in a murine model of familial adenomatous polyposis, Nutr. Cancer 56 (2006) 172–181. [128] Y. Huang, A. Pledgie, R.A. Casero Jr., N.E. Davidson, Molecular mechanisms of polyamine analogs in cancer cells, Anticancer Drugs 16 (2005) 229–241. [129] N.A. Ignatenko, H.F. Yerushalmi, R. Pandey, K.L. Kachel, D.E. Stringer, L.J. Marton, et al., Gene expression analysis of HCT116 colon tumor-derived cells treated with the polyamine analog PG-11047, Cancer Genomics Proteomics 6 (2009) 161–175. [130] J.A. Zell, N.A. Ignatenko, H.F. Yerushalmi, A. Ziogas, D.G. Besselsen, E.W. Gerner, et al., Risk and risk reduction involving arginine intake and meat consumption in colorectal tumorigenesis and survival, Int. J. Cancer 120 (2007) 459–468. [131] N.A. Ignatenko, D.G. Besselsen, D.E. Stringer, K.A. Blohm-Mangone, H. Cui, E. W. Gerner, Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis, Nutr. Cancer 60 (Suppl. 1) (2008) 30–35. [132] F.L. Meyskens Jr., S.S. Emerson, D. Pelot, H. Meshkinpour, L.R. Shassetz, J. Einspahr, et al., Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps, J. Natl. Cancer Inst. 86 (1994) 1122–1130. [133] F.L. Meyskens Jr., E.W. Gerner, S. Emerson, D. Pelot, T. Durbin, K. Doyle, et al., Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention, J. Natl. Cancer Inst. 90 (1998) 1212–1218. [134] M.R. Burns, G.F. Graminski, R.S. Weeks, Y. Chen, T.G. O’Brien, Lipophilic lysinespermine conjugates are potent polyamine transport inhibitors for use in combination with a polyamine biosynthesis inhibitor, J. Med. Chem. 52 (2009) 1983–1993.

ADVANCES IN CLINICAL CHEMISTRY, VOL. 54

ACQUIRED HEMOPHILIA A Massimo Franchini*,1 and Giuseppe Lippi† *Department of Pathology and Laboratory Medicine, Immunohematology and Transfusion Center, University Hospital of Parma, Parma, Italy † Clinical Chemistry Laboratory, Department of Pathology and Laboratory Medicine, University Hospital of Parma, Parma, Italy

1. 2. 3. 4.

Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Pathogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Laboratory Diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.1. Epidemiology and Clinical Manifestations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.2. Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.3. Treatment of Bleeds . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.4. Inhibitor Eradication . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

71 71 72 73 73 75 75 77 78 79

1. Abstract Acquired hemophilia A is a rare but often life-threatening hemorrhagic disorder characterized by an autoantibody directed against coagulation factor VIII. Fifty per cent of cases are idiopathic whereas the remaining 50% are associated with pregnancy, autoimmune conditions, malignancies and drugs. In this review the actual knowledge on diagnostic and therapeutic aspects of this disease will be summarized.

1

Corresponding author: Massimo Franchini, e-mail: [email protected] 71

0065-2423/11 $35.00 DOI: 10.1016/B978-0-12-387025-4.00003-0

Copyright 2011, Elsevier Inc. All rights reserved.

72

FRANCHINI AND LIPPI

2. Introduction Acquired hemophilia A (AHA) is a rare disorder caused by circulating autoantibodies against factor VIII (FVIII) that inhibit the coagulation cascade. The majority of bleeding episodes in AHA are subcutaneous, but bleeds affecting gastrointestinal, lung, intracranial, and retroperitoneal sites, among others, also occur, and these are associated with increased mortality. This chapter will review the pathogenesis, diagnosis, epidemiology, and treatment of AHA.

3. Pathogenesis AHA is a rare disorder with an incidence of between 1.3 and 1.5 cases per million population annually [1,2]. AHA results in a defect in the coagulation cascade caused by autoantibodies against FVIII. These autoantibodies are oligoclonal and are generally of the IgG4 subclass, although IgG1 and IgG2 antibodies are also observed [3]. There are a number of differences between the FVIII autoantibodies in AHA and the alloantibodies that some individuals with hemophilia develop following treatment with recombinant or plasma-derived FVIII. Autoantibodies to FVIII predominantly target the A2, A3, and C2 domains of the molecule, and the majority of individuals (62%, 13/21) only have antibodies targeting one of these domains [4]. In contrast, 85% (29/34) of individuals with alloantibodies have antibodies that target multiple domains of the FVIII molecule [4]. Antibodies against FVIII are characterized as showing either type 1 (> 98% inhibition of FVIII and a linear relationship between the log of residual FVIII activity and antibody concentration) or type 2 kinetics (incomplete inactivation of FVIII at maximum available antibody concentrations and nonlinear kinetics) [5]. It has been reported that alloantibodies and autoantibodies exhibit type 1 and type 2 kinetics, respectively [6]. However, the clinical picture may be more complex, as type 1 kinetics were demonstrated in 5/7 (71%) of patients with AHA and an underlying pathology (post-pregnancy, drug-related, diabetes, hypertension, gastric ulcer, bullous pemphigoid and idiopathic thrombocytopenic purpura), while type 2 antibody kinetics were observed in 9/9 (100%) of individuals with AHA and no associated pathology [3]. The A2, A3, and C2 domains of FVIII that are targeted by autoantibodies are functionally important. The C2 domain contains the binding site for von Willebrand factor (VWF), which is vital for maintaining circulating levels of FVIII in the plasma [7]. Following vascular injury, FXa or thrombin induces the dissociation of FVIII and VWF. This dissociation allows FVIIIa to bind FIXa via the A2 and A3 domains of FVIII [8]. In addition, phospholipid

ACQUIRED HEMOPHILIA A

73

binding sites on the C2 domain of FVIII are involved in directing the complex to the membrane surface of activated platelets [8]. The membranebound complex of FVIII and FIXa then acts to induce thrombin formation via the proteolytic activation of FX [7]. There are at least two potential mechanisms by which autoantibodies can inhibit FVIII activity. Catalytic/hydrolyzing IgG targeting FVIII is observed in around 50% of individuals with AHA [9]. Catalytic antibodies appear to have a functional effect, as changes in the levels of IgG-mediated hydrolysis over time were associated with changes in inhibitory activity in 9/12 individuals with AHA [9,10]. A second mechanism may involve direct inhibition of functional activity, such as antibodies that bind to the C2 region and interfere with phospholipid binding [11,12]. Antibodies inhibiting FIXa binding have also been described [13].

4. Laboratory Diagnosis Cases of unexplained bleeding with an isolated prolonged activated partial thromboplastin time (aPTT) suggest a diagnosis of AHA [14]. An aPTT mixing test, in which equal volumes of test and normal plasma are mixed, enables factor deficiency to be distinguished from the presence of inhibitors. FVIII inhibitors are time- and temperature-dependent, so prolongation should occur after incubation (1–2 h) at 37 C [14]. Other potential reasons for a prolonged aPTT, such as heparin contamination and lupus anticoagulants, should be ruled out before confirming the presence of FVIII inhibitors (Fig. 1) [15]. AHA is then confirmed by demonstrating low FVIII activity and raised inhibitor titer [1,14]. The inhibitor titer is measured by the Bethesda test, which assays the ability of the test versus control plasma to reduce a known amount of FVIII activity. The Nijmegen modification of this test reflects changes to the buffer in the test sample and the use of immunodepleted factor VIII deficient plasma in the control sample to increase discrimination between positive and negative samples [16]. The Bethesda assay classifies inhibitors as high >5 BU/ mL and low <5 BU/mL titer. 4.1. EPIDEMIOLOGY AND CLINICAL MANIFESTATIONS Approximately 80% of AHA cases occur in elderly individuals aged > 65 years [1,17]. Thus, the median age of affected individuals was 72 years (range 13–19) in interim analysis of 319 individuals from the European Acquired Hemophilia registry (EACH2) [18] and 78 years (range 2–98) in a UK surveillance study of 154 patients [1]. These data do not appear to support a sex association, with between 43% and 53% of cases occurring in men

74

FRANCHINI AND LIPPI Sudden onset of bleeding episode Negative personal and family hemorrhagic history Confirmed prolonged APTT with normal PT

Exclude presence of heparin

Mixing study patient plasma/normal plasma Incubation 2 h at 37 °C

APTT mix normal

APTT mix prolonged Exclude lupus anticoaguant

Intrinsic pathway clotting factors deficiency

FVIII reduction FVIII inhibitor titration

Diagnosis of AHA

FIG. 1. Laboratory diagnosis of AHA.

[1,18]. There are a number of cases in younger females (often aged between 20 and 30 years), which reflects the development of postpartum inhibitors [19]. AHA is extremely rare in children, with only one case reported in the UK during a 2-year surveillance study [1]. Over half of all cases of AHA are idiopathic (Table 1) [1,18]. Underlying clinical conditions observed in the remaining individuals include autoimmune disorders, solid tumors, lymphoproliferative disorders, and pregnancy (Table 1). In addition, cases of AHA associated with penicillin, sulfonamides, chloramphenicol, the anticonvulsant diphenylhydantoin, and the immunomodulatory agents fludarabine and interferon-a have been reported [20]. Although AHA and congenital hemophilia A both result in deficiency in FVIII, bleed pathology is quite different. In AHA, the majority of bleeds (80%) are subcutaneous, while intramuscular (45%) or gastrointestinal (approximately 25%) bleeds are also common [1]. Joint bleeds were less common (approximately 2–8%) [1,18]. In contrast, joints are the most common site of bleeding episodes in individuals with congenital hemophilia [21]. Fatal bleeds were observed in 13/143 (9.1%) individuals with AHA [1]. Gastrointestinal and lung bleeds were associated with early deaths (within the first week of presentation), whereas intracranial and retroperitoneal bleeds resulted in later deaths (between 2 and 21 weeks) [1].

ACQUIRED HEMOPHILIA A

75

TABLE 1 AHA AND UNDERLYING CLINICAL CONDITIONS [1,18]

Underlying diagnosis, % (n) None Pregnancy Autoimmune disorder Hematological malignancy History of malignancy Active malignancy Monoclonal gammopathy Other (drug association, infection) Dermatologic

EACH2 (N ¼ 319)

UK surveillance study (N ¼ 150)

55.0 (176) 8.5 (27) 7.2 (23) 2.2 (7) 3.1 (10) 4.4 (14) 2.5 (8) 19.4 (62) Not reported

63.3 (95) 2.0 (3) 16.6 (25) Not reported Not reported 14.6 (22) Not reported Not reported 3.3 (5)

4.2. TREATMENT AHA is a rare disorder with few comparative trials to guide treatment. There have been a number of published treatment guidelines, including a recent consensus guideline published in 2009, which are largely in agreement with treatment options [14,15,22–24]. Because AHA is a rare disorder and is associated with bleeding episodes in individuals who may not have a history of bleeding, initial presentation is often to non-specialist clinicians. Therefore, clinicians seeing a patient with an acute bleed and an unexplained prolonged aPTT test, particularly in elderly individuals or postpartum women, should consider AHA as a diagnosis and ensure that their patient receives specialist care at a hemophilia center [14]. The choice of treatment in AHA is dependent on the site of bleeding and the underlying disorder, although the two main goals are to control any bleeds and eradicate inhibitor antibodies to reduce the risk of further bleeds [14,15,23]. Treatment of the underlying disease may be appropriate [15,23], as there have been reports of inhibitors disappearing following successful treatment of malignancies [25,26].

4.3. TREATMENT OF BLEEDS Subcutaneous bleeds may not need immediate hemostatic treatment but should be closely observed; however, retroperitoneal, retropharyngeal, muscle, intracranial, gastrointestinal, pulmonary, or postoperative bleeds, as well as severe hematuria or bleeds from multiple sites, should be treated [14].

76

FRANCHINI AND LIPPI

Clinicians should take into account the risk and benefits of hemostatic treatment, particularly as many individuals with AHA are elderly with risk factors for thromboembolic events. 4.3.1. Bypassing Agents Recombinant-activated FVII (rFVIIa) and activated prothrombin complex concentrates (aPCCs) are recommended as first-line treatment for severe bleeds [14,15,23]. They are effective in 80–90% of bleeds; however, there are no comparative trials of rFVIIa and aPPC to demonstrate superior efficacy for either product [14,15,23]. rFVIIa is a recombinant protein that is manufactured to exclude the risk of human pathogen transmission, whereas aPCC is a plasma-derived product. The potential for human pathogen transmission with aPPC, although small, has led to suggestions that rFVIIa may be more appropriate in certain populations (e.g., postpartum women) [14]. EACH2 registry data suggest that rFVIIa is the more commonly used of the bypassing agents (Table 2) [27]. If one bypassing agent fails, individuals should be switched to the alternative agent [14]. Therapy with both rFVIIa and aPPC in alternating sequence has been reported in a limited number of individuals with congenital hemophilia, but no case reports exist in AHA [14]. Therefore, if this approach is used, it should be limited to limb-or life-threatening bleeds [14]. Thromboembolic complications with bypassing agents appear to be more common in AHA than in congenital hemophilia, reflecting the risk factors present in the generally older AHA population [14]. 4.3.2. Other Options Other hemostatic treatments such as human plasma-derived or recombinant FVIII or desmopressin may be used in individuals with low-titer inhibitors and minor bleeding episodes if bypassing agents are unavailable [14].

TABLE 2 HEMOSTATIC TREATMENT USED IN THE EACH2 REGISTRY [26] Hemostatic treatment rFVIIa aPCC Human FVIII Desmopressin Multiple therapies Not specified

Bleed treatment, n (%) (N ¼ 294) 143 (49) 72 (24) 35 (12) 8 (3) 13 (4) 23 (8)

ACQUIRED HEMOPHILIA A

77

If a bleed is refractory to first-line treatment, the removal of the inhibitor antibody by plasmapheresis or immunoadsorption may be appropriate [14].

4.4. INHIBITOR ERADICATION Two first-line options for inhibitor eradication are a corticosteroid or a corticosteroid plus cyclophosphamide (Table 3) [14]. If no response is observed after 4–6 weeks, rituximab alone or with a corticosteroid is a second-line option [14]. Some experts recommend a more conservative approach to inhibitor eradication in some cases, for example postpartum AHA, in which inhibitors may resolve spontaneously [28]. However, other guidelines favor inhibitor eradication in all cases because of the continuing risk of fatal bleeds as long as inhibitor antibodies remain and the inability of clinical factors such as the patient’s presenting characteristics or inhibitor titer to predict bleed risk [14,23]. If inhibitor eradication is attempted in women of child-bearing age, cytotoxic agents should be avoided due to the potential risk of infertility [14,15]. Immunosuppressive therapy for inhibitor eradication can be associated with serious side effects such as neutropenia-related infections and sepsis, particularly in elderly individuals. Sepsis was reported in 37/112 (33%) of AHA patients with non-bleeding-related morbidity and caused death in 11% of cases [1]. In a smaller case series of 17 elderly patients aged > 76 years, 13 died, of which bleeding caused three deaths (23%) and infection related to immunosuppressive treatment caused five deaths (38%) [29]. Another case series including 13 patients aged 70 years or older demonstrated better outcomes (overall 31% mortality) [30]. However, treatment toxicity (infections

TABLE 3 AHA TREATMENT RECOMMENDATIONS Anti-hemorrhagic treatment – First line – Alternative treatmenta – Second line Inhibitor eradication – First line – Second line – Alternative treatment – Not useful

rFVIIa, aPCC hFVIII, DDAVP Immunoadsorption or plasmapheresis Corticosteroids cyclophosphamide Rituximab corticosteroids Azathioprine, vincristine, mycophenolate, cyclosporine Intravenous immunoglobulin

rFVIIa, recombinant activated factor VII; aPCC, activated prothrombin complex concentrates; hFVIII, human plasma-derived FVIII; DDAVP, desmopressin. a Low-titer inhibitors and minor bleeding.

78

FRANCHINI AND LIPPI

and hematological toxicity) was observed in 5/7 individuals on classical immunosuppression and 2/6 individuals receiving rituximab [30]. Rituximab is a monoclonal antibody that targets the CD20 antigen expressed on the cell surface of B cells [31]. Rituximab treatment depletes peripheral B cells and was initially developed for the treatment of CD20þ non-Hodgkin’s lymphomas [31], but has also been used in other disorders associated with autoantibodies [32]. Two literature reviews have reported efficacy rates of 80–90% in AHA, with no reported cases of opportunistic infection [32,33]. Data from the EACH2 registry did not show an advantage for rituximab (mostly administered with other agents) over steroids alone or steroids plus cytotoxic agents (complete response in 63%, 60%, and 84% of cases, respectively) [34]. Adverse events were seen in a higher proportion of individuals treated with steroids and cytotoxic agents (39%) than those treated with rituximab (26%) or steroids alone (25%) [34]. Although initial data are promising, they reflect uncontrolled studies and case reports in individuals also receiving other agents for inhibitor eradication, so rituximab is currently recommended as second-line therapy until further efficacy and long-term safety data become available [14]. Successful cases of inhibitor eradication after failure of first line-therapy have been reported with the use of cyclosporine, azathioprine, vincristine, or mycophenolate. Finally, current evidence does not support the use of intravenous immunoglobulin for inhibitor eradication in AHA, either as a single agent or in combination with steroids and cytotoxic agents [14,15].

5. Conclusions AHA is a rare bleeding disorder that can lead to fatal bleeds. The disease is characterized by autoantibodies against FVIII that inhibit the coagulation cascade by at least two potential mechanisms: catalysis of FVIII and functional blockade of FVIII interactions. Treatment needs to address both the control of acute bleeds and eradication of the inhibitor autoantibody to reduce the risk of further bleeding. Bypassing agents offer a clear first-line treatment choice for acute bleeds. Of the two bypassing agents, rFVIIIa excludes the risk of any transfer of human viral pathogens, which is a small risk in plasma-derived products. Inhibitor eradication with corticosteroids with or without cytotoxic agents is associated with high rates of morbidity and mortality due to neutropenia and infections. Rituximab is a promising agent for inhibitor eradication, with the potential for less treatment-related adverse side effects than classical immunosuppressive treatments; however, further studies are required to confirm initial efficacy and safety results.

ACQUIRED HEMOPHILIA A

79

ACKNOWLEDGMENTS The authors take full responsibility for this chapter but are grateful to Mike Lappin, PhD, of Watermeadow Medical (supported by Novo Nordisk Farmaceutici S.p.A.) for writing assistance.

REFERENCES [1] P.W. Collins, S. Hirsch, T.P. Baglin, G. Dolan, J. Hanley, M. Makris, et al., Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation, Blood 109 (2007) 1870–1877. [2] P. Collins, N. Macartney, R. Davies, S. Lees, J. Giddings, R. Majer, A population based, unselected, consecutive cohort of patients with acquired haemophilia A, Br. J. Haematol. 124 (2004) 86–90. [3] T. Matsumoto, M. Shima, K. Fukuda, K. Nogami, J.C. Giddings, T. Murakami, et al., Immunological characterization of factor VIII autoantibodies in patients with acquired hemophilia A in the presence or absence of underlying disease, Thromb. Res. 104 (2001) 381–388. [4] R. Prescott, H. Nakai, E.L. Saenko, I. Scharrer, I.M. Nilsson, J.E. Humphries, et al., The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies, Blood 89 (1997) 3663–3671. [5] M.S. Gawryl, L.W. Hoyer, Inactivation of factor VIII coagulant activity by two different types of human antibodies, Blood 60 (1982) 1103–1109. [6] D. Green, J. Blanc, N. Foiles, Spontaneous inhibitors of factor VIII: kinetics of inactivation of human and porcine factor VIII, J. Lab. Clin. Med. 133 (1999) 260–264. [7] B.W. Shen, P.C. Spiegel, C.H. Chang, J.W. Huh, J.S. Lee, J. Kim, et al., The tertiary structure and domain organization of coagulation factor VIII, Blood 111 (2008) 1240–1247. [8] J.C. Ngo, M. Huang, D.A. Roth, B.C. Furie, B. Furie, Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa, Structure 16 (2008) 597–606. [9] B. Wootla, A. Nicoletti, N. Patey, J.D. Dimitrov, C. Legendre, O.D. Christophe, et al., Hydrolysis of coagulation factors by circulating IgG is associated with a reduced risk for chronic allograft nephropathy in renal transplanted patients, J. Immunol. 180 (2008) 8455–8460. [10] B. Wootla, A. Mahendra, J.D. Dimitrov, A. Friboulet, A. Borel-Derlon, D.N. Rao, et al., Factor VIII-hydrolyzing IgG in acquired and congenital hemophilia, FEBS Lett. 583 (2009) 2565–2572. [11] M.G. Jacquemin, B.G. Desqueper, A. Benhida, L. Vander Elst, M.F. Hoylaerts, M. Bakkus, et al., Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor, Blood 92 (1998) 496–506. [12] D. Scandella, G.E. Gilbert, M. Shima, H. Nakai, C. Eagleson, M. Felch, et al., Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site, Blood 86 (1995) 1811–1819. [13] D. Zhong, E.L. Saenko, M. Shima, M. Felch, D. Scandella, Some human inhibitor antibodies interfere with factor VIII binding to factor IX, Blood 92 (1998) 136–142.

80

FRANCHINI AND LIPPI

[14] A. Huth-Ku¨hne, F. Baudo, P. Collins, J. Ingerslev, C.M. Kessler, H. Le´vesque, et al., International recommendations on the diagnosis and treatment of patients with acquired hemophilia A, Haematologica 94 (2009) 566–575. [15] M. Franchini, G. Lippi, Acquired factor VIII inhibitors, Blood 112 (2008) 250–255. [16] B. Verbruggen, I. Novakova, H. Wessels, J. Boezeman, M. van den Berg, E. MauserBunschoten, The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability, Thromb. Haemost. 73 (1995) 247–251. [17] F. Baudo, F. de Cataldo, Acquired hemophilia: a critical bleeding syndrome, Haematologica 89 (2004) 96–100. [18] H. Levesque, P. Collins, F. Baudo, A. Huth-Kuhne, P. Knoebl, P. Marco, et al., Acquired haemophilia: descriptive data of the European acquired haemophila registry (EACH 2), J. Thromb. Haemost. 7 (Suppl. 2) (2009) PP-WE-604 (abstract). [19] M. Franchini, Postpartum acquired factor VIII inhibitors, Am. J. Hematol. 81 (2006) 768–773. [20] M. Franchini, F. Capra, N. Nicolini, D. Veneri, F. Manzato, F. Baudo, et al., Drug-induced anti-factor VIII antibodies: a systematic review, Med. Sci. Monit. 13 (2007) RA55–RA61. [21] N.W. Jansen, G. Roosendaal, F.P. Lafeber, Understanding haemophilic arthropathy: an exploration of current open issues, Br. J. Haematol. 143 (2008) 632–640. [22] M. Franchini, G. Targher, M. Montagnana, G. Lippi, Laboratory, clinical and therapeutic aspects of acquired hemophilia A, Clin. Chim. Acta 395 (2008) 14–18. [23] P.W. Collins, Treatment of acquired hemophilia A, J. Thromb. Haemost. 5 (2007) 893–900. [24] F. Baudo, T. Caimi, F. de Cataldo, Diagnosis and treatment of acquired hemophilia, Haemophilia 16 (2010) 102–106. [25] S. Ichikawa, K. Kohata, Y. Okitsu, M. Suzuki, S. Nakajima, M.F. Yamada, et al., Acquired hemophilia A with sigmoid colon cancer: successful treatment with rituximab followed by sigmoidectomy, Int. J. Hematol. 90 (2009) 33–36. [26] M. Shurafa, S. Raman, I. Wollner, Disappearance of factor VIII antibody after removal of primary colon adenocarcinoma, Am. J. Hematol. 50 (1995) 149–150. [27] F. Baudo, P. Collins, A. Huth-Ku¨hne, P. Knoebl, H. Le´vesque, M. Pascual, et al., Hemostatic therapy in acquired haemophilia: data from the European Acquired Haemophilia (EACH2) Registry, J. Thromb. Haemost. 7 (Suppl. 2) (2009) OC-WE-058 (abstract). [28] P.M. Mannucci, F. Peyvandi, Autoimmune hemophilia at rescue, Haematologica 94 (2009) 459–461. [29] O. Lambotte, J. Dautremer, B. Guillet, T. Boutekedjiret, M. Dreyfus, R. Kotb, et al., Acquired hemophilia in older people: a poor prognosis despite intensive care, J. Am. Geriatr. Soc. 55 (2007) 1682–1685. [30] S. Girault, K. Ly, A. Jaccard, V. Loustaud, P. Turlure, A. Julia, et al., Prognosis of acquired hemophilia in older people, J. Am. Geriatr. Soc. 56 (2008) 956–958. [31] D.G. Maloney, A.J. Grillo-Lo´pez, C.A. White, D. Bodkin, R.J. Schilder, J.A. Neidhart, et al., IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma, Blood 90 (1997) 2188–2195. [32] M. Franchini, Rituximab in the treatment of adult acquired hemophilia A: a systematic review, Crit. Rev. Oncol. Hematol. 63 (2007) 47–52. [33] W.R. Sperr, K. Lechner, I. Pabinger, Rituximab for the treatment of acquired antibodies to factor VIII, Haematologica 92 (2007) 66–71. [34] P. Collins, F. Baudo, A. Huth-Ku¨hne, P. Knobl, H. Levesque, P. Marco, et al., First line immunosuppressive treatment for acquired factor VIII antibodies: results of the European Acquired Haemophilia Registry (EACH2), J. Thromb. Haemost. 7 (Suppl. 2) (2009) PP-MO-609 (abstract).

ADVANCES IN CLINICAL CHEMISTRY, VOL. 54

HYPOBETALIPOPROTEINEMIA: GENETICS, BIOCHEMISTRY, AND CLINICAL SPECTRUM Patrizia Tarugi*,1 and Maurizio Averna† *Department of Biomedical Sciences, University of Modena and Reggio Emilia, Modena, Italy † Department of Clinical Medicine and Emerging Diseases, University of Palermo, Palermo, Italy

1. Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2. Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3. Pathways of apoB-Containing Lipoproteins Production . . . . . . . . . . . . . . . . . . . . . . . . 3.1. Assembly and Secretion of apoB-Containing Lipoproteins . . . . . . . . . . . . . . . . 3.2. Control of the Secretion of apoB-Containing Lipoproteins . . . . . . . . . . . . . . . . 3.3. Intracellular Degradation of apoB and Secretion of apoB-Containing Lipoproteins. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3.4. Clearance of apoB-Containing Lipoproteins via LDL-Receptor . . . . . . . . . . . 4. Dominant Forms of Primary HBL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.1. FHBL Due to Defective Secretion of apoB-Containing Lipoproteins . . . . . . 4.2. FHBL Due to Increased Liver Uptake of apoB-Containing Lipoproteins via LDL-Receptor. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.3. Prevalence of Primary FHBL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5. Recessive Forms of Primary HBL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5.1. Abetalipoproteinemia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5.2. Chylomicron Retention Disease. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6. Primary Orphan FHBL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7. Spectrum of Clinical Manifestations in Primary HBL. . . . . . . . . . . . . . . . . . . . . . . . . . . 8. Main Clinical Issues of FHBL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8.1. FHBL and Fatty Liver Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8.2. FHBL and Cardiovascular Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8.3. FHBL and Cancer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9. Secondary Hypobetalipoproteinemias . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1

82 83 83 83 84 86 86 87 87 89 91 91 91 91 92 92 94 94 95 96 96 97 101

Corresponding author: Patrizia Tarugi, e-mail: [email protected] 81

0065-2423/11 $35.00 DOI: 10.1016/B978-0-12-387025-4.00004-2

Copyright 2011, Elsevier Inc. All rights reserved.

82

TARUGI AND AVERNA

Abbreviations ABL apoB CVD CM CMRD COP CHD ER ERAD FHBL HBL LDL-C LDL-R MTP PERPP PCSK9 TC TG

abetalipoproteinemia apolipoprotein B cardiovascular disease chylomicron chylomicron retention disease coat protein coronary heart disease endoplasmic reticulum endoplasmic reticulum associated degradation familial hypobetalipoproteinemia hypobetalipoproteinemia LDL-cholesterol LDL-receptor microsomal triglyceride transfer protein post-ER presecretory proteolysis proprotein convertase subtilisin/kexin type 9 total cholesterol triglyceride

1. Abstract Hypobetalipoproteinemias (HBL) represent a heterogeneous group of disorders characterized by reduced plasma levels of total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C) and apolipoprotein B (apoB) below the 5th percentile of the distribution in the population. HBL are defined as primary or secondary according to the underlying causes. Primary monogenic HBL are caused by mutations in several known genes (APOB, PCSK9, MTP, SARA2) or mutations in genes not yet identified. Familial hypobetalipoproteinemia (FHBL) is the most frequent monogenic form of HBL with a dominant mode of inheritance. It may be due to loss-of-function mutations in APOB or, less frequently, in PCSK9 genes. The rare recessive forms of primary monogenic HBL are represented by abetalipoproteinemia (ABL) and chylomicron retention disease (CMRD) due to mutations in MTP and SARA2 genes, respectively. The clinical phenotype of heterozygous FHBL is usually mild, being frequently characterized by fatty liver. The clinical phenotype of homozygous FHBL, ABL, and CMRD is usually severe being characterized by intestinal lipid malabsorption and fat-soluble vitamin deficiency. Secondary HBL are due to several nongenetic factors such as diet, drugs, and disease-related conditions. The aim of this review is to discuss the biochemistry, genetics, and clinical spectrum of HBL and to provide a clinical and laboratory diagnostic algorithm.

HYPOBETALIPOPROTEINEMIAS

83

2. Introduction HBL include a heterogeneous group of disorders characterized by reduced plasma levels of TC, LDL-C, and apoB below the 5th percentile of the distribution in the population. LDL, previously known as beta-lipoprotein, plays a key role in the transport of hydrophobic neutral lipids (mainly cholesterol) throughout the body. Since apoB is the main structural protein component of LDL, this lipoprotein class belongs to apoB-containing lipoproteins which also include plasma very low density lipoproteins (VLDL) and chylomicrons (CM) [1]. HBL may be caused by mutations in several known genes or mutations in unidentified genes (primary monogenic HBL) and by several nongenetic factors such as diet, drugs, and disease-related conditions (secondary HBL). In primary HBL, the biochemical phenotype segregates as an autosomal dominant or a recessive trait. The diagnosis of dominant HBL is driven by the multigenerational presence of related individuals carrying the biochemical HBL trait (low LDL-C and apoB plasma levels). The diagnosis of recessive HBL is primed by the presence, early in life, of the biochemical HBL trait associated with a generally severe clinical phenotype in offsprings of normolipidemic parents. Dominant HBL includes FHBL (OMIM 107730), recessive HBL includes ABL (OMIM 200100) and CMRD (OMIM 246700)—also called Anderson’s disease [1,2]. The spectrum of the clinical features in primary HBL ranges from absence or paucity of symptoms to a very severe syndrome (e.g., Section 7). In general, the genetic or acquired mechanisms that may reduce LDL-C and apoB plasma levels and cause primary or secondary HBL, respectively, must alter the production, assembly, secretion, or catabolism of apoB-containing lipoproteins. This chapter critically reviews the current knowledge on the pathophysiology, molecular genetics, and clinical features of HBL, and describes a diagnostic approach that may be helpful in a clinical setting.

3. Pathways of apoB-Containing Lipoproteins Production 3.1. ASSEMBLY AND SECRETION OF APOB-CONTAINING LIPOPROTEINS Liver and intestine are the main site of production of apoB-containing lipoproteins. apoB is expressed primarily in liver and intestine and plays a central role in the transport and metabolism of plasma cholesterol and triglycerides (TG) [1]. In human plasma, apoB occurs in two forms: apoB100 and apoB-48, which are encoded by the same gene (APOB) located on

84

TARUGI AND AVERNA

chromosome 2. apoB-100 (the full-length translation product of apoB mRNA) is a large monomeric protein of 4536 amino acids that is synthesized in the liver. apoB-100 is an essential component of liver-derived VLDLs, IDLs, and LDLs, where it serves as ligand for the LDL-receptor (LDL-R). apoB-48, a peptide consisting of the N-terminal 2152 amino acids of apoB100 (corresponding to 48% of apoB-100), is synthesized by the intestine and is essential for CM production, the lipoproteins that transport dietary lipids. apoB-48 results from a posttranscriptional modification of apoB mRNA (mRNA editing), which converts a glutamine codon at position 2153 into a stop codon [1]. apoB is essential for the production of apoB-containing lipoproteins. Naturally occurring mutations in APOB gene that result in structurally abnormal apoBs (e.g., apoB truncated at the C-terminal end) are associated with a reduction of plasma levels of apoB-containing lipoproteins [1–3] (e.g., Section 4.1.1). The assembly of VLDL in the liver and CM in the intestine occurs cotranslationally (during the synthesis of apoB): while the C-terminal end of apoB is still being synthesized, the N-terminal portion is translocated across the endoplasmic reticulum (ER) and is assembled as small lipoprotein particles for correct targeting to the pathways of lipoprotein secretion. The apoB is targeted to the ER via the signal sequence (spanning amino acids 1–27); its translocation occurs through the translocon, a proteinaceus channel in the ER membrane [4,5]. 3.2. CONTROL OF THE SECRETION OF APOB-CONTAINING LIPOPROTEINS In view of the essential role of apoB in the assembly and secretion of apoBcontaining lipoproteins, apoB levels are regulated at multiple levels. Several factors influence the translocation process of newly synthesized apoB. Most relevant is the availability of lipids at the site of apoB synthesis in the ER, which appears to dictate the amount of apoB secreted. In addition, the process of translocation is affected by the characteristics of apoB itself, including length, signal peptide polymorphism, and apoB folding to attain lipid-binding capability, which regulate its ability to assemble into lipoproteins [6]. Successful transport and correct conformation of apoB may lead to its final secretion as a lipoprotein constituent. In the case of lipid shortage, nascent apoB translocation into the ER lumen is inefficient and domains of apoB are exposed to the cytosol, where newly synthesized apoB undergoes rapid intracellular degradation (e.g., Section 3.3) [5]. The N-terminal assembly of lipids onto apoB during translocation requires the microsomal triglyceride transfer protein (MTP), an 894 amino acid protein located in the ER lumen that is a component of a protein complex involved in the early stages of apoB lipidation in liver and intestine [7]. MTP has been shown to bind to

HYPOBETALIPOPROTEINEMIAS

85

the first 1000 amino acids of apoB which form a domain capable of initiating nascent lipoprotein assembly (i.e., capable of recruiting lipids and facilitating the conversion of apoB into a buoyant lipoprotein particle) [8–12]. This ‘‘lipoprotein initiating’’ domain of apoB contains the regions spanning amino acid residues 1–264 and 512–721 or 270–570 involved in the binding with MTP [7,13]. The physical interaction between apoB and MTP is important for the initiation of translocation of the nascent apoB chain and for the cotranslational addition of lipids to this chain [4,5,7]. Via these mechanisms, MTP is believed to avoid improper folding and premature degradation of apoB. The crucial role of MTP in the assembly and secretion of apoBcontaining lipoproteins is substantiated by the observation that mutations in the MTP gene, which abolish MTP activity, are the cause of ABL, a severe recessive disorder in which VLDL and CM are not secreted (e.g., Section 5.1) [7,14]. Pharmacological inhibition of MTP in cultured cells and in vivo results in a dose-dependent inhibition of the secretion of apoB [15,16]. Recent evidence suggests that, in addition to MTP, other molecules with lipid transferase activity in the ER, chaperones, and modifying enzymes (such as PDI, BiP, Grp94, chaperon-like lectins, and cyclophilin) in different subcellular compartments may be involved in the lipoprotein formation [17]. The addition of lipids to apoB is believed to occur in two steps. In the first step, a small amount of lipids is added to apoB during its translation and translocation into the ER lumen. This initial lipidation prevents apoB degradation and leads to the formation of a partially lipidated small lipoprotein particle. In the second step, after apoB translation is completed, the bulk of neutral lipids is added to the primordial lipoprotein particle to form a mature particle [18,19]. The maturation of VLDLs and CMs, which starts in the ER, is completed in the Golgi [20]. Mature VLDLs and CMs present in the lumen of the smooth ER are transported from the ER via specialized vesicles to the Golgi apparatus for secretion [21]. The transport through the secretory pathway is mediated by the coat protein (COP) machinery. The COPII complex functions in ER-derived vesicle formation for anterograde transport. One of the subunits of the COPII complex (Sar1-GTPase) has been found to be critical for the vesicular transport of apoB-containing lipoproteins in rat hepatoma cells [22]. COPII associates with apoB-containing lipoprotein particles and forms ER-derived vesicles that initiate their intracellular transport to the Golgi apparatus before release into the circulation [22]. In humans there are two Sar1 proteins, designated Sar1a and Sar1b (encoded by Sar1-ADP-ribosylation GTPase, SARA1 and SARA2 genes, respectively), which differ by 20 amino acid residues. The role of Sar1b in vesicular transport of apoB-containing lipoproteins was demonstrated by the observation that mutations in the SARA2 gene are the cause of CMRD [23]. Whether the Sar1a isoform plays a distinct role in the transport of

86

TARUGI AND AVERNA

apoB-containing lipoproteins (e.g., is specifically required for VLDL secretion by the liver) is an appealing hypothesis that remains to be tested. 3.3. INTRACELLULAR DEGRADATION OF APOB AND SECRETION OF APOB-CONTAINING LIPOPROTEINS In contrast to most secreted proteins, the amount of apoB-containing lipoproteins excreted by the cells is mostly regulated by apoB degradation along the ER/Golgi secretory pathway. Targeting of apoB for degradation occurs when: (i) lipid availability is reduced, (ii) MTP activity is low, (iii) apoB is misfolded, or (iv) under cellular stress conditions. Two intracellular apoB degradation mechanisms have been described: (i) ER associated degradation (ERAD), catalyzed by the ubiquitin–proteasome system, occurs cotranslationally via retrotranslocation when misfolded apoB is present in the cell or lipid supply/availability is reduced; (ii) post-ER presecretory proteolysis (PERPP), achieved by autophagy, which delivers oxidized, aggregated apoB and partially assembled apoB lipoproteins to lysosomes for destruction [24,25]. Thus, intracellular degradation of apoB reduces the assembly and secretion of apoB-containing lipoproteins. Another mechanism involved in the control of the secretion of apoBcontaining lipoproteins is the LDL-R-mediated degradation. LDL-R promotes intracellular degradation of apoB-100 resulting in decreased secretion of VLDL by the liver. LDL-R knockout mice secrete apoB at a higher rate than control mice; this increase is prevented by overexpression of the LDL-R [26]. An in vivo turnover study in humans demonstrated that complete deficiency of the LDL-R is associated with an increased apoB production rate [27]. In addition, some naturally occurring mutations in LDL-R have been identified which cause retention of both the mutant LDL-R and apoB within the ER [28]. Taken together, these observations suggest that the LDLR facilitates the retention of apoB in the ER and its presecretory degradation and possibly also the reuptake of newly secreted apoB-containing lipoproteins on the cell surface. 3.4. CLEARANCE OF APOB-CONTAINING LIPOPROTEINS VIA LDL-RECEPTOR Most of the LDL particles are cleared from plasma by the liver via the LDL-R. LDL-R-mediated uptake and degradation of LDL is an important determinant of the concentration of LDL in the plasma, as clearly demonstrated by some monogenic disorders (autosomal dominant hypercholesterolemias) affecting LDL-R activity/number or the capacity of LDL to bind LDL-R. These disorders may result from: (i) loss-of-function mutations of LDL-R gene (reducing the number of LDL-Rs or their function),

HYPOBETALIPOPROTEINEMIAS

87

(ii) mutations in APOB gene (reducing the affinity of apoB for the LDL-R), or (iii) gain-of-function mutations of PCSK9 gene (resulting in a reduced number of LDL-Rs on the cell surface) [29]. The role of PCSK9 gene in the regulation of LDL-R number (and the regulation of plasma LDL level) has received great attention in recent years. PCSK9 gene, located on chromosome 1, encodes a 692 amino acid protein designated proprotein convertase subtilisin/kexin type 9 (PCSK9). This protein is mainly expressed in the liver where it is produced in the ER as a precursor protein which undergoes cotranslational autocatalytic cleavage in the Golgi to create the processed protease that is secreted. Cell culture and animal models have established that the LDL-R is one of the main downstream targets of PCSK9. Secreted mature PCSK9 binds the LDL-Rs on the surface of hepatocytes and promotes their internalization and degradation in a post-ER complex [30,31]. Thus, PCSK9 exerts its effect on the posttranslational regulation of LDL-R by controlling the LDL-R degradation and the number of receptors available on the cell surface. The mechanism by which PCSK9 reduces the number of LDL-R is only partially known. There is evidence that the secreted form of PCSK9 binds directly to the first epidermal growth factor-like repeat of the extracellular domain of the LDL-R. PCSK9 binding to this site is required for LDL-R degradation [32]. The ability of PCSK9 to promote LDL-R degradation, however, is independent of its catalytic activity [33]. PCSK9 would function as a chaperone molecule that prevents LDL-R recycling to the plasma membrane from endosomes and/or targets LDL-R to the lysosome for degradation [33].

4. Dominant Forms of Primary HBL FHBL is the main form of dominant primary HBL. FHBL is a genetically heterogeneous disorder which may be due to defective secretion or increased catabolism of apoB-containing lipoproteins. The majority of FHBL patients are heterozygotes; homozygous and compound heterozygous FHBL are very rare. 4.1. FHBL DUE TO DEFECTIVE SECRETION OF APOB-CONTAINING LIPOPROTEINS The main candidate gene in subjects with FHBL with a dominant inheritance is the APOB gene. Approximately 50% of FHBL heterozygotes are carriers of pathogenic mutations in the APOB gene (APOB-related FHBL) [34]. A large number of APOB mutations have been reported to be the cause of FHBL and novel mutations are continually being identified in FHBL subjects [2,3,34,35].

88

TARUGI AND AVERNA

4.1.1. APOB Gene Mutations Producing Truncated APOBs Most APOB gene mutations cause the formation of premature termination codons in the apoB mRNA. The translation of these mRNAs leads to the formation of truncated apoBs of various size which, to a variable extent, lose the capacity to form plasma lipoproteins in liver and/or intestine and to export lipids from these organs [2,3,34–37]. Truncated apoBs may or may not be detectable in plasma according to their size. Truncated apoBs longer than apoB-29/30 (i.e., with a size corresponding to 29–30% of that of apoB-100, according to a centile nomenclature) are detectable in plasma (by immunoblot with an anti-apoB antibody), as they are secreted into the plasma as constituents of plasma lipoproteins. The detection of a truncated apoB in plasma suggests the presence of a mutation located in a genomic region spanning from exon 26 to exon 29 of APOB gene. Truncated apoBs shorter than apoB-29/30, due to mutations located in the first 25 exons of APOB gene, are not detectable in plasma, as they are not secreted [3,34,35]. These short truncated apoBs account for 30% of all APOB mutations reported so far in FHBL [34]. Heterozygous FHBL subjects carrying truncated apoBs have a reduced production of apoB-containing lipoproteins in liver and, in some cases, in the intestine, which prevents the formation of VLDL and CM, respectively [38,39]. The production rate (in liver and intestine) of truncated apoBs, as compared with the corresponding wild-type forms of apoB (apoB48 and apoB-100), is greatly reduced for two main reasons: (i) the reduced lipid-binding capacity of structurally abnormal apoBs (notably short truncations) makes them prone to a rapid intracellular degradation, (ii) the presence of premature stop codons in apoB mRNAs due to frameshift or nonsense mutations may induce a rapid mRNA degradation (nonsense-mediated mRNA decay). In addition, FHBL carriers of long apoB truncations, which are secreted into the plasma, may have an increased removal of truncated apoB-containing lipoproteins by the liver (via the LDL-R) [38] or by the kidney via megalin receptor [40]. The plasma levels of LDL-C and apoB in FHBL heterozygotes carrying truncated apoBs are less than 30% of the values found in age- and gendermatched controls [3,34]. This reduction, which is far below the expected 50% values, is due not only to the extremely low levels of the secreted truncated forms of apoB but also to the reduced production rate of apoB-100 encoded by the normal allele which is 70–75% lower than that found in normal subjects [41,42]. The lower production of normal apoB-100 is the result of a reduced synthesis combined with an increased intracellular degradation. Very few FHBL homozygotes and compound heterozygotes have been reported. In APOB-related FHBL homozygotes or compound heterozygotes carrying apoB truncations, LDL-C and apoB are either not detectable

HYPOBETALIPOPROTEINEMIAS

89

(if both mutant alleles encode truncated apoB shorter than apoB-29/30) or are 10–20% of the control values (if both mutant alleles or at least one mutant allele encode(s) truncated apoBs longer than apoB-29/30) [34,43]. 4.1.2. APOB Gene Mutations Producing Amino Acid Substitutions in apoB Few nonconservative amino acid substitutions in apoB have been reported to be the cause of FHBL [44,45]. Two mutations, R463W and L343V, were found to cosegregate with FHBL in two large Libanese kindred. These mutations involve the N-terminal beta-alpha1 domain of apoB which contains sequence elements shown to be important for the proper folding of apoB [13,46], for the physical interaction between apoB and MTP (the chaperone molecule required for apoB lipidation) [8,10] and for lipid recruitment during lipoprotein assembly and secretion [9]. These missense mutations are associated with a decreased secretion of the mutant apoBs that are retained in the ER because of an increased binding to MTP [44,45]. Other carriers of R463W have been recently identified in Italian, Dutch, and Spanish FHBL subjects, suggesting that R463W may be a recurrent mutation in the population [34,37]. Recently, other missense mutations have been reported to be the cause of FHBL. Five missense APOB mutations located within the N-terminal 1000 amino acids of apoB, namely A31P, G275S, L324M, G912D, and G945S, were identified in heterozygous carriers of FHBL in the Italian population. Among these mutations, the A31P substitution in apoB completely blocked apoB-48 secretion when expressed in rat hepatoma cells [47]. In contrast to the two missense mutations L343V and R463W, the A31P mutant did not lead to ER retention as the aberrantly folded protein is degraded intracellularly by proteasomes and autophagosome/lysosome pathway [47]. Plasma levels of LDL-C and apoB in heterozygous carriers of the APOB missense mutations are comparable with those present in FHBL due to apoB truncations. The two homozygotes for the missense mutation R463W described so far have barely detectable apoB-containing lipoproteins in plasma [44] as observed in patients homozygotes/compound heterozygotes for short truncated apoBs [43,48]. 4.2. FHBL DUE TO INCREASED LIVER UPTAKE OF APOB-CONTAINING LIPOPROTEINS VIA LDL-RECEPTOR The large number of FHBL subjects in whom no APOB gene mutations were found suggests that other genes are involved in the pathogenesis of FHBL [3]. In the past few years, loss-of-function mutations in PCSK9 gene emerged as possible cause of FHBL (PCSK9-related FHBL).

90

TARUGI AND AVERNA

Studies in mice had shown that the inactivation of PCSK9 gene [49] was associated with a marked reduction of plasma cholesterol and LDL-C. This effect was due to an increased plasma LDL clearance, secondary to an increased number of LDL-Rs in the liver. This observation suggested that loss-of-function mutations of PCSK9 in humans would increase the receptormediated uptake and catabolism of plasma LDL, possibly resulting in reduced plasma level of LDL and a lipid phenotype similar to that found in APOB-related FHBL (e.g., Section 4.1). This hypothesis was confirmed when inactivating mutations in human PCSK9 (resulting in truncated proteins) were discovered in different populations (African-American, African, Caucasian, and Japanese populations) [50–54]. Heterozygous subjects carrying the loss-of-function mutations causing PCSK9 truncations (C679X, Y142X, A68fsL82X, and W428X) were found to have a reduction of plasma LDL-C levels ranging from 30% to 70% [50–54]. One homozygote for C679X and one compound heterozygote (Y142X/R97) were found to have an 80% reduction of LDL-C with respect to control values [51,52,55]. Population studies have demonstrated that some amino acid substitutions of PCSK9 (p.R46L, p.G106R, p.N157K, p.G236S, p.R237W, p.L253F, p. A443T, and p.S462P) are associated with a significant but variable reduction (ranging from 4% to 30%) in plasma levels of LDL-C [56–59]. All these variants were found to be more frequent in hypocholesterolemic subjects; however, only some of them were demonstrated to be loss-of-function mutations in vitro. Taken together, these observations strongly suggest that in humans, loss-of-function mutations of PCSK9 cause an FHBL phenotype by increasing the hepatic uptake of LDL. In subjects with PCSK9-related FHBL, the magnitude of reduction of plasma LDL-C and apoB appears to be less striking than that observed in subjects with APOB-related FHBL in whom the reduction usually ranges from 60% to 80% with respect to control values [34]. PCSK9-related FHBL homozygotes or compound heterozygotes have a less severe reduction of LDL-C and apoB with respect to APOB-related FHBL homozygotes/compound heterozygotes [43,48,51,52]. Plasma levels of LDL-C and apoB show large interindividual variability in FHBL heterozygotes, regardless of the gene involved (APOB or PCSK9) [34,50,60] that may be due to environmental factors (notably the diet) or to genetic factors affecting secretion and catabolism of apoB-containing lipoproteins. For example, it was shown that apoE genotype accounts for 15–60% of this variation in APOB-related FHBL heterozygotes carrying truncated apoBs [61]. It is also possible that factors affecting intestinal cholesterol absorption (i.e., variations in NPC1L1 gene) play a role in regulating apoB and LDL-C concentration in plasma of FHBL subjects [62].

HYPOBETALIPOPROTEINEMIAS

91

4.3. PREVALENCE OF PRIMARY FHBL Epidemiological data on the prevalence of primary FHBL are scarce. The population frequency of heterozygous APOB-related FHBL has been estimated to be 1 in 3000 [63]. Heterozygous PCSK9-related FHBL seems to be rare among Caucasians, while in African-Americans this disorder due to the two nonsense mutations (Y142X and C679X) has a prevalence of 2–2.6% [50]. The prevalence of homozygous and compound heterozygous APOBand PCSK9-related FHBL is exceedingly rare [2,59]. 5. Recessive Forms of Primary HBL Two very rare primary monogenic HBLs, usually diagnosed in infancy, segregate as autosomal recessive traits: ABL and CMRD. These disorders are characterized by the complete absence of apoB-containing lipoproteins (ABL) or by a selective absence of apoB-48-containing lipoproteins (CMRD) due to a defective assembly and secretion of these lipoproteins by liver and/or intestine [1]. 5.1. ABETALIPOPROTEINEMIA ABL is an ‘‘exceedingly rare’’ disorder that occurs in less than one in 1 million individuals. The plasma lipid profile of ABL patients is characterized by extremely low plasma levels of TC, VLDL, and LDL and an almost complete absence of apoB-100 and apoB-48. ABL-obligate heterozygotes have normal plasma lipids; in some cases, however, a mild reduction of TC and LDL-C has been reported [14]. ABL is due to mutations in the MTP gene which is required for the assembly and secretion of apoB-containing lipoproteins in both liver and intestine (e.g., Section 3.2). A variety of mutations in this gene, located on chromosome 4, have been described; most of them result in truncated proteins devoid of function [14,48,64–68]. Some MTP missense mutations have also been reported, which affect either the apoB-binding ability of MTP or its interaction with other components of the protein complex; they are associated with a milder form of the disease [65,66]. It is conceivable that the severity of ABL phenotype is related to the residual activity of MTP and the capacity to form VLDL and CM. The absence of MTP activity leads to the accumulation of large lipid droplets in the cytoplasm in hepatocytes and enterocytes. 5.2. CHYLOMICRON RETENTION DISEASE CMRD is a very rare recessive disorder characterized by the selective absence of apoB-48 in plasma, low plasma cholesterol, and fat-soluble vitamins. apoB-48-containing lipoproteins are not secreted into the plasma,

92

TARUGI AND AVERNA

neither fasting nor postprandially [1]. In CMRD the plasma levels of LDL-C and apoB are 25–40% of the control levels [69]. Affected subjects have an inability to export dietary lipids as CMs, leading to a marked accumulation of CM-like particles in membrane-bound compartments of enterocytes, which contain large cytosolic lipid droplets. CMRD is due to mutations in the SARA2 gene belonging to the Sar1ADP-ribosylation factor family of small GTPases. The SARA2 gene, located on chromosome 5, encodes the Sar1b protein, a single polypeptide of 198 amino acids [23,70] that is involved in the control of the intracellular trafficking of CMs in COPII-coated vesicles. CMs are selectively recruited by the COPII machinery for transport through the cellular secretory pathway [21,22]. Thus, CMRD may arise as a result of defects in the transport of CMs through the secretory pathway. Up to now, 14 mutations in the SARA2 gene have been identified in patients with the clinical diagnosis of CMRD-Anderson disease [23,71–74]. Missense mutations of SARA2 represent the most common cause of CMRD; these mutations were found in the Sar1b b-sheets region and are predicted to perturb the geometry of the guanosine diphosphate and guanosine triphosphate binding site of Sar1b [70]. Only two frameshift mutations have been reported so far [72,74].

6. Primary Orphan FHBL In a significant number of FHBL kindred, the search for causative mutations in the candidate genes is often inconclusive. Orphan FHBL kindred in which the HBL phenotype segregates as dominant trait have been studied by linkage analysis in order to identify the causative genes. Susceptibility loci have been identified in chromosomes 13q, 3p21.1-22, and 10 but no candidate genes have emerged so far [75–77].

7. Spectrum of Clinical Manifestations in Primary HBL Monogenic hypobetalipoproteinemias are characterized by a wide spectrum of clinical features. The clinical phenotypes of primary HBL due to defective secretion of apoB-containing lipoproteins (APOB-related FHBL, ABL, and CMRD) are highly variable, their severity being directly related to the degree of the impairment of the production of apoB-100 and/or apoB-48 [3]. The clinical phenotype is more severe in the primary recessive HBLs: in ABL and in CMRD the impaired formation/secretion of apoB-48 explains the severe

HYPOBETALIPOPROTEINEMIAS

93

intestinal lipid malabsorption and the related disorders (such as the growth retardation and the neurological manifestations caused by vitamin E deficiency) [78,79]. ABL displays a cluster of severe clinical manifestations such as malabsorption of dietary fat and fat-soluble vitamins, steatorrhea, ‘‘failure to thrive’’ and acanthocytosis that are present in infancy and childhood. Later in life, because of the deficiency of fat-soluble vitamins, coagulopathy, posterior column neuropathy and myopathy, anemia, spinocerebellar ataxia, and retinitis pigmentosa develop [78]. Few reports have documented a possible association of ABL with ileal adenocarcinoma [80] and metastatic spinal cord glioblastoma [81] and fatty liver was reported in some cases [82,83]. In CMRD, the clinical phenotype is strictly related to the impaired capacity to form CMs after a fat-containing meal. This leads to the development of steatorrhea, growth retardation, malnutrition, and an accumulation of lipid droplets within the enterocyte [84,85]. No neurological symptoms have been reported. However, the description of variable clinical phenotypes and a weak genotype–phenotype correlation in CMRD suggest that this disease might represent a more complex trait rather than a simple autosomal recessive disorder [69,74,79]. FHBL heterozygotes are generally asymptomatic but most of them develop fatty liver and sometimes a mild intestinal malabsorption [34,35]. FHBL homozygotes or compound heterozygotes have fatty liver and may suffer from severe fat malabsorption [43,48]. In homozygotes or compound heterozygotes of APOB-related FHBL carrying truncated apoBs, the severity of the clinical phenotype depends on the capacity of the truncated apoBs to bind lipids and to be secreted as lipoprotein particles by liver and intestine. apoBs shorter than apoB-29/30 are degraded intracellularly, mimicking an ABL-like condition [43,48]. The presence in these individuals of at least one mutant APOB allele producing truncations longer than apoB-48 may allow the secretion of small amounts of apoB-containing lipoproteins (specifically CMs), which contribute to mitigate the clinical phenotype [34,43]. In homozygotes/compound heterozygotes for long truncations (truncations longer than apoB-48), the clinical phenotype is usually mild, being characterized only by fatty liver [34]. Heterozygous APOB-related FHBL carrying short truncations (i.e., truncated apoBs shorter than apoB-48) usually have fatty liver and mild intestinal lipid malabsorption [34,86]; carriers of long truncations are generally asymptomatic but they tend to develop fatty liver [34]. Carriers of apoB missense mutations may be asymptomatic or manifest mild fatty liver disease and sometimes a mild fat malabsorption [44,45,47,87]. A common characteristic of the severe forms of primary HBL is fat-soluble vitamin deficiency, including vitamin E, secondary to fat malabsorption.

94

TARUGI AND AVERNA

Before the introduction of high-dose vitamin (A, D, K, and E) therapy, the majority of ABL patients did not survive past the third decade of life. The long-term vitamin treatment in ABL patients [78] was able to arrest the progression of the neurological complications, especially when initiated before the 16th month of life [88]. The current standard treatment for ABL, which can be extended to CMRD and homozygous FHBL, is based on a low fat diet eventually supplemented with medium-chain triglyceride and the administration of fat-soluble vitamins [79]. The rare cases of PCSK9-related FHBL homozygotes, despite a substantial reduction of plasma LDL-C (0.36–0.41 mmol/l), appear to be in good health since they are free of gastrointestinal symptoms and detectable increase in hepatic TG [51,52]. FHBL heterozygotes carrying PCSK9 mutations are completely asymptomatic in contrast with APOB-related FHBL. This difference is probably due to the biochemical pathways underlying PCSK9- and APOB-related FHBL. Increased hepatic catabolism of LDL present in PCSK9-related FHBL does not result in lipid accumulation within the hepatocytes or entherocytes, while such an accumulation is a key feature in the disorders characterized by defective assembly/secretion of apoB-containing lipoproteins (APOB-related FHBL, ABL, and CMRD).

8. Main Clinical Issues of FHBL 8.1. FHBL AND FATTY LIVER DISEASE In APOB-related FHBL the presence of fatty liver has been documented by abdominal ultrasound examination, magnetic resonance, or liver biopsy [89–93]. In FHBL heterozygous carriers of truncated forms of apoB, the mean liver TG content is approximately fivefold that of controls with a great interindividual variability despite similar apoB truncations and similar measures of obesity and glucose tolerance; this could indicate that other modifier genes than APOB may affect the magnitude of hepatic TG accumulation [94]. Histologically fatty liver of FHBL is similar to nonalcoholic fatty liver disease, which is highly prevalent in the general population, often being associated with obesity, dyslipidemia, hypertension, insulin resistance, type 2 diabetes mellitus; all these features, when clustered, characterize the metabolic syndrome [95,96]. In contrast to metabolic syndrome, in FHBL subjects the increased hepatic fat content is neither associated with glucose intolerance nor with insulin resistance [97]. The pathophysiology of fatty liver in APOB-related FHBL has been elucidated in animal models: apoB truncation-inducing mutations lead to the production of VLDL particles smaller than normal, with reduced

HYPOBETALIPOPROTEINEMIAS

95

capacities to bind TG; in addition apoB-100 produced by the normal allele is also reduced. The two combined defects of the VLDL export system produce the accumulation of TG in hepatocytes [98,99]. Fatty liver is also present in FHBL heterozygotes carrying missense mutations of APOB; these mutant apoBs are poorly lipidated and secreted as lipoprotein particles, causing an impaired export of hepatic TG [25]. The long-term outcome of fatty liver in FHBL is still unknown; anecdotal reports have documented an association between fatty liver and steatohepatitis, liver cirrhosis and hepatocarcinoma in FHBL patients [86,89–91,100]. Interestingly, fatty liver is not present in other forms of primary HBL such as PCSK9-related FHBL [51] and the orphan FHBL (linked to chromosomes 3 and 10 loci) [76,77]. 8.2. FHBL AND CARDIOVASCULAR DISEASE Elevated LDL-C is a major risk factor for cardiovascular disease (CVD). A recent meta-analysis of 61 prospective studies demonstrated that higher TC levels were associated with higher risks of coronary heart disease (CHD) and that there is no lower threshold. The association is log-linear suggesting that greater LDL-C absolute reductions should be associated with greater proportional reductions in risk of CHD [101]. In view of the low plasma LDL-C levels, it is reasonable to assume that primary HBL subjects: (i) might be naturally protected against CVD owing to reduced life-time exposure to atherogenic apoB-containing lipoproteins and (ii) represent a unique setting to verify the effects of a lifelong exposure to very low levels of LDL-C on the development of cardiovascular atherosclerosis-related diseases. To date no prospective studies have tested this hypothesis mainly because of the relatively small size of existing FHBL case series. Recently 14 APOB-related FHBL subjects have been clinically evaluated and found to be completely free from CVD [37]. A study designed to assess the noninvasive surrogate markers of CVD in FHBL showed that heterozygous APOB-related FHBL subjects (no. 41) were found to have a significant decrease in arterial stiffness as compared to control subjects, despite an increased prevalence of traditional cardiovascular risk factors [102]. Convincing evidence of the protection of lifelong reduction of plasma LDL-C has emerged with the observation that individuals with PCSK9-related FHBL have a marked reduction of CHD risk. Cohen et al. [103] examined the effect of PCSK9 loss-of-function mutations associated with reduced plasma levels of LDL-C on the incidence of CHD in a large population (Atherosclerosis Risk in Communities Study, ARIC). During a 15-year follow-up period among the carriers of the C679X mutation and the R46L variants, there was an 88% and a 47% reduction in the risk of CHD,

96

TARUGI AND AVERNA

respectively. These findings represent a strong ‘‘proof of concept’’ in favor of earlier initiation of lifestyle or, when appropriate, of drug interventions to lower LDL-C levels. 8.3. FHBL AND CANCER The association between low plasma cholesterol concentrations and increased risk of cancer has been reported in several studies and it has been explained as an example of ‘‘reverse causality’’ (subclinical cancer could reduce cholesterol levels) [104–106]. To test whether long-term low plasma cholesterol levels may increase cancer risk, cancer incidence has been evaluated in the ARIC study, among PCSK9-related FHBL [107]. There was no evidence that cholesterol-lowering variants of PCSK9 were associated with increased risk of total cancer.

9. Secondary Hypobetalipoproteinemias Environmental factors and several diseases may contribute to reduce the LDL-C and apoB plasma levels. Vegetarians who do not eat meat, fish, diary, or eggs have mean plasma TC and LDL-C levels lower than expected values of the control population. TC and LDL-C average plasma levels are 3.10–3.36 and 1.55–1.81 mmol/l, respectively, which are very close to the 5th percentile of the population distribution [108,109]. In patients with chronic parenchymal liver disease, lipid and lipoprotein plasma levels tend to be reduced [110]. The TC and LDL-C decrease parallels, the impairment of the hepatic synthesis due to the progressive liver failure [111]. Among cirrhotic patients classified according to the MELD score which determines the residual liver function, TC ranges between 3.88 and 2.58 mmol/l and LDL-C between 2.07 and 1.29 mmol/l [112]. Conditions like chronic pancreatitis (adults) and cystic fibrosis (children) are characterized by intestinal fat malabsorption which is associated with HBL. In these common diseases, exocrine pancreatic insufficiency causes steatorrhea when pancreas function is below 5% of normal function. Patients with chronic pancreatitis suffer from malabsorption and nutritional deficiencies. In advanced disease, TC and LDL-C are generally low, 3.10–4.14 and 1.81–2.33 mmol/l, respectively [113]. In cystic fibrosis, the presence of pancreatic insufficiency is associated with lower levels of TC (2.58–2.32 mmol/l) and LDL-C (1.29–1.81 mmol/l) [114]. In end-stage renal disease patients on hemodialysis, the LDL-C distribution curve is shifted to the left [115]; malnutrition and inflammation are

HYPOBETALIPOPROTEINEMIAS

97

believed responsible for the hypocholesterolemia associated with this condition [116]. Hyperthyroidism exhibits an enhanced excretion of cholesterol, a reduced output of hepatic VLDL and an increased turnover of LDL resulting in a decrease of plasma TC and LDL-C [117,118]. Low plasma levels of TC have been frequently described in a variety of hematologic disorders characterized by the presence of anemia [119]. The existence of HBL has been reported in all phenotypes of beta-thalassemia with TC and LDL-C levels in homo- and heterozygotes about 50% lower compared with healthy controls [120,121]. The mechanisms underlying the hypocholesterolemia observed in beta-thalassemia patients are unknown, and several explanations have been proposed: anemia, liver dysfunction, increased cholesterol consumption by the bone marrow, hyper-stimulation of the LDL-R by inflammatory cytokines, or an overactive reticuloendothelial system [122]. Hypocholesterolemia has also been documented in Sickle cell disease patients and it recognizes the same putative mechanisms as beta-thalassemia [123,124]. Hypocholesterolemia has been associated with cancer; there is no cause– effect relationship but the so-called unsuspected sickness phenomenon [125,126]: subclinical disease may lower cholesterol levels by a LDL-R hyperactivity in tumor cells [127].

10. Conclusions The plasma levels of LDL-C and apoB below the 5th percentile of the reference population’s values represent the biochemical landmark which drives the clinical diagnosis of monogenic hypobetalipoproteinemias. The magnitude of plasma LDL-C and apoB reduction is affected by: (i) the mode of transmission, dominant (APOB- or PCSK9-related FHBL) versus recessive (ABL and CMRD) and (ii) the heterozygous or homozygous state in the case of FHBL (Table 1). The first step in the differential diagnosis of HBL is the exclusion of the secondary forms of HBL that are associated with a variety of clinical conditions. If the clinical diagnosis suggests primary HBL, the study of the transmission of HBL trait in the family of the index case provides a guide for the molecular diagnosis. A mild clinical phenotype (moderate reduction of TC, LDL-C, and apoB possibly associated with fatty liver), when combined with the presence of the HBL trait in family members, strongly suggests the clinical diagnosis of heterozygous FHBL. A diagnosis of possible FHBL should also be considered in a subject with a mild phenotype whenever the mode of transmission of HBL trait is undefined (i.e., it cannot be ascertained

TABLE 1 MONOGENIC PRIMARY HYPOBETALIPOPROTEINEMIAS

Primary HBL

Mode of inheritance

Candidate gene

apoB or LDL plasma levels versus controls

APOB-related FHBL

Codominant

APOB

<30%

PCSK9-related FHBL

Codominant

PCSK9

30–70%

ABL

Recessive

MTP

Undetectable (absence of apoBcontaining lipoproteins)

CMRD

Recessive

SARA2

25–40% (absence of apoB-48containing lipoproteins)

Orphan FHBL

Codominant

Unknown

<50%

Clinical phenotype Heterozygotes: asymptomatic or fatty liver; mild fat malabsorpion in carriers of short truncated apoBs Homozygotes: fatty liver; mild/severe intestinal fat malabsorption (ABLlike phenotype) Heterozygotes: asymptpmatic Homozygotes: asymptomatic Malabsorption of dietary fat and fatsoluble vitamins, steatorrhea, ‘‘failure to thrive,’’ acanthocytosis, neuropathy and myopathy, anemia, spinocerebellar ataxia, retinitis pigmentosa, and fat laden enterocytes (free lipid droplets in the cytoplasm) Steatorrhea, growth retardation, malnutrition, and fat laden enterocytes (free lipid droplets coexist with membrane-bound lipoprotein-like particles) FHBL-like phenotype

ABL, abetalipoproteinemia; APOB, apolipoprotein B; CMRD, chylomicron retention disease; FHBL, familial hypobetalipoproteinemia; MTP, microsomal triglyceride transfer protein; PCSK9, proconvertase subtilisin/kexin type 9.

HYPOBETALIPOPROTEINEMIAS

99

on firm bases). A severe clinical phenotype (extremely low or undetectable levels of LDL-C and apoB associated with intestinal fat malabsorption and severe fatty liver), notably in children or young adults, suggests the clinical diagnosis of ABL, CMRD, or homozygous FHBL. In case of recessive transmission of the HBL trait, FHBL may be excluded and the differential diagnosis is restricted to ABL and CMRD. The analysis of candidate genes may reveal the presence of pathogenic mutations (e.g., frameshift, nonsense mutations, or missense mutations known to be pathogenic) or other rare sequence variants with unknown biological effect. In the latter case, the molecular diagnosis remains undefined until cosegregation of the mutant allele with HBL is demonstrated or in vitro functional studies of the mutant allele are available. It should be emphasized that approximately 50% of individuals with the clinical diagnosis of heterozygous FHBL do not have mutations in the two major candidate genes (APOB and PCSK9) (Orphan FHBL) [34]. This suggests that other major genes affecting the metabolism of apoB-containing lipoproteins remain to be identified. The flow chart shown in Fig. 1 is provided to guide the clinicians in the identification of the etiology and the molecular bases of HBL.

Addendum After the submission of the present review, a novel phenotype of primary HBL, designated Familial Combined Hypolipidemia, was reported (Musunuru K et al. N. Engl. J. Med 2010, 363.2220-2227). This disorder, characterized by low plasma levels of LDL-C, TG and HDL-C, was identified in two siblings who were compound heterozygotes for two distinct nonsense mutations in ANGPTL3 (encoding the angiopoietin-like 3 protein). This finding indicates that loss of function mutations of ANGPTL3 are a novel cause of monogenic HBL.

100

TARUGI AND AVERNA

Plasma lipid profile (TC, LDL-C, apoB < 5th percentile) with or without mild or severe clinical phenotype

Hypobetalipoproteinemia (HBL)

Secondary HBL Primary HBL

No

Yes

Mode of transmission

Recessive

Dominant

Malabsorption Malnutrition Hyperthyroidism Liver diseases Cancer Etc.

Undefined Severe phenotype* Mild phenotype**

APOB gene sequencing

MTP gene sequencing

Positive ABL

Negative

Negative

Positive

APOB-related FHBL

PCSK9 gene sequencing

Negative

SARA2 gene sequencing

Positive CMRD

Negative

Orphan HBL

PCSK9-related FHBL FIG. 1. Flow-chart for the diagnosis of hypobetalipoproteinemias. Mild phenotype** indicates a reduction of plasma TC, LDL-C, and apoB, without relevant clinical manifestations apart from fatty liver. Severe phenotype* indicates a substantial reduction of plasma TC, LDLC, and apoB associated with clinical manifestations such as intestinal fat malabsorption, growth retardation, fat-soluble vitamins deficiency, severe fatty liver, and possibly neurological disorders. Undefined mode of transmission refers to those HBL cases in which no family history is available. ABL, abetalipoproteinemia; CMRD, chylomicron retention disease; FHBL, familial hypobetalipoproteinemia; HBL, hypobetalipoproteinemia.

HYPOBETALIPOPROTEINEMIAS

101

ACKNOWLEDGMENT The authors thank the ‘‘Amici del Cuore’’ foundation for supporting their research work.

REFERENCES [1] J.P. Kane, R.J. Havel, Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins, in: C.R. Scriver, A.L. Beaudet, D. Valle, W.S. Sly (Eds.), The Metabolic and Molecular Bases of Inherited Disease, vol. II, eigth ed., McGraw-Hill, New York, 2001, pp. 2717–2752. [2] A.J. Hooper, F.M. van Bockxmeer, J.R. Burnett, Monogenic hypocholesterolaemic lipid disorders and apolipoprotein B metabolism, Crit. Rev. Clin. Lab. Sci. 42 (2005) 515–545. [3] G. Schonfeld, X. Lin, P. Yue, Familial hypobetalipoproteinemia: genetics and metabolism, Cell. Mol. Life Sci. 62 (2005) 1372–1378. [4] E.A. Fisher, H.N. Ginsberg, Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins, J. Biol. Chem. 277 (2002) 17377–17380. [5] J.L. Brodsky, E.A. Fisher, The many intersecting pathways underlying apolipoprotein B secretion and degradation, Trends Endocrinol. Metab. 19 (2008) 254–259. [6] A.-B. Wang, D.-P. Liu, C.-C. Liang, Regulation of human apolipoprotein B gene expression at multiple levels, Exp. Cell Res. 290 (2003) 1–12. [7] M.M. Hussain, J. Shi, P. Dreizen, Microsomal triglyceride transfer protein and its role in ApoB-lipoprotein assembly, J. Lipid Res. 44 (2003) 22–32. [8] D.G. Gretch, S.L. Sturley, L. Wang, et al., The amino terminus of apolipoprotein B is necessary but not sufficient for microsomal triglyceride transfer protein responsiveness, J. Biol. Chem. 271 (1996) 8682–8691. [9] R.S. McLeod, Y. Wang, S. Wang, A. Rusin˜ol, P. Links, Z. Yao, Apolipoprotein B sequence requirements for hepatic very low density lipoproteins assembly. Evidence that hydrophobic sequences within apolipoprotein B48 mediate lipid recruitment, J. Biol. Chem. 271 (1996) 18445–18455. [10] J.P. Segrest, M.K. Jones, N. Dashti, N-terminal domain of apolipoprotein B has structural homology to lipovitellin and microsomal triglyceride transfer protein: a ‘‘lipid pocket’’ model for self-assembly of apoB-containing lipoprotein particles, J. Lipid Res. 40 (1999) 1401–1416. [11] J.P. Segrest, M.K. Jones, H. De Loof, N. Dashti, Structure of apolipoprotein B-100 in low density lipoproteins, J. Lipid Res. 42 (2001) 1346–1367. [12] G.S. Shelness, L. Hou, A.S. Ledford, J.S. Parks, R.B. Weinberg, Identification of the lipoprotein initiating domain of apolipoprotein B, J. Biol. Chem. 278 (2003) 44702–44707. [13] C.J. Mann, T.A. Anderson, J. Read, et al., The structure of vitellogenin provides a molecular model for the assembly and secretion of atherogenic lipoproteins, J. Mol. Biol. 285 (1999) 391–408. [14] N. Berriot-Varoqueaux, L.P. Aggerbeck, M. Samson-Bouma, J.R. Wetterau, The role of the microsomal triglyceride transfer protein in abetalipoproteinemia, Annu. Rev. Nutr. 20 (2000) 663–697. [15] C.E. Chandler, D.E. Wilder, J.L. Pettini, et al., CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans, J. Lipid Res. 44 (2003) 1887–1901. [16] M. Cuchel, L.T. Bloedon, P.O. Szapary, et al., Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia, N. Engl. J. Med. 356 (2007) 148–156.

102

TARUGI AND AVERNA

[17] J. Zhang, H. Herscovitz, Nascent lipidated apolipoprotein B is transported to the Golgi as an incompletely folded intermediate as probed by its association with network of endoplasmic reticulum molecular chaperones, GRP94, ERp72, BiP, Calreticulin, and Cyclophilin B, J. Biol. Chem. 278 (2003) 7459–7468. [18] G.F. Gibbons, D. Wiggins, A.-M. Brown, A.-M. Hebbachi, Synthesis and function of hepatic very-low-density lipoprotein, Biochem. Soc. Trans. 32 (2004) 59–64. [19] M.M. Hussain, S. Fatma, X. Pan, J. Iqbal, Intestinal lipoprotein assembly, Curr. Opin. Lipidol. 16 (2005) 281–285. [20] L.L. Swift, K. Valyi-Nagy, C. Rowland, C. Harris, Assembly of very low density lipoproteins in mouse liver: evidence of heterogeneity of particle density in the Golgi apparatus, J. Lipid Res. 42 (2001) 218–224. [21] R. Duden, ER-to-Golgi transport: COPI and COPII function (review), Mol. Membr. Biol. 20 (2003) 197–207. [22] V. Gusarova, J.L. Brodsky, E.A. Fisher, Apolipoprotein B100 exit from the endoplasmic reticulum (ER) is COPII-dependent, and its lipidation to very low density lipoprotein occurs post-ER, J. Biol. Chem. 278 (2003) 48051–48058. [23] B. Jones, E.L. Jones, S.A. Bonney, et al., Mutations in a Sar1 GTPase of COPII vesicles are associated with lipid absorption disorders, Nat. Genet. 34 (2003) 29–31. [24] H.N. Ginsberg, E.A. Fisher, The ever-expanding role of degradation in the regulation of apolipoprotein B metabolism, J. Lipid Res. 50 (2009) S162–S166. [25] M. Sundaram, Z. Yao, Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion, Nutr. Metab. 7 (2010) 35–51. [26] J. Twisk, D.L. Gillian-Daniel, A. Tebon, L. Wang, P.H.R. Barrett, A.D. Attie, The role of the LDL receptor in apolipoprotein B secretion, J. Clin. Invest. 105 (2000) 521–532. [27] J.S. Millar, C. Maugeais, K. Ikewaki, et al., Complete deficiency of the low density lipoprotein receptor is associated with increased apolipoprotein B-100 production, Arterioscler. Thromb. Vasc. Biol. 25 (2005) 560–565. [28] D.L. Gillian-Daniel, P.W. Bates, A. Tebon, A.D. Attie, Endoplasmic reticulum localization of the low density lipoprotein receptor mediates pre-secretory degradation of apolipoprotein B, Proc. Natl. Acad. Sci. USA 99 (2002) 4337–4342. [29] A.K. Soutar, R.P. Naoumova, Mechanisms of disease: genetic causes of familial hypercholesterolemia, Nat. Clin. Pract. Cardiovasc. Med. 4 (2007) 214–225. [30] J.D. Horton, J.C. Cohen, H.H. Hobbs, PCSK9: a convertase that coordinates LDL catabolism, J. Lipid Res. 50 (2009) S172–S177. [31] S.A. Mousavi, K.E. Berge, T.P. Leren, The unique role of proprotein convertase subtilisin/ kexin 9 in cholesterol homeostasis, J. Intern. Med. 266 (2009) 507–519. [32] D.-W. Zhang, T.A. Lagace, R. Garuti, et al., Binding of PCSK9 to EGF-A repeat of LDL receptor decreases receptor recycling and increases degradation, J. Biol. Chem. 282 (2007) 18602–18612. [33] M.C. McNutt, T.A. Lagace, J.D. Horton, Catalytic activity is not required for secreted PCSK9 to reduce LDL receptors in HepG2 cells, J. Biol. Chem. 282 (2007) 20799–20803. [34] P. Tarugi, M. Averna, E. Di Leo, et al., Molecular diagnosis of hypobetalipoproteinemia: an ENID review, Atherosclerosis 195 (2007) e19–e27. [35] G. Schonfeld, Familial hypobetalipoproteinemia: a review, J. Lipid Res. 44 (2003) 878–883. [36] A.J. Whitfield, P.H.R. Barrett, F.M. van Bockxmeer, J.R. Burnett, Lipid disorders and mutations in the APOB gene, Clin. Chem. 50 (2004) 1725–1732. [37] S.W. Fouchier, R.R. Sankatsing, J. Peter, et al., High frequency of APOB gene mutations causing familial hypobetalipoproteinaemia in patients of Dutch and Spanish descent, J. Med. Genet. 42 (2005) e23.

HYPOBETALIPOPROTEINEMIAS

103

[38] K.G. Parhofer, P.H. Barrett, C.A. Aguilar-Salinas, G. Schonfeld, Positive linear correlation between the length of truncated apolipoprotein B and its secretion rates: in vivo studies in human apoB-89, apoB-75, apoB-54.8, and apoB-31 heterozygotes, J. Lipid Res. 37 (1996) 844–852. [39] A.J. Hooper, K. Robertson, P.H.R. Barrett, K.G. Parhofer, F.M. van Bockxmeer, J.R. Burnett, Postprandial lipoprotein metabolism in familial hypobetalipoproteinemia, J. Clin. Endocrinol. Metab. 92 (2007) 1474–1478. [40] Z. Chen, J.E. Saffitz, M.A. Latour, G. Schonfeld, Truncated apo B-70.5-containing lipoproteins bind to megalin but not the LDL receptor, J. Clin. Invest. 103 (1999) 1419–1430. [41] C.A. Aguilar-Salinas, P.H. Barrett, K.G. Parhofer, et al., Apoprotein B-100 production is decreased in subjects heterozygous for truncations of apoprotein B, Arterioscler. Thromb. Vasc. Biol. 15 (1995) 71–80. [42] N. Elias, B.W. Patterson, G. Schonfeld, Decreased production rates of VLDL triglycerides and ApoB-100 in subjects heterozygous for familial hypobetalipoproteinemia, Arterioscler. Thromb. Vasc. Biol. 19 (1999) 2714–2721. [43] E. Di Leo, L. Magnolo, M. Bertolotti, et al., Variable phenotypic expression of homozygous familial hypobetalipoproteinaemia due to novel APOB gene mutations, Clin. Genet. 74 (2008) 267–273. [44] J.R. Burnett, J. Shan, B.A. Miskie, et al., A novel nontruncating APOB gene mutation, R463W, causes familial hypobetalipoproteinemia, J. Biol. Chem. 278 (2003) 13442–13452. [45] J.R. Burnett, S. Zhong, Z.G. Jiang, et al., Missense mutations in APOB within the ba1 domain of human ApoB-100 result in impaired secretion of ApoB and ApoB-containing lipoproteins in familial hypobetalipoproteinemia, J. Biol. Chem. 282 (2007) 24270–24283. [46] Z.G. Jiang, D. Gantz, E. Bullitt, C.J. McKnight, Defining lipid-interacting domains in the N-terminal region of apolipoprotein B, Biochemistry 45 (2006) 11799–11808. [47] S. Zhong, A.L. Magnolo, M. Sundaram, et al., Non synonymous mutations within APOB in human familial hypobetalipoproteinemia: evidence for feedback inhibition of lipogenesis and postendoplasmic reticulum degradation of apolipoprotein B, J. Biol. Chem. 285 (2010) 6453–6464. [48] M. Najah, E. Di Leo, J. Awatef, et al., Identification of patients with abetalipoproteinemia and homozygous familial hypobetalipoproteinemia in Tunisia, Clin. Chim. Acta 401 (2009) 51–56. [49] S. Rashid, D.E. Curtis, R. Garuti, et al., Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9, Proc. Natl. Acad. Sci. USA 102 (2005) 5374–5379. [50] J. Cohen, A. Pertsemlidis, I.K. Kotowski, R. Graham, C.K. Garcia, H.H. Hobbs, Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9, Nat. Genet. 37 (2005) 161–165. [51] Z. Zhao, Y. Tuakli-Wosornu, T.A. Lagace, et al., Molecular characterization of loss-offunction mutations in PCSK9 and identification of a compound heterozygote, Am. J. Hum. Genet. 79 (2006) 514–523. [52] A.J. Hooper, A.D. Marais, D.M. Tanyanyiwa, J.R. Burnett, The C679X mutation in PCSK9 is present and lowers blood cholesterol in a southern African population, Atherosclerosis 193 (2007) 445–448. [53] T. Fasano, A.B. Cefalu`, E. Di Leo, et al., A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol, Arterioscler. Thromb. Vasc. Biol. 27 (2007) 677–681. [54] Y. Miyake, R. Kimura, Y. Kokubo, et al., Genetic variants in PCSK9 in the Japanese population: rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population, Atherosclerosis 196 (2008) 29–36.

104

TARUGI AND AVERNA

[55] J. Davignon, G. Dubuc, N.G. Seidah, The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis, Curr. Atheroscler. Rep. 12 (2010) 308–315. [56] J. Cameron, Ø.L. Holla, T. Ranheim, M.A. Kulseth, K.E. Berge, T.P. Leren, Effect of mutations in the PCSK9 gene on the cell surface LDL receptors, Hum. Mol. Genet. 15 (2006) 1551–1558. [57] J. Cameron, Ø.L. Holla, J.K. Laerdahl, et al., Characterization of novel mutations in the catalytic domain of the PCSK9 gene, J. Intern. Med. 263 (2008) 420–431. [58] J. Cameron, Ø.L. Holla, J.K. Laerdahl, M.A. Kulseth, K.E. Berge, T.P. Leren, Mutation S462P in the PCSK9 gene reduces secretion of mutant PCSK9 without affecting the autocatalytic cleavage, Atherosclerosis 203 (2009) 161–165. [59] M. Abifadel, J.P. Rabe`s, M. Devillers, et al., Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease, Hum. Mutat. 30 (2009) 520–529. [60] K.E. Berge, L. Ose, T.P. Leren, Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy, Arterioscler. Thromb. Vasc. Biol. 26 (2006) 1094–1100. [61] P. Yue, W.L. Isley, W.S. Harris, S. Rosipal, C.D. Akin, G. Schonfeld, Genetic variants of ApoE account for variability of plasma low-density lipoprotein and apolipoprotein B levels in FHBL, Atherosclerosis 178 (2005) 107–113. [62] J.C. Cohen, A. Pertsemlidis, S. Fahmi, et al., Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels, Proc. Natl. Acad. Sci. USA 103 (2006) 1810–1815. [63] F.K. Welty, C. Lahoz, K.L. Tucker, J.M. Ordovas, P.W. Wilson, E.J. Schaefer, Frequency of apoB and apoE gene mutations as causes of hypobetalipoproteinemia in the Framingham offspring population, Arterioscler. Thromb. Vasc. Biol. 18 (1998) 1745–1751. [64] T.M. Narcisi, C.C. Shoulders, S.A. Chester, et al., Mutations of the microsomal triglyceride-transfer-protein gene in abetalipoproteinemia, Am. J. Hum. Genet. 57 (1995) 1298–1310. [65] J. Wang, R.A. Hegele, Microsomal triglyceride transfer protein (MTP) gene mutations in Canadian subjects with abetalipoproteinemia, Hum. Mutat. 15 (2000) 294–295. [66] K. Ohashi, S. Ishibashi, J. Osuga, et al., Novel mutations in the microsomal triglyceride transfer protein gene causing abetalipoproteinemia, J. Lipid Res. 41 (2000) 1199–1204. [67] L. Benayoun, E. Granot, L. Rizel, S. Allon-Shalev, D.M. Behar, T. Ben-Yosef, Abetalipoproteinemia in Israel: evidence for a founder mutation in the Ashkenazi Jewish population and a contiguous gene deletion in an Arab patient, Mol. Genet. Metab. 90 (2007) 453–457. [68] E. Di Leo, S. Lancellotti, J.Y. Pennacchioni, et al., Mutations in MTP gene in abeta- and hypobeta-lipoproteinemia, Atherosclerosis 180 (2005) 311–318. [69] N. Peretti, C.C. Roy, A. Sassolas, et al., Chylomicron retention disease: a long term study of two cohorts, Mol. Genet. Metab. 97 (2009) 137–142. [70] C.C. Shoulders, D.J. Stephens, B. Jones, The intracellular transport of chylomicrons requires the small GTPase, Sar1b, Curr. Opin. Lipidol. 15 (2004) 191–197. [71] M. Silvain, D. Bligny, T. Aparicio, et al., Anderson’s disease (chylomicron retention disease): a new mutation in the SARA2 gene associated with muscular and cardiac abnormalities, Clin. Genet. 74 (2008) 546–552. [72] M. Charcosset, A. Sassolas, N. Peretti, et al., Anderson or chylomicron retention disease: molecular impact of five mutations in the SAR1B gene on the structure and the functionality of Sar1b protein, Mol. Genet. Metab. 93 (2008) 74–84.

HYPOBETALIPOPROTEINEMIAS

105

[73] S. Treepongkaruna, N. Chongviriyaphan, U. Suthutvoravut, D. Charoenpipop, L. Choubtum, D. Wattanasirichaigoon, Novel missense mutations of SAR1B gene in an infant with chylomicron retention disease, J. Pediatr. Gastroenterol. Nutr. 48 (2009) 370–373. [74] A.B. Cefalu`, P.L. Calvo, D. Noto, et al., Variable phenotypic expression of chylomicron retention disease in a kindred carrying a mutation of the Sara2 gene, Metabolism 59 (2010) 463–467. [75] H. Knoblauch, B. Muller-Myhsok, A. Busjshn, et al., A cholesterol-lowering gene maps to chromosome 13q, Am. J. Hum. Genet. 66 (2000) 157–166. [76] B. Yuan, R. Neuman, S.H. Duan, et al., Linkage of a gene for familial hypobetalipoproteinemia to chromosome 3p21.1-22, Am. J. Hum. Genet. 66 (2000) 1699–1704. [77] R. Sherva, P. Yue, G. Schonfeld, R.J. Neuman, Evidence for a quantitative trait locus affecting low levels of apolipoprotein B and low density lipoprotein on chromosome 10 in Caucasian families, J. Lipid Res. 48 (2007) 2632–2639. [78] R. Zamel, R. Khan, R.L. Pollex, R.A. Hegele, Abetalipoproteinemia: two case reports and literature review, Orphanet J. Rare Dis. 8 (2008) 3–19. [79] N. Peretti, A. Sassolas, C.C. Roy, et al., Guidelines for the diagnosis and management of chylomicron retention disease based on a review of the literature and the experience of two centers, Orphanet J. Rare Dis. 5 (2010) 24. [80] K. Al-Shali, J. Wang, F. Rosen, R.A. Hegele, Ileal adenocarcinoma in a mild phenotype of abetalipoproteinemia, Clin. Genet. 63 (2003) 135–138. [81] R.P. Newman, E.J. Schaefer, C.B. Thomas, E.H. Oldfield, Abetalipoproteinemia and metastatic spinal cord glioblastoma, Arch. Neurol. 41 (1984) 554–556. [82] A. Kudo, N. Tanaka, S. Oogaki, T. Niimura, T. Kanehisa, Hypobetalipoproteinemia with abnormal prebetalipoprotein, J. Neurol. Sci. 31 (1977) 411–419. [83] J.C. Collins, I.H. Scheinberg, D.R. Giblin, I. Sternlieb, Hepatic peroxisomal abnormalities in abetalipoproteinemia, Gastroenterology 97 (1989) 766–770. [84] C.C. Roy, E. Levy, P.H. Green, et al., Malabsorption, hypocholesterolemia, and fat-filled enterocytes with increased intestinal apoprotein B. Chylomicron retention disease, Gastroenterology 92 (1987) 390–399. [85] A. Nemeth, U. Myrdal, B. Veress, et al., Studies on lipoprotein metabolism in a family with jejunal chylomicron retention, Eur. J. Clin. Invest. 25 (1995) 271–280. [86] E. Di Leo, L. Magnolo, E. Pinotti, et al., Functional analysis of two novel splice site mutations of APOB gene in familial hypobetalipoproteinemia, Mol. Genet. Metab. 96 (2009) 66–72. [87] D. Noto, A.B. Cefalu`, A. Cannizzaro, et al., Familial hypobetalipoproteinemia due to apolipoprotein B R463W mutation causes intestinal fat accumulation and low postprandial lipemia, Atherosclerosis 206 (2009) 193–198. [88] L. Chardon, A. Sassolas, B. Dingeon, et al., Identification of two novel mutations and long-term follow-up in abetalipoproteinemia: a report of four cases, Eur. J. Pediatr. 168 (2009) 983–989. [89] P. Tarugi, A. Lonardo, G. Ballarini, et al., Fatty liver in heterozygous hypobetalipoproteinemia caused by a novel truncated form of apolipoprotein B, Gastroenterology 111 (1996) 1125–1133. [90] P. Tarugi, A. Lonardo, Heterozygous familial hypobetalipoproteinemia associated with fatty liver, Am. J. Gastroenterol. 92 (1997) 1400–1402. [91] P. Tarugi, A. Lonardo, C. Gabelli, et al., Phenotypic expression of familial hypobetalipoproteinemia in three kindreds with mutations of apolipoprotein B gene, J. Lipid Res. 42 (2001) 1552–1561.

106

TARUGI AND AVERNA

[92] P. Yue, T. Tanoli, O. Wilhelm, B. Patterson, D. Yablonskiy, G. Schonfeld, Absence of fatty liver in familial hypobetalipoproteinemia linked to chromosome 3p21, Metabolism 54 (2005) 682–688. [93] T. Tanoli, P. Yue, D. Yablonskiy, G. Schonfeld, Fatty liver in familial hypobetalipoproteinemia: roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity, J. Lipid Res. 45 (2004) 941–947. [94] G. Schonfeld, B.W. Patterson, D.A. Yablonskiy, et al., Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis, J. Lipid Res. 44 (2003) 470–478. [95] G. Marchesini, M. Brizi, A.M. Morselli-Labate, et al., Association of nonalcoholic fatty liver disease with insulin resistance, Am. J. Med. 107 (1999) 450–455. [96] G. Marchesini, M. Brizi, G. Bianchi, et al., Nonalcoholic fatty liver disease: a feature of the metabolic syndrome, Diabetes 50 (2001) 1844–1850. [97] A. Amaro, E. Fabbrini, M. Kars, et al., Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia, Gastroenterology 139 (2010) 149–153. [98] Z. Chen, R.L. Fitzgerald, M.R. Averna, G. Schonfeld, A targeted apolipoprotein B-38.9producing mutation causes fatty livers in mice due to the reduced ability of apolipoprotein B-38.9 to transport triglycerides, J. Biol. Chem. 275 (2000) 32807–32815. [99] Z. Chen, R.L. Fitzgerald, G. Li, N.O. Davidson, G. Schonfeld, Hepatic secretion of apoB100 is impaired in hypobetalipoproteinemic mice with an apoB-38.9-specifying allele, J. Lipid Res. 45 (2004) 155–163. [100] A. Lonardo, P. Tarugi, G. Ballarini, A. Bagni, Familial heterozygous hypobetalipoproteinemia, extrahepatic primary malignancy and hepatocellular carcinoma, Dig. Dis. Sci. 43 (1998) 2489–2492. [101] S. Lewington, G. Whitlock, R. Clarke, et al., Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths, Lancet 37 (2007) 1829–1839. [102] R.R. Sankatsing, S.W. Fouchier, S. de Haan, et al., Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia, Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1979–1984. [103] J.C. Cohen, E. Boerwinkle, T.H. Mosley Jr., H.H. Hobbs, Sequence variations in PCSK9, low LDL, and protection against coronary heart disease, N. Engl. J. Med. 354 (2006) 1264–1272. [104] S.B. Kritchevsky, T.C. Wilcosky, D.L. Morris, K.N. Truong, H.A. Tyroler, Changes in plasma lipid and lipoprotein cholesterol and weight prior to the diagnosis of cancer, Cancer Res. 51 (1991) 3198–3203. [105] D. Jacobs, H. Blackburn, M. Higgins, et al., Report of the conference on low blood cholesterol: mortality associations, Circulation 86 (1992) 1046–1060. [106] M.R. Law, S.G. Thompson, Low serum cholesterol and the risk of cancer: an analysis of the published prospective studies, Cancer Causes Control 2 (1992) 253–261. [107] A.R. Folsom, J.M. Peacock, E. Boerwinkle, Sequence variation in proprotein convertase subtilisin/kexin type 9 serine protease gene, low LDL cholesterol, and cancer incidence, Cancer Epidemiol. Biomarkers Prev. 16 (2007) 2455–2458. [108] F.M. Sacks, W.P. Castelli, A. Donner, E.H. Kass, Plasma lipids and lipoproteins in vegetarians and controls, N. Engl. J. Med. 292 (1975) 1148–1151. [109] K. Resnicow, J. Barone, A. Engle, et al., Diet and serum lipids in vegan vegetarians: a model for risk reduction, J. Am. Diet. Assoc. 91 (1991) 447–453. [110] N. McIntyre, Plasma lipids and lipoproteins in liver disease, Gut 19 (1978) 526–530.

HYPOBETALIPOPROTEINEMIAS

107

[111] A. Habib, A.A. Mihas, S.G. Abou-Assi, et al., High-density lipoprotein cholesterol as an indicator of liver function and prognosis in noncholestatic cirrhotics, Clin. Gastroenterol. Hepatol. 3 (2005) 286–291. [112] M. Jiang, F. Liu, W.-J. Xiong, et al., Combined MELD and blood lipid level in evaluating the prognosis of decompensated cirrhosis, World J. Gastroenterol. 16 (2010) 1397–1401. [113] D. Quilliot, E. Walters, P. Bohme, et al., Fatty acid abnormalities in chronic pancreatitis: effect of concomitant diabetes mellitus, Eur. J. Clin. Nutr. 57 (2003) 496–503. [114] B. Rhodes, E.F. Nash, E. Tullis, et al., Prevalence of dyslipidemia in adults with cystic fibrosis, J. Cyst. Fibros. 9 (2010) 24–28. [115] T. Shoji, Y. Nishizawa, T. Kawagishi, et al., Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis, Atherosclerosis 131 (1997) 229–236. [116] K. Iseki, M. Yamazato, M. Tozawa, S. Takishita, Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients, Kidney Int. 61 (2002) 1887–1893. [117] M. Heimberg, J.O. Olubadewo, H.G. Wilcox, Plasma lipoproteins and regulation of hepatic metabolism of fatty acids in altered thyroid states, Endocr. Rev. 6 (1985) 590–607. [118] L.H. Duntas, Thyroid disease and lipids, Thyroid 12 (2002) 287–293. [119] M.P. Westerman, Hypocholesterolemia and anemia, Br. J. Haematol. 31 (1975) 87–94. [120] P. Fessas, G. Stamatoyannopoulos, A. Keys, Serum-cholesterol and thalassemia trait, Lancet 1 (1963) 1182–1183. [121] M. Maioli, S. Pettinato, G.M. Cherchi, et al., Plasma lipids in b-thalassemia minor, Atherosclerosis 75 (1989) 245–248. [122] C. Hartman, H. Tamary, A. Tamir, et al., Hypocholesterolemia in children and adolescents with b-thalassemia intermedia, J. Pediatr. 141 (2002) 543–547. [123] J. Shores, J. Peterson, D. VanderJagt, R.H. Glew, Reduced cholesterol levels in AfricanAmerican adults with sickle cell disease, J. Natl. Med. Assoc. 95 (2003) 813–817. [124] M.S. Buchowski, L.L. Swift, S.A. Akohoue, S.M. Shankar, P.J. Flakoll, N. Abumrad, Defects in postabsorptive plasma homeostasis of fatty acids in sickle cell disease, J. Parenter. Enteral Nutr. 31 (2007) 263–268. [125] G. Rose, M.J. Shipley, Plasma lipids and mortality: a source of error, Lancet 1 (1980) 523–526. [126] S.A. Tornberg, L.E. Holm, J.M. Carstensen, G.A. Eklund, Cancer incidence and cancer mortality in relation to serum cholesterol, J. Natl. Cancer Inst. 81 (1989) 1917–1921. [127] S. Vitols, G. Gahrton, M. Bjorkholm, C. Peterson, Hypocholesterolaemia in malignancy due to elevated activity in tumour cells: evidence from studies in patients with leukaemia, Lancet 2 (1985) 1150–1154.

This page intentionally left blank

ADVANCES IN CLINICAL CHEMISTRY, VOL. 54

Sm PEPTIDES IN DIFFERENTIATION OF AUTOIMMUNE DISEASES Michael Mahler1 INOVA Diagnostics Inc., San Diego, California, USA

1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13.

Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Systemic Lupus Erythematosus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Mixed Connective Tissue Disease. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Biochemical Aspects of the Sm Antigen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Characteristics of Anti-Sm Antibodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Detection of Anti-Sm Antibodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Clinical Association of Anti-Sm Antibodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Meta-Analysis of Anti-Sm Antibodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Genesis of Anti-Sm Antibodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (Sm) Peptides as Antigens . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Summary and Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Take Home Messages . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

109 110 110 112 112 113 114 118 118 119 119 122 122 122

1. Abstract Systemic lupus erythematosus (SLE) and related diseases are characterized by circulating autoantibodies to defined intracellular targets. Among the earliest identified autoantibodies were those directed to components of U2–U6 small nuclear ribonucleoproteins (snRNPs) known as Smith (Sm) antigen, which are highly specific for SLE. The Sm-antigen is composed of at least nine different polypeptides with molecular weights ranging from 9 to 29.5 kDa (B (B1, 28 kDa), B0 (B2, 29 kDa), N (B3, 29.5 kDa), D1 (16 kDa), D2 (16.5 kDa), D3 (18 kDa), E (12 kDa), F (11 kDa), and G (9 kDa)). All of the nine core proteins, but most frequently the B and D polypeptides, are

1

Corresponding author: Michael Mahler, e-mail: [email protected] 109

0065-2423/11 $35.00 DOI: 10.1016/B978-0-12-387025-4.00005-4

Copyright 2011, Elsevier Inc. All rights reserved.

110

MICHAEL MAHLER

targets of the anti-Sm autoimmune response. However, since SmBB0 and U1 specific RNPs share the cross-reactive epitope motif PPPGMRPP, SmD is regarded as the most SLE specific Sm-antigen. It has been shown that the polypeptides D1, D3, and BB0 contain symmetrical dimethylarginine, constituting a major autoepitope within the C-terminus of SmD1 and SmD3. Several synthetic peptides have been used for the detection of anti-Sm antibodies and thus for the diagnosis of SLE. Anti-Sm antibodies have been reported to occur later than other SLE associated autoantibodies and, on average, around 1 year before the clinical onset of SLE. The present review provides a comprehensive summary on the history of anti-Sm antibodies and their use as biochemical tools to study cellular processes and as biomarker in the diagnosis of SLE. Additionally, a meta-analysis focused on recent data analyzes the prevalence of anti-Sm antibodies in SLE.

2. Introduction Systemic rheumatic diseases are characterized by circulating autoantibodies to defined intracellular targets (reviewed in Refs. [1,2]). Among the earliest identified autoantibodies were those directed to nuclear antigens, the Sm antigens, today known as components of U2–U6 snRNPs, which are highly specific for SLE ([3], reviewed in Ref. [4]). Some years later in 1971 anti-U1- RNP antibodies were first described in a patient suffering from SLE [5]. Apart from autoantibodies targeting the Sm-complex, more than 100 different autoantibodies such as anti-dsDNA, anti-proliferating cell nuclear antigen (PCNA), anti-U1-RNP, anti-nucleosome, anti-histone, anti-Ro/SS-A, anti-La/SS-B, anti-ribosome RNP, and anti-phospholipid antibodies have been identified and characterized in sera from SLE patients [6]. However, clinical relevance has only been shown for a few of those autoantibodies (see Fig. 1). Recent studies suggest that SLE-associated antibodies are present before the clinical onset of the disease and thus have high prognostic value [7,8]. Anti-Sm antibodies have been reported to occur later than other SLE associated autoantibodies and, on average, around 1 year before the clinical onset of SLE [7] (see Fig. 2).

3. Systemic Lupus Erythematosus SLE is an autoimmune disorder which is characterized by chronic inflammatory connective tissue disease affecting about 0.5% of the population worldwide (reviewed in Ref. [9]). The etiology is still poorly understood, but involves a broad range of factors such as genetic background, immunological

100 90 80 70 60 50 40 30 20 10 0

111

BB

′

P

Sm

N

S-

R

B)

0 La

(S

R

so

m

R

o6

o5

2

P al

Sm R

C

ib o

hr

ds

om

D

at

N

D

in

Sensitivity Specificity

A

Percent

SM PEPTIDES IN DIFFERENTIATION OF AUTOIMMUNE DISEASES

SLE associated antibodies

SLE specific antibodies

FIG. 1. Sensitivity and specificity of SLE associated and SLE specific autoantibodies. Anti-dsDNA, anti-chromatin, anti-SmD, and anti-ribosomal P antibodies are SLE specific and anti-Ro52, anti-Ro60, anti-La(SS-B), anti-RNP, and SmBB0 are SLE associated. Note: The prevalence (sensitivity) of the individual antibodies can vary depending on the patient cohort under investigation.

0.88

Anti-RNP antibodies Anti-Sm antibodies

1.47 2.24

Anti-dsDNA antibodies

2.94

Anti-phospholipid antibodies

3.61

Anti-La antibodies

3.68

Anti-Ro antibodies

3.01 5

4

3

2

Anti-nuclear antibodies 1

0

Years before diagnosis

FIG. 2. Interval between positive autoantibody test result and diagnosis of SLE. Anti-Sm antibodies are detectable 1.47 (0.34) years before the diagnosis of SLE. Values were taken from Ref. [7].

112

MICHAEL MAHLER

and environmental aspects, as well as possible infectious agents. Clinical findings vary greatly. SLE may begin abruptly with fever, simulating acute infection, or may develop insidiously over months or years with episodes of fever and malaise. Vascular headaches, epilepsy, or psychoses may be initial findings. Manifestations referable to any organ system may appear. Articular symptoms, ranging from intermittent arthralgia to acute polyarthritis, occur in approximately 90% of patients and may exist for years before other manifestations appear. The classification criteria for SLE were published by the American College of Rheumatology (ACR) in 1982 [10] and revised in 1997.

4. Mixed Connective Tissue Disease Mixed connective tissue disease (MCTD) is a rheumatic disease syndrome characterized by overlapping clinical features of SLE, systemic sclerosis (SSc), polymyositis (PM) or dermatomyositis (DM), and rheumatoid arthritis (RA) [11,12]. The diagnostic hallmark of MCTD is very high titers of circulating antinuclear antibody to a nuclear ribonucleoprotein antigen [13–15]. A significant portion of anti-RNP antibody positive sera show reactivity against a conformational epitope on the U1–RNP complex [16]. Among the individual RNP antigens, especially the 70 kDa antigen and a fragment thereof represent antigenic targets of anti-RNP antibodies [15,17,18]. In some patients, the disorder evolves over time into classic SSc, SLE, or even RA. Nevertheless, several features support the suggestion that MCTD is a distinct clinical entity [12]. The typical clinical syndrome is characterized by Raynaud’s phenomenon (RP), polyarthralgia or arthritis, swollen hands (dactylitis), inflammatory proximal myopathy, esophageal hypomotility, and pulmonary disease. RP may precede other disease manifestations by years, and frequently the initial findings suggest early SLE, SSc, PM or DM, or RA. Whatever the initial presentation, there is a tendency for more limited disease to progress and become widespread and for transitions in the clinical pattern to occur over time (reviewed in Ref. [19]). Although different classification criteria (e.g., Sharp, Alarcon-Segovia and Villareal, or Kasukawa) for MCTD have been published, all criteria include the presence of high titers of anti-U1-RNP antibodies (reviewed in Ref. [19]).

5. Biochemical Aspects of the Sm Antigen The snRNP particles are RNA–protein complexes that are abundant in the nuclei of all eukaryotic cells [20]. Together with other nuclear proteins, the snRNP build the spliceosome which is involved in the processing of

SM PEPTIDES IN DIFFERENTIATION OF AUTOIMMUNE DISEASES

113

pre-mRNA. The Sm-antigen is composed of at least nine different polypeptides with molecular weights ranging from 9 to 29.5 kDa (B (B1, 28 kDa), B0 (B2, 29 kDa), N (B3, 29.5 kDa), D1 (16 kDa), D2 (16.5 kDa), D3 (18 kDa), E (12 kDa), F (11 kDa), and G (9 kDa)) (reviewed in Refs. [2,19]) (see Fig. 3).

6. Characteristics of Anti-Sm Antibodies Anti-Sm reactivity is found in 5–30% of patients with SLE, where the frequency varies depending on the detection system and the ethnicity of the SLE population under investigation (reviewed in Refs. [1,19]). The prevalence of anti-Sm antibodies in African American is significantly higher than in Latin Americans and Caucasians (reviewed in Refs. [1,19]). All of the nine core proteins, but most frequently the B and D polypeptides, are targets of the anti-Sm autoimmune response [21,22]. However, since SmBB0 and U1 specific RNPs share the cross-reactive epitope motif PPPGMRPP, SmD is regarded as the most SLE specific Sm-antigen [23]. Within the SmD autoantigen family, reactivity with SmD1/D3 pattern is at least four A

B Splicosome Smith antigens

C Immunoblot with cellular extract

Indirect immunofluorescence on HEp-2 cells

SmN (B3, 29.5 kDa) SmB′ (B2, 29 kDa) SmB (B1, 28 kDa) SmD3 (18 kDa) SmD2 (16.5 kDa) SmD1 (16 kDa)

~29 kDa

SmE (12 kDa) SmF (11 kDa)

16–18 kDa

SmG (9 kDa) ......

FIG. 3. Anti-Sm antibodies. (A) Anti-Sm antibodies target at least nine polypeptides with molecular weights ranging from 9 to 29.5 kDa. All Sm core proteins, but most frequently the B and D polypeptides, are targets of the anti-Sm autoimmune response. (B) Sera with those antibodies generate mainly two bands in immunoblot using cellular extracts, one double band, and one single band (see arrows). (C) In indirect immunofluorescence on HEp-2 cells, anti-Sm antibodies produce a nuclear speckled staining pattern.

114

MICHAEL MAHLER

times more common than SmD1/D2/D3 recognition with a pronounced immunoreactivity to SmD1 [24]. In epitope-mapping studies, several linear and conformational epitopes have been mapped on the SmB- and D-proteins [23,25–31] (see Fig. 4). Most epitopes on Sm antigens are highly basic and are exposed surface structures of the spliceosomal macromolecular complex [25]. On SmD1 and BB0 the major reactivity was predominantly found in the C-terminal extensions [26–31]. Follow-up studies and immunization experiments with the C-terminal epitope motif revealed that this motif is consistently the earliest detectable SmBB0 epitope. This epitope acts as a potential starting point for epitope-spreading events associated with the BB0 molecule and to the SmD-polypeptides [30,31]. The immune response to SmBB0 starts with reactivity toward the crossreactive epitope motif PPPGMRPP and expands with reactivity to prolinerich epitope with sequence similarity to the initial epitope [30,31]. Later, an increase in the diversity of noncross-reactive antibodies to nonproline-rich regions 29–40 (GTFKAFDKHMNL) and 131–139 (VRGVGGPSQ) as well as the accrual of additional cross-reactive antibodies to 204–213 (GIPPGRGTPM) can be observed [30,31]. In 1983, it has been demonstrated that dimethylarginine is a key component of the Sm protein family contain [32]. Recently, it has been shown that the polypeptides D1, D3, and BB0 contain symmetrical dimethylarginine (sDMA; see Fig. 5) which constitute a major autoepitope within the C-terminus of SmD1 and SmD3 [33,34]. Whether this modified amino acid plays a central role in the development of the SLE-specific B-cell immune response to the Sm particles remains a matter of speculation. As for most other autoantibodies, the majority of self-reactive antibodies are of the IgG isotype. However, anti-Sm IgM [35,36] and recently anti-Sm IgE [37] have been described in the sera of patients suffering from SLE. Of high interest, anti-Sm antibodies have been reported to penetrate into living cells [38]. The biologic relevance of these findings remains to be determined.

7. Detection of Anti-Sm Antibodies Various techniques, in combination with a variety of different antigens, have been proposed for the detection of Sm antibodies: passive hemagglutination [39], counterimmunoelectrophoresis [40–46], double immunodiffusion, immunoblotting [41,42,44–46], immunoprecipitation [44], ELISA [29,47–55], line immunoassays (LIAs) [56–58], protein microarrays ([60], reviewed in Refs. [61,62]), bead arrays [63–66], a filtration-assisted nanodot array luminometric immunoassay (NALIA) [67], and the UltraPlex platform [68]. In addition, a broad spectrum of antigens can be used for the detection

SM PEPTIDES IN DIFFERENTIATION OF AUTOIMMUNE DISEASES

A SmD1–119 amino acids

N

1–20

C 44–67

Barakat et al. (1990)

95–119

Riemekasten et al. (1998)

83–119

B N

C N

95–119

Sabbatini et al. (1993) James et al. (1994)

95–119

Brahms et al. (2000)

SmD2–118 amino acids

C

30–41

1–13

74–84

83–105

111–118

SmD3–126 amino acids 24–37

115

McClain et al. (2002)

C 60–68

76–106

104–126 108–122

McClain et al. (2002) Mahler et al. (2005)

FIG. 4. Epitope distribution on the SmD protein family. Several studies were addressed to identify the epitopes on SmD1, D2, and D3 using recombinant protein fragments and synthetic peptides. Major and minor epitopes are shown. Epitopes (A) SmD1 VEPKVKSKKREAVAGRGRGRGRGRGRGRGRGRGGPRR, (B) SmD1 VAGRGRGRG RGRGRGRGRGRGGPRR, and (C) SmD 3 AARGRGRGMGRGNIF have been used to develop diagnostic assays which are now commercially available. Symmetrical dimethylarginine residues are marked in red.

116

MICHAEL MAHLER

Arginine CH3 +

H2N

NH2

asDMA

sDMA CH3

HN

+

NH

CH3 CH3

+

N

NH2

CH

CH

CH

NH

NH

NH

(CH2)3

(CH2)3

(CH2)3

HC NH2COOH

HC NH2COOH

HC NH2COOH

FIG. 5. Structure of arginine, symmetrical dimethylarginine, and asymmetrical dimethylarginine. Antibodies in sera from SLE patients specifically recognize proteins containing symmetrical, but not asymmetrical dimethylarginine. Arginine is converted into symmetrical dimethylarginine by methyltransferases (e.g., PRMT1, PRMT5, and PRMT6) in glycine- and arginine-rich regions.

of anti-Sm antibodies, namely native antigens from different sources, purified or recombinant proteins, and synthetic peptides (reviewed in Refs. [1,29,40–56]). Historically, most anti-Sm antibody tests used Sm antigens purified from a native source containing all Sm polypeptides or even low concentrations of other proteins such as U1 specific RNPs. About 10 years ago, recombinant SmBB0 from bacteria or insect cells became a favored antigen of researchers and diagnostic kit manufacturers for the detection of anti-Sm antibodies. However, recombinant SmBB0 and purified Sm antigen containing SmBB0 both bear the disadvantage that they contain the crossreactive epitope PPPGMRPP, which is present in SmBB0 and in the U1specific RNPs [23]. Since this epitope is frequently targeted by antibodies in sera from MCTD patients, common anti-Sm antibody assays with purified Sm or recombinant SmBB0 fail to differentiate between SLE and MCTD patients (see Fig. 6). In contrast, when utilizing anti-Sm assays based on a single peptide derived from the SmD sequence, only a subset of anti-Sm antibodies is detected [48,69]. Other Sm autoantibody specificities such as the cross-reactive antibodies recognizing the epitope PPPGMRPP which is shared between SmBB0 and U1 specific RNPs are not detected by the SmD peptide-based assays. In two recent studies from independent groups, it was elegantly shown that peptide-based immunoassays using either a SmD1 or a SmD3 peptide are superior to conventional anti-Sm immunoassays for the detection of anti-Sm

SM PEPTIDES IN DIFFERENTIATION OF AUTOIMMUNE DISEASES

MCTD

117

SLE SmD1

U1-RNP-A

SmBB⬘

SmD2 SmD3

U1-RNP-C

U1-RNP70 kDa SmF

Cross-reactive epitope PPPGMRPP Symmetrical dimethylarginine

SmE

SmG

FIG. 6. Anti-Sm/RNP reactivity in SLE and MCTD. The anti-Sm/RNP reactivity in SLE is primarily directed against SmBB0 , SmD1, and SmD3, all containing symmetrical dimethylarginine. Since SmBB0 contains the cross-reactive epitope PPPGMRPP, SmBB0 is also the target of autoantibodies in MCTD. However, the major targets of autoantibodies in MCTD are the U1-specific RNPs U1-RNP-A, -C and -70 kDa.

antibodies [69,70]. One of these SmD peptides contains a dimethylarginine residue (see Fig. 5) at position 112 of SmD3 comprising the sequence 108 AARG sDMA GRGMGRGNIF122 [48,69]. In 2006, it was shown that a SmD1 peptide binds anti-dsDNA antibodies mediated by strong binding of dsDNA to the peptide [71]. One year later, these results were confirmed and it was shown that the SmD3 peptide showed significantly lower DNA binding [72]. The correlation between the results of conventional anti-Sm immunoassays with purified Sm antigen from native sources and peptide assays is relatively poor [69,72]. Therefore, one might conclude that antibodies targeting SmD derived peptides represent only a minor subpopulation of anti-Sm antibodies [69]. Nevertheless, based on the high sensitivity and specificity and on the observation that anti-Sm peptide antibodies can be used to discriminate MCTD from SLE patients, it was concluded that this subpopulation represents an important SLE specific antibody [69]. In 2000, human recombinant autoantibodies have been generated and their epitopes on SmBB0 have been identified [73]. Those antibodies represent promising tools for the characterization of the autoimmune response [73]. The history of anti-Sm antibodies is summarized in Table 1.

118

MICHAEL MAHLER TABLE 1 MILESTONES IN THE DISCOVERY OF ANTI-SM PEPTIDE ANTIBODIES

Year

Milestone

1959

Stephanie Smith, a patient for Drs. Henry Kunkel and Eng M. Tan, was diagnosed as SLE Discovery of the Sm autoantigen Epitope mapping of SmD Cloning and application of recombinant SmD1 in ELISA for the detection of anti-SmD antibodies A synthetic SmD1 peptide was used to develop an ELISA showing high sensitivity Characterization of epitope spreading events on SmBB0 Characterization of the immune response to the SmD protein family; identification of SmD1 and SmD3 as the main targets Identification of symmetrical dimethylarginine as the prime target of autoantibodies in SmD1 and SmD3 Generation and epitope mapping of the first human recombinant autoantibody Epitope characterization on the SmD protein family A novel SmD3 peptide was described for the specific detection of anti-SmD antibodies Improved differentiation between SLE and MCTD using Sm peptides Strong binding of dsDNA to SmD1 peptide Comparison between SmD1 and SmD3 peptides Identification of IgE specific for the Sm antigen in sera from SLE patients

1966 1990 1997 1998 1999 1999 2000 2000 2002 2005 2005 2006 2007 2010

Reference – [3] [26] [47] [29] [31] [21] [22] [73] [25] [48] [69] [71] [72] [37]

8. Clinical Association of Anti-Sm Antibodies Several studies have investigated serological and clinical associations of anti-Sm antibodies with controversial results [74–85]. Anti-Sm antibodies have been associated with neuropsychiatric manifestations, central nerve system (CNS) dysfunction [77], renal disease [79,80], and disease activity [81–83]. However, based on the controversial findings of the association between anti-Sm antibodies and disease activity combined with the low prevalence of anti-Sm antibodies, the use of those autoantibodies as a prognostic and activity marker in SLE is limited.

9. Meta-Analysis of Anti-Sm Antibodies PubMed was queried for studies that investigated the prevalence of anti-Sm antibodies in SLE, with special focus on more recent studies. A variety of studies have been identified but a significant number of those studies had significant limitation in the method description [86–92]. In total, 15 studies

SM PEPTIDES IN DIFFERENTIATION OF AUTOIMMUNE DISEASES

119

were identified and included in the meta-analysis (for details see Table 2). The reported prevalence of anti-Sm antibodies in SLE ranged from 5.7% to 83.3% and a broad range of technologies were used. Cumulatively, anti-Sm antibodies were detected in 1584/5550 (28.5%) SLE patients. When only anti-SmD was considered, 72/579 (12.4%) patients were tested positive (for details see Table 2). Interestingly, a very high prevalence of anti-Sm antibodies were found in Omani SLE patients (83.3%) which is consistent with previously reported difference in the prevalence of anti-Sm antibodies [94]. Further studies are required to verify these findings. The data is summarized in Table 2.

10. Genesis of Anti-Sm Antibodies The precise mechanism which triggers the immune response to the Sm antigen and which finally leads to the production of self-reactive antibodies is still not fully understood. However, it has been shown that anti-Sm antibodies might be triggered or even generated by molecular mimicry [95–100]. Several studies found an association between anti-Sm antibodies and EpsteinBarr virus [95–100]. Of high interest, antibodies to the SmD1 epitope 95–119 cross-react with a homologous sequence on EBNA-I (amino acid 35–58) and immunization with Epstein-Barr virus nuclear antigen (EBNA) peptides induced autoreactivity in different animal models [96]. Additionally, a cryptic epitope motif has also been identified on SmD which is the target of crossreactive antibodies targeting EBNA-I and a variety of other known autoantigens [101]. Besides the Sm proteins, also a Sm-like protein LSm4 is the target of antibodies in sera with EBV infection and SLE [102]. In animal models, it has been shown that immunization with EBV antigens can induce autoantibodies to a variety of autoantigens [97,103]. Epidemiological data strongly support this hypothesis, suggesting that SLE is associated with previous EBV exposure. In children and young adults with SLE, the prevalence of EBV is significantly higher compared to age-matched controls. Virtually all the SLE patients had anti-viral antibodies compared to 70% of the controls [98]. In adults with SLE, the difference was less marked (99.5% vs. 94.4%), but still significant [99]. Taken together, these findings suggest that EBV infection might induce anti-Sm antibodies by molecular mimicry.

11. (Sm) Peptides as Antigens Bruce Merrifield was awarded the Nobel Prize in 1985 for the development of chemical synthesis of peptides on solid supports (SPPS — solid phase peptide synthesis), a technique, which, ever since, has tremendously

TABLE 2 META-ANALYSIS OF ANTI-SM ANTIBODIES No. (%) positive

Country

Method/antigen used

56/146 (39.2) 30/151 (19.7) a 278/917 (30.3) 32/192 (16.7) 14/187 (7.5)

Tunesia Dubai China United States

Immunodot/n.p. n.p./n.p. Immunoblotting/n.p. ALBIA ELISA

50/60 (83.3)

Oman

InnoLIATM ANA Update

216/624 (41.6)

Saudi Arabia United Kingdom China Belgium

n.p./n.p.

9/45 (20.0) 469/1584 37/280 (13.6)a,b 79/280 (28.1) a 28/176 (15.9%)b 69/148 (46.6%)

Germany Germany

n.p./n.p. InnoLIATM ANA Update SmD InnoLIATM ANA Update SmB ELISA, SmD3 peptide with sDMA ELISA IMTEC-SmD1-Antibodies, ITC60029/SmD1 peptide ELISA/SmD1 peptide (without sDMA)

117/167 (70.0)

Germany

21/113 (18.6)

Israel

7/123 (5.7)b 10/123 (8.1) 22/123 (17.9) 40/111 (36.0)

Belgium

Germany

1584/5550 (28.5%)

All

AtheNA Multi-LyteÒ Anti-Nuclear Antibodies (ANA) ELISA, Phadia/native SmD1 CIA LIA recomLine ANA/ENA (Mikrogen) ELISA IMTEC-SmD1-Antibodies, ITC60029/SmD1 peptide Diverse

72/579 (12.4%)

All

Diverse

a b

Comment

Association with Malar rash, pericarditis, leukopenia Association with SLEDAI (stronger with ELISA than with BioPLEX) ELISA data from different kit manufacturer No information provided with Sm antigen was interpreted; high prevalence

Reference [87] [86] [91] [63]

[88] [89]

P ¼ 0.57 with SLEDAI

[83]

Trend to early disease Unclear how many SLE had anti-Sm antibodies

[90] [59] [69] [72]

Correlation with dsDNA antibodies and disease activity

[29] [93] [57]

[70] Meta-analysis of all studies and all methods within one study Anti-SmD onlyb

Information in the method was missing. Number of positive patients were calculated or estimated (in case discrepancies were observed). Included into the meta-analysis.

SM PEPTIDES IN DIFFERENTIATION OF AUTOIMMUNE DISEASES

121

advanced research in the fields of chemistry, biochemistry, molecular biology, and medicine. Modification of peptides is of high interest for autoimmune research, diagnostics, and therapeutics. The most widespread modifications are biotinylation, fluorescent labels, methylation, phosphorylation, disulfidebridged cyclic peptides, MAP-peptides, branched peptides, and peptides containing nonnatural amino acids. Arginine residues in the C-terminal part of the Sm polypeptides become methylated by the methylosome, a complex of type II methyltransferases, which significantly enhances the affinity of the Sm polypeptides to the survival motor neuron (SMN) complex, a machine designed to bind Sm proteins (reviewed in Refs. [2,19]). Depending on the amino acid sequence, the length, and the biochemical properties of the peptide of interest, one of the following coupling strategies can be used to link the peptide to the solid phase of the respective immunoassay (e.g., microtiter plate). Peptides with a length of more than 10 amino acids and an isoelectric point of more than 8 can directly be coated onto microtiter plates [48]. Alternatively, peptides can be covalently bound to paramagnetic particles which are commonly used with chemiluminescence analyzers. Depending on the structure of the peptide, there is a risk of blocking the epitope when direct coating is used. To increase the absorption properties of synthetic peptides, the peptide must be converted to high molecular weight products. This can be achieved using two strategies. The first possibility is to synthesize the peptide on a special resin, the so-called MAP resin (MAP — multiple antigen peptide). In this approach, four to eight copies of the peptide are synthesized on a polylysine core. After cleavage from the synthesis resin, the resulting MAP construct reaches a molecular weight of about 13–17 kDa, which is sufficient for direct coating onto microtiter plates. Alternatively, the peptide of interest can be covalently coupled to the so-called carrier proteins such as human serum albumin (HSA) or bovine serum albumin (BSA), keyhole limpet hemocyanin (KLH) or ovalbumin (OVA), which leads to a surface exposure of the peptide and to a higher accessibility of the epitope. Sophisticated surface modifications of mircotiter plates, microbeads, or microchips allow for the covalent and direct linking of peptides to the respective surface. Similarly, avidin coated surfaces can be used to immobilize biotinylated peptides with high affinity. Once a synthetic peptide is recognized by a considerable number of sera within a defined cohort of patients with a certain autoimmune disease, it represents an ideal antigenic target for immunoassays because it can be easily produced in high quality and quantity. Furthermore, lower lot to lot variations will be observed since the production is not dependent on the biological variation of native sources of antigens. On the other hand, there are pitfalls to the use of synthetic peptides. False positive results may seldom occur

122

MICHAEL MAHLER

because the peptides share amino acid sequences with foreign or self antigens, or because chemical conjugation alters the antigenicity of the peptide. Nevertheless, today’s sophisticated epitope mapping methods [9] will likely lead to the identification of additional peptides, which can be used as specific targets in diagnostic and therapeutic approaches to patient management. This may lead to a new scientific research area with high impact for the development of diagnostic and therapeutic products, in the area of peptide engineering.

12. Summary and Conclusion Anti-SmD antibodies represent a specific marker for SLE. Although antiSm antibodies target various antigens, only highly purified SmD or synthetic SmD1 or SmD3 peptides are specific antigens for the diagnosis of SLE. Based on our meta-analysis we conclude that anti-Sm antibodies are found in 28.5% and anti-SmD antibodies in 12.4% of SLE patients.

13. Take Home Messages Anti-SmD antibodies have high disease specificity for SLE but a low sensitivity (10–20%). SmBB0 contains a cross-reactive epitope which is also present in U1RNPs. SmD1/D3 peptides containing symmetrical dimethyl arginine or highly purified SmD represent the preferred antigens for anti-Sm antibody detection. The Sm antigen is the target of IgM, IgG, and IgE isotypes. Molecular mimicry might play an important role in the genesis of antiSm antibodies.

REFERENCES [1] C.A. von Muhlen, E.M. Tan, Autoantibodies in the diagnosis of systemic rheumatic diseases, Semin. Arthritis Rheum. 24 (1995) 323–358. [2] G.W. Zieve, P.R. Khusial, The anti-Sm immune response in autoimmunity and cell biology, Autoimmun. Rev. 2 (2003) 235–240. [3] E.M. Tan, H.G. Kunkel, Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erythematosus, J. Immunol. 96 (1966) 464–471. [4] G.C. Tsokos, In the beginning was Sm, J. Immunol. 176 (2006) 1295–1296.

SM PEPTIDES IN DIFFERENTIATION OF AUTOIMMUNE DISEASES

123

[5] M. Mattioli, M. Reichlin, Characterization of a soluble nuclear ribonucleoprotein antigen reactive with SLE sera, J. Immunol. 107 (1971) 1281–1290. [6] Y. Sherer, A. Gorstein, M.J. Fritzler, Y. Shoenfeld, Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients, Semin. Arthritis Rheum. 34 (2004) 501–537 (Review). [7] M.R. Arbuckle, M.T. McClain, M.V. Rubertone, et al., Development of autoantibodies before the clinical onset of systemic lupus erythematosus, N. Engl. J. Med. 349 (2003) 1526–1533. [8] L.D. Heinlen, L.L. Ritterhouse, M.T. McClain, et al., Ribosomal P autoantibodies are present before SLE onset and are directed against non-C-terminal peptides, J. Mol. Med. 88 (2010) 719–727. [9] M. Mahler, M.J. Fritzler, Epitope specificity and significance in systemic autoimmune diseases, Ann. NY Acad. Sci. 1183 (2010) 267–287 (Review). [10] E.M. Tan, A.S. Cohen, J.F. Fries, et al., The 1982 revised criteria for the classification of systemic lupus erythematosus, Arthritis Rheum. 25 (1982) 1271–1277. [11] G.C. Sharp, W.S. Irvin, R.L. LaRoque, et al., Association of autoantibodies to different nuclear antigens with clinical patterns of rheumatic disease and responsiveness to therapy, J. Clin. Invest. 50 (1971) 350–359. [12] G.C. Sharp, W.S. Irvin, E.M. Tan, R.G. Gould, H.R. Holman, Mixed connective tissue disease—an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA), Am. J. Med. 52 (1972) 148–159. [13] M.E. Maldonado, M. Perez, J. Pignac-Kobinger, et al., Clinical and immunologic manifestations of mixed connective tissue disease in a Miami population compared to a Midwestern US Caucasian population, J. Rheumatol. 35 (2008) 429–437. [14] C.C. Vaz, M. Couto, D. Medeiros, et al., Undifferentiated connective tissue disease: a seven-center cross-sectional study of 184 patients, Clin. Rheumatol. 28 (2009) 915–921. [15] W. Salmhofer, J. Hermann, M. Joch, H. Kerl, W. Graninger, High serum levels of antibodies against the recombinant 70 kDa ribonucleoprotein are useful for diagnosing mixed connective tissue disease, J. Eur. Acad. Dermatol. Venereol. 21 (8) (2007) 1047–1053. [16] A. Murakami, K. Kojima, K. Ohya, K. Imamura, Y. Takasaki, A new conformational epitope generated by the binding of recombinant 70-kd protein and U1 RNA to anti-U1 RNP autoantibodies in sera from patients with mixed connectivetissue disease, Arthritis Rheum. 46 (2002) 3273–3282. [17] E.L. Greidinger, L. Casciola-Rosen, S.M. Morris, R.W. Hoffman, A. Rosen, Autoantibody recognition of distinctly modified forms of the U1-70-kd antigen is associated with different clinical manifestations, Arthritis Rheum. 43 (2000) 881–888. [18] D. Hof, K. Cheung, D.J. de Rooij, et al., Autoantibodies specific for apoptotic U1-70K are superior serological markers for mixed connective tissue disease, Arthritis Res. Ther. 7 (2005) R302–R309. [19] P. Migliorini, C. Baldini, V. Rocchi, S. Bombardieri, Anti-Sm and anti-RNP antibodies, Autoimmunity 38 (2005) 47–54 (Review). [20] C.L. Will, R. Luhrmann, Spliceosomal UsnRNP biogenesis, structure and function, Curr. Opin. Cell Biol. 13 (2001) 290–301. [21] S.O. Hoch, The Sm antigens, in: R.N. Maini, W.J. van Venrooji (Eds.), Manual of Biological Markers of Disease, Kluwer Academic, Dordrecht, The Netherlands, 1994, pp. 1–29, B2.4. [22] H. Brahms, V.A. Raker, W.J. van Venrooij, R. Lu¨hrmann, A major, novel systemic lupus erythematosus autoantibody class recognizes the E, F, and G Sm snRNP proteins as an E-F-G complex but not in their denatured states, Arthritis Rheum. 40 (1997) 672–682.

124

MICHAEL MAHLER

[23] F. De Keyser, S.O. Hoch, M. Takei, et al., Cross-reactivity of the B/B0 subunit of the Sm ribonucleoprotein autoantigen with proline-rich polypeptides, Clin. Immunol. Immunopathol. 62 (1992) 285–290. [24] S.O. Hoch, R.A. Eisenberg, G.C. Sharp, Diverse antibody recognition patterns of the multiple Sm-D antigen polypeptides, Clin. Immunol. 92 (1999) 203–208. [25] M.T. McClain, P.A. Ramsland, K.M. Kaufman, J.A. James, Anti Sm autoantibodies in systemic lupus target highly basic surface structures of complexed spliceosomal autoantigens, J. Immunol. 168 (2002) 2054–2062. [26] S. Barakat, J.P. Briand, J.C. Weber, M.H. Van Regenmortel, S. Muller, Recognition of synthetic peptides of Sm-D autoantigen by lupus sera, Clin. Exp. Immunol. 81 (1990) 256–262. [27] A. Sabbatini, M.P. Dolcher, B. Marchini, S. Bombardieri, P. Migliorini, Mapping of epitopes on the SmD molecule: the use of multiple antigen peptides to measure autoantibodies in systemic lupus erythematosus, J. Rheumatol. 20 (1993) 1679–1683. [28] J.A. James, M.J. Mamula, J.B. Harley, Sequential autoantigenic determinants of the small nuclear ribonucleoprotein Sm D shared by human lupus autoantibodies and MRL lpr/lpr antibodies, Clin. Exp. Immunol. 98 (1994) 419–426. [29] G. Riemekasten, J. Marell, G. Trebeljahr, et al., A novel epitope on the C-terminus of SmD1 is recognized by the majority of sera from patients with systemic lupus erythematosus, J. Clin. Invest. 102 (1998) 754–763. [30] J.A. James, T. Gross, R.H. Scofield, J.B. Harley, Immunoglobulin epitope spreading and autoimmune disease after peptide immunization: Sm B/B0-derived PPPGMRPP and PPPGIRGP induce spliceosome autoimmunity, J. Exp. Med. 181 (1995) 453–461. [31] M.R. Arbuckle, M. Reichlin, J.B. Harley, J.A. James, Shared early autoantibody recognition events in the development of anti-Sm B/B’ in human lupus, Scand. J. Immunol. 50 (1999) 447–455. [32] M.J. Fritzler, M.D. O’Brien, The purification, characterization and amino acid analysis of nuclear ribonuclear protein and Sm antigens reacting with human autoimmune sera, Clin. Invest. Med. 6 (2) (1983) 61–71. [33] H. Brahms, L. Meheus, V. de Brabandere, U. Fischer, R. Luhrmann, Symmetrical dimethylation of arginine residues in spliceosomal Sm protein B/B0 and the Sm-like protein LSm4, and their interaction with the SMN protein, RNA 7 (2001) 1531–1542. [34] H. Brahms, J. Raymackers, A. Union, F. de Keyser, L. Meheus, R. Lu¨hrmann, The C-terminal RG dipeptide repeats of the spliceosomal Sm proteins D1 and D3 contain symmetrical dimethylarginines, which form a major B-cell epitope for anti-Sm autoantibodies, J. Biol. Chem. 275 (2000) 17122–17129. [35] M. Mahmoudi, J.Y. Edwards, D.A. Bell, E. Cairns, V region gene analysis of human IgM hybridoma monoclonal anti-Sm antibodies, Lupus 6 (1997) 578–589. [36] K. Tsuzaka, T. Ogasawara, T. Tojo, T. Mimori, M. Satoh, M. Homma, Nonprecipitating IgG or IgM anti-Sm antibody: clinical significance and changes in immunoglobulin class, J. Rheumatol. 20 (1993) 822–830. [37] A.M. Atta, M.B. Santiago, F.G. Guerra, M.M. Pereira, Sousa Atta ML. Autoimmune response of IgE antibodies to cellular self-antigens in systemic Lupus Erythematosus, Int. Arch. Allergy Immunol. 152 (2010) 401–406. [38] T.D. Golan, A.E. Gharavi, K.B. Elkon, Penetration of autoantibodies into living epithelial cells, J. Invest. Dermatol. 100 (1993) 316–322. [39] R.M. Nakamura, C.L. Peebles, E.M. Tan, Microhemagglutination test for detection of antibodies to nuclear Sm and ribonucleoprotein antigens in systemic lupus erythematosus and related diseases, Am. J. Clin. Pathol. 70 (1978) 800–807.

SM PEPTIDES IN DIFFERENTIATION OF AUTOIMMUNE DISEASES

125

[40] N. Kurata, E.M. Tan, Identification of antibodies to nuclear acid antigens by counterimmunoelectrophoresis, Arthritis Rheum. 193 (1976) 574–580. [41] E. Navarro, J. Palau, Anti-Sm sera are misdetected by counterimmunoelectrophoresis. A critical analysis of CIE and western blotting on the detection of human antinuclear antibodies, J. Autoimmun. 4 (1991) 213–222. [42] A.A. Westgeest, H.G. Van den Brink, J. de Jong, A.J. Swaak, R.J. Smeenk, Routine testing for antinuclear antibodies: a comparison of immunofluorescence, counterimmunoelectrophoresis and immunoblotting, J. Autoimmun. 1 (1988) 159–170. [43] M.J. Walravens, H. Vanherrewegwn, F. Lacquet, et al., Counterimmunoelectrophoresis with serum prediffusion: an improved method for the detection and identification of antibodies against extractable nuclear and cytoplasmic antigens, J. Immunol. Methods 201 (1997) 89–98. [44] C.G. Kallenberg, E.J. ter Borg, D. Jaarsma, P.C. Limburg, Detection of autoantibodies to ribonucleoproteins by counterimmunoelectropheresis, immunoblotting and RNA-immunoprecipitation: comparison of results, Clin. Exp. Rheumatol. 8 (1990) 35–40. [45] A.A. Westgeest, H.G. Van den Brink, J. de Jong, et al., Antinuclear antibodies in patients with systemic lupus erythematosus: a comparison of counterimmunoelectrophoresis and immunoblotting, Rheumatol. Int. 7 (1987) 77–82. [46] A. Delpech, D. Gilbert, S. Daliphard, X. Le Loet, M. Godin, F. Tron, Antibodies to Sm, RNP and SSB detected by solidphase ELISAs using recombinant antigens: a comparison study with counter immunoelectrophoresis and immunoblotting, J. Clin. Lab. Anal. 7 (1993) 197–202. [47] Y. Ou, S. Sun, G.C. Sharp, S.O. Hoch, Screening of SLE sera using purified recombinant Sm-D1 protein from a baculovirus expression system, Clin. Immunol. Immunopathol. 83 (1997) 310–317. [48] M. Mahler, M.J. Fritzler, M. Blu¨thner, Identification of a SmD3 epitope with a single symmetrical dimethylation of an arginine residue as specific target of a subpopulation of anti-Sm antibodies, Arthritis Res. Ther. 7 (2005) R19–R29. [49] T.G. Phan, W.W. Ng, D. Bird, et al., High-quality, cost effective strategy for detection of autoantibodies to extractable nuclear antigens, Clin. Diagn. Lab. Immunol. 8 (2001) 471–474. [50] H.L.P. Van Duijnhoven, F.J.M. Van de Warenburg, R.J.W.P. Willems, A.A.M. Ermens, A comparison of ELISA assays as routine diagnostic test for detection of autoantibodies against extractable nuclear antigens, Clin. Biochem. 32 (1999) 179–183. [51] E.M. Tan, J.S. Smolen, J.S. Mc Dougal, et al., Clinical significance of antinuclear antibodies: comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays, Arthritis Rheum. 40 (1997) 1612–1618. [52] E.M. Tan, J.S. Smolen, J.S. McDougal, et al., A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. II. Potential for quantitation of antibody content, J. Rheumatol. 29 (2002) 68–74. [53] N. Bizzaro, R. Tozzoli, E. Tonutti, et al., Variability between methods to determine ANA, anti-dsDNA and anti-ENA autoantibodies: a collaborative study with the biomedical industry, J. Immunol. Methods 219 (1998) 99–107. [54] C. Gonzales, T. Martin, T. Arroyo, M. Garcia-Isidoro, J.A. Navajo, J.M. GonzalesBuitrago, Comparison and variation of different methodologies for the detection of autoantibodies to nuclear antigens (ANA), J. Clin. Lab. Anal. 11 (1997) 388–392. [55] T.D. Jaskowski, C. Schroder, T.B. Martins, L. Mouritsen, H.R. Hill, Comparison of three commercially available enzyme immunoassays for the screening of autoantibodies to extractable nuclear antigens, J. Clin. Lab. Anal. 9 (1995) 166–172.

126

MICHAEL MAHLER

[56] F.J. Lopez Longo, M. Rodriguez-Mahou, M. Escalona-Monge, C.M. Gonzales, I. Monteagudo, L. Carreno-Perez, Simultaneous identification of various antinuclear antibodies using an automated multiparameter line immunoassay system, Lupus 12 (2003) 623–629. [57] J. Damoiseaux, K. Boesten, J. Giesen, J. Austen, J.W. Tervaert, Evaluation of a novel lineblot immunoassay for the detection of antibodies to extractable nuclear antigens, Ann. NY Acad. Sci. 1050 (2005) 340–347. [58] P. Eissfeller, M. Sticherling, D. Scholz, et al., Comparison of different test systems for simultaneous autoantibody detection in connective tissue diseases, Ann. NY Acad. Sci. 1050 (2005) 327–339. [59] I.E. Hoffman, I. Peene, L. Meheus, T.W. Huizinga, L. Cebecauer, D. Isenberg, et al., Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann. Rheum. Dis. 63 (2004) 1155–1158. [60] W.H. Robinson, C. DiGennaro, W. Hueber, et al., Autoantigen microarrays for multiplex characterization of autoantibody responses, Nat. Med. 8 (2002) 295–301. [61] W. Hueber, P.J. Utz, L. Steinman, W.H. Robinson, Autoantibody profiling for the study and treatment of autoimmune disease, Arthritis Res. 4 (2002) 290–295 (Review). [62] S. Pang, J. Smith, D. Onley, J. Reeve, M. Walker, C. Foy, A comparability study of the emerging protein array platforms with established ELISA procedures, J. Immunol. Methods 302 (1–2) (2005) 1–12. [63] J.G. Hanly, L. Su, V. Farewell, M.J. Fritzler, Comparison between multiplex assays for autoantibody detection in systemic lupus erythematosus, J. Immunol. Methods 30 (358) (2010) 75–80. [64] G. Zandman-Goddard, B. Gilburd, et al., The homogeneous multiplexed system—a new method for autoantibody profile in systemic lupus erythematosus, Clin. Dev. Immunol. 12 (2005) 107–111. [65] S.S. Copple, T.B. Martins, C. Masterson, E. Joly, H.R. Hill, Comparison of three multiplex immunoassays for detection of antibodies to extractable nuclear antibodies using clinically defined sera, Ann. NY Acad. Sci. 1109 (2007) 464–472. [66] J.G. Hanly, K. Thompson, G. McCurdy, L. Fougere, C. Theriault, K. Wilton, Measurement of autoantibodies using multiplex methodology in patients with systemic lupus erythematosus, J. Immunol. Methods 352 (2010) 147–152. [67] J.D. McBride, F.G. Gabriel, J. Fordham, et al., Screening autoantibody profiles in systemic rheumatic disease with a diagnostic protein microarray that uses a filtrationassisted nanodot array luminometric immunoassay (NALIA), Clin. Chem. 54 (2008) 883–890. [68] J. Smith, D. Onley, C. Garey, S. Crowther, N. Cahir, A. Johanson, et al., Determination of ANA specificity using the UltraPlex platform, Ann. NY Acad. Sci. 1050 (2005) 286–294. [69] M. Mahler, L.M. Stinton, M.J. Fritzler, Improved serological differentiation between systemic lupus erythematosus and mixed connective tissue disease by use of an SmD3 peptide-based immunoassay, Clin. Diagn. Lab. Immunol. 12 (2005) 107–113. [70] H.P. Jaekel, T. Klopsch, B. Benkenstein, et al., Reactivities to the Sm autoantigenic complex and the synthetic SmD1-aa83-119 peptide in systemic lupus erythematosus and other autoimmune diseases, Autoimmunity 17 (2001) 347–354. [71] J.W. Dieker, C.C. Van Bavel, G. Riemekasten, J.H. Berden, J. van der Vlag, The binding of lupus-derived autoantibodies to the C-terminal peptide (83-119) of the major SmD1 autoantigen can be mediated by double-stranded DNA and nucleosomes, Ann. Rheum. Dis. 65 (2006) 1525–1528.

SM PEPTIDES IN DIFFERENTIATION OF AUTOIMMUNE DISEASES

127

[72] M. Mahler, A. Waka, F. Hiepe, M.J. Fritzler, Effect of dsDNA binding to SmD-derived peptides on clinical accuracy in the diagnosis of systemic lupus erythematosus, Arthritis Res. Ther. 9 (2007) R68. [73] I. del Rincon, M. Zeidel, E. Rey, J.B. Harley, J.A. James, M. Fischbach, I. Sanz, Delineation of the human systemic lupus erythematosus anti-Smith antibody response using phage-display combinatorial libraries. J. Immunol. 165 (2000) 7011–7016. [74] S. Janwityanuchit, O. Verasertniyom, M. Vanichapuntu, M. Vatanasuk, Anti-Sm: its predictive value in systemic lupus erythematosus, Clin. Rheumatol. 12 (1993) 350–353. [75] E.J. ter Borg, H. Groen, G. Horst, P.C. Limburg, A.A. Wouda, C.G. Kallenberg, Clinical associations of antiribonucleoprotein antibodies in patients with systemic lupus erythematosus, Semin. Arthritis Rheum. 20 (1990) 164–173. [76] D.M. Grennan, C. Bunn, G.R. Hughes, W.W. Buchanan, W.C. Dick, Frequency and clinical significance of antibodies to ribonucleoprotein in SLE and other connective tissue disease subgroups, Ann. Rheum. Dis. 36 (1977) 442–447. [77] J.B. Winfield, C.M. Brunner, D. Koffler, Serologic studies in patients with systemic lupus erythematosus and central nervous system dysfunction, Arthritis Rheum. 21 (1978) 289–294. [78] D.M. Winn, J.F. Wolfe, D.A. Lindberg, F.H. Fristoe, L. Kingsland, G.C. Sharp, Identification of a clinical subset of systemic lupus erythematosus by antibodies to the SM antigen, Arthritis Rheum. 22 (1979) 1334–1337. [79] P. Alba, L. Bento, M.J. Cuadrado, et al., Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis, Ann. Rheum. Dis. 62 (2003) 556–560. [80] H.M. Bastian, J.M. Roseman, G. McGwin Jr., et al., LUMINA Study Group. LUpus in MInority populations: NAture vs nurture. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis, Lupus 11 (2002) 152–160. [81] F.A. Barada Jr., B.S. Andrews, J.S. Davis 4th, R.P. Taylor, Antibodies to Sm in patients with systemic lupus erythematosus. Correlation of Sm antibody titers with disease activity and other laboratory parameters, Arthritis Rheum. 24 (1981) 1236–1244. [82] M. Gripenberg, A.M. Teppo, C. Friman, Antibodies to Sm and SS-A demonstrated by enzyme immunoassay. Correlation to clinical manifestations and disease activity in patients with systemic lupus erythematosus, Rheumatol. Int. 11 (1991) 209–213. [83] S. Agarwal, J. Harper, P.D. Kiely, Concentration of antibodies to extractable nuclear antigens and disease activity in systemic lupus erythematosus, Lupus 18 (2009) 407–412. [84] R. Prasad, D. Iban˜ez, D. Gladman, M. Urowitz, Anti-dsDNA and anti-Sm antibodies do not predict damage in systemic lupus erythematosus, Lupus 15 (2006) 285–291. [85] M.L. Paz, D.H. Gonza´lez Maglio, M. Pino, et al., Anti-ribonucleoproteins autoantibodies in patients with systemic autoimmune diseases. Relation with cutaneous photosensitivity, Clin. Rheumatol. 30 (2011) 209–216. [86] J. AlSaleh, V. Jassim, M. ElSayed, N. Saleh, D. Harb, Clinical and immunological manifestations in 151 SLE patients living in Dubai, Lupus 17 (2008) 62–66. [87] M. Jallouli, M. Frigui, M.B. Hmida, S. Marzouk, N. Kaddour, Z. Bahloul, Clinical and immunological manifestations of systemic lupus erythematosus: study on 146 south Tunisian patients, Saudi J. Kidney Dis. Transpl. 19 (2008) 1001–1008. [88] A.A. Al-Jabri, A.K. Al-Gahdani, I. Al-Shuaili, High frequency of Smith autoantibodies in Omani patients with systemic lupus erythematosus, Rheumatol. Int. 30 (2009) 51–56. [89] A.S. Al Arfaj, N. Khalil, Clinical and immunological manifestations in 624 SLE patients in Saudi Arabia, Lupus 18 (2009) 465–473. [90] J.D. Ni, X. Yao, H.F. Pan, X.P. Li, J.H. Xu, D.Q. Ye, Clinical and serological correlates of anti-Sm autoantibodies in Chinese patients with systemic lupus erythematosus: 1,584 cases, Rheumatol. Int. 29 (2009) 1323–1326.

128

MICHAEL MAHLER

[91] X. Tang, Y. Huang, W. Deng, L. Tang, W. Weng, X. Zhang, Clinical and serologic correlations and autoantibody clusters in systemic lupus erythematosus: a retrospective review of 917 patients in South China, Medicine (Baltimore) 89 (2010) 62–67. [92] L.H. Li, H.F. Pan, W.X. Li, X.P. Li, J.H. Xu, D.Q. Ye, Study on clinical features and complications with systemic lupus erythematosus (SLE) activity in Chinese Han population, Clin. Rheumatol. 28 (2009) 1301–1307. [93] O. Shovman, B. Gilburd, G. Zandman-Goddard, A. Yehiely, P. Langevitz, Y. Shoenfeld, Multiplexed AtheNA multi-lyte immunoassay for ANA screening in autoimmune diseases, Autoimmunity 38 (2005) 105–109. [94] F.C. Arnett, R.G. Hamilton, M.G. Roebber, J.B. Harley, M. Reichlin, Increased frequencies of Sm and nRNP autoantibodies in American blacks compared to whites with systemic lupus erythematosus, J. Rheumatol. 15 (1988) 1773–1776. [95] D.A. Thorley-Lawson, Epstein-Barr virus: exploiting the immune system, Nat. Rev. Immunol. 1 (2001) 75–82. [96] A. Sabbatini, S. Bombardieri, P. Migliorini, Autoantibodies from patients with systemic lupus erythematosus bind a shared sequence of SmD and Epstein-Barr virus-encoded nuclear antigen EBNA I, Eur. J. Immunol. 23 (1993) 1146–1152. [97] B.D. Poole, T. Gross, S. Maier, J.B. Harley, J.A. James, Lupus-like autoantibody development in rabbits and mice after immunization with EBNA-1 fragments, J. Autoimmun. 31 (2008) 362–371. [98] J.A. James, K.M. Kaufman, A.D. Farris, E. Taylor-Albert, T.J. Lehman, J.B. Harley, An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus, J. Clin. Invest. 100 (1997) 3019–3026. [99] J.A. James, B.R. Neas, K.L. Moser, et al., Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure, Arthritis Rheum. 44 (2001) 1122–1126. [100] B. Marchini, M.P. Dolcher, A. Sabbatini, G. Klein, P. Migliorini, Immune response to different sequences of the EBNA I molecule in Epstein-Barr virus-related disorders and in autoimmune diseases, J. Autoimmun. 7 (1994) 179–191. [101] M. Mahler, R. Mierau, W. Schlumberger, M. Blu¨thner, A population of autoantibodies against a centromere-associated protein A major epitope motif cross-reacts with related cryptic epitopes on other nuclear autoantigens and on the Epstein-Barr nuclear antigen 1, J. Mol. Med. 79 (2001) 722–731. [102] T. Eystathioy, C. Peebles, J.C. Hamel, J.H. Vaughan, E.K.L. Chan, Autoantibody to hLSm4 and the hepatameric LSm complex in anti-Sm sera, Arthritis Rheum. 46 (2002) 726–734. [103] B.D. Poole, R.H. Scofield, J.B. Harley, J.A. James, Epstein-Barr virus and molecular mimicry in systemic lupus erythematosus, Autoimmunity 39 (1) (2006) 63–70.

ADVANCES IN CLINICAL CHEMISTRY, VOL. 54

AROMATASE ACTIVITY AND BONE LOSS Luigi Gennari,1 Daniela Merlotti, and Ranuccio Nuti Department of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, University of Siena, Siena, Italy

1. 2. 3. 4. 5.

6. 7. 8.

9.

Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Aromatase and Sources of Estrogen Production . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . The Aromatase Gene and Its Tissue-Specific Regulation. . . . . . . . . . . . . . . . . . . . . . . . . Aromatase Deficiency and the Bone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5.1. Aromatase Deficiency Syndrome. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5.2. Animal Models of Aromatase Deficiency. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5.3. Inhibition of Aromatase Activity: Clinical Studies in Men. . . . . . . . . . . . . . . . . . 5.4. Inhibition of Aromatase Activity: Use of AIs in Women . . . . . . . . . . . . . . . . . . . Skeletal Consequences of Aromatase Excess . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Threshold Estradiol Hypothesis for Skeletal Sufficiency . . . . . . . . . . . . . . . . . . . . . . . . . Variability in the Level of Aromatase Activity: Effects on Bone Metabolism . . . . . 8.1. Inherited Variation in Aromatase Activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8.2. Acquired Variation in Aromatase Activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Summary and Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

129 130 131 133 134 135 138 139 142 145 146 148 148 151 153 154

1. Abstract Aromatase is a specific component of the cytochrome P450 enzyme system that is responsible for the transformation of C19 androgen precursors into C18 estrogenic compounds. This enzyme is encoded by the CYP19A1 gene located at chromosome 15q21.2, that is expressed in ovary and testis not only but also in many extraglandular sites such as the placenta, brain, adipose tissue, and bone. The regulation of the level and activity of aromatase determines the levels of estrogens that have endocrine, paracrine, and autocrine effects on target issues including bone. Importantly, extraglandular aromatization of circulating 1

Corresponding author: Luigi Gennari, e-mail: [email protected] 129

0065-2423/11 $35.00 DOI: 10.1016/B978-0-12-387025-4.00006-6

Copyright 2011, Elsevier Inc. All rights reserved.

130

GENNARI ET AL.

androgen precursors is the major source of estrogen not only in men (since only 15% of circulating estradiol is released directly by the testis) but also in women after the menopause. Several lines of clinical and experimental evidence now clearly indicate that aromatase activity and estrogen production are necessary for longitudinal bone growth, attainment of peak bone mass, the pubertal growth spurt, epiphyseal closure, and normal bone remodeling in young individuals. Moreover, with aging, individual differences in aromatase activity and thus in estrogen levels may significantly affect bone loss and fracture risk in both genders.

2. Introduction Sex steroid hormones are important for the acquisition and maintenance of bone mass in both sexes [1,2]. Alterations in their levels can become relevant in the pathogenesis of osteoporosis either because their deficiency leads to suboptimal acquisition of peak bone mass or because deficits in adulthood can directly lead to bone loss. While estrogens have been shown to be critically important in these respects for the female skeleton (as estrogen deficiency after menopause leads to an imbalance between bone resorption by osteoclasts and bone formation by osteoblasts), the role for estrogen in male skeletal health has only recently become appreciated [3–6]. This is due, in part, to attributions of gender-specific effects: estrogens for women; androgens for men. The assumption is rational especially since circulating androgens predominate in men and estrogens predominate in women. In addition, alterations in circulating androgen in the growing male skeleton or in the context of the aging male skeleton have been associated with low bone mass and impaired bone strength [7]. However, while androgens are undoubtedly playing a role in male skeletal health, their primacy has been increasingly questioned as direct and indirect evidence has emerged suggesting that estrogens also play a major role in male skeletal health [3–7]. These new observations underscore the normal biosynthetic pathway by which estrogens are made. In fact, estrogens in men are mainly derived from androgens via the activity of aromatase, a cytochrome P450 product of the CYP19A1 gene [8–10]. The obligate precursors are the androgenic steroids. The human P450 aromatase enzyme is found in many tissues such as placenta, ovary, testis, brain, adipocyte, and also in bone. Moreover, peripheral aromatization of adrenal androgen precursors also represents a major source of estrogen in women after menopause for many target tissues including bone. This review summarizes the evidence that aromatase activity plays an important role in the skeleton in females as well as in males by its actions to convert androgens to estrogens.

131

AROMATASE ACTIVITY AND BONE LOSS

3. Aromatase and Sources of Estrogen Production Aromatase is a specific component of the cytochrome P450 enzyme system that catalyzes three consecutive hydroxylation reactions converting the delta 4-3-one A-ring of C19 androgen precursors into the corresponding phenolic A-ring characteristic of C18 estrogenic compounds (Fig. 1). Thus, in a threestep process (each step requiring 1 mol of O(2), 1 mol of NADPH, and coupling with its redox partner cytochrome P450 reductase), aromatase converts androstenedione, testosterone, and 16alpha-hydroxytestosterone to estrone, 17beta-estradiol, and 17beta,16alpha-estriol, respectively. The first experimental and indirect evidence of the presence of this enzyme dates back to 1937, when Steinach and Kun demonstrated enhanced estrogenic activity in urine following the administration of unlabeled testosterone propionate to men [11]. The definitive and direct proof occurred in the 1980s, with the purification of the human aromatase cytochrome P450 protein from placental microsomes and the demonstration of the conversion of androstenedione to estrone [10,12,13]. In fertile women, the ovary represents the major source of circulating estrogen, which acts on distal target tissues [8,14,15]. Ovarian estrogen synthesis starts in theca interna cells, by the synthesis of androstenedione from cholesterol. Then androstenedione crosses the basal membrane into the

17b-HSDH Androstenedione

Testosterone AR

5a-Red. Aromatase enzyme complex

DHT

ERa Estrone

Estradiol 17b-HSDH

ERb

FIG. 1. Metabolic pathways for conversion of androgens to estrogens by aromatase and mechanisms of sex hormone action on bone.

132

GENNARI ET AL.

surrounding granulosa cells, where it is converted to estrone or estradiol, either immediately or through testosterone. From menarche to menopause, the primary estrogen is estradiol. However, extraglandular aromatase activity has been demonstrated since the 1970s in both men and women [10,15]. The standard dogma before that time indicated that steroid hormones were only produced in endocrine glands such as ovary, testis, and adrenal. On the contrary, it is now well established that extraglandular tissues such as the adipose tissue provide a major source of estrogen synthesis not only in men but also in women after menopause. Thus, in the postmenopausal woman, the principal estrogen formed is estrone that it is derived by peripheral aromatization of circulating androstenedione. Of interest, the rate of estrogen production after menopause has been shown to be dependent on the degree of adiposity. In fact, estrogen synthesis from androgen precursors in the adipose tissue of overly obese postmenopausal women can be 10-fold higher than in lean controls [16]. Notably, peripheral estrogen biosynthesis may also be relevant in the fertile woman during pregnancy, where approximately 20 mg daily of estradiol are produced by the enzymatic action of placental aromatase, accounting for the greatly increased amounts of estrogen produced by pregnant women [17]. In men, the testes account at most for 15% of circulating estrogens, while the remaining 85% is due to peripheral aromatization of circulating androgen precursors in different tissues, including not only the adipose tissue but also the brain, skin, endothelium, and bone [18,19]. Testicular androgen precursors contribute more to the total amount of circulating estradiol than adrenal androgens [20], since dexamethasone induced suppression of adrenal steroid synthesis moderately decreases estradiol concentrations [21], whereas orchidectomy (ORX) leads to a more dramatic suppression of plasma estradiol [22,23]. Importantly, extragonadal sites of estrogen biosynthesis, unlike the ovaries and the testes, lack the ability to synthesize C19 precursors from cholesterol, hence their estrogen-producing activity totally depends on the availability of these circulating C19 steroids [24]. Apart from contributing to the circulating estrogen pool, the estrogen synthesized within these extragonadal compartments may be locally active in a paracrine or intracrine fashion [18,25]. Thus, although the total amount of estrogen synthesized at any site could be small, local tissue concentrations, on the other hand, could be substantial. In human bone, aromatase has been reported to be expressed in osteoblast or osteoblast-like cells from fetal and normal tissue [26–28], in articular cartilage chondrocytes, in adipocytes adjacent to bone trabeculae, and in osteocytes, but not in osteoclasts [28]. Importantly, both aromatase activity and amounts of aromatase-specific mRNA in bone have been shown, in some

AROMATASE ACTIVITY AND BONE LOSS

133

studies, to vary widely among subjects [28,29] and in different conditions [30]. Indeed, a recent study demonstrated that aromatase gene is expressed in bone tissue in high amounts, at levels similar to those found in adipose tissue [30]. Moreover, osteoblasts appear as the major source of aromatase within the bone microenvironment [30].

4. The Aromatase Gene and Its Tissue-Specific Regulation Aromatase is encoded by the CYP19A1 gene located at chromosome 15q21.2 [31]. Cloning of this gene demonstrated several unusual features when compared to other genes of the P450 enzyme system. In tissue-specific fashion, a number of untranslated initial exons are found in aromatase transcripts due to differential splicing by multiple tissue-specific promoters [9,32,33]. Only the 30-kb 30 region of the gene (containing exons 2–10) encodes aromatase while a larger 93-kb 50 flanking region serves as the regulatory unit of the gene [32,33]. In fact, the multiple exons 1 are not translated, so that the different splicing patterns lead to transcripts that are all translated as the same protein. However, this complex structure of the promoter region of the gene appears to be extremely important since it defines the tissue-specific regulation of aromatase activity and estrogen biosynthesis. Thus the ovary, testes, adipose tissue, brain, and bone each utilize their own promoters and associated enhancers and suppressors leading to different amounts of mRNA transcripts, mRNA stability and/or protein translation [9,10,34]. To date, at least 10 different tissue-specific promoters defining their respective first exons have been identified in the human aromatase gene (Fig. 2) [32,33]. In the ovary and the testes, aromatase expression is mediated by a proximal promoter PII, and occurs via a cyclic AMP/cyclic AMP response element binding pathway, which can be enhanced or suppressed by several factors [10]. Aromatase expression in the placenta is mainly regulated by a powerful distal promoter I.1, whereas in mesenchymal cells of adipose tissue and skin, aromatase expression is regulated by another distal promoter I.4 via a JAK/STAT pathway which is stimulated by class I cytokines [10,32,33]. In bone tissues, the majority of aromatase transcripts contain exon 1.4 and exon 1.6 [35–37]. Some minor transcripts by promoter I.3, PII, and If have also been described [35]. Experiments in osteoblast cell lines demonstrated that cortisol may induce aromatase gene expression transiently and that 1,25dihydroxyvitamin D can maintain its expression, dependent on vitamin D receptor density [38–40]. Moreover, a recent study demonstrated that Runx2, a master regulator of osteoblast differentiation, also increases aromatase gene expression in human osteoblast cell lines by increasing promoter

GENNARI ET AL.

134

PGE2 Glucocorticoids

Gonadotropins

Class/Cytochines

Genistein

Exon 2 5’-UTR

Runx2, Calcitriol

ATG

5¢

I.1

2a l.4

l.5

l.f

l.2 l.6

Exon 3

cAMP

Exon 2

Retinoids

3¢

l.3 Pll

FIG. 2. Aromatase gene (CYP19A1) promoters and untranslated first exons. The various tissue-specific promoters employ different signaling pathways.

I.4 and I.6 activity [41]. Consistently, Runx2-deficient mice exhibit decreased aromatase expression in bone tissues [41]. Thus, the overall control of aromatase activity between and within different tissues is a complex interplay of factors acting via the expression of different promoters. Experimental studies generally demonstrated the highest amounts of aromatase protein with promoters I.1 and PII and the lowest amounts with promoters I.3 and I.4, even though the relative protein levels from any given promoter can vary in different cell lines [34]. This latter evidence further underscores the importance of different trans-acting factors under different cellular contexts for overall aromatase activity and estrogen biosynthesis. Moreover, this complex control system can also be relevant in pathological conditions, such as breast cancer. In fact, while in normal breast adipose tissue, aromatase expression is stimulated primarily by class I cytokines through promoter I.4, local estrogen production in breast cancer tissue can be increased due to overexpression of promoter II specific transcripts by PGE2 produced by the breast cancer itself [9,42]. The endothelialtype promoter I.7 also appears to be upregulated in breast cancer [43].

5. Aromatase Deficiency and the Bone Several clinical and experimental observations recently underscored the importance of aromatization of androgens into estrogen for skeletal homeostasis in females as well as in males.

AROMATASE ACTIVITY AND BONE LOSS

135

5.1. AROMATASE DEFICIENCY SYNDROME Our knowledge of the physiologic roles of estrogen in women and particularly in men has been consistently advanced by recent descriptions of mutations disrupting estrogen biosynthesis and action [2–5]. Importantly, the discovery of human cases of aromatase deficiency preceded the construction of aromatase knockout animals and, in fact, provided the first seminal insights into the role of estrogens and aromatase in male skeletal physiology. Human aromatase deficiency is a very rare autosomal recessive syndrome characterized by congenital estrogen deprivation that is caused by loss-offunction mutations in the CYP19A1 gene [44]. In both genders, the overall severity of the phenotype may be variable according to residual enzyme activity level [44,45]. In females, these mutations give rise to ambiguous genitalia at birth, with various degree of virilization. At puberty, affected girls have hypergonadotropic hypogonadism, fail to develop secondary sexual characteristics, and exhibit progressive virilization. The high concentrations of ovarian androgens and gonadotropins facilitate the formation of ovarian cysts. Bone mineralization can be affected and bone aging is delayed. Moreover, in some cases, bone mineral density (BMD) was low and improved after treatment with low doses of estrogens [46]. In contrast to females, the affected male individuals have normal male sexual differentiation and pubertal maturation and their clinical phenotype mostly develops after puberty [5,47]. So far, there are nine known cases of aromatase deficiency in men, due to inactivating mutations in the CYP19A1 gene [5,48–56] and in at least six of the nine described subjects parental consanguinity was evident. All known mutations showed absent or minimal enzyme activity in transient expression systems. Accordingly, circulating estrogens were markedly low or undetectable while androgens were normal or elevated. Serum FSH was elevated or in the upper range, while serum LH was normal except in one patient. Interestingly, skeletal maturation and bone homeostasis were severely impaired in these subjects, with a virtually identical phenotype to a previously described male case of loss-of-function mutation at the estrogen receptor alpha (ESR1) gene [57]. Common characteristics include tall stature, continued longitudinal growth, unfused epiphyses, delayed bone age, lack of pubertal growth spurt, eunuchoid skeletal proportions (with upper segment/lower segment ratio from 0.84 to 0.92), genu valgum, elevated bone resorption markers, and low bone mass. Lipid abnormalities, increased body mass index, hyperinsulinemia, and various degrees of glucose impairment (including diabetes and achantosis nigricans in 1 and 2 cases, respectively) have also been reported. When some of these male cases of aromatase deficiency were treated with intramuscular testosterone, there was no benefit, an understandable observation since aromatase deficiency does not lead to low testosterone levels.

136

GENNARI ET AL.

On the other hand, estrogen treatment in all cases of aromatase deficiency was associated with marked changes in the skeletal phenotype. Epiphyses closed quickly, longitudinal growth ceased, and BMD increased dramatically [48,49,54,58,59]. Importantly, a dose-dependent effect of estrogen replacement therapy on bone mass was suggested, since a very low dose of estradiol (below 25 mcg twice weekly) was not sufficient for maintaining a normal BMD in one of these aromatase-deficient men [59]. Long-term data are available with a 5-year follow-up in the patient described by Morishima, Bilezikian, and their colleagues [48,58]. Starting on low-dose conjugated estrogen, 0.3 mg, he was quickly raised to 0.75 mg daily, the dosage that he has consistently taken for most of the period of observation. Estradiol concentration rose from undetectable into the normal range for men. Androgen levels fell from markedly elevated to normal. The concomitant return of the gonadotropins, LH and FSH, to normal illustrates well the role of estrogens in controlling gonadotropin production in the male. He immediately stopped growing with closure of all open epiphyses within 6 months of starting estrogen therapy. Bone markers that were elevated at baseline returned slowly to normal. Most impressively, this man experienced a dramatic increase in bone density with estrogen therapy. During the first 3 years, BMD increases in the lumbar spine, femoral neck, and forearm were 20.7%, 15.7%, and 12.9%, respectively. Over the next 2 years of estrogen therapy, the gains in the lumbar spine and femoral neck were maintained with further marked increases in the forearm bone density (now totaling 26%) [5]. A more recent report of a 16-year-old boy with aromatase deficiency further sharpened our views of how bone is affected in this syndrome [53]. While all previous reports up to this recent one assessed BMD by dual-energy X-ray absorptiometry (DXA, an approach that gives only areal density, not true volumetric bone density), in this case, the skeleton of a 16-year-old boy with congenital aromatase deficiency was assessed by both DXA and peripheral quantitative computed tomography (pQCT) of the radius. The use of pQCT allows measurements not easily made or even possible by DXA such as cross-sectional area (CSA), cortical thickness, trabecular volumetric BMD, and cortical volumetric BMD. As expected, estrogen replacement in this boy was associated with normalization of sex hormone concentrations, reduced bone turnover rate, and increased areal BMD of the lumbar spine (23%) and femoral neck (14%). However, the gain in volumetric BMD, either estimated by the calculation of the bone mineral apparent density from DXA or assessed directly by pQCT was limited at the lumbar spine and even absent at the femoral neck and the radius. Interestingly, longitudinal bone growth, cross-sectional area, and cortical thickness, as measured by pQCT, increased significantly by 8.5%, 46%, and 12%, respectively. Thus, the observed increase in areal BMD at peripheral sites was mainly driven by an increase in

AROMATASE ACTIVITY AND BONE LOSS

137

bone size, rather than bone density. These changes are similar to those associated with normal pubertal growth and support the notion that in growing bones, except for the spine, true density does not increase [60,61]. Moreover, these observations not only account more completely for the densitometric observations but they also lead to a reconsideration of functional sex steroid assignments on bone size. It is well known that during normal male puberty, periosteal diameter continues to expand and cortical thickness increases due to reduced endocortical expansion and accelerated periosteal apposition [62]. These effects, leading to increased bone size, have classically been attributed to androgens and in fact help to account for greater areal density in the male skeleton. Conversely, when females enter puberty, periosteal apposition is inhibited, an action classically believed to be an estrogen effect. However, according to the effects of estrogen administration on cross-sectional area and cortical thickness in this young boy with aromatase deficiency [53], some actions on bone size, previously attributed to androgens, must at least in part be an estrogen effect. It is likely that estrogens, rather than androgens, at least in this single example of a growing boy, are helping to drive periosteal bone apposition. Thus, a biphasic, dosedependent effect of estrogen could exist. At low levels (as observed in males and in early pubertal females) estrogen may stimulate periosteal apposition and increase bone size, whereas at higher concentrations (as observed in late pubertal and adult females) estrogen may inhibit cross-sectional bone growth. This latter effect could be due to stimulation of a different receptor, the estrogen receptor beta (ESR2). Recently, the concomitant presence of mild hypogonadism in a man with aromatase deficiency has offered a useful model to study the effects of testosterone and estradiol replacement, separately or in combination [63]. In this man, estradiol treatment alone increased BMD with a greater gain than the one obtained with testosterone alone. Interestingly, the combination of testosterone (6 mg/day) and estrogen (25 mcg twice weekly) replacement led to a further increase in cortical thickness at the radius and the tibia as measured by pQCT, further supporting the concomitant importance of both sex steroids for periosteal apposition. In this case, however, an increase in volumetric BMD at the tibia and the radius as well as an increase of areal BMD of the lumbar spine and the femoral neck was also described after 2 years of combined therapy. From these human experiments of nature, it seems reasonable to conclude that in the male as well as in female, estrogens are important in the control of linear growth, in the pubertal growth spurt, in epiphyseal maturation, and in the achievement of optimal peak bone mass and size. While one does not expect to ‘‘find’’ many examples of aromatase deficiency syndrome, there are possible more subtle abnormalities in those genes (i.e., polymorphisms) that

138

GENNARI ET AL.

would render aging men as well as women after menopause at higher risk for bone loss and osteoporosis on this basis [19]. 5.2. ANIMAL MODELS OF AROMATASE DEFICIENCY The skeletal consequences of aromatase deficiency have been illustrated further by studies of the aromatase knock-out (ArKO) mouse models [64–66]. At birth, the skeleton of ArKO animals demonstrated no consistent differences in bone and mineralized cartilage from wild-type (WT) littermates [67]. In contrast, growing and adult male and female ArKO mice showed reduced BMD and micro-CT parameters, particularly at trabecular sites [67–69]. The reduction in BMD in these mice was completely prevented by estrogen replacement [69]. Histologically, knockout animals of both sexes showed significant reductions in trabecular bone volume, trabecular thickness, and cortical thickness, as compared with WT littermates [68]. Surprisingly, despite the similarity in the skeletal phenotype, the analysis of the effects of aromatase inactivation on bone remodeling parameters in these different ArKO models has shown conflicting results. In one study on static and histomorphometric parameters of the spine, adult ArKO males showed a low turnover pattern, with significant reductions in osteoblastic, osteoid, and eroded surfaces and with reduced mineralizing surface as observed from tetracycline uptake [68]. In contrast, adult ArKO females showed a high turnover pattern, suggesting a sexual dimorphism in bone remodeling of 5to 7-month-old ArKO animals [68]. These observations were confirmed in a subsequent study utilizing fluorine-18 PET imaging [67]. By this technique, ArKO males clearly demonstrated reduced vertebral remodeling as compared to WT littermates, and estradiol treatment in these mice increased fluorine-18 uptake to normal levels. The sexual dimorphism in bone remodeling in ArKO animals was not appreciated in another ArKO mice model, in which increased bone resorption was observed in both male and female animals [69]. Treatment with estrogen restored the increased parameters of bone remodeling to the WT level in both sexes [69]. Although it is not clear how to account for the differences in these observations, what is clear is that aromatase deficiency profoundly influences processes associated with bone turnover in both male and female animals. Of interest, it should be underlined that ArKO mice also develop other metabolic alterations including abdominal obesity, insulin resistance, and dyslipidemia, with some of these conditions occurring prevalently in male than female animals [70]. Thus, given the intimate relationship between energy and bone homeostasis, it is likely that these metabolic alterations may particularly impact bone health in the male mice and constitute the basis for the observed gender-dependent differences in bone turnover [71].

AROMATASE ACTIVITY AND BONE LOSS

139

To further clarify the relationship between estrogen and androgen in bone, in a more recent study, male ArKO mice were orchidectomized [72]. In this model (characterized by a double deficiency of estrogen and androgen), ORX induced a further decrease in BMD and in endosteal bone resorption compared with sham-operated ArKO mice, without any major difference in periosteal bone formation. Consistent with ArKO models, different experiments of aromatase inhibition in aged male rats by vorozole treatment demonstrated increases in bone resorption and bone loss to an extent similar to that of ORX [73–75]. Interestingly, in these experiments the inhibition of aromatase did not significantly affect cortical thickness in contrast to ORX, suggesting a direct role of androgens on this geometric property at cortical sites [74]. This latter observation is in keeping with data from androgen receptor knockout mice and ORX mice where a similar degree of reduction in cortical area and thickness were evidenced, as a result of a reduced bone formation at the periosteum [76]. Indeed, testosterone replacement stimulated periosteal bone formation in ORX but not androgen receptor knockout mice, again supporting the concept that androgen receptor activation plays a major role at the periosteum [76]. Taken together, these studies on CYP19A1 deficient mice as well as other rodent models of aromatase inhibition provide general confirmation of the human gene disorders and suggest that estrogen may be more protective in the growing skeleton than androgens not only in women but also in man. A minimum circulating estrogen level is also required for maximal androgeninduced stimulation of periosteal apposition [5]. However, these observations, left open the issues of what, if any, are the roles of estrogen in regulating bone remodeling in adult men with mature skeletons, whether estrogen is necessary for the maintenance of bone mass in adult men, and what, if any, is the role of estrogen (or estrogen deficiency) in mediating age-related bone loss in men. 5.3. INHIBITION OF AROMATASE ACTIVITY: CLINICAL STUDIES IN MEN A first indirect indication about the importance of aromatase and the relative roles of estrogen versus testosterone in the adult male skeleton came from cross-sectional observations in middle-aged and elderly men relating sex steroid concentrations to BMD at various sites. It was shown that BMD is more directly related to declining estrogen levels than declining androgen levels, particularly when circulating bioavailable fractions of these steroids were considered [77–84]. Importantly, these initial cross-sectional data were confirmed generally in longitudinal studies [77,85,86]. Moreover, in one of these studies, the ratio between estradiol and testosterone, presumed to be an

GENNARI ET AL.

140

indirect index of aromatase activity, increased significantly with age and was higher in normal than in osteoporotic subjects or men with fragility fractures [86] (Fig. 3). Consistent with these findings, other clinical studies have found significant effects of estrogen on the adult male skeleton. Thus, in a preliminary observation, Taxel and Raisz treated nine elderly men with either 0.5 or 2.0 mg daily of micronized 17b-estradiol and found significant reductions in bone resorption markers [87]. In addition, Anderson et al. treated 21 eugonadal men with osteoporosis with intramuscular testosterone and found a significant increase in lumbar spine BMD, which was correlated with changes in serum estradiol, but not testosterone concentrations [88]. In order to definitively dissect out estrogen versus testosterone effects on the adult male skeleton, more dynamic short-term interventional observations have been performed through pharmacological inhibition of aromatase activity. Falhati-Nini et al. [89] examined the differential effects of estrogen versus testosterone replacement in a group of 59 elderly men (mean age 68 years) rendered temporarily hypogonadal by the use of a GnRH agonist (Lupron). Selective replacement of testosterone, or estrogen, or both in the presence of the aromatase inhibitor (AI), letrozole (2.5 mg daily), permitted a specific sex steroid assignment to the bone dynamics that were observed. The increase in bone resorption markers (deoxypyridinoline and N-telopeptide of type I collagen) following induction of the hypogonadal state was almost completely prevented by estradiol but not by testosterone therapy alone, indicating that the increase in bone resorption was due primarily to estrogen

A

B

E2/T ratio (pmol/nmol )

10 9 8 7 6 5 4 3

12 P < 0.01 ANOVA

P < 0.05 ANOVA

10 8 6 4

2

2

1 0

0 Osteoporotic men

Non-osteoporotic men

Vertebral Control fracture

FIG. 3. Estradiol to testosterone ratio (as an indirect evaluation of aromatase activity) in (A) osteoporotic and non-osteoporotic elderly men and (B) men with and without fragility fractures (adapted from Ref. [86]).

141

AROMATASE ACTIVITY AND BONE LOSS

loss, not to testosterone loss (Fig. 4A). In the case of bone formation indices, there was evidence for stimulatory effects of both estrogen and testosterone independently on serum osteocalcin but not the amino-terminal propeptide of type I procollagen that only increased with estrogen replacement (Fig. 4B). Since osteocalcin is produced primarily by mature osteoblastic cells and osteocytes [90], these findings are consistent with an important role for both estrogen and testosterone in maintaining the functional integrity of these cells, perhaps by preventing apoptosis [91]. Type I collagen, by contrast, is produced by cells of the entire osteoblastic lineage [92], and these data would suggest that it is primarily estrogen that regulates this process. In a similar study in younger individuals, Leder et al. [93] confirmed an increase in bone resorption markers following induction of the hypogonadal state by the GnRH agonist, goserelin acetate. In this model, evidence was provided for independent effects of testosterone and estrogen on bone resorption. Moreover, in that study, bone formation markers also appeared to be dependent both upon androgens and estrogens. These observations are in keeping with the increase in bone formation markers described in aromatase deficient or gonadectomized men [94]. A subsequent study by Taxel et al. [95] with a longer observation period (9 weeks) gave similar results, further indicating that treatment of elderly men with an AI (in this specific case anastrozole 2 mg/day) produces significant increases in bone resorption and

Change (%) from baseline

A 10

B 50

5

40

Bone formation

0

30

Bone resorption

∗ #

§ ∗

–5 20 –10

–20 –25

§

10

–15 ∗

# ∗ ∗

Serum Osteocalcin

Testosterone

–

–

Estradiol

–

+

0 Serum PINP

Urinary DPD

–10

Urinary NTx

+

+

–

–

+

+

–

+

–

+

–

+

*P < 0.001; #P < 0.005; and §P < 0.05 vs. baseline

FIG. 4. Changes in (A) bone formation and (B) bone resorption markers in adult men after the pharmacological induction of hypogonadism (by Lupron, a GnRH agonist) and aromatase inhibition (by letrozole 2.5 mg daily). The effects of testosterone and/or estradiol replacement at 3 weeks are indicated as percent change from baseline levels (adapted from Ref. [89]).

142

GENNARI ET AL.

decreases in bone formation. These effects on bone turnover may be less evident with lower doses of AIs (i.e., anastrozole 1 mg/day or less), at least over a short-term period of treatment and/or in case of borderline hypogonadism (testosterone levels less than 350 ng/dl), as demonstrated by Leder et al. [96]. A more recent study assessed the 12 months effects of anastrozole (1.0 mg/day) administration on BMD and bone turnover markers in 69 men aged 60 years or older with low or low normal testosterone levels, who participated in double-blind, randomized, placebo-controlled trial [97,98]. Interestingly, even though anastrozole therapy increased mean serum testosterone at all time points over placebo, these increases in androgen concentrations and the parallel mild decrease in estradiol were associated with a statistically significant decrease in posterior–anterior spine BMD versus placebo as measured by DXA and qualitatively similar, although nonsignificant, changes at the other bone sites. Conversely, bone turnover was not significantly affected by aromatase inhibition in this study. A similar approach to boys with constitutional delay of puberty gave partly different results. Suppression of estrogen production by the AI letrozole for 1 year during testosterone treatment did not negatively affect bone mineral content, BMD or bone mineral apparent density with respect to testosterone treatment alone [99]. In both testosterone alone and testosterone plus letrozole groups, bone mass parameters increased with respect to baseline values and untreated group. However, the increase in bone mineral apparent density in the testosterone plus letrozole group was statistically significant only at 18 months, 6 months after discontinuation of letrozole treatment. Moreover, a decrease in BMD was observed in four letrozoletreated boys but only in one of the boys treated with testosterone alone. These findings suggest that 1-year treatment with an AI in pubertal boys is unlikely to have any major harmful effect on BMD and the attainment of peak bone mass, but such short-term studies do not diminish the clear effects of long-term estrogen deficiency (i.e., aromatase deficiency) on the developing male skeleton. Collectively, all these observational and direct interventional data provided conclusive evidence for an important and indeed, dominant role for aromatase activity and peripheral estrogen biosynthesis from androgen precursors in the male skeleton. 5.4. INHIBITION OF AROMATASE ACTIVITY: USE OF AIS IN WOMEN AIs actually represent a well-established class of compounds for the endocrine management of breast cancer patients and have largely replaced tamoxifen (a selective estrogen receptor modulator) as the first-line treatment for postmenopausal women with metastatic, hormone receptor-positive breast

AROMATASE ACTIVITY AND BONE LOSS

143

cancer [100,101]. However, concerns exist regarding the effects of these compounds on bone health, due to the sustained suppression of estrogen levels [2,102,103]. Indeed, before the widespread use of AIs in women with breast cancer, the importance of aromatase activity and the extragonadal production of residual estrogen levels for bone health in postmenopausal women were poorly recognized. In a first pivotal study performed in normal postmenopausal women, Heshmati et al. [104] evaluated the skeletal effects of blockade of aromatase activity in 42 normal postmenopausal women randomly assigned to receive either placebo or letrozole 2.5 mg daily for 6 months. Letrozole treatment reduced serum estrone and estradiol to near undetectable levels. Moreover, even though bone formation markers were not significantly affected, letrozole therapy significantly increased bone resorption markers as compared with the placebo group, anticipating the negative skeletal consequences recently observed with the widespread use of AIs. Currently, there are two classes of AIs, steroidal agents (i.e., exemestane) and nonsteroidal compounds (anastrozole and letrozole). While the former act as irreversible inactivator of the aromatase, the latter reduce enzyme activity in a reversible manner [2,101,105]. During the past few years, considerable evidence has been developed confirming that both steroidal and nonsteroidal AIs exert negative effects on skeletal metabolism and bone strength. A potential caveat to the available evidence relates to the fact that in most studies the skeletal effects of AIs have been compared with tamoxifen treatment, which in addition to antitumoral activity also retains a mild positive action on bone. Thus, in several trials, both letrozole and anastrozole treatments were associated with increased bone turnover, reduced BMD and increased fracture incidence compared with tamoxifen group (Fig. 5), which was generally associated with small increases in BMD with respect to baseline [106–109]. In a different trial of women who had already completed 5 years adjuvant therapy with tamoxifen, letrozole treatment was compared to placebo [110,111]. In this case, despite a greater BMD decrease at the hip but not the lumbar spine, the incidence of clinical fractures was higher but did not significantly differ between letrozole and placebo groups (3.6% vs. 2.9%). Steroidal AIs such as exemestane, likely due to its structural relationship with androstenedione, may have more androgenic activity and exert somewhat different and less negative effects on bone metabolism than nonsteroidal agents [109,112]. However, a bone density substudy from a large trial comparing 5 years tamoxifen with two to three tamoxifen followed by exemestane evidenced a significant decrease in BMD at 6 and 12 months in those patients who switched from tamoxifen to exemestane compared to patients that continued tamoxifen [113,114]. In the overall study, a nonsignificant trend indicating higher fracture incidence was evidenced after a

GENNARI ET AL.

144

5-yr fracture risk vs. tamoxifen

3 RR 1.49

RR 1.38

[95%Cl 1.25–1.77]

[95%Cl 1.13–1.69]

2 P < 0.0001

P < 0.001

Anastrozole (ATAC Trial)

Letrozole (BIG Study)

1

0

FIG. 5. Risk of any fractures after 5-year treatment with aromatase inhibitors (anastrozole and letrozole) compared with tamoxifen treatment. Data were obtained from results of the ‘‘Arimidex, Tamoxifen, Alone or in Combination’’ (ATAC) study [106] and the fracture outcome arm of the ‘‘Breast International Group’’ (BIG) study [108].

median follow-up of 31 months in patients switched to exemestane than in 5 years tamoxifen group (3.1% vs. 2.3%, P ¼ 0.08). Thus, despite additional information is required, there is considerable evidence that even the low residual levels of estrogen present in postmenopausal women are important for skeletal health and that either steroidal and nonsteroidal AIs may increase fracture risk. Indeed, in women under AIs treatment bone loss generally occurs at a rate at least twofold higher than in healthy postmenopausal women [115]. For these reasons, a close follow-up of BMD and a more aggressive approach to initiating pharmacological therapy are actually recommended in women on treatment with AIs [115–118]. Importantly, given the complex and tissue-specific regulation of aromatase expression and activity, the future development of selective inhibitors of CYP19A1 promoter region may allow to treat breast cancer while permitting aromatase expression via alternative promoters in the bone or other tissues and thus obviate the key side effects of the current AIs [119]. Combination therapies with AIs and other compounds such as Src (a nonreceptor tyrosine kinase component of signaling pathways that regulate breast cancer cell proliferation, invasion, and metastasis but also osteoclast-mediated bone turnover) are actually under investigation with the hope to increase antitumoral activity while reducing bone resorption in women with breast cancer [120]. Similarly, in a different experimental study, calcitriol (the hormonally active form of vitamin D) significantly decreased aromatase expression in

AROMATASE ACTIVITY AND BONE LOSS

145

human breast cancer cells and adipocytes but caused substantial increases in human osteosarcoma cells (a bone cell model exhibiting osteoblast phenotype in culture) [121]. Thus, the combination of calcitriol and an AI may have potential benefits for breast cancer therapy, augmenting the ability of AIs to inhibit tumoral growth, and ameliorating the AI-induced side effect of osteoporosis.

6. Skeletal Consequences of Aromatase Excess The human cases of aromatase deficiency gene have a counterpart of interest, namely the syndrome of aromatase excess in which the aromatase gene is overly active [122]. The disorder is inherited as autosomal dominant and is due to heterozygous inversions in chromosome 15q21.2-3, which cause the coding region of the CYP19A1 gene to lie adjacent to constitutively active cryptic promoters that normally transcribe other genes. This induces the overexpression of aromatase in many tissues [123,124]. In this setting, the clinical characteristics are generally the opposite to those in the aromatase deficiency syndrome and include high systemic estrogen concentrations, advanced bone age, short stature, prepubertal gynecomastia and testicular failure in males, and premature breast development and uterine pathology in females. Despite increased estrogen concentrations and testosterone levels that are low or in the lower end of the normal range, males with aromatase excess appear to be fertile. In some of these cases, short-term treatment with an AI (testolactone or anastrozole) was successful in decreasing serum estrogen, restoring gonadotropins and testosterone to normal levels, and arresting skeletal age [122,123,125]. Even though different families with affected male and female subjects and sporadic cases of aromatase excess syndrome have been described, the effects of estrogen excess on bone turnover and bone density in humans remain as yet unknown. The only available data in this respect relate to BMD that was in the upper limits of the normal range in two siblings with familial hyperestrogenism. It is a remarkable observation considering the additional point that the man had hypogonadism and the woman had irregular menses [125]. Of interest, the skeletal manifestations of estrogen excess due to enhanced aromatase activity have been investigated in more detail in mice models. Male and female mice overexpressing aromatase showed increased bone mass and strength at the tibia [126]. All these changes were generally more striking in males than in females. Moreover, histomorphometric data of young animals showed decreased longitudinal growth rate of the tibia, and a decreased bone formation rate in trabecular bone and particularly in

146

GENNARI ET AL.

periosteum, consistent with the concept the very high estrogen levels may have negative effects on periosteal expansion. Aged transgenic mice showed similar changes in trabecular bone as young animals, but their bone formation rate was increased. Despite a shorter length of the tibia ( 23.2%), these mice had a much heavier ash weight (þ 24.0%) and a markedly higher bending strength (þ 21.2%) compared with WT animals. To study the importance of high local aromatization within the bone and thereby of increased estrogen to testosterone ratio specifically in osteoblasts, a transgenic mouse model has been recently developed (Coll-1a1-Arom mice) that overexpresses the human aromatase gene under the control of the osteoblast-specific rat type Ia I procollagen promoter [127]. As expected, these mice expressed human aromatase mRNA specifically in bone and had unaffected serum estrogen and testosterone concentrations. The adult male animals had increased trabecular and cortical BMD, increased cortical thickness associated with elevated osteoprotegerin mRNA levels and reduced number of osteoclasts compared with the WT mice. Conversely, the female Coll-1a1-Arom mice, with low levels of endogenous serum androgens, and thereby, little substrate for aromatase, had no major skeletal phenotype, and ovariectomy resulted in a similar loss of trabecular bone than WT mice. However, treatment of ovariectomized mice with testosterone increased cortical and trabecular thickness in the Coll-1a1-Arom mice but not in the WT mice. Taken together all the above clinical and experimental evidences on the skeletal consequences of aromatase excess further underscore the importance of estrogen over androgen for bone homeostasis, with a relevant role of local aromatase activity in bone. Future development of osteoblast-specific inducers of aromatase expression might identify substances with stimulatory effects on bone without systemic adverse effects.

7. Threshold Estradiol Hypothesis for Skeletal Sufficiency Data from clinical and experimental studies on aromatase deficiency also reinforced the hypothesis of a threshold estradiol level for skeletal sufficiency in the male as well as in female [1–4], as previously suggested by considerable indirect evidence. In fact, in a cross-sectional analysis from the MINOS Study, men in the lowest quartile for bioavailable estradiol level showed significantly lower BMD at multiple sites as compared to men in the upper three estradiol quartiles [84]. Moreover, in two subsequent longitudinal studies in elderly males, rates of bone loss at different skeletal sites were unrelated to serum estradiol concentrations when the latter were above the

AROMATASE ACTIVITY AND BONE LOSS

147

median value, while clearly associated with estradiol at concentrations below the median [85,86]. The threshold estradiol hypothesis in men gained further support from a study in which raloxifene (a selective estrogen receptor modulator) was given to men of varying estradiol levels [128]. Subjects with serum total estradiol levels below 96 pmol/l responded to raloxifene with a decrease in bone resorption markers. In this group, raloxifene was serving as an agonist. Above this estrogen value, raloxifene caused an increase in bone resorption markers. In this group with higher estrogen concentrations, raloxifene was acting as an estrogen antagonist. The data argue that men need a sufficient concentration of estrogen, defined as a threshold value, for normal skeletal remodeling. In all these studies, the required concentration of bioavailable estradiol appeared to be remarkably similar, ranging from 40 to 55 pmol/l. This apparent threshold value is higher than typical estradiol concentrations for postmenopausal women who are not receiving exogenous estrogens. On the other hand, premenopausal women and young men are typically above this apparent threshold level. Because about 50% of middleaged men fall below this estradiol threshold, it could be a determinant in agerelated bone loss as shown in several cross-sectional and longitudinal studies [1–4]. A more recent cross-sectional analysis in which volumetric BMD and bone geometry at different sites were assessed by QCT, further extend these observations, and indicated that in men the relationship between bioavailable estradiol and volumetric BMD at cortical versus trabecular sites appears to be different [129]. The supposed threshold level for estrogen deficiency appeared to be lower for cortical than for trabecular bone. In other words, trabecular bone seems to be more sensitive to small declines in estrogen levels with aging, while cortical bone appears to be more insensitive. The same associations were confirmed in a similar QCT study in women [130]. Importantly, not only are estradiol levels above a given threshold necessary to regulate bone turnover and maintain BMD in older individuals, but are also important for preventing fractures, as recently demonstrated in a prospective study of men from the MrOS cohort [131]. Thus, since only a small fraction of circulating estradiol is derived directly from the testes in men and given the low estradiol levels typically observed in women after menopause, it is likely that peripheral aromatization of androgen precursors into estrogen exert a key role in maintaining estradiol levels above the required threshold with ageing. A major unsolved issue is which tissue site of aromatase is the most important in terms of bone metabolism. Moreover, is paracrine/intracrine estradiol or endocrine estradiol the most important for bone physiology? The consistent association between circulating estradiol levels, BMD and fracture risk, reported in different crosssectional and longitudinal studies, suggests that although local aromatization in bone may contribute significantly to skeletal homeostasis [132], a

148

GENNARI ET AL.

minimum circulating level of estradiol (derived from nonskeletal peripheral aromatization) is necessary to prevent bone loss. It is also likely that circulating estrogen levels could just reflect the estrogen status within the bone, due to local aromatase activity. Further experimental observations are needed to clarify this important issue.

8. Variability in the Level of Aromatase Activity: Effects on Bone Metabolism The experiments of nature or of clinical research, in which aromatase activity is absent or inhibited, have shown clearly that aromatase and estrogen production are important factors in skeletal health. But these models have made this important point in the context of complete estrogen deficiency. They do raise the possibility, however, that significant differences in estrogen concentrations might be present [5,19] due to variability in aromatase efficiency and that this variability may be important for skeletal homeostasis in both genders. Such differences in aromatase activity, and hence estrogen levels, might become particularly evident in elderly males in whom age-related declines in testicular and adrenal androgen precursors are common. However, this aspect could become even more relevant in postmenopausal women, where the availability of androgen precursors for aromatization to estrogen is much lower than in men. In fact, testosterone levels are at least an order of magnitude greater in men than in postmenopausal women, while adrenal androgen levels are rather similar [133]. 8.1. INHERITED VARIATION IN AROMATASE ACTIVITY Several polymorphic regions (including 74 single nucleotide polymorphisms) have been detected in the human CYP19A1 gene that could be responsible for qualitative and/or quantitative differences in gene expression and aromatase activity. The most widely studied include a silent polymorphism (G/A at Val80) in exon 3, a tetranucleotide (TTTA)n tandem repeat polymorphism in intron 4, an Arg264Cys (C/T) substitution in exon 7, and a single nucleotide change (C/T) in exon 10. In particular, the tetranucleotide repeat polymorphism of the CYP19A1 gene was initially shown to be related to estrogen levels, breast cancer and osteoporotic risk in postmenopausal women or with BMD men [134–140] (Fig. 6). More recently, other polymorphic variants within the promoter region of the CYP19A1 gene have been widely investigated and associated with BMD in both genders as well as with susceptibility to breast or uterine cancer in females [141–143]. Despite the results of different studies were somewhat contradictory and often

AROMATASE ACTIVITY AND BONE LOSS

Genotype S/S

149

Genotype L/L and L/S

LS-BMD loss (Δ %/4yrs)

0 –1 –2 –3 –4 –5 –6

P < 0.05 ANOVA

FIG. 6. Rates of bone loss at 4 years in elderly men with long or short (TTTA)n repeat genotype of the CYP19A1 aromatase gene. Subjects were grouped according to short (S; TTTA 9) and long (L; TTTA > 9) repeats number.

underpowered, more recent meta-analyses and large-scale studies generally evidenced an association between polymorphisms in the CYP19A1 gene and circulating estradiol levels or osteoporotic risk in both genders as well as with breast cancer risk in females [144–148]. Thus, it is possible that the presence of particular CYP19A1 variants could be responsible of higher aromatase activity and increased estrogen production. If so, these polymorphisms should be protective for bone loss in elderly men or postmenopausal women while potentially also increasing the risk of estrogen-related cancer. Interestingly, these associations appear to be modulated by fat mass, particularly in men. Differences between CYP19A1 genotypes were greater in male subjects with a normal BMI, while the association progressively decreased in magnitude when overweight and obese men were analyzed [138] (Fig. 7A and B). This point suggests that fat mass may be a mitigating factor in the expression of CYP19A1 genotypes on bone. It is possible that with more adipose tissue, the associated overall increase in adipose aromatase activity dominates any effect of the polymorphisms on intrinsic aromatase activity. This effect could be less important in postmenopausal females, where the amount of circulating androgen precursors for aromatization into estrogen is low. Moreover, the observed interaction between CYP19A1 polymorphism and BMI is also consistent with the hypothesis of a threshold estradiol level for skeletal sufficiency [1–4]. In fact, either the presence of more efficient allelic variants or the abundance of adipose tissue (with increased source for aromatization) could each operate in a similar manner to maintain sufficient amounts of circulating estradiol to prevent bone loss.

GENNARI ET AL.

150 A

Lumbar BMD (g/cm2)

1.05

Normal weight (BMI ≤ 25)

B

Overweight (BMI > 25)

P < 0.05 ANOVA 1 0.95 0.9 0.85 0.8 SS

S/L

L/L S/S CYP19A1 genotype

S/L

L/L

FIG. 7. Lumbar BMD values according to CYP19A1 (TTTA)n repeat genotype in subjects divided by BMI in (A) normal (BMI 25) and (B) overweight or obese groups (BMI > 25). Subjects were grouped according to short (S; TTTA 9) and long (L; TTTA > 9) repeats number (adapted from Ref. [138]).

Given the importance of estrogen in bone accrual, it is likely that deleterious CYP19A1 polymorphisms exert even a greater role in young individuals. Despite an early study in 140 middle-aged Finnish men that revealed an association between the number of TTTA repeat sequences and height and BMI but not with BMD [149], a larger analysis confirmed that CYP19A1 polymorphisms significantly affect the attainment of peak bone mass [150]. In a well-characterized cohort of 1068 men at the age of peak bone mass (18.9 0.6 years), both the TTTA repeat variation and a silent G/A polymorphism at Val80 of the CYP19A1 gene were predictors of areal BMD of the radius, lumbar spine, total body, and cortical bone size (cortical crosssectional area and thickness) of both the radius and tibia. To date, the molecular mechanisms through which the different CYP19A1 variants affect aromatase activity and bone metabolism remain in great part unknown. In a preliminary study in elderly men, higher in vitro aromatase efficiency and greater estrogen production were observed in fibroblasts from subjects with a high TTTA repeat sequence genotype in comparison to fibroblasts from a low TTTA repeat sequence genotype [138]. However, due to its location in intron 4 of the CYP19A1 gene, it is unlikely that this polymorphism directly affects aromatase activity. It is more likely that the different TTTA alleles are in linkage disequilibrium with other functional variants in the gene or with a nearby gene. Indeed, a different study described a strong degree of linkage disequilibrium between the (TTTA)n repeat polymorphism and the C/T substitution in exon 10, just 19 bp downstream of the termination site of translation [135]. In that study, the T allele was associated

AROMATASE ACTIVITY AND BONE LOSS

151

with a higher number of TTTA repeat sequences and showed a high activity phenotype, with increased aromatase activity, increased aromatase mRNA levels, and with a switch in promoter usage from adipose tissue promoter to the more active ovary promoter. Different studies also evidenced a functional role of other polymorphisms located within the complex promoter region of the CYP19A1 gene. In particular, a C/G polymorphisms in promoter I.2 (rs1062033) was shown to influence gene transcription by interacting with CEBPb [151], a transcription factor acting either as a stimulator or inhibitor of aromatase expression in different tissues [152,153]. In fact, in experiments of transient transfections of osteoblastic cell lines with luciferase reporters, inserts with the rs1062033 region stimulated the expression of the reporter gene, in an allele-specific way. The expression of the reporter gene was significantly higher in constructs bearing the G allele (which was also associated with higher BMD in population studies) than in those with the C allele. In the same model, cotransfecting with CEBPb increased luciferase expression by the aromatase constructs, especially in those with the G allele. Furthermore, evidence for differential allelic expression was found in bone tissue samples, again indicating the G allele as the more overexpressed. Although these studies, in the aggregate, provide data to argue for the importance of polymorphisms in CYP19A1 as determinants of estrogen production and bone strength, larger and more definitive studies are needed before any firm conclusions can be drawn. Finally, recent evidence also suggested that CpG methylation represents an important epigenetic mechanism for regulating CYP19A1 expression and that different methylation patterns may be responsible for the observed interindividual variation in promoter-driven expression of aromatase, at least in skin fibroblasts [154]. In fact, unmethylated constructs showed consistently higher promoter activity than methylated constructs. 8.2. ACQUIRED VARIATION IN AROMATASE ACTIVITY Besides genetic or epigenetic considerations, several additional mechanisms have been proposed in which aromatase activity could be modulated under certain circumstances in different tissues. It is known, for example, that aromatase is a marker of the undifferentiated adipose mesenchymal cell phenotype and that on a per cell basis, it is more highly expressed in these cells than in mature adipocytes. Thus, factors that stimulate adipocyte differentiation such as ligands of the PPARg receptor (i.e., troglitazone) could also lead to downregulation of aromatase gene and a reduction in aromatase activity. Of course, if there are more adipocytes, there could be more aromatase activity even with reduced production of estrogen per fat cell. In vitro studies support this hypothesis [155–157]. Similarly, phthalates, ubiquitous

152

GENNARI ET AL.

environmental toxins found in plasticizers, have been reported to activate the PPARg and PPARa pathways and to decrease aromatase activity, mRNA and protein levels in ovarian granulosa cells [158]. The clinical relevance of these environmental modulators on global aromatase activity and estrogen production in man remains unknown. Of interest, the activation of PPARa pathway by fenofibrate in female mice significantly reduced aromatase mRNA and activity, resulting in decreased femoral BMD and uterine size [159]. Several other contaminants may affect aromatase activity and estrogen production. In particular, glyphosate-based herbicides are toxic and endocrine disruptors in human cell lines that are widely used across the world. Their residues are frequent pollutants in the environment and are spread on most eaten transgenic plants, modified to tolerate high levels of these compounds in their cells. While up to 400 ppm of their residues are accepted in some feed, recent experimental studies demonstrated that aromatase transcription and activity were disrupted with subagricultural doses and with residues from 10 ppm [160]. In addition, cycloxygenase (COX) inhibitors, by reducing PGE2 production, may inhibit aromatase activity, at least in breast cancer cells, and in some studies showed strong chemopreventive activity against mammary carcinogenesis [161,162]. However, PGE2 appears also involved in the regulation of bone turnover [163], and its inhibition by the combination of relative COX-2 selective nonsteroidal anti-inflammatory drugs and aspirin was associated with high and not low BMD at multiple skeletal sites both in men and women [164]. A recent study showed that phytochemicals such as procyanidin B dimers contained in red wine and grape seeds inhibit aromatase activity in vitro and suppress aromatase-mediated breast tumor formation in vivo [165]. It has been estimated that daily consumption of 125 ml of red wine would provide adequate amounts of procyanidin B dimers to suppress in situ aromatase in an average postmenopausal woman. Similarly, myosmine, a minor tobacco alkaloid widely occurring in food products of plant and animal origin, inhibits the conversion of testosterone to estradiol by human aromatase with potential implications for sex hormone homoeostasis [166]. Another important and well-recognized modulator of aromatase efficiency in bone cells is vitamin D that has been shown to stimulate glucocorticoidinduced aromatase activity in cultured osteoblasts [167]. The magnitude of this effect varies largely among individuals, depending on the level of vitamin D receptor [168]. Of interest, vitamin D receptor knock-out mice showed reduced aromatase activity with respect to WT animals [169]. Finally, aromatase efficiency may be influenced by pathological conditions. It is known that increased androgen aromatization can be caused by hepatocellular carcinoma [170], adrenocortical tumors [171], and testicular

AROMATASE ACTIVITY AND BONE LOSS

153

tumors [172,173]. In these neoplastic conditions, inappropriate amounts of aromatase enzyme are expressed and estrogen levels are increased. Elevated plasma estradiol concentrations have also been described in men with liver cirrhosis together with decreased plasma testosterone [173,174]. In these patients, the metabolic clearance rate of estrogens seems to be unaltered, suggesting that the observed hyperestrogenism could be caused solely by an increase in androgen aromatization. Much less is known about a possible negative influence of pathological conditions on aromatase activity. In a preliminary study on elderly men, significant differences in estradiol levels in relation to Helicobacter pylori infection were observed, independently from circulating testosterone levels [175]. Levels of estradiol in infected CagApositive patients were significantly lower than in infected CagA-negative patients and this variation was associated with differences in bone turnover. The mechanism underlying this association is unknown and deserves further investigations. Indeed, aromatase activity and production of estradiol were recently demonstrated in gastric parietal cells [176]. Recent observations also suggested that diabetes negatively affects expression levels of aromatase both in ovary and testis [177,178]. However, the effects of this condition on major extragonadal sites of aromatase activity including bone remains to be determined. Moreover, experimental studies also evidenced that metformin, an oral antidiabetic agent, inhibits aromatase expression in both granulosa luteal cells and breast adipose cells while insulin stimulates aromatase mRNA expression in different cell lines [179,180]. Since a recent study evidenced that metformin-induced inhibition of aromatase expression occurs via downregulation of promoter II, I.3, and 1.4 [180], its potential negative effects on estrogen production and skeletal health should be investigated.

9. Summary and Conclusions Aromatase, the enzyme responsible for the transformation of androgens into estrogens, has a complex, tissue-specific regulation. The regulation of the level and activity of this enzyme determines the concentrations of estrogens that have endocrine, paracrine, and autocrine effects on several tissues including bone. Importantly, extraglandular aromatization of circulating androgen precursors is the major source of estrogen not only in men but also in women after the menopause. Several lines of clinical and experimental evidence now clearly indicate that aromatase activity and estrogen production are necessary for longitudinal bone growth, attainment of peak bone mass, the pubertal growth spurt, epiphyseal closure, and normal bone remodeling in young individuals. Moreover, with aging, individual differences in aromatase activity may significantly affect bone loss and fracture risk in both genders.

154

GENNARI ET AL.

Further studies are needed to better understand the role of glandular versus peripheral aromatization, to clarify the androgen contribution on bone homeostasis, and to identify how genetic, environmental, pathologic, and pharmacological influences might modulate aromatase activity, increasing or reducing estrogen production in ageing individuals, and thereby affecting skeletal health. REFERENCES [1] B.L. Riggs, S. Khosla, L.J. Melton 3rd, Sex steroids and the construction and conservation of the adult skeleton, Endocr. Rev. 23 (2002) 279–302. [2] S. Khosla, Update on estrogens and the skeleton, J. Clin. Endocrinol. Metab. 95 (2010) 3569–3577. [3] S. Khosla, L.J. Melton 3rd, B.L. Riggs, Clinical review 144: estrogen and the male skeleton, J. Clin. Endocrinol. Metab. 87 (2002) 1443–1450. [4] L. Gennari, S. Khosla, J.P. Bilezikian, Estrogen and fracture risk in men, J. Bone Miner. Res. 23 (2008) 1548–1551. [5] L. Gennari, S. Khosla, J.P. Bilezikian, Estrogen effects on bone in the male skeleton, in: J.P. Bilezikian, L.G. Raisz, J. Martin (Eds.), Principles of Bone Biology, third ed., Elsevier Academic Press, San Diego, CA, 2008, pp. 1801–1818. [6] L. Vandenput, C. Ohlsson, Estrogens as regulators of bone health in men, Nat. Rev. Endocrinol. 5 (2009) 437–443. [7] B.L. Clarke, S. Khosla, Androgens and bone, Steroids 74 (2009) 296–305. [8] E.R. Simpson, M.S. Mahendroo, G.D. Means, et al., Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis, Endocrinol. Rev. 15 (1994) 342–355. [9] E.V. Simpson, S.R. Davis, Minireview: aromatase and the regulation of estrogen biosynthesis – some new perspectives, Endocrinology 142 (2001) 4589–4594. [10] R.J. Santen, H. Brodie, E.R. Simpson, P.K. Siiteri, A. Brodie, History of aromatase: saga of an important biological mediator and therapeutic target, Endocr. Rev. 30 (2009) 343–375. [11] E. Steinach, H. Kun, Transformation of male sex hormones into a substance with the action of a female hormone, Lancet 133 (1937) 845. [12] M. Pasanen, O. Pelkonen, Solubilization and partial purification of human placental cytochromes P-450, Biochem. Biophys. Res. Commun. 103 (1981) 1310–1317. [13] J.T. Kellis Jr., L.E. Vickery, Purification and characterization of human placental aromatase cytochrome P-450, J. Biol. Chem. 262 (1987) 4413–4420. [14] L.R. Nelson, S.E. Bulun, Estrogen production and action, J. Am. Acad. Dermatol. 45 (2001) S116–S124. [15] E.R. Simpson, Sources of estrogen and their importance, J. Steroid Biochem. Mol. Biol. 86 (2003) 225–230. [16] J.M. Grodin, P.K. Siiteri, P.C. MacDonald, Source of estrogen production in postmenopausal women, J. Clin. Endocrinol. Metab. 36 (1973) 207–214. [17] P.K. Siiteri, P.C. MacDonald, Placental estrogen biosynthesis during human pregnancy, J. Clin. Endocrinol. Metab. 26 (1966) 751–761. [18] E.R. Simpson, Role of aromatase in sex steroid action, J. Mol. Endocrinol. 25 (2000) 149–156. [19] L. Gennari, R. Nuti, J.P. Bilezikian, Aromatase activity and bone homeostasis in men, J. Clin. Endocrinol. Metab. 89 (2004) 5898–5907.

AROMATASE ACTIVITY AND BONE LOSS

155

[20] W. de Ronde, H.A.P. Pols, J.P.T.M. van Leeuwen, F.H. de Long, The importance of estrogen in males, Clin. Endocrinol. 58 (2003) 529–542. [21] J.D. Vedhuis, G. Lizarralde, A. Iranmanesh, Divergent effects of short term glucocorticoid excess on the gonadotrophic and somatotrophic axis in normal men, J. Clin. Endocrinol. Metab. 74 (1992) 96–102. [22] W. Bartsh, H.J. Horst, H. Becker, G. Nehse, Sex hormone binding globulin binding capacity, testosterone, 5a-dihydrotestosterone, oestradiol and prolactin in plasma of patients with prostatic carcinoma under various types of hormonal treatment, Acta Endocrinol. 85 (1977) 650–664. [23] S. Moorjani, A. Dupont, F. Labrie, et al., Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, oestrogen and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide, J. Clin. Endocrinol. Metab. 66 (1988) 314–3122. [24] E. Simpson, M. Jones, S. Davis, G. Rubin, Do intracrine mechanisms regulate aromatase expression? J. Steroid Biochem. Mol. Biol. 69 (1999) 447–452. [25] F. Labrie, A. Belanger, L. Cusan, B. Candas, Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology, J. Clin. Endocrinol. Metab. 82 (1997) 2403–2409. [26] H.R. Bruch, L. Wolf, R. Budde, G. Romalo, H.U. Schweikert, Androstenedione metabolism in cultured human osteoblast-like cells, J. Clin. Endocrinol. Metab. 75 (1992) 101–105. [27] S. Tanaka, M. Haji, Y. Nishi, T. Yanase, R. Takayanagi, H. Nawata, Aromatase activity in human osteoblast-like osteosarcoma cell, Calcif. Tissue Int. 52 (1993) 107–109. [28] H. Sasano, M. Uzuki, T. Sawai, et al., Aromatase in human bone tissue, J. Bone Miner. Res. 12 (1997) 1416–1423. [29] H.-U. Schweikert, L. Wolf, G. Romalo, Oestrogen formation from androstenedione in human bone, Clin. Endocrinol. 43 (1995) 37–42. [30] J.L. Herna´ndez, C.M. Garce´s, M. Sumillera, et al., Aromatase expression in osteoarthritic and osteoporotic bone, Arthritis Rheum. 58 (2008) 1696–1700. [31] S.A. Chen, M.J. Besman, R.S. Sparkes, et al., Human aromatase: cDNA cloning, Southern blot analysis, and assignment of the gene to chromosome 15, DNA 7 (1988) 27–38. [32] S. Sebastian, S.E. Bulun, A highly complex organization of the regulatory region of the human CYP19 (aromatase) gene revealed by the Human Genome Project, J. Clin. Endocrinol. Metab. 6 (2001) 4600–4602. [33] S.E. Bulun, S. Sebastian, K. Takayama, T. Suzuki, H. Sasano, M. Shozu, The human cyp19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters, J. Steroid Biochem. Mol. Biol. 86 (2003) 219–224. [34] H. Wang, R. Li, Y. Hu, The alternative non-coding cxons 1 of aromatase (Cyp19) gene modulate gene expression in a post-transcriptional manner, Endocrinology 150 (2009) 3301–3307. [35] M. Shozu, E.R. Simpson, Aromatase expression of human osteoblast-like cells, Mol. Cell. Endocrinol. 39 (1998) 117–129. [36] M. Shozu, Y. Zhao, S.E. Bulun, E.R. Simpson, Multiple splicing events involved in regulation of human aromatase expression by a novel promoter, I.6, Endocrinology 139 (1998) 1610–1617. [37] M. Watanabe, E.R. Simpson, N. Pathirage, S. Nakajin, C.D. Clyne, Aromatase expression in the human fetal osteoblastic cell line SV-HFO, J. Mol. Endocrinol. 32 (2004) 533–545. [38] H. Nawata, S. Tanaka, S. Tanaka, et al., Aromatase in bone cell: association with osteoporosis in postmenopausal women, J. Steroid Biochem. Mol. Biol. 53 (1995) 165–174.

156

GENNARI ET AL.

[39] S. Tanaka, M. Haji, R. Takayanagi, S. Tanaka, Y. Sugioka, H. Nawata, 1,25-Dihydroxyvitamin D3 enhances the enzymatic activity and expression of the messenger ribonucleic acid for aromatase cytochrome P450 synergistically with dexamethasone depending on the vitamin D receptor level in cultured human osteoblasts, Endocrinology 137 (1996) 1860–1869. [40] T. Yanase, S. Suzuki, K. Goto, et al., Aromatase in bone: roles of Vitamin D3 and androgens, J. Steroid Biochem. Mol. Biol. 86 (2003) 393–397. [41] J.H. Jeong, Y.K. Jung, H.J. Kim, et al., The gene for aromatase, a rate-limiting enzyme for local estrogen biosynthesis, is a downstream target gene of Runx2 in skeletal tissues, Mol. Cell. Biol. 30 (2010) 2365–2375. [42] N. Harada, T. Utsumi, Y. Takagi, Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis, Proc. Natl. Acad. Sci. USA 90 (1993) 11312–11316. [43] S. Sebastian, K. Takayama, M. Shozu, S.E. Bulun, Cloning and characterization of a novel endothelial promoter of the human CYP19 (aromatase P450) gene that is upregulated in breast cancer tissue, Mol. Endocrinol. 16 (2002) 2243–2254. [44] S.E. Bulun, Aromatase deficiency and estrogen resistance: from molecular genetics to clinic, Semin. Reprod. Med. 18 (2000) 31–39. [45] A. Belgorosky, G. Guercio, C. Pepe, N. Saraco, M.A. Rivarola, Genetic and clinical spectrum of aromatase deficiency in infancy, childhood and adolescence, Horm. Res. 72 (2009) 321–330. [46] P.E. Mullis, N. Yoshimura, B. Kuhlmann, K. Lippuner, P. Jaeger, H. Harada, Aromatase deficiency in a female who is compound heterozygote for two new point mutations in the P450arom gene: impact of estrogens on hypergonadotropic hypogonadism, multicystic ovaries, and bone densitometry in childhood, J. Clin. Endocrinol. Metab. 82 (1997) 1739–1745. [47] V. Rochira, C. Carani, Aromatase deficiency in men: a clinical perspective, Nat. Rev. Endocrinol. 5 (2009) 559–568. [48] A. Morishima, M.M. Grumbach, E.R. Simpson, C. Fisher, K. Qin, Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens, J. Clin. Endocrinol. Metab. 80 (1995) 3689–3698. [49] C. Carani, K. Qin, M. Simoni, et al., Effect of testosterone and estradiol in a man with aromatase deficiency, N. Engl. J. Med. 337 (1997) 91–95. [50] J. Deladoey, C. Fluck, M. Bex, N. Yoshimur, N. Harada, P.E. Mullis, Aromatase deficiency caused by a novel P450 arom gene mutation: impact of absent estrogen production on serum gonadotropin concentration in a boy, J. Clin. Endocrinol. Metab. 84 (1999) 4050–4054. [51] B.L. Hermann, B. Saller, O.E. Janssen, et al., Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 gene, J. Clin. Endocrinol. Metab. 87 (2002) 5476–5484. [52] M.H. Herve, M.L. Kottler, M. Pura, Human gene mutations. Gene symbol: CYP19. Disease: aromatase deficiency, Hum. Genet. 114 (2004) 224. [53] R. Boullion, M. Bex, D. Vanderschueren, S. Boonen, Estrogen are essential for male pubertal periosteal expansion, J. Clin. Endocrinol. Metab. 89 (2004) 6025–6029. [54] L. Maffei, Y. Murata, V. Rochira, et al., Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate and estradiol treatment, J. Clin. Endocrinol. Metab. 89 (2004) 61–70.

AROMATASE ACTIVITY AND BONE LOSS

157

[55] L. Maffei, V. Rochira, L. Zirilli, et al., A novel compound heterozygous mutation of the aromatase gene in an adult man: reinforced evidence on the relationship between congenital oestrogen deficiency, adiposity and the metabolic syndrome, Clin. Endocrinol. 67 (2007) 218–224. [56] F. Lanfranco, L. Zirilli, M. Baldi, et al., A novel mutation in the human aromatase gene: insights on the relationship among serum estradiol, longitudinal growth and bone mineral density in an adult man under estrogen replacement treatment, Bone 43 (2008) 628–635. [57] E.P. Smith, J. Boyd, G.R. Frank, et al., Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man, N. Engl. J. Med. 331 (1994) 1056–1061. [58] J.P. Bilezikian, A. Morishima, J. Bell, M.M. Grumbach, Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency, N. Engl. J. Med. 339 (1998) 599–603. [59] V. Rochira, M. Faustini-Fustini, A. Balestrieri, C. Carani, Estrogen replacement therapy in a man with congenital aromatase deficiency: effects of different doses of transdermal estradiol on bone mineral density and hormonal parameters, J. Clin. Endocrinol. Metab. 85 (2000) 1841–1845. [60] E. Seeman, Clinical review 137: sexual dimorphism in skeletal size, density, and strength, J. Clin. Endocrinol. Metab. 86 (2001) 4576–4584. [61] M. Sundberg, P. Ga¨rdsell, O. Johnell, E. Ornstein, S. I. Karlsson, Pubertal growth in the femoral neck is predominantly characterized by increased bone size and not by increased bone density: a 4-year longitudinal study, Osteoporos. Int. 14 (2003) 548–558. [62] E. Seeman, Pathogenesis of bone fragility in women and men, Lancet 359 (2002) 1841–1850. [63] V. Rochira, L. Zirilli, B. Madeo, et al., Skeletal effects of long-term estrogen and testosterone replacement treatment in a man with congenital aromatase deficiency: evidence of a priming effect of estrogen for sex steroids action on bone, Bone 40 (2007) 1662–1668. [64] C.R. Fisher, K.H. Graves, A.F. Parlow, E.R. Simpson, Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene, Proc. Natl. Acad. Sci. USA 95 (1998) 6965–6970. [65] S. Honda, N. Harada, S. Ito, Y. Takagi, S. Maeda, Disruption of sexual behaviour in male aromatase-deficient mice lacking exons 1 and 2 of the cyp 19 gene, Biochem. Biophys. Res. Commun. 252 (1998) 445–449. [66] K. Toda, T. Saibara, T. Okada, S. Onishi, Y. Shizuta, A loss of aggressive behaviour and its reinstantement by oestrogen in mice lacking the aromatase gene (Cyp 19), J. Endocrinol. 168 (2001) 217–220. [67] O.K. Oz, G. Hirasawa, J. Lawson, et al., Bone phenotype of the aromatase deficient mouse, J. Steroid Biochem. Mol. Biol. 79 (2001) 49–59. [68] O.K. Oz, J.E. Zerwekh, C. Risher, et al., Bone has a sexually dimorphic response to aromatase deficiency, J. Bone Miner. Res. 15 (2000) 507–514. [69] C. Miyaura, K. Toda, M. Inada, et al., Sex- and age-related response to aromatase deficiency in bone, Biochem. Biophys. Res. Commun. 280 (2001) 1062–1068. [70] M.E.E. Jones, K.J. McInnes, W.C. Boon, E.R. Simpson, Estrogen and adiposity—utilizing models of aromatase deficiency to explore the relationship, J. Steroid Biochem. Mol. Biol. 106 (2007) 3–7. [71] L. Vico, J.M. Vanacker, Sex hormones and their receptors in bone homeostasis: insights from genetically modified mouse models, Osteoporos. Int. 21 (2010) 365–372. [72] C. Matsumoto, M. Inada, K. Toda, C. Miyaura, Estrogen and androgen play distinct roles in bone turnover in male mice before and after reaching sexual maturity, Bone 38 (2006) 220–226.

158

GENNARI ET AL.

[73] D. Vanderschueren, E. Van Herck, R. De Coster, R. Bouillon, Aromatization of androgens is important for skeletal maintenance of aged male rats, Calcif. Tissue Int. 59 (1996) 179–183. [74] D. Vanderschueren, E. van Herck, J. Nijs, A.G. Ederveen, R. De Coster, R. Bouillon, Aromatase inhibition impairs skeletal modeling and decreases bone mineral density in growing male rats, Endocrinology 138 (1997) 2301–2307. [75] D. Vanderschueren, S. Boonen, A.G.H. Ederveen, et al., Skeletal effects of estrogen deficiency induced by an aromatase inhibitor in an aged male rat model, Bone 27 (2000) 611–617. [76] K. Venken, K. De Gendt, S. Boonen, et al., Relative impact of androgen and estrogen receptor activation in the effects of androgens on trabecular and cortical bone in growing male mice: a study in the androgen receptor knockout mouse model, J. Bone Miner. Res. 21 (2006) 576–585. [77] C.W. Slemenda, C. Longcope, L. Zhou, S.L. Hui, M. Peacock, C.C. Johnston, Sex steroids and bone mass in older men: positive associations with serum estrogens and negative associations with androgens, J. Clin. Invest. 100 (1997) 1755–1759. [78] G.A. Greendale, S. Edelstein, E. Barrett-Connor, Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo study, J. Bone Miner. Res. 12 (1997) 1833–1843. [79] S. Khosla, L.J. Melton III, E.J. Atkinson, W.M. O’Fallon, G.G. Klee, B.L. Riggs, Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen, J. Clin. Endocrinol. Metab. 83 (1998) 2266–2274. [80] B. Ongphiphadhanakul, R. Rajatanavin, S. Chanprasertyothin, N. Piaseu, L. Chailurkit, Serum oestradiol and oestrogen-receptor gene polymorphism are associated with bone mineral density independently of serum testosterone in normal males, Clin. Endocrinol. (Oxford) 49 (1998) 803–809. [81] J.R. Center, T.V. Nguyen, P.N. Sambrook, J.A. Eisman, Hormonal and biochemical parameters in the determination of osteoporosis in elderly men, J. Clin. Endocrinol. Metab. 84 (1999) 3626–3635. [82] S. Amin, Y. Zhang, C.T. Sawin, et al., Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham Study, Ann. Intern. Med. 133 (2000) 951–963. [83] E. Barrett-Connor, J.E. Mueller, D.G. von Muhlen, G.A. Laughlin, D.L. Schneider, D.J. Sartoris, Low levels of estradiol are associated with vertebral fractures in older men, but not women: the Rancho Bernardo Study, J. Clin. Endocrinol. Metab. 85 (2000) 219–223. [84] P. Szulc, B. Munoz, B. Claustrat, et al., Bioavailable estradiol may be an important determinant of osteoporosis in men. The MINOS study, J. Clin. Endocrinol. Metab. 86 (2001) 192–199. [85] S. Khosla, L.J. Melton III, E.J. Atkinson, W.M. O’Fallon, Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men, J. Clin. Endocrinol. Metab. 86 (2001) 3555–3561. [86] L. Gennari, D. Merlotti, G. Martini, et al., Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men, J. Clin. Endocrinol. Metab. 88 (2003) 5327–5333. [87] P. Taxel, L.G. Raisz, The effect of estrogen therapy on older men with low bone mass, J. Bone Miner. Res. 12 (1997) S353.

AROMATASE ACTIVITY AND BONE LOSS

159

[88] F.H. Anderson, R.M. Francis, R.T. Peaston, H.J. Wastell, Androgen supplementation in eugonadal men with osteoporosis: effects of six months’ treatment on markers of bone formation and resorption, J. Bone Miner. Res. 12 (1997) 472–478. [89] A. Falahati-Nini, B.L. Riggs, E.J. Atkinson, W.M. O’Fallon, R. Eastell, S. Khosla, Relative contributions of testosterone versus estrogen in regulating bone resorption and formation in normal elderly men, J. Clin. Invest. 106 (2000) 1553–1560. [90] J.B. Lian, G.S. Stein, E. Canalis, P. Gehron Robey, A.L. Boskey, Bone formation: osteoblast lineage cells, growth factors, matrix proteins, and the mineralization process, in: M.F. Favus (Ed.), Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, fourth ed., Lippincott Williams & Wilkins, Philadelphia, 1999, pp. 14–38. [91] S.C. Manolagas, Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis, Endocr. Rev. 21 (2000) 115–137. [92] E. Orwoll, Gender differences in the skeleton: osteoporosis, J. Women’s Health 4 (1995) 429–431. [93] B.Z. Leder, K.M. LeBlanc, D.A. Schoenfeld, R. Eastell, J.S. Finkelstein, Differential effects of androgens and estrogens on bone turnover in normal men, J. Clin. Endocrinol. Metab. 88 (2003) 204–210. [94] J.J. Stepan, M. Lachman, J. Zverina, V. Pacovsky, D.J. Baylink, Castrated men exhibit bone loss. Effect of calcitonin treatment on biochemical indeces of bone remodeling, J. Clin. Endocrinol. Metab. 69 (1989) 523–527. [95] P. Taxel, D.G. Kennedy, P.M. Fall, A.K. Willard, J.M. Clive, L.G. Raisz, The effect of aromatase inhibition on sex steroids, gonadotropins, and markers of bone turnover in older men, J. Clin. Endocrinol. Metab. 86 (2001) 2869–2874. [96] B.Z. Leder, J.S. Finkelstein, Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men, Osteoporos. Int. 16 (2005) 1487–1494. [97] S.M. Burnett-Bowie, K.C. Roupenian, M.E. Dere, H. Lee, B.Z. Leder, Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial, Clin. Endocrinol. Oxf. 70 (2009) 116–123. [98] S.A. Burnett-Bowie, E.A. McKay, H. Lee, B.Z. Leder, Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels, J. Clin. Endocrinol. Metab. 94 (2009) 4785–4792. [99] S. Wickman, E. Kajantie, L. Dunkel, Effects of suppression of estrogen action by the P450 aromatase inhibitor letrozole on bone mineral density and bone turnover in pubertal boys, J. Clin. Endocrinol. Metab. 88 (2003) 3785–3793. [100] H.S. Rugo, The breast cancer continuum in hormone-receptor positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors, Ann. Oncol. 19 (2008) 16–27. [101] R. Riemsma, C.A. Forbes, A. Kessels, K. Lykopoulos, M.M. Amonkar, D.W. Rea, et al., Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer, Breast Cancer Res. Treat. 123 (1) (2010) 9–24 , Epub Jun 10, 2010. [102] N.J. Bundred, Aromatase inhibitors and bone health, Curr. Opin. Obstet. Gynecol. 21 (1) (2009 Feb) 60–67. [103] S. Pant, C.L. Shapiro, Aromatase inhibitor-associated bone loss: clinical considerations, Drugs 68 (2008) 2591–2600. [104] H.M. Heshmati, S. Khosla, S.P. Robins, W.M. O’Fallon, L.J. Melton 3rd, B.L. Riggs, Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women, J. Bone Miner. Res. 17 (2002) 172–178.

160

GENNARI ET AL.

[105] R. Ponzone, P. Mininanni, E. Cassina, F. Pastorino, P. Sismondi, Aromatase inhibitors for breast cancer: different structures, same effects? Endocr. Relat. Cancer 15 (2008) 27–36. [106] A. Howell, J. Cuzick, M. Baum, et al., Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer, Lancet 365 (2005) 60–62. [107] R. Eastell, J.E. Adams, R.E. Coleman, et al., Effect of anastrozole on bone mineral density: 5-year results from the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230, J. Clin. Oncol. 26 (2008) 1051–1057. [108] A.S. Coates, A. Keshaviah, B. Thurlimann, et al., Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrineresponsive early breast cancer: update of study BIG 1-98, J. Clin. Oncol. 25 (2007) 486–492. [109] M. Ghazi, C. Roux, Hormonal deprivation therapy-induced osteoporosis in postmenopausal women with breast cancer, Best Pract. Res. Clin. Rheumatol. 23 (2009) 805–811. [110] P.E. Goss, J.N. Ingle, S. Martino, et al., A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer, N. Engl. J. Med. 349 (2003) 1793–1802. [111] E.A. Perez, R.G. Josse, K.I. Pritchard, et al., Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA. 17, J. Clin. Oncol. 24 (2006) 3629–3635. [112] P.E. Lønning, J. Geisler, L.E. Krag, et al., Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer, J. Clin. Oncol. 23 (2005) 5126–5137. [113] R.C. Coombes, E. Hall, L.J. Gibson, et al., A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer, N. Engl. J. Med. 350 (2004) 1081–1092. [114] R.E. Coleman, L.M. Banks, S.I. Girgis, et al., Skeletal effects of exemestane on bonemineral density, bone, biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study, Lancet Oncol. 8 (2007) 119–127. [115] P. Hadji, Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis, Crit. Rev. Oncol. Hematol. 69 (2009) 73–82. [116] B.E. Hillner, J.N. Ingle, R.T. Chlebowski, et al., American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer, J. Clin. Oncol. 21 (2003) 4042–4057. [117] D.M. Reid, Prevention of osteoporosis after breast cancer, Maturitas 64 (2009) 4–8. [118] S. Rozenberg, B. Carly, F. Liebens, C. Antoine, Risks of osteoporosis associated with breast cancer treatment: the need to access to preventive treatment, Maturitas 64 (2009) 1–3. [119] S.E. Bulun, Z. Lin, H. Zhao, et al., Regulation of aromatase expression in breast cancer tissue, Ann. NY Acad. Sci. 1155 (2009) 121–131. [120] S. Hiscox, P. Barrett-Lee, A.C. Borley, R.I. Nicholson, Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss, Eur. J. Cancer 46 (2010) 2187–2195. [121] A.V. Krishnan, S. Swami, L. Peng, J. Wang, J. Moreno, D. Feldman, Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy, Endocrinology 151 (2010) 32–42.

AROMATASE ACTIVITY AND BONE LOSS

161

[122] C.A. Stratakis, A. Vottero, A. Brodie, et al., The aromatase excess syndrome is associated with feminization of both sexes and autosomal dominant transmission of aberrant P450 aromatase gene transcription, J. Clin. Endocrinol. Metab. 83 (1998) 1348–1357. [123] M. Shozu, S. Sebastian, K. Takayama, et al., Estrogen excess associated with novel gainof-function mutations affecting the aromatase gene, N. Engl. J. Med. 348 (2003) 1855–1865. [124] M. Demura, R.M. Martin, M. Shozu, et al., Regional rearrangements in chromosome 15q21 cause formation of cryptic promoters for the CYP19 (aromatase) gene, Hum. Mol. Genet. 16 (2007) 2529–2541. [125] R.M. Martin, C.J. Lin, M.Y. Nishi, et al., Familial hyperestrogenism in both sexes: clinical, hormonal, and molecular studies of two siblings, J. Clin. Endocrinol. Metab. 88 (2003) 3027–3034. [126] Z. Peng, X. Li, S. Makela, H.K. Vaananen, M. Poutanen, Skeletal changes in transgenic male mice expressing human cytochrome p450 aromatase, J. Bone Miner. Res. 19 (2004) 1320–1328. [127] K. Sjogren, M. Lagerquist, S. Moverare-Skrtic, et al., Elevated aromatase expression in osteoblasts leads to increased bone mass without systemic adverse effects, J. Bone Miner. Res. 24 (2009) 1263–1270. [128] P.M. Doran, B.L. Riggs, E.J. Atkinson, S. Khosla, Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men, J. Bone Miner. Res. 16 (2001) 2118–2125. [129] S. Khosla, L.J. Melton III, R.A. Robb, et al., Relationship of volumetric BMD and structural parameters at different skeletal sites to sex steroid levels in men, J. Bone Miner. Res. 20 (2005) 730–740. [130] S. Khosla, B.L. Riggs, R.A. Robb, et al., Relationship of volumetric bone density and structural parameters at different skeletal sites to sex steroid levels in women, J. Clin. Endocrinol. Metab. 90 (2005) 5096–5103. [131] D. Mellstro¨m, L. Vandenput, H. Mallmin, et al., Older men with low serum estradiol and high serum SHBG have an increased risk of fractures, J. Bone Miner. Res. 23 (2008) 1552–1560. [132] E. Simpson, G. Rubin, C. Clyne, et al., The role of local estrogen biosynthesis in males and females, Trends Endocrinol. Metab. 11 (2000) 184–188. [133] F. Labrie, A. Belanger, V. Luu-The, et al., DHEA and the intracrine formation of androgens and estrogens in peripheral target tissue: its role during aging, Steroids 63 (1998) 322–328. [134] N. Siegelmann-Danieli, K.H. Buetow, Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk, Br. J. Cancer 79 (1999) 456–463. [135] V.N. Kristensen, N. Harada, N. Yoshimura, et al., Genetic variants of cyp19 (aromatase) and breast cancer, Oncogene 19 (2000) 1329–1333. [136] L. Masi, L. Becherini, L. Gennari, et al., Polymorphism of the aromatase gene in postmenopausal Italian women: distribution and correlation with bone mass and fracture risk, J. Clin. Endocrinol. Metab. 86 (2001) 2263–2269. [137] I. Van Pottelbergh, S. Goemaere, J.M. Kaufman, Bioavailable estradiol and aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age, J. Clin. Endocrinol. Metab. 88 (2003) 3075–3081. [138] L. Gennari, L. Masi, D. Merlotti, et al., A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism, J. Clin. Endocrinol. Metab. 89 (2004) 2803–2810.

162

GENNARI ET AL.

[139] J. Somner, S. McLellan, J. Cheung, et al., Polymorphisms in the P450 c17 (17-hydroxylase/ 17, 20-lyase) and P450 c19 (aromatase) genes: association with serum sex steroid concentrations and bone mineral density in postmenopausal women, J. Clin. Endocrinol. Metab. 89 (2004) 344–351. [140] H. Ahsan, A.S. Whittemore, Y. Chen, et al., Variants in estrogen-biosynthesis genes CYP17 and CYP19 and breast cancer risk: a family-based genetic association study, Breast Cancer Res. 7 (2005) R71–R81. [141] J.A. Riancho, Polymorphisms in the CYP19 gene that influence bone mineral density, Pharmacogenomics 8 (2007) 339–352. [142] K.E. Talbott, M.D. Gammon, M.G. Kibriya, et al., A CYP19 (aromatase) polymorphism is associated with increased premenopausal breast cancer risk, Breast Cancer Res. Treat. 111 (2008) 481–487. [143] H.P. Yang, J. Gonzalez Bosquet, Q. Li, et al., Common genetic variation in the sex hormone metabolic pathway and endometrial cancer risk: pathway-based evaluation of candidate genes, Carcinogenesis 31 (2010) 827–833. [144] A.L. Eriksson, M. Lorentzon, L. Vandenput, et al., Genetic variations in sex steroidrelated genes as predictors of serum estrogen levels in men, J. Clin. Endocrinol. Metab. 94 (2009) 1033–1041. [145] V.W. Setiawan, J.A. Doherty, X.O. Shu, et al., Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium, Cancer Epidemiol. Biomarkers Prev. 18 (2009) 242–247. [146] K.L. Limer, S.R. Pye, W. Thomson, et al., Genetic variation in sex hormone genes influences heel ultrasound parameters in middle-aged and elderly men: results from the European Male Aging Study (EMAS), J. Bone Miner. Res. 24 (2009) 314–323. [147] R.C. Travis, F. Schumacher, J.N. Hirschhorn, et al., CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the Breast and Prostate Cancer Cohort Consortium, Cancer Epidemiol. Biomarkers Prev. 18 (2009) 2734–2744. [148] X. Ma, X. Qi, C. Chen, et al., Association between CYP19 polymorphisms and breast cancer risk: results from 10, 592 cases and 11, 720 controls, Breast Cancer Res. Treat. 122 (2010) 495–501. [149] T. Remes, S.B. Vaisanen, A. Mahonen, et al., Aerobic exercise and bone mineral density in middle-aged Finnish men: a controlled randomized trial with reference to androgen receptor, aromatase, and estrogen receptor a gene polymorphisms, Bone 32 (2003) 412–420. [150] M. Lorentzon, C. Swanson, A.L. Eriksson, D. Mellstro¨m, C. Ohlsson, Polymorphisms in the aromatase gene predict areal BMD as a result of affected cortical bone size: the GOOD study, J. Bone Miner. Res. 21 (2006) 332–339. [151] J.A. Riancho, C. San˜udo, C. Valero, et al., Association of the aromatase gene alleles with BMD: epidemiological and functional evidence, J. Bone Miner. Res. 24 (2009) 1709–1718. [152] S. Yang, Z. Fang, T. Suzuki, et al., Regulation of aromatase P450 expression in endometriotic and endometrial stromal cells by CCAAT/enhancer binding proteins (C/EBPs): decreased C/EBPbeta in endometriosis is associated with overexpression of aromatase, J. Clin. Endocrinol. Metab. 87 (2002) 2336–2345. [153] H. Ishikawa, V. Fencki, E.E. Marsh, et al., CCAAT/enhancer binding protein beta regulates aromatase expression via multiple and novel cis-regulatory sequences in uterine leiomyoma, J. Clin. Endocrinol. Metab. 93 (2008) 981–991. [154] M. Demura, S.E. Bulun, CpG dinucleotide methylation of the CYP19 I.3/II promoter modulates cAMP-stimulated aromatase activity, Mol. Cell. Endocrinol. 283 (2008) 127–132.

AROMATASE ACTIVITY AND BONE LOSS

163

[155] T. Yanase, Y.M. Mu, Y. Nishi, et al., Regulation of aromatase by nuclear receptors, J. Steroid Biochem. Mol. Biol. 79 (2001) 187–192. [156] Y.M. Mu, T. Yanase, Y. Nishi, R. Takayanagi, K. Goto, H. Nawata, Combined treatment with specific ligands for PPARgamma:RXR nuclear receptor system markedly inhibits the expression of cytochrome P450arom in human granulosa cancer cells, Mol. Cell. Endocrinol. 181 (2001) 239–248. [157] Y.M. Mu, T. Yanase, Y. Nishi, et al., Insulin sensitizer, troglitazone, directly inhibits aromatase activity in human ovarian granulosa cells, Biochem. Biophys. Res. Commun. 271 (2000) 710–713. [158] T. Lovekamp-Swan, A.M. Jetten, B.J. Davis, Dual activation of PPARalpha and PPARgamma by mono-(2-ethylhexyl) phthalate in rat ovarian granulosa cells, Mol. Cell. Endocrinol. 201 (2003) 133–141. [159] K. Toda, T. Okada, C. Miyaura, T. Saibara, Fenofibrate, a ligand for PPARg, inhibits aromatase cytocrome P450 expression in the ovary of mouse, J. Lipid Res. 44 (2003) 265–270. [160] C. Gasnier, C. Dumont, N. Benachour, E. Clair, M.C. Chagnon, G.E. Se´ralini, Glyphosate-based herbicides are toxic and endocrine disruptors in human cell lines, Toxicology 262 (2009) 184–191. [161] R.E. Harris, G.A. Alshafie, H. Abou-Issa, K. Seibert, Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor, Cancer Res. 60 (2000) 2101–2103. [162] H.M. Abou-Issa, G.A. Alshafie, K. Seibert, A.T. Koki, J.L. Masferrer, R.E. Harris, Doseresponse effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis, Anticancer Res. 21 (2001) 3425–3432. [163] L. Raisz, Physiologic and pathologic roles of prostaglandins and other eicosanoids in bone metabolism, J. Nutr. 125 (1995) 2024S–2027S. [164] L. Carbone, F.A. Tylavsky, J.A. Cauley, et al., Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity, J. Bone Miner. Res. 18 (2003) 1795–1802. [165] E.T. Eng, J.J. Ye, D. Williams, et al., Suppression of estrogen biosynthesis by procyanidin dimers in red wine and grape seeds, Cancer Res. 63 (2003) 8516–8522. [166] I.L. Doering, E. Richter, Inhibition of human aromatase by myosmine, Drug Metab. Lett. 3 (2009) 83–86. [167] R. Takayanagi, K. Goto, S. Suzuki, S. Tanaka, S. Shimoda, H. Nawata, Dehydroepiandrosterone (DHEA) as a possible source for estrogen formation in bone cells: correlation between bone mineral density and serum DHEA-sulfate concentration in postmenopausal women, and the presence of aromatase to be enhanced by 1,25-dihydroxyvitamin D3 in human osteoblasts., Mech. Ageing Dev. 123 (2002) 1107–1114. [168] S. Tanaka, M. Haji, R. Takayanagi, H. Nawata, 1,25-Dihydroxyvitamin D3 enhances the enzymatic activity and expression of the messenger ribonucleic acid for aromatase cytochrome P450 synergistically with dexamethasone depending on the vitamin D receptor level in cultured human osteoblasts, Endocrinology 137 (1996) 1860–1869. [169] K. Kinuta, H. Tanaka, T. Moriwake, K. Aya, S. Kato, Y. Seino, Vitamin D is an important factor in estrogen biosynthesis of both female and male gonads, Endocrinology 141 (2000) 1317–1324. [170] S.E. Bulun, L.S. Noble, K. Takayama, et al., Endocrine disorders associated with inappropriately high aromatase expression, J. Steroid Biochem. Mol. Biol. 61 (1997) 133–139. [171] J. Young, S.E. Bulun, V. Agarwal, et al., Aromatase expression in a feminizing adrenocortical tumor, J. Clin. Endocrinol. Metab. 81 (1996) 3173–3176. [172] P. Aiginger, H. Kolbe, J. Kuhbock, J. Spona, G. Geyer, The endocrinology of testicular germinal cell tumors, Acta Endocrinol. 97 (1981) 419–426.

164

GENNARI ET AL.

[173] G.G. Gordon, J. Olivo, F. Rafil, A.L. Southren, Conversion of androgens to estrogens in cirrhosis of the liver, J. Clin. Endocrinol. Metab. 40 (1975) 1018–1026. [174] C. Longcope, J.H. Pratt, E. Finenberg, Oestrogen and androgen dynamics in liver disease, J. Endocrinol. Invest. 7 (1984) 629–634. [175] N. Figura, L. Gennari, D. Merlotti, et al., Helicobacter pylori infection in male patients with osteoporosis and controls, Dig. Dis. Sci. 50 (2005) 847–852. [176] T. Ueyama, N. Shirasawa, M. Numazawa, et al., Gastric parietal cells: potent endocrine role in secreting estrogen as a possible regulator of gastro-hepatic axis, Endocrinology 143 (2002) 3162–3170. [177] N. Burul-Bozkurt, C. Pekiner, P. Kelicen, Diabetes alters aromatase enzyme levels in gonadal tissues of rats, Naunyn Schmiedebergs Arch. Pharmacol. 382 (2010) 33–41. [178] A. Prabhu, Q. Xu, M.B. Manigrasso, et al., Expression of aromatase, androgen and estrogen receptors in peripheral target tissues in diabetes, Steroids 75 (2010) 779–787. [179] K.A. Brown, N.I. Hunger, M. Docanto, E.R. Simpson, Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase, Breast Cancer Res. Treat. 123 (2010) 591–596. [180] S. Rice, L. Pellatt, K. Ramanathan, S.A. Whitehead, H.D. Mason, Metformin inhibits aromatase via an extracellular signal-regulated kinase-mediated pathway, Endocrinology 150 (2009) 4794–4801.

ADVANCES IN CLINICAL CHEMISTRY, VOL. 54

BIOCHEMISTRY OF ADOLESCENT IDIOPATHIC SCOLIOSIS Giovanni Lombardi,* Marie-Yvonne Akoume,†,‡ Alessandra Colombini,* Alain Moreau,†,‡,} and Giuseppe Banfi*,1 *IRCCS Istituto Ortopedico Galeazzi, Milano, Italy † Viscogliosi Laboratory in Molecular Genetics of Musculoskeletal Diseases, Sainte-Justine University Hospital ´ al, Quebec, Canada Research Center, Montre ‡ Department of Biochemistry, Faculty of Medicine, ´ de Montre ´ al, Montre ´ al, Quebec, Canada Universite } Department of Stomatology, Faculty of Dentistry, ´ de Montre ´ al, Montre ´ al, Quebec, Canada Universite

1. 2. 3. 4. 5. 6. 7.

Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Bone Biochemical Parameters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hormones . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Trace Elements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hematological Parameters—Platelets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Melatonin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7.1. Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7.2. Melatonin Receptors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7.3. Interaction with Calcium Metabolism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7.4. Role of Melatonin in Pathogenesis of Scoliosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1

165 166 168 168 171 171 172 172 173 175 176 178 179

Corresponding author: Giuseppe Banfi, e-mail: [email protected] 165

0065-2423/11 $35.00 DOI: 10.1016/B978-0-12-387025-4.00007-8

Copyright 2011, Elsevier Inc. All rights reserved.

166

LOMBARDI ET AL.

1. Abstract This chapter reviews the biochemical, hormonal, and hematological factors in the onset and development of adolescent idiopathic scoliosis (AIS), an orthopedic entity of unknown etiology. Briefly, AIS is defined as a lateral curvature of the spine combined with vertebral rotation that occurs in patients of 10 years of age or older until bone maturity (18–20 years of age). AIS is predominant in females. If untreated, the curvature could evolve with negative long-term prognosis including psychosocial impact, back pain, pulmonary compromise, cor pulmonale, and even death due to respiratory failure. Causes of the disease have been postulated to involve genetics, abnormal muscle, connective tissue and bone structures, and neuroendocrine disorders. Psychological pathways have also been studied. Little data, however, have been collected on bone turnover in these patients. Some studies demonstrated decreased bone mineral density which may be suggestive of increased osteoblast activity. Other studies suggested a correlation to abnormal platelet morphology. Alterations in the spinal muscle contractile function may be responsible for spinal curvature. Measurement of trace elements in serum revealed impaired zinc and selenium metabolism, probably secondary to hormonal deregulation. Subsequent endocrine studies suggested a role for leptin and growth hormone in AIS. Recently, a neuroendocrine hypothesis has been proposed. This theory involves a unique melatonin-signaling dysfunction and opens new frontiers in the elucidation of the pathologic mechanisms for onset and progression of this disease.

2. Introduction Scoliosis is a three-dimensional deformity of the spine where lateral curvature may be combined with vertebral rotation. Throughout the eighteenth and nineteenth centuries, scoliosis was believed to be caused by postural positioning of the body. In addition, idiopathic scoliosis has historically been attributed to a wide variety of conditions ranging from poor posture to poor nutrition [1]. The Scoliosis Research Society (SRS) defined AIS as occurring in patients of 10 years of age or older, up until bone maturity at 18–20 years of age. This condition is distinct from the infantile, under 3 years of age, and juvenile, 3– 10 years of age spinal disorders. AIS is defined by a curvature of at least 10 as measured using the Cobb technique and vertebral rotation on a standing

BIOCHEMISTRY OF ADOLESCENT IDIOPATHIC SCOLIOSIS

167

longitudinal radiograph of the spine combined with asymmetry on forward bending. The Cobb angle is defined as the angle formed by the intersection point of the perpendiculars of the parallel lines to the upper and lower plate of the curve-limiting vertebrae. The estimated worldwide prevalence of the disease is 0.5–3.0% with an incidence of 1–3% in adolescents, predominantly females [2,3]. As such, AIS represents an important pathologic entity with high clinical management costs and significant lifestyle psychosocial impact. Approximately 15–20% of spinal curvatures are attributable to developmental/genetic causes, neuromuscular, or metabolic disorders [4]. The remaining cases are deemed idiopathic. Although a small percentage of these cases are attributed to familial causes, the majority (85%) of these remain sporadic [5]. Spinal curvature is frequently recognized during a growth spurt, but varies in vertebral location and clinical impact. For example, thoracic curvatures are more prone to progression than lumbar or thoracolumbar scoliosis. Early onset of curvature is associated with poor prognosis [6]. If untreated, the curvature evolves with negative long-term prognosis, including psychosocial effects, back pain, pulmonary compromise, cor pulmonale, and even death due to respiratory failure [7]. Curve progression is the most important factor in the natural history of AIS. The risk of curve progression appears to predict spinal growth potential. Patients with skeletal immaturity and major curvature are at high risk for progression and warrant immediate treatment [3]. Although the clinical manifestations of scoliosis have been well described, the etiology of AIS, the most common form of scoliosis, continues to elude investigators. Various hypotheses have been postulated for defining the source of the disease. Genetic, neuroendocrine, muscle, connective tissue, and bone structure abnormalities have been suggested. Psychological pathways have also been studied and proposed as possible causes of scoliosis. Biochemical variations have been described and could be linked to the pathogenesis and evolution of this disease. The biochemistry of this disease is particularly important for evaluating the mechanisms of signaling dysfunction which appears to have a crucial role in clinical manifestation and for the development of potential diagnostic and prognostic tools. To date, diagnosis remains based on radiographic evaluation of the vertebral column. The lack of good prognostic indicators typically leads to therapies based on physician experience or diagnostic symptoms. This review summarizes biochemical, hormonal, and hematological parameters in AIS.

168

LOMBARDI ET AL.

3. Bone Biochemical Parameters Surprisingly, bone biochemical parameters have not been well studied in scoliosis. A study published 30 years ago investigated a variety of serum analytes in this disease [8]. This report found that calcium, phosphate, alkaline phosphatase (ALP), calcitonin, and parathyroid hormone (PTH) were not significantly different in scoliotic patients. A recent study compared a wide cohort of Asiatic AIS females (11–16 years of age) with 300 age-matched healthy females [9]. This study evaluated bone formation by measurement of serum bone-specific ALP and bone resorption by measurement of urine deoxypyridinoline. No differences were reported in the group of 12-years-old children. In AIS children aged 13 years and older, a significant difference was found for bone-specific ALP. The median concentration of bone-specific ALP was substantially increased in the 13-years group in AIS subjects versus healthy females (158 vs. 112 U/L). Bone-specific ALP was also increased in AIS in the 14-years (110 vs. 84 U/L) and 15-to-16-years groups (80 vs. 61.2 U/L) versus healthy females. Bone-specific ALP values were lower in absolute values as expected with decreased growth rate. Interestingly, urine deoxypyridinoline was significantly different only in the 15- to 16-years groups with higher median values in healthy females (13.5 nmol/ mmol creatinine) versus AIS subjects (9.4 nmol/mmol creatinine). A strong inverse correlation was found between bone-specific ALP and bone mass in AIS females. This appeared to be due to calcium intake and lower bone mass as determined by dual energy radiograph absorptiometry. Bone formation seems to be stimulated in AIS patients, despite low bone mass density. Bone resorption is not modified at all until 15 years of age [9].

4. Hormones Scoliotic adolescents, especially females, are usually taller than nonaffected age-matched subjects. Although higher secretion of growth hormone (hGH) has been described in scoliotic females, provocative tests were inconclusive [10]. Fasting hGH morning levels and 24-h testing regimes were, however, more indicative of association between this hormone and AIS [8,11]. Interpretation of these data was based on altered sensitivity of the hGH release mechanism in scoliotic females [10]. A large study investigated five different polymorphisms of the hGH receptor in 510 scoliotic females and 363 controls [12]. The hGH receptor did not appear to be a predisposing or disease-modifier gene in AIS. Bioassay measurements have found that insulin-like growth factors are not changed in scoliotic patients [13].

BIOCHEMISTRY OF ADOLESCENT IDIOPATHIC SCOLIOSIS

169

An association between melatonin and hGH in scoliosis has been suggested [14], but appears limited to sporadic cases involving hGH therapy [15]. Sex hormones, namely estrogens, have a role in bone formation and promote increased ALP activity, collagen synthesis, and calcium deposition in the extracellular matrix. It has been demonstrated that estrogens are involved in the melatonin-signaling pathway in osteoblasts and exacerbate melatonin-signaling defects in AIS osteoblasts. Increased cAMP concentration, observed in a few scoliotic cases, was reduced in the presence of 17b-estradiol. This finding suggests a partial rescue of the signaling dysfunction that exists in this functional subgroup of scoliotic patients [16]. Although plasma estrogen concentration was initially found to be decreased in scoliotic females [17], this observation was not confirmed in subsequent studies [18,19]. A study of 174 scoliotic females revealed that mean estradiol levels were lower (50 pg/mL) versus age-matched (13–19 years) healthy controls (90 pg/mL). The same finding was also described for progesterone [20]. The influence of estrogens on AIS development is not concentration dependent, but appears to be associated with activity on their respective target cells [21]. The role of estrogens in AIS has been assumed due to the apparent association of age at menarche and scoliosis development. Late age of menarche, associated with null estrogen concentration, is associated with increased AIS prevalence [22]. Interestingly, the geographic latitude also matters, because sunlight exposure influences melatonin secretion, which can modify the sexual maturation and favor AIS development [23]. For example, low estrogen level predisposes young ballet dancers to scoliosis [22]. Estrogens appear to have a key role in regulating or triggering the melatonin-signaling dysfunction in AIS patients and activity of bone cells during bone remodeling. It is of particular interest that estrogens suppress cytokine IL-6, which induces osteoclast proliferation and bone resorption; a polymorphism of the IL-6 gene is associated with high risk of scoliosis [21,24]. Estrogen signaling is mediated by two receptors, ERa and ERb. These receptors belong to the nuclear receptor hormone superfamily which is widely expressed and present in osteoblasts. The CC genotype of the exon ØK of ERb is overrepresented in AIS patients [25]. It is also linked to curvature severity, suggesting that circulating estrogen concentration may impact different signaling pathways. In another study, four polymorphisms in exons encoding for the steroid-binding domain were identified [20]. Estradiol showed higher values with respect to peak height velocity in 24 females with AIS. The average peak was 10.5 1.8 cm/year at age 11.7 1 years. However, interindividual variability was high; very few high estradiol (> 100 pg/mL) values were obtained before the peak, but low values after the peak were nondiscriminatory. Other hormones

170

LOMBARDI ET AL.

such as dehydroepiandrosterone (DHEA) and osteocalcin were nondiscriminatory, whereas insulin growth factor 1 (IGF-1) was discriminatory, increasing 6 months before and continuing to do so until 12 months after the peak [26]. Only two contradictory studies reported androgen levels in scoliotic females. Testosterone concentration in 27 AIS patients was found to be higher than those in seven age-matched controls, whereas estradiol was not significantly different [19]. Interestingly, testosterone values in 174 AIS females aged 13–19 years were significantly lower than those measured in 104 healthy controls [20]. It should be noted that the controls demonstrated a high average testosterone value (4 ng/mL) for females. A recent hypothesis involves hormones that regulate energy balance, particularly leptin. Hypothalamic hypersensitivity to circulating leptin could induce an asymmetry as an adverse response through the sympathetic nervous system and the hGH–insulin axis, which worsens the axial abnormality during bone growth [27]. A comparison between a group of 120 scoliotic Chinese females and 80 nonscoliotic individuals showed a marked decrease in serum leptin in morning fasted subjects and during the follicular phase of menstrual cycle, independent from age and menstrual status. Leptin concentration was associated with body mass and height, but not with curvature magnitude, and was inversely correlated with age at menarche. This finding is of interest because leptin is a neurohormone that regulates satiety and displays high circulating levels in obese subjects due to increased adipose tissue mass. Leptin binds membrane receptors having a single transmembrane domain that belong to type I cytokine receptors exhibiting tyrosine kinase activity. There are two leptin receptor forms: the long one (OB-Rb) expressed in skeletal muscles and the short form (OB-Ra). Canpolat et al. [28] demonstrated that exogenous administration of melatonin in rats led to decreased circulating leptin. This finding is further strengthened by the fact that circulating leptin is increased in pinealectomized rats. As such, the melatonin deficiency hypothesis proposed by Machida and others cannot explain why circulating leptin is lower in AIS. However, Alonso-Vale et al. [29,30] demonstrated that increased cytosolic cAMP strongly inhibited leptin synthesis, which can be prevented by melatoninsignaling activity via interaction with MT1 receptors. This result provides insight into the role of melatonin-signaling dysfunction and could explain the diminution of circulating levels typically observed in AIS. Reduced leptin concentration could influence lower bone mass typically seen in AIS females [31]. The role of leptin could also be important in the genesis of scoliosis due to its critical role in bone formation and remodeling [32].

BIOCHEMISTRY OF ADOLESCENT IDIOPATHIC SCOLIOSIS

171

5. Trace Elements Some research on the etiology of AIS has focused on trace elements. In 1980, a study described increased copper concentration in hair obtained from scoliotic patients [33]. High levels of copper in hair were also found in a subsequent study [34]. Interestingly, this report also found high hair zinc concentration, but low selenium concentration. Additional studies reported decreased blood selenium concentration in AIS, but no significant difference in zinc and copper concentrations [35]. In a separate study, zinc concentration in hair and serum in AIS subjects was similar to controls, but the back muscles of surgically treated scoliotic subjects were found to contain decreased zinc [36]. It is noteworthy that pinealectomized chickens show decreased serum zinc concentration versus control animals. It is likely that melatonin affects zinc metabolism, regulating mineral absorption in the gut [37]. The possible link between trace elements and axial skeleton disease is likely due to their seminal role in connective tissue metabolism. For example, copper is a coenzyme of lysyl oxidase, an enzyme involved in the synthesis and maturation of collagen. Variation in trace element concentrations could be linked to endocrine dysfunction, for example, increased hair copper and zinc concentration in hGH deficiency. Finally, trace elements are crucial to ensure optimal antioxidant enzyme function including superoxide dismutase and glutathione peroxidase. Both are regulated by melatonin.

6. Hematological Parameters—Platelets Because platelets and muscle have a similar actin:myosin contractile apparatus, they may share common abnormalities in AIS. In fact, a number of platelet abnormalities have been described including increased intracellular calcium and phosphorus and abnormal peptide structure of myosin chains [38], decreased activity of intracellular contractile proteins [39], decreased platelet aggregation [40], and increased intracellular dense bodies [41]. Poor aggregation and impairment of the contractile properties suggested a calcium transport defect related to membrane and contractile protein metabolism in scoliotic subjects [41]. Researchers have clearly demonstrated defective platelet maturation in AIS. Altered expression level of different Ca2þ ATPases (PMCA and SERCA) has been demonstrated in AIS patients [42]. Interestingly, AIS patients with low SERCA3a and high PMCA4b levels exhibited a right thoracic curvature, while a second group expressing high SERCA3a and PMCA4b levels exhibited a thoracolumbar curvature. Although these

172

LOMBARDI ET AL.

reports strongly associate defective megakaryocyte differentiation in AIS patients, they appear contradictory with a previous study that reported no morphologic or functional platelet abnormalities [43]. Irrespective of these findings, it is unlikely that these functional platelet characteristics can be used clinically for diagnostic or prognostic purposes in AIS. Calmodulin, a calcium-binding receptor protein, is a regulator of various enzymatic systems and intracellular calcium function [44]. It regulates the contractile apparatus of platelets and muscles via interaction of ionized calcium with actin and myosin. Platelet calmodulin concentration is increased in AIS. Increased calmodulin appears associated with disease progression and ultimately to therapeutic intervention via brace stabilization or vertebral fusion. Conversely, the calmodulin levels in stable nonprogressive and control groups were very similar [45]. Although platelet calmodulin levels were higher in those individuals with curvatures exceeding 30 and those with double major curves, this difference was not statistically significant. A recent report, however, did not find differences in platelet calmodulin concentration in 20 scoliotic adolescents. Analysis of intracellular calmodulin concentration in paravertebral muscles did not show differences between patients and controls, whereas comparison between left and right sides in AIS patients displayed higher levels on the convex side [46]. With respect to hematologic parameters, increased hemoglobin (Hgb) concentration was found in 23.2% of patients with early onset scoliosis (n ¼ 138). However, high Hgb concentration and hematocrit were secondary to hypoxemia due to thoracic deformation [47].

7. Melatonin 7.1. BACKGROUND Most biochemical evidence in AIS is linked to melatonin metabolism and its influence on bone formation and resorption. Melatonin (N-acetyl-5-methoxytryptamine) is produced by the pineal gland. Tryptophan is first converted by tryptophan hydroxylase to 5-hydroxytryptophan, which is decarboxylated to serotonin. The synthesis of melatonin is catalyzed by two enzymes (arylalkylamine N-acetyltransferase and hydroxyindole-O-methyltransferase) located in the pineal gland. It is known that the synthesis and release of melatonin are both stimulated by darkness and inhibited by light. The sympathetic nervous system transmits light exposure information from the retinal photoreceptors to the pineal gland. When darkness occurs, the release of norepinephrine from retinal receptors

BIOCHEMISTRY OF ADOLESCENT IDIOPATHIC SCOLIOSIS

173

upregulates pinealocyte a1 and b1 adrenergic receptors. Some diseases interrupt the typical circadian rhythm, inducing low melatonin concentration during daylight. These include Turner and Klinefelter syndromes, Cushing’s disease, psoriasis, and sarcoidosis [48].

7.2. MELATONIN RECEPTORS There are two types of melatonin receptors: ML1 (high affinity) and ML2 (low affinity). ML1 is a Gi-protein-coupled receptor that inhibits adenylate cyclase activity, through GTPase activity. The high density of ML1 receptors in the hypothalamus (suprachiasmatic nucleus) is responsible for the chronobiology of the nervous system [48]. There are two subtypes of ML1 receptor: MT1 and MT2. The roles of both these types of receptors are illustrated in Fig. 1. Melatonin in normal osteoblasts binds to MT2 receptors inhibiting cAMP production by adenylyl cyclases via coupling to G inhibitory (Gi) proteins. A common melatonin-signaling defect in all AIS patients allows their functional classification into three groups or endophenotypes. Interestingly, the same group showed that, in a minority of AIS patients (functional group 1), when melatonin binds to its receptor, it activates cAMP production through Gs protein activation, as a consequence of an affinity switch in G-protein subtypes. Exposure to 17b-estradiol decreases the coupling of Gs protein with MT2 receptor. Receptor phosphorylation enhances the coupling with Gi proteins. Thus, the control of the phosphorylation of the Gi a subunit is of importance in the regulation of biologic processes and could represent candidate molecules in AIS pathogenesis. The modulation of Gi proteins is of crucial importance. Among kinases and phosphatases which modulate this protein, the protein kinase C d (PKCd), a serine–threonine kinase, has a role in desensitization of the MT2 receptor. It induces the blocking of inhibition of adenylyl cyclase causing increased cAMP in the cell [49,50]. Phosphorylation of the serine residues of Gi a subunits at their N-terminus is well known to block formation of heterotrimers with Gb and Gg subunits, thus preventing inhibition of adenylyl cyclase activity in the presence of melatonin. The translocation of PKCd within the cell membrane involves specific interactions with the receptor for activated protein C kinase 1 (RACK1) which acts as a scaffold protein binding only the activated form of PKCd. Different patterns of interaction between melatonin, receptors, and regulator proteins were found in osteoblasts derived from scoliotic subjects. However, the signaling dysfunction could be considered a real pathogenic mechanism in the development of scoliotic symptoms.

LOMBARDI ET AL.

174 A

Mel

MT1

AC PI2P Gqα

Giβγ Giα

ATP

cAMP

PLC

PKA DAG + IP3

[Ca2+]i

CREB

P-CREB

B Mel

MT2

AC PI2P Gqα

Giβγ Giα

PLC

ATP

cAMP

GC

GTP

cGMP

PKA

DAG + IP3

PKC

[Ca2+]i

CREB

P-CREB

Protein kinase cascades FIG. 1. Melatonin-signaling cascade through ML1 receptor subtypes (MT1 and MT2). (A) The signaling cascade through MT1. Melatonin binding to MT1 receptor inhibits cAMP production by adenylyl cyclase (AC) through Gia protein activation, thus inhibiting the protein kinase A (PKA) and phospho-CREB signaling; moreover, it activates phospholipase C, through the Gibg subunits and the Gqa activation, which in turn induces the intracellular calcium concentration increase. (B) The signaling cascade through MT2. The binding of melatonin to this receptor subtype, other than the induction of the signaling reported for MT1, is also able to inhibit the activity of guanilate cyclase (GC) and thus reduce the cGMP cellular content.

BIOCHEMISTRY OF ADOLESCENT IDIOPATHIC SCOLIOSIS

175

7.3. INTERACTION WITH CALCIUM METABOLISM Melatonin biosynthesis is regulated by acetyltransferase expression and posttranslational control mechanisms via the changes in intracellular concentration of cAMP/calmodulin/Ca2þ following adrenergic stimulation [51]. Calmodulin is also a melatonin-binding protein of considerable regulatory significance. Its affinity to melatonin is sufficient for mediating effects at elevated physiological concentrations, and this binding is responsible for inhibition of calmodulin action. In particular, this interaction is specific to calcium-activated calmodulin and results in the inhibition of the CaM (calmodulin) kinase II. Moreover, melatonin binding to membrane receptors induces the activation of the bg complex of G proteins that stimulate PLCb and thus induces the activation of PKCa that in turn catalyzes production of phosphorylate calmodulin, perpetuating its inhibition. These interactions are important in inducing cytoskeleton rearrangements [51,52]. As reported above, calmodulin is a calcium-binding receptor protein that regulates cAMP-based enzyme systems, and thereby the contractile properties of muscle cells via cell membrane regulation of Ca2þ transport [53]. As such, melatonin may modulate diurnally many cellular functions involving calcium transport [52]. Melatonin modulates a specific cellular function through the kinetics of its binding to calmodulin [54]. Since calmodulin and melatonin exert a reciprocal antagonism in various tissues, and probably on skeletal muscle as well, it is reasonable to assume that the melatonin and calmodulin interplay could contribute to modulating paraspinal muscle tone and activity in AIS [48]. Because pineal deficiency modulates calcium-activated calmodulin, the spinal cord contractile proteins may be affected and neural cells may fail to grow in response to stretch. In addition, scavengers may not satisfactorily ‘‘mop-up’’ free radicals produced by stretch, causing cellular damage and inadequate cord growth. It has been proposed that asynchronous growth between the spinal cord and vertebrae (bone growth) could be part of the pathologic mechanism leading to scoliosis [55]. It has been demonstrated that administration of calmodulin antagonists, such as tamoxifen and trifluoperozine, mimicks the inhibitory effects of melatonin and can stop progression of this disease in mice [53]. Experiments conducted on bone-derived cell lines have proven that melatonin can increase expression of bone sialoprotein as well as several other essential bone marker proteins, including ALP, osteocalcin, and type I collagen. Melatonin stimulated both osteoblast differentiation and mineralization. In ovariectomized rats (a model of postmenopausal osteoporosis),

176

LOMBARDI ET AL.

the administration of physiologic melatonin doses with adequate estrogen or pharmacologic melatonin doses is required to increase bone mineral content and/or bone mineral density [56]. 7.4. ROLE OF MELATONIN IN PATHOGENESIS OF SCOLIOSIS The role of melatonin in scoliosis was first identified by experiments in chickens. Pinealectomy, performed in chickens shortly after they hatch, induced scoliosis [57–59]. Chickens, as bipedal animals, developed spinal disease with anatomic features similar to human AIS. It has been hypothesized that melatonin deficiency interferes with the normal symmetrical growth of the proprioceptive system involving the paraspinal muscles and the spine [60]. An asymmetric expression in bilateral paravertebral muscles of melatonin receptor MT2 mRNA in scoliotic patients was actually demonstrated, but it may merely be a secondary effect caused by forces exerted on the abnormally curved spine [61]. The administration of melatonin in pinealectomized chickens prevented scoliosis onset and development [60]. The same group also reported a significant decrease of nocturnal serum melatonin concentration in adolescents characterized by progressive scoliosis, whereas in patients with a stable deformity the concentration was not significantly different from controls [54]. Although experimental spinal disease was also reproduced in pinealectomized rats, it should be mentioned that scoliosis only developed in bipedal rats with surgically removed forelimbs and tails [62]. Similar findings were reported in a strain of mice (C57BL/6) where the gene controlling the melatonin pathway is naturally knocked out [63]. Melatonin deficiency secondary to pinealectomy alone does not produce scoliosis if the quadruped condition is maintained: the postural mechanism is thus crucial for inducing vertebral column abnormalities [1]. Although low melatonin concentration in severe progressive human scoliosis was corroborated by experimental animal studies [54], additional studies did not unequivocally confirm melatonin deficiency in AIS. For example, a study was performed using morning and evening urine samples collected from adolescent scoliotic females [64]. This report showed no difference in melatonin concentration (measured by high pressure liquid chromatography) versus controls [64]. Another study found that serum melatonin concentrations during the day (2 p.m.) and at night (2 a.m.) were not significantly different between a group of seven AIS patients and seven age-matched controls [14]. The same authors also did not confirm the previously demonstrated melatonin preventive effect on scoliotic development in pinealectomized chickens. In their experiments, the intraperitoneal injection of melatonin had no effect on scoliosis genesis or on disease progression [65].

BIOCHEMISTRY OF ADOLESCENT IDIOPATHIC SCOLIOSIS

177

Melatonin is rapidly metabolized in the liver by hydroxylation. The principal catabolite in urine is 6-sulfatoxymelatonin, whose concentration can reflect the serum melatonin levels. The evaluation of its excretion in urine from AIS patients did not show differences during the entire 24-h collection period (or in diurnal and nocturnal collections) versus age- and gendermatched controls [66]. Similar results were reported by another team that compared serum melatonin and urine 6-sulfatoxymelatonin [67]. No differences in melatonin concentration were observed in homogenates of paravertebral muscles obtained from scoliotic and nonscoliotic adolescents or in comparison between sides (convex and concave) in AIS patients [46]. It should be noted that absolute melatonin concentration may be less important than its secretion rhythm, a property that could greatly influence cell metabolism through receptor occupancy and regulation. The role of melatonin in AIS remained uncertain due to the questionable relevance of avian studies versus humans. These issues were compounded by experimental data obtained from primates. For example, a 2-years study on 18 pinealectomized monkeys failed to induce scoliosis [68]. Positron emission tomography (PET) was used to evaluate F-18 fluorodeoxyglucose metabolism in the pineal gland versus the cerebellar area. No metabolic differences were found in AIS versus control subjects [69]. Urine 6-sulfatoxymelatonin concentration was also similar in the two groups. Biochemical and metabolic data did not support the hypothesis of absolute melatonin deficiency as a cause of AIS. Increased incidence of AIS was not found in children after surgical or radio-therapeutic pinealectomy due to cancers, despite melatonin deficiency. Interestingly, scoliotic patients typically suffer from sleep difficulty and disturbance. Transient deficiencies of melatonin synthesis or perturbation in its signal transduction could explain the discrepancies found between these reports. Administration of melatonin in AIS patients with a low concentration of endogenous melatonin was studied in a group of 40 subjects (28 with stable scoliosis and 12 with progressive scoliosis). Melatonin was measured by a radioimmunoassay from samples drawn every 3 h for 24 h. Environmental illumination was held constant from 7 a.m. to 9 p.m. Integrated melatonin concentration in 25 control subjects was 368 pg/mL (standard error 28.5) within a 24-h period: 183 (49.8) pg/mL for the nocturnal period (from midnight to 6 a.m.) and 10 (2.5) pg/mL for daytime (from 9 a.m. to 6 p.m.). The circadian rhythm was preserved in patients as well. Twenty two patients had melatonin concentrations similar to those of controls whilst 18 patients had lower concentrations. The administration of melatonin to patients did not alter the biologic rhythm, and prevented, in mild cases (curvature <35 ) disease progression [70].

178

LOMBARDI ET AL.

The neuroendocrine hypothesis centered on melatonin had a reappraisal upon consideration of effects on cells, possibly induced by interaction pitfalls between melatonin and their receptors, especially on calcium metabolism. Melatonin signaling has been demonstrated to be impaired in osteoblasts derived from vertebrae of AIS patients. In these cases, there is a block of inhibition of adenylyl cyclase and accumulation of cAMP into the cells [49]. The distribution and function of receptors was regular: the dysfunction resides in the transmission of signaling, determined by a reduced functionality of Gi proteins. The accumulation of cAMP in osteoblasts can suppress cell functionality through proteolytic degradation of Cbfa1, a member of the RUNX family of transcription factors with a Runt DNA-binding domain. It is essential for osteoblastic differentiation and skeletal morphogenesis and acts as a scaffold for nucleic acids and regulatory factors involved in skeletal gene expression [49].

8. Conclusions No single cause for the development of AIS has been identified and the condition is thus currently considered multifactorial. Despite the involvement of numerous factors in AIS development, the etiology of AIS continues to elude investigators. Identification of factors clearly involved in causation will likely lead to methods for early identification and thus to the development of more effective treatment regimes and its eventual eradication. Currently, diagnosis of AIS is solely based on clinical observation and confirmed by radiological findings. This approach is not, however, without risk due to serial X-ray exposures to assess curvature progression. Radiologic risk, especially in growing children, is certainly of consequence in determining timeliness of intervention. Pathogenesis of AIS appears to involve defective control of the growing spine with varying degrees of susceptibility between individuals. Females may be more vulnerable because of the short and rapid adolescent growth of the spine versus males. It is unlikely that the single cause of the spine deformity is decreased melatonin. A downstream signaling defect appears more conceivable. It is likely that genomic alterations, that is, single nucleotide polymorphisms (SNPs), are important in the determination of onset and severity of progression. These molecular determinants have, however, complex interrelationships intracellularly including protein:protein interaction and the structural microenvironment. As such, advances in proteomic assessment may be particularly relevant in the further elucidation of this disease.

BIOCHEMISTRY OF ADOLESCENT IDIOPATHIC SCOLIOSIS

179

REFERENCES [1] M. Machida, I. Murai, Y. Miyashita, J. Dubousset, T. Yamada, J. Kimura, Pathogenesis of idiopathic scoliosis. Experimental study in rats, Spine 24 (19) (1999) 1985–1989. [2] H.J. Kim, J.S. Blanco, R.F. Widmann, Update on the management of idiopathic scoliosis, Curr. Opin. Pediatr. 21 (1) (2009) 55–64. [3] J.R. Schiller, N.A. Thakur, C.P. Eberson, Brace management in adolescent idiopathic scoliosis, Clin. Orthop. Relat. Res. 468 (3) (2010) 670–678. [4] M.J. McMaster, K. Ohtsuka, The natural history of congenital scoliosis. A study of two hundred and fifty-one patients, J. Bone Joint Surg. Am. 64 (8) (1982) 1128–1147. [5] E.J. Riseborough, R. Wynne-Davies, A genetic survey of idiopathic scoliosis in Boston, Massachusetts, J. Bone Joint Surg. Am. 55 (5) (1973) 974–982. [6] R. Wynne-Davies, Infantile idiopathic scoliosis. Causative factors, particularly in the first six months of life, J. Bone Joint Surg. Br. 57 (2) (1975) 138–141. [7] L.A. Karol, Effectiveness of bracing in male patients with idiopathic scoliosis, Spine 26 (18) (2001) 2001–2005. [8] S. Willner, O. Johnell, Study of biochemical and hormonal data in idiopathic scoliosis in girls, Arch. Orthop. Trauma Surg. 98 (4) (1981) 251–255. [9] C.S.K. Cheung, W.T.K. Lee, Y.K. Tse, K.M. Lee, X. Guo, L. Qin, et al., Generalized osteopenia in adolescent idiopathic scoliosis—association with abnormal pubertal growth, bone turnover, and calcium intake? Spine 31 (3) (2006) 330–338. [10] S. Willner, K.O. Nilsson, K. Kastrup, C.G. Bergstrand, Growth hormone and somatomedin A in girls with adolescent idiopathic scoliosis, Acta Paediatr. Scand. 65 (5) (1976) 547–552. [11] T. Ahl, K. Albertsson-Wikland, R. Kalen, Twenty-four-hour growth hormone profiles in pubertal girls with idiopathic scoliosis, Spine 13 (2) (1988) 139–142. [12] Y. Qiu, N.L. Tang, H.Y. Yeung, Y. Qiu, J.C. Cheng, Genetic association study of growth hormone receptor and idiopathic scoliosis, Clin. Orthop. Relat. Res. 462 (2007) 53–58. [13] G.S. Spencer, P.A. Zorab, Plasma somatomedin activity in normal and scoliotic children, Pediatr. Res. 11 (8) (1977) 883–885. [14] K.M. Bagnall, V.J. Raso, D.L. Hill, M. Moreau, J.K. Mahood, H. Jiang, et al., Melatonin levels in idiopathic scoliosis. Diurnal and nocturnal serum melatonin levels in girls with adolescent idiopathic scoliosis, Spine 21 (17) (1996) 1974–1978. [15] T.G. Lowe, M. Edgar, J.Y. Margulies, N.H. Miller, J. Raso, K.A. Reinker, et al., Etiology of idiopathic scoliosis: current trends in research, J. Bone Joint Surg. Am. 82-A (8) (2000) 1157–1168. [16] K. Letellier, B. Azeddine, S. Parent, H. Labelle, P.H. Rompre´, A. Moreau, et al., Estrogen cross-talk with the melatonin signaling pathway in human osteoblasts derived from adolescent idiopathic scoliosis patients, J. Pineal Res. 45 (4) (2008) 383–393. [17] A. Kulis, D. Zarzycki, J. Jas´kiewicz, Concentration of estradiol in girls with idiopathic scoliosis, Ortop. Traumatol. Rehabil. 8 (4) (2006) 455–459. [18] J.O. Sanders, R.H. Browne, S.J. McConnell, S.A. Margraf, T.E. Cooney, D.N. Finegold, Maturity assessment and curve progression in girls with idiopathic scoliosis, J. Bone Joint Surg. Am. 89 (1) (2007) 64–73. [19] J.W. Raczkowski, The concentrations of testosterone and estradiol in girls with adolescent idiopathic scoliosis, Neuroendocrinol. Lett. 28 (3) (2007) 302–304. [20] T. Esposito, R. Uccello, R. Caliendo, G.F. Di Martino, U.A. Gironi Carnevale, S. Cuomo, et al., Estrogen receptor polymorphism, estrogen content and idiopathic scoliosis in human: a possible genetic linkage, J. Steroid Biochem. Mol. Biol. 116 (1–2) (2009) 56–60.

180

LOMBARDI ET AL.

[21] D. Leboeuf, K. Letellier, N. Alos, P. Edery, F. Moldovan, Do estrogens impact adolescent idiopathic scoliosis? Trends Endocrinol. Metab. 20 (4) (2008) 147–152. [22] M.P. Warren, J. Brooks-Gunn, L.H. Hamilton, L.F. Warren, W.G. Hamilton, Scoliosis and fractures in young ballet dancers. Relation to delayed menarche and secondary amenorrhea, N. Engl. J. Med. 314 (21) (1986) 1348–1353. [23] T. Grivas, E. Vasiliadis, V. Mouzakis, C. Mihas, G. Koufopoulos, Association between adolescent idiopathic scoliosis prevalence and age at menarche in different geographic latitudes, Scoliosis 1 (2006) 9. [24] L. Aulisa, P. Papaleo, E. Pola, F. Angelini, A.G. Aulisa, F.C. Tanburrelli, et al., Association between IL-6 and MMP-3 gene polymorphisms and adolescent idiopathic scoliosis: a case-control study, Spine 32 (24) (2007) 2700–2702. [25] H.Q. Zhang, S.J. Lu, M.X. Tang, L.Q. Chen, S.H. Liu, C.F. Guo, et al., Association of estrogen receptor b gene polymorphisms with susceptibility to adolescent idiopathic scoliosis, Spine 34 (8) (2009) 760–764. [26] J.O. Sanders, R.H. Browne, T.E. Cooney, D.N. Finegold, S.J. McConnell, S.A. Margraf, Correlates of the peak height velocity in girls with idiopathic scoliosis, Spine 31 (20) (2006) 2289–2295. [27] R.G. Burwell, R.K. Auljia, M.P. Grevitt, P.H. Dangerfield, A. Moulton, T.L. Randell, et al., Pathogenesis of adolescent idiopathic scoliosis in girls—a double neuro-osseous theory involving disharmony between two nervous systems, somatic and autonomic expressed in the spine and trunk: possible dependency on sympathetic nervous system and hormones with implications for medical therapy, Scoliosis 4 (2009) 24. [28] S. Canpolat, S. Sandal, B. Yilmaz, A. Yasar, S. Kutlu, G. Baydas, et al., Effects of pinealectomy and exogenous melatonin on serum leptin levels in male rat, Eur. J. Pharmacol. 428 (1) (2001) 145–148. [29] M.I. Alonso-Vale, S. Andreotti, S.B. Peres, G.F. Anheˆ, C. Borges-Silva, J.C. Net, et al., Melatonin enhances leptin expression by rat adipocytes in the presence of insulin, Am. J. Physiol. Endocrinol. Metab. 288 (4) (2005) E805–E812. [30] M.I. Alonso-Vale, S. Andreotti, C.N. Borges-Silva, P.Y. Mukai, J. Cipolla-Neto, F. B. Lima, Intermittent and rhythmic exposure to melatonin in primary cultured adipocytes enhances the insulin and dexamethasone effects on leptin expression, J. Pineal Res. 41 (1) (2006) 28–34. [31] Y. Qiu, X. Sun, X. Qiu, W. Li, Z. Zhu, F. Zhu, et al., Decreased circulating leptin level and its association with body and bone mass in girls with adolescent idiopathic scoliosis, Spine 32 (24) (2007) 2703–2710. [32] C.B. Confavreux, R.L. Levine, G. Karsenty, A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms, Mol. Cell. Endocrinol. 310 (1–2) (2009) 21–29. [33] W.B. Pratt, W.G. Phippen, Elevated hair copper level in idiopathic scoliosis: preliminary observation, Spine 5 (3) (1980) 230–233. [34] M. Dastych, J. Cienciala, M. Krbec, Changes of selenium, copper, and zinc content in hair and serum of patients with idiopathic scoliosis, J. Orthop. Res. 26 (9) (2008) 1279–1282. [35] M. Dastych, J. Cienciala, Idiopathic scoliosis and concentration of zinc, copper, and selenium in blood plasma, Biol. Trace Elem. Res. 89 (2) (2002) 105–110. [36] M. Dastych, O. Vlach, Zinc status in patients with idiopathic scoliosis, Spine 15 (2) (1990) 65–66. [37] M. Turgut, C. Yenisey, M. Bozkurt, F.A. Ergin, T. Bic¸akc¸i, Analysis of zinc and magnesium levels in pinealectomized chicks. Roles on development of spinal deformity? Biol. Trace Elem. Res. 113 (1) (2006) 67–75.

BIOCHEMISTRY OF ADOLESCENT IDIOPATHIC SCOLIOSIS

181

[38] I. Peleg, A. Eldor, I. Kahane, A. Muhlrad, M. Liebergall, Y. Floman, Altered structural and functional properties of myosins from platelets of idiopathic scoliosis patients, J. Orthop. Res. 7 (2) (1989) 260–265. [39] A. Muhlrad, R. Yarom, Contractile proteins in platelets from patients with idiopathic scoliosis, Haemostasis 11 (3) (1982) 154–160. [40] S. Sabato, A. Rotman, G.C. Robin, Y. Floman, Platelet aggregation abnormalities in idiopathic scoliosis, J. Pediatr. Orthop. 5 (5) (1985) 558–563. [41] R. Yarom, A. Muhlard, S. Hodges, G.C. Robin, Platelet pathology in patients with idiopathic scoliosis: ultrastructural morphometry, aggregations, x-ray spectrometry, and biochemical analysis, Lab. Invest. 43 (3) (1980) 208–216. [42] R. Bredoux, E. Corvazier, S. Dally, C. Chaabane, R. Bobe, A. Raies, et al., Human platelet Ca2þ-ATPases: new markers of cell differentiation as illustrated in idiopathic scoliosis, Platelets 17 (6) (2006) 421–433. [43] R.D. Kahmann, J.M. Donohue, D.S. Bradford, J.C. White, G.H. Rao, Platelet function in adolescent idiopathic scoliosis, Spine 17 (2) (1992) 145–148. [44] T. Lowe, D. Lawellin, D. Smith, C. Price, T. Haher, A. Merola, et al., Platelet calmodulin levels in adolescent idiopathic scoliosis, Spine 27 (7) (2002) 768–775. [45] K. Kindsfater, T.G. Lowe, D. Lawellin, D. Weinstein, J. Akmakjian, Levels of platelet calmodulin for the prediction of progression and severity of adolescent idiopathic scoliosis, J. Bone Joint Surg. Am. 76 (8) (1994) 1186–1192. [46] E. Acaroglu, I. Akel, A. Alanay, M. Yazici, R. Marcucio, Comparison of the melatonin and calmodulin in paravertebral muscle and platelets of patients with or without adolescent idiopathic scoliosis, Spine 34 (18) (2009) E659–E663. [47] J.F. Caubet, J.B. Emans, J.T. Smith, H. vanBosse, N. Ramirez, J. Flynn, et al., Increased hemoglobin levels in patients with early onset scoliosis, Spine 34 (23) (2009) 2534–2536. [48] T. Grivas, O.D. Savvidou, Melatonin the ‘‘light of night’’ in human biology and adolescent idiopathic scoliosis, Scoliosis 2 (2007) 6. [49] A. Moreau, D.S. Wang, S. Forget, B. Azeddine, D. Angeloni, F. Fraschini, et al., Melatonin signaling dysfunction in adolescent idiopathic scoliosis, Spine 29 (16) (2004) 1772–1781. [50] B. Azeddine, K. Letellier, D.S. Wang, F. Moldovan, A. Moreau, Molecular determinants of melatonin signaling dysfunction in adolescent idiopathic scoliosis, Clin. Orthop. Relat. Res. 462 (2007) 45–52. [51] R. Hardeland, Melatonin, hormone of darkness and more-occurrence, control mechanism, actions and bioactive metabolites, Cell. Mol. Life Sci. 65 (13) (2008) 2001–2018. [52] G. Benı`tez-King, Melatonin as a cytoskeletal modulator: implications for cell physiology and disease, J. Pineal Res. 40 (1) (2006) 1–9. [53] I. Akel, G. Demirkiran, A. Alanay, S. Karahan, R. Marcucio, E. Acaroglu, The effect of calmodulin antagonists on scoliosis: bipedal C57BL/6 mice model, Eur. Spine J. 18 (4) (2009) 499–505. [54] M. Machida, J. Dubousset, Y. Imamura, Y. Miyshita, T. Yamada, J. Kimura, Melatonin: a possible role in pathogenesis of adolescent idiopathic scoliosis, Spine 21 (10) (1996) 1147–1152. [55] R.W. Porter, The pathogenesis of idiopathic scoliosis: uncoupled neuro-osseous growth? Eur. Spine J. 10 (6) (2001) 473–481. [56] N. Suzuki, M. Somei, A. Seki, R.J. Reiter, A. Hattori, Novel bromomelatonin derivatives as potentially effective drugs to treat bone diseases, J. Pineal Res. 45 (3) (2008) 229–234. [57] M.J. Thillard, Deformations de la colonne vertebrale consecutives a` l’e´piphysectomie chez le poussin, Extrat. C. R. Assoc. Anat. 248 (8) (1959) 751–758.

182

LOMBARDI ET AL.

[58] J. Dubousset, P. Queneau, M.J. Thillard, Experimental scoliosis induced by pineal and diencephalic lesions in young chickens. Its relation with clinical findings, Orthop. Trans. 7 (1983) 7. [59] M. Machida, J. Dubousset, Y. Imamura, T. Iwaya, T. Yamada, J. Kimura, et al., Pathogenesis of idiopathic scoliosis: SEPs in chicken with experimentally induced scoliosis and in patients with idiopathic scoliosis, J. Pediatr. Orthop. 14 (3) (1994) 29–35. [60] M. Machida, J. Dubousset, Y. Imamura, T. Iwaya, T. Yamada, J. Kimura, Role of melatonin deficiency in the development of scoliosis in pinealectomised chickens, J. Bone Joint Surg. Br. 77 (1) (1995) 134–138. [61] Y. Qiu, L. Wu, B. Wang, Y. Yu, Z. Zhu, Asymmetric expression of melatonin receptor mRNA in bilateral paravertebral muscles in adolescent idiopathic scoliosis, Spine 32 (6) (2007) 667–672. [62] M. Machida, M. Saito, J. Dubousset, T. Yamada, J. Kimura, K. Shibasaki, Pathological mechanism of idiopathic scoliosis: experimental scoliosis in pinealectomized rats, Eur. Spine J. 14 (9) (2005) 843–848. [63] M. Machida, J. Dubousset, T. Yamada, J. Kimura, M. Saito, T. Shiraishi, et al., Experimental scoliosis in melatonin-deficient C57BL/6J mice without pinealectomy, J. Pineal Res. 41 (1) (2006) 1–7. [64] A.S. Hilibrand, L.C. Blakemore, R.T. Loder, M.L. Greenfield, F.A. Farley, R. N. Hensinger, et al., The role of melatonin in the pathogenesis of adolescent idiopathic scoliosis, Spine 21 (10) (1996) 1140–1146. [65] K.M. Bagnall, V.J. Raso, M. Moreau, J. Mahood, X. Wang, J. Zhao, The effects of melatonin therapy on the development of scoliosis after pinealectomy in the chicken, J. Bone Joint Surg. 83 (2) (1999) 191–199. [66] A.B. Fagan, D.J. Kennaway, A.D. Sutherland, Total 24-hour melatonin secretion in adolescent idiopathic scoliosis: a case-control study, Spine 23 (1) (1998) 41–46. [67] W. Brodner, P. Krepler, M. Nicolakis, M. Langer, A. Kaider, W. Lack, et al., Melatonin and adolescent idiopathic scoliosis, J. Bone Joint Surg. Br. 82 (3) (2000) 399–403. [68] K.M. Cheung, T. Wang, A.M. Poon, A. Carl, B. Trammer, Y. Hu, et al., The effect of pinealectomy on scoliosis development in young nonhuman primates, Spine 30 (18) (2005) 2009–2013. [69] K.T. Suh, S.S. Lee, S.J. Kim, Y.K. Kim, J.S. Lee, Pineal gland metabolism in patients with adolescent idiopathic scoliosis, J. Bone Joint Surg. Br. 89 (1) (2007) 66–71. [70] M. Machida, J. Dubousset, T. Yamada, J. Kimura, Serum melatonin levels in adolescent idiopathic scoliosis prediction and prevention for curve progression—a prospective study, J. Pineal Res. 46 (3) (2009) 344–348.

INDEX A Acquired hemophilia A (AHA) aPTT, 73 epidemiology and clinical manifestations bleed pathology, 74 interim analysis, 73 inhibitor eradication, 77–78 laboratory diagnosis, 73, 74 pathogenesis, FVIII A2, A3 and C2 domains, 72–73 autoantibodies against FVIII, 72 potential mechanisms, 73 type 2 kinetics, 72 treatment bypassing agents, 76 guidelines, 75 options, 76–77 subcutaneous bleeds, 75 ACS. See Acute coronary syndrome Activated partial thromboplastin time (aPTT) AHA diagnosis, 73 test, 75 Activated prothrombin complex concentrates (aPCCs), 76 Acute coronary syndrome (ACS) heart disease patients, 13 HSP70, 9–10 HSP27 plasma levels, 11 myocardial infarction, 13 predict risk, 14–15 sex‐matched healthy controls, 9–10 Acute myocardial infarction (AMI), 10 Adenomatous polyposis coli (APC) adenoma dysplasia, 60 animal models, 62 and c‐MYC mutations, 51 pharmacological inhibition, 51–52 polyamine biosynthesis and tumorigenesis, 51–52 Adolescent idiopathic scoliosis (AIS)

biochemical variations, 167 bone biochemical parameters, 168 Cobb technique and vertebral rotation, 166–167 curve progression, 167 description, 166 hematological parameters calmodulin, 172 myosin chains, 171 thoracolumbar curvature, 171–172 hormones androgen levels, 170 bioassay measurements, 168 hypothalamic hypersensitivity, 171 interindividual variability, 169–170 melatonin‐signaling dysfunction, 169 plasma estrogen concentration, 169 sex hormones, 169 melatonin calcium metabolism, 175–176 receptors, types, 173–174 role, pathogenesis, 176–178 tryptophan, 172 spinal curvatures, 167 trace elements, 171 AHA. See Acquired hemophilia A AIS. See Adolescent idiopathic scoliosis Alkaline phosphatase (ALP) activity, 169 bone resorption, 168 AMD1 gene, 47–48 Antigenic detection HSP27, 10–11 HSP60, 9 HSP70, 9–10 HSP90, 11 Anti‐Sm antibodies characteristics, 113–114 clinical association, 118 detection autoimmune response, 117 diagnostic kit manufacturers, 116 183

184

INDEX

Anti‐Sm antibodies (cont. ) epitope distribution, 115 passive hemagglutination, 114 subpopulation, 117 genesis, 119 meta‐analysis, 118–119 APC. See Adenomatous polyposis coli Apolipoprotein B (apoB) assembly and secretion, 83–84 clearance, LDL‐receptor, 86–87 control, secretion, 84–86 FHBL, 88 gene mutations, 88–89 intracellular degradation, 86 LDL‐receptor, 89–90 plasma levels, 83 primary/secondary HBL, 83 aPTT. See Activated partial thromboplastin time Aromatase activity and bone loss acquired variation CagA‐negative patients, 153 cycloxygenase (COX) inhibitors, 152 estrogen levels, 153 mature adipocytes, 151 pathological conditions, 152–153 procyanidin B dimers, 152 RNA and protein levels, 151–152 activity inhibition, men bone formation and resorption markers, 141 estrogen vs. testosterone, 139 fragility fractures, 140 observational and direct interventional data, 142 short‐term interventional observations, 140 testosterone treatment, 142 activity inhibition, women aromatase inhibitors, 144 estrogen levels, 142–143 human osteosarcoma cells, 144–145 letrozole and placebo groups, 143 nonsteroidal compounds, 143 pharmacological therapy, 144 animal models aromatase knock‐out (ArKO) mouse models, 138 CYP19A1 gene, 139 energy and bone homeostasis, 138

estrogen vs. androgen, 139 sexual dimorphism, 138 deficiency syndrome endocortical expansion, 137 epiphyseal maturation, 137–138 ESR1 gene, 135 intramuscular testosterone, 135–136 loss‐of‐function mutations, 135 mild hypogonadism, 137 physiologic roles, 135 skeletal phenotype, 136 X‐ray absorptiometry, 136 estrogen production cytochrome P450 enzyme system, 131 distal target tissues, 131 extraglandular aromatase activity, 132 extragonadal sites, 132 fetal and normal tissue, 132–133 metabolic pathways, 131–132 gene and tissue‐specific regulation complex control system, 134 human aromatase gene, 133–134 osteoblast cell lines, 133 P450 enzyme system, 133 inherited variation adipose tissue promoter, 151 BMD values, 149–150 CpG methylation, 151 CYP19A1 variants, 149 genotype vs. fibroblasts, 150 polymorphic regions, 148 rates, bone loss, 148–149 sex steroid hormones, 130 skeletal consequences autosomal dominant, 145 clinical and experimental evidences, 146 estrogen excess, 145 local aromatization, 146 osteoblast‐specific inducers, 146 skeletal sufficiency, threshold estradiol hypothesis cross‐sectional and longitudinal studies, 147 endocrine estradiol, 147 estradiol level, 146 Aromatase deficiency syndrome endocortical expansion, 137 epiphyseal maturation, 137–138 ESR1 gene, 135

INDEX intramuscular testosterone, 135–136 loss‐of‐function mutations, 135 mild hypogonadism, 137 physiologic roles, 135 skeletal phenotype, 136 X‐ray absorptiometry, 136 Atherogenesis and possible stimuli hypercholesterolemia, 7 LDLs levels, 7 phagocytic cells, 4, 7 SMCs, 8 steps, 4 Atherothrombosis biomarkers antigenic detection HSP27, 10–11 HSP60, 9 HSP70, 9–10 HSP90, 11 anti‐HSP antibodies anti‐HSP60/65, 12–13 HSP27, 13 HSP70, 13 HSP90, 13 limitations, 14–15 definition, 8 Western blots, plasma, 8 Autoantibodies against factor VIII (FVIII) inhibitors, 72, 73 B Bovine serum albumin (BSA), 121 C Cardiovascular disease (CVD). See also Heat‐shock proteins (HSPs) gene therapy, 25–26 immune therapy, 27–28 pharmacological compounds, 26–27 thermal preconditioning, 25 Chemoprevention strategies, polyamine pathway DFMO and NSAIDS, animal models, 62 in humans, 62–63 ODC suppression, 60 SAT1 induction COX‐independent mechanisms., 60 gene expression, 61 intracellular effects, 62

185

polyamine analogs, 61 polyamine‐dependent cell proliferation, 61 Cobb technique and vertebral rotation, 166–167 CYP19A1 gene active cryptic promoters, 145 aromatase, 133 complex promoter region, 151 cytochrome P450, 130 deficient mice, 139 epigenetic mechanism, 151 genotypes, 149 loss‐of‐function mutations, 135 polymorphisms, 149 selective inhibitors, 144 D Decarboxylated S‐adenozylmethionine (dcSAM), 47–48 –Difluoromethylornithine (DFMO) antitumorigenic properties, 62 nonsteroidal anti‐inflammatory drug, 61 nontoxic dose, 63 ODC inhibitor, 52 polyamine metabolism, 60 E Estrogen receptor alpha (ESR1) gene, 135 Eukaryotic initiation factor 5A (EIF5A) copy number and cell growth rate, 58–59 DHS and DOHH, 57 EIF5A2, 58–59 elongation factor, 58 hypusination, 56 large sequence homology, 59–60 nuclear shuttling, 57 protein synthesis, 56 sequence homology, 58 structural homology, 57 tumor formation, 59 Eukaryotic translation initiation factor 5A2 (EIF5A2) adult neuronal tissues, 58 role, 59 tumor formation, 59

186

INDEX F

Familial hypobetalipoproteinemia (FHBL) APOB‐containing lipoproteins, 87 and cancer, 96 cardiovascular disease C679X mutation, 95–96 LDL‐C, risk factor, 95 fatty liver disease anecdotal reports, 95 apoB, 94 pathophysiology, 94–95 gene mutations, APOB, 88–89 liver uptake, 89–91 prevalence, 91 primary orphan, 92 H HBL. See Hypobeta lipoproteinemia HDF. See Human diploid fibroblasts Heat‐shock proteins (HSPs) atherogenesis and possible stimuli hypercholesterolemia, 7 LDLs levels, 7 phagocytic cells, 4, 7 SMCs, 8 steps, 4 atherothrombosis antigenic detection, 8–11 anti‐HSP antibodies, 12–15 definition, 8 gene therapy, 25–26 immune therapy, 27–28 pharmacological compounds, 26–27 thermal preconditioning, 25 Western blots, plasma, 8 classification, molecular weight, 4 compartmentalization, 4 Drosophila, 4 intra/extracellular functions and use, 3–6 molecular mechanisms extracellular effects, 21–24 intracellular effects, 15–21 stress stimuli, 3 HSA. See Human serum albumin HSP27 antigenic detection, 10–11 anti‐HSP antibodies, 13

extracellular effects, 24 intracellular effects, 18–19 HSP60 antigenic detection, 9 extracellular effects, 22–23 intracellular effects, 16 HSP70 antigenic detection, 9–10 anti‐HSP antibodies, 13 extracellular effects, 23–24 intracellular effects, 16–18 HSP90 antigenic detection, 11 anti‐HSP antibodies, 13 extracellular effects, 24 intracellular effects, 20–21 Human diploid fibroblasts (HDF), 16 Human serum albumin (HSA), 121 Hypobeta lipoproteinemia (HBL) apoB‐containing lipoproteins production assembly and secretion, 83–84 clearance, LDL‐receptor, 86–87 control, secretion, 84–86 intracellular degradation, 86 causes, mutations, 83 chronic pancreatitis and cystic fibrosis, 96 clinical features, 83 clinical manifestation spectrum apoB‐containing lipoproteins, 92 CMRD, 92–93 fat‐containing meal, 93 fat‐soluble vitamin deficiency, 93–94 mild intestinal malabsorption, 93 PCSK9‐related, 94 description, 83 dominant forms APOB‐containing lipoproteins, 87–89 FHBL, 89–91 FHBL clinical issues, 94–96 primary orphan, 92 LDL‐C and apoB plasma levels, 96 malnutrition and inflammation, 96–97 recessive forms abetalipoproteinemia, 91 chylomicron retention disease (CMRD), 91–92 TC plasma levels, 97

INDEX I Inhibitor eradication, AHA first‐line options, 77 immunosuppressive therapy, 77 rituximab, 78 second‐line therapy, 78 K Keyhole limpet hemocyanin (KLH), 121 L Low density lipoprotein‐cholesterol (LDL‐C) cardiovascular disease (CVD), 95 FHBL subjects, 90 plasma levels, 83, 89 Low‐density lipoproteins (LDLs) animal models, 7–8 circulating levels, 7 M MCTD. See Mixed connective tissue disease Melatonin calcium metabolism bone‐derived cell lines, 175–176 calmodulin, 175 pineal deficiency, 175 receptors, types, 173–174 role, pathogenesis anatomic features, 176 neuroendocrine hypothesis, 178 pinealectomized rats, 176 radioimmunoassay, 177 secretion rhythm, 177 tryptophan, 172 Mixed connective tissue disease (MCTD) anti‐Sm/RNP reactivity, 117 diagnostic hallmark, 112 vs. SLE, 116 Molecular mechanisms, HSP chaperoning and antiapoptotic functions, 15 extracellular effects HSP27, 24 HSP60, 22–23 HSP70, 23–24 HSP90, 24

187 lysosomes‐like vesicles, 22 potent immunogenic role, 21–22 intracellular effects heat‐shock response (HSR), 15 HSP27, 18–19 HSP60, 16 HSP70, 16–18 HSP90, 20–21 synthesis, 15–16 N

Non‐Hodgkin’s lymphomas, 78 Nonsteroidal anti‐inflammatory drugs (NSAIDs) in animal models, 62 antitumor activity, 62 COX‐dependent mechanisms, 60 O Ornithine decarboxylase (ODC) affecting carcinogenesis chemoprevention strategies, 54–55 E‐box elements, 54 genetic variability and G316A ODC SNP, 55 GG genotype, 56 invasive cancer and metastasis, 54 APC and c‐MYC mutations, 51 pharmacological inhibition, 51–52 polyamine biosynthesis and tumorigenesis, 51–52 mutant K‐RAS cellular processes via signaling pathways, 52 partial‐loss‐of‐function, 53 polyamine levels, 52–53 neoplastic transformation, 50 regulation AMD1, 46 decarboxylated S‐adenozylmethionine (dcSAM), 47–48 diamine exporter (DAX), 49 mammalian spermidine and spermine synthase, 48 metabolic effector, 46 structure and metabolism, 47–48 uORFs, 49

188

INDEX P

Parathyroid hormone (PTH), 168 PCSK9 gene candidate genes, 99 gain‐of‐function mutations, 87 loss‐of‐function mutations, 90, 95 Polyamines, cancer chemoprevention strategies DFMO and NSAIDS, animal models, 62 in humans, 62–63 ODC suppression, 60 SAT1 induction, 60–62 complex regulation, 46 deregulation APC, 51–52 mutant K‐RAS, 52–53 ODC, 50–51 polyamine transport, 53–54 SAT1, 53 tumorigenesis, 50, 53–54 EIF5A copy number and cell growth rate, 58–59 DHS and DOHH, 57 EIF5A2, 58–59 elongation factor, 58 hypusination, 56 large sequence homology, 59–60 nuclear shuttling, 57 protein synthesis, 56 sequence homology, 58 structural homology, 57 tumor formation, 59 molecular weight, 46 ODC affecting carcinogenesis chemoprevention strategies, 54–55 E‐box elements, 54 genetic variability and G316A ODC SNP, 55 GG genotype, 56 invasive cancer and metastasis, 54 regulation, ODC AMD1, 46 decarboxylated S‐adenozylmethionine (dcSAM), 47–48 diamine exporter (DAX), 49 mammalian spermidine and spermine synthase, 48 metabolic effector, 46 structure and metabolism, 47–48 uORFs, 49

PPAR receptor adipocyte differentiation, 151 pathways, 152 PTH. See Parathyroid hormone S SAT1. See Spermidine/spermine N1‐ acetyltransferase Smooth muscle cells (SMCs) glycoproteins proteoglycans, 4–5 proliferation, 8 serum starvation, 23 Sm peptides, autoimmune diseases antibodies characteristics, 113–114 clinical association, 118 detection, 114–118 genesis, 119 meta‐analysis, 118–119 antigens amino acid sequence, 121 epitope mapping methods, 122 modification, 121 biochemical aspects, 112–113 intracellular targets, 110 MCTD, 112 SLE, 110–112 Spermidine/spermine N1‐acetyltransferase (SAT1) deregulation, 53 gene, 49, 51 induction, 60–62 polyamine catabolic enzyme, 48–49 Spermine oxidase (SMO), 47 Survival motor neuron (SMN), 121 Systemic lupus erythematosus (SLE) etiology, 110 sensitivity and specificity, 111 T Tryptophan, 172 U Upstream open reading frames (uORFs), 49

INDEX V Vascular SMCs (VSMCs ) apoptosis, 11 apoptotic features, 19 calcification, 23 cell detachment, 19 HSP60, 16 HSP70, 10

inflammatory markers, 17 proliferation, 20 Very low density lipoproteins (VLDL) apoB‐containing lipoproteins, 83 assembly, 84 export system, 95 maturation, 85 plasma levels, 91 secretion, 86 von Willebrand factor (VWF), 72

189